0000950170-24-12227610-Q SOLENO THERAPEUTICS INC 20241106202411061606371606371606371

jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 100 Marine Parkway, Suite 400 Redwood City, California (Address of principal executive offices) 94065 (Zip Code) (650) 213-8444 (Registrantâ€™s telephone number, including area code) Â Â Securities registered pursuant to Section 12(b) of the Act: Â Â Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of October 31, 2024, there were 43,117,432 shares of the registrantâ€™s Common Stock, par value $0.001 per share, outstanding. Â Â SOLENO THERAPEUTICS, INC. TABLE OF CONTENTS Â Page PART Iâ€”FINANCIAL INFORMATION 3 Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (unaudited) 3 Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) 4 Condensed Consolidated Statements of Stockholdersâ€™ Equity (unaudited) 5 Condensed Consolidated Statements of Cash Flows (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 23 Item 4. Controls and Procedures 23 PART IIâ€”OTHER INFORMATION 25 Item 1. Legal Proceedings 25 Item 1A. Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26 EXHIBIT INDEX 27 SIGNATURES 27 Â Â Â Â Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements Soleno Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) Â Â Â September 30,2024 Â Â December 31,2023 Â Assets Â (unaudited) Â Â Â Â Current assets Â Â Â Â Â Â Cash and cash equivalents Â $ 48,413 Â Â $ 169,681 Â Marketable securities Â Â 208,363 Â Â Â â€” Â Prepaid expenses and other current assets Â Â 1,423 Â Â Â 1,677 Â Total current assets Â Â 258,199 Â Â Â 171,358 Â Long-term assets Â Â Â Â Â Property and equipment, net Â Â 196 Â Â Â 12 Â Operating lease right-of-use assets Â Â 2,992 Â Â Â 407 Â Intangible assets, net Â Â 7,291 Â Â Â 8,749 Â Long-term marketable securities Â Â 27,945 Â Â Â - Â Other long-term assets Â Â 83 Â Â Â 165 Â Total assets Â $ 296,706 Â Â $ 180,691 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Current liabilities Â Â Â Â Â Â Accounts payable Â $ 6,243 Â Â $ 3,149 Â Accrued compensation Â Â 3,408 Â Â Â 3,135 Â Accrued clinical trial site costs Â Â 1,762 Â Â Â 3,393 Â Operating lease liabilities Â Â 448 Â Â Â 273 Â Other current liabilities Â Â 3,101 Â Â Â 1,555 Â Total current liabilities Â Â 14,962 Â Â Â 11,505 Â Long-term liabilities Â Â Â Â Â Â Contingent liability for Essentialis purchase price Â Â 14,464 Â Â Â 11,549 Â Long-term lease liabilities Â Â 2,581 Â Â Â 130 Â Total liabilities Â Â 32,007 Â Â Â 23,184 Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Stockholdersâ€™ equity Â Â Â Â Â Â Preferred stock, $0.001Â par value; 10,000,000Â shares authorized, noÂ shares issued and outstanding Â Â â€” Â Â Â â€” Â Common stock, $0.001Â par value, 100,000,000Â shares authorized,Â 41,041,216Â and 31,678,159Â shares issued and outstanding atÂ Â Â September 30, 2024 and December 31, 2023, respectively Â Â 41 Â Â Â 32 Â Additional paid-in-capital Â Â 660,041 Â Â Â 433,885 Â Accumulated other comprehensive gain Â Â 895 Â Â Â - Â Accumulated deficit Â Â (396,278) Â Â (276,410) Total stockholdersâ€™ equity Â Â 264,699 Â Â Â 157,507 Â Total liabilities and stockholdersâ€™ equity Â $ 296,706 Â Â $ 180,691 Â Â See accompanying notes to condensed consolidated financial statements 3 Â Soleno Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share data) Â Â Three Months EndedSeptember 30, Â Â Nine Months EndedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development $ 30,138 Â Â $ 6,043 Â Â $ 57,082 Â Â $ 16,500 Â General and administrative Â 49,197 Â Â Â 3,318 Â Â Â 68,558 Â Â Â 9,341 Â Change in fair value of contingent consideration Â 877 Â Â Â 1,021 Â Â Â 2,915 Â Â Â 1,633 Â Total operating expenses Â 80,212 Â Â Â 10,382 Â Â Â 128,555 Â Â Â 27,474 Â Operating loss Â (80,212) Â Â (10,382) Â Â (128,555) Â Â (27,474) Other income (expense), net Â Â Â Â Â Â Â Â Â Â Change in fair value of warrants liabilities Â â€” Â Â Â (653) Â Â â€” Â Â Â (652) Interest income, net Â 3,596 Â Â Â 174 Â Â Â 8,687 Â Â Â 434 Â Total other income (expense), net Â 3,596 Â Â Â (479) Â Â 8,687 Â Â Â (218) Net loss $ (76,616) Â $ (10,861) Â $ (119,868) Â $ (27,692) Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) Â Â Â Â Â Â Â Â Â Â Net unrealized gain on marketable securities Â 1,049 Â Â Â â€” Â Â Â 898 Â Â Â â€” Â Foreign currency translation adjustment Â (1) Â Â (1) Â Â (3) Â Â (1) Total comprehensive loss $ (75,568) Â $ (10,862) Â $ (118,973) Â $ (27,693) Â Â Â Â Â Â Â Â Â Â Net loss per common share, basic and diluted $ (1.83) Â $ (0.95) Â $ (3.08) Â $ (2.65) Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share Â 41,879,025 Â Â Â 11,436,748 Â Â Â 38,917,169 Â Â Â 10,443,186 Â Â Â Â Â Â Â Â Â Â Â Â See accompanying notes to condensed consolidated financial statements 4 Â Soleno Therapeutics, Inc. Condensed Consolidated Statements of Stockholdersâ€™ Equity For the Three and Nine Months Ended September 30, 2024 and 2023 (unaudited) (in thousands, except share data) Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Other Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balances at January 1, 2024 Â Â 31,678,159 Â Â Â $ 32 Â Â Â $ 433,885 Â Â Â $ - Â Â Â $ (276,410) Â Â $ 157,507 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 6,445 Â Â Â - Â Â Â - Â Â Â 6,445 Â Issuance of restricted stock units under equity incentive plans Â Â 11,034 Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Exercise of common stock warrants and pre-funded common stock warrants Â Â 1,644,886 Â Â Â 1 Â Â Â 922 Â Â Â - Â Â Â - Â Â Â 923 Â Exercise of stock options Â Â 3,000 Â Â Â - Â Â Â 15 Â Â Â - Â Â Â - Â Â Â 15 Â Unrealized loss on marketable securities Â Â - Â Â Â - Â Â Â - Â Â Â (105) Â Â - Â Â Â (105) Foreign currency translation adjustment Â Â - Â Â Â - Â Â Â - Â Â Â (1) Â Â - Â Â Â (1) Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (21,398) Â Â (21,398) Balances at March 31, 2024 Â Â 33,337,079 Â Â Â 33 Â Â Â 441,267 Â Â Â (106) Â Â (297,808) Â Â 143,386 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 7,160 Â Â Â - Â Â Â - Â Â Â 7,160 Â Issuance of restricted stock units under equity incentive plans Â Â 75,750 Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Â Â - Â Sale of common stock, net of issuance costs of $9,746 Â Â 3,450,000 Â Â Â 4 Â Â Â 148,951 Â Â Â - Â Â Â - Â Â Â 148,955 Â Exercise of common stock warrants and pre-funded common stock warrants Â Â 1,435,319 Â Â Â 1 Â Â Â 2,619 Â Â Â - Â Â Â - Â Â Â 2,620 Â Exercise of stock options Â Â 88,631 Â Â Â - Â Â Â 537 Â Â Â - Â Â Â - Â Â Â 537 Â Unrealized loss on marketable securities Â Â - Â Â Â - Â Â Â - Â Â Â (46) Â Â - Â Â Â (46) Foreign currency translation adjustment Â Â - Â Â Â - Â Â Â (1) Â Â - Â Â Â (1) Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (21,854) Â Â (21,854) Balances at June 30, 2024 Â Â 38,386,779 Â Â Â 38 Â Â Â 600,534 Â Â Â (153) Â Â (319,662) Â Â 280,757 Â Stock-based compensation Â Â - Â Â Â - Â Â Â 56,598 Â Â Â - Â Â Â - Â Â Â 56,598 Â Issuance of restricted stock units under equity incentive plans Â Â 789,500 Â Â Â 1 Â Â Â - Â Â Â - Â Â Â - Â Â Â 1 Â Exercise of common stock warrants and pre-funded common stock warrants Â Â 1,782,048 Â Â Â 2 Â Â Â 2,145 Â Â Â - Â Â Â - Â Â Â 2,147 Â Exercise of stock options Â Â 82,889 Â Â Â - Â Â Â 764 Â Â Â - Â Â Â - Â Â Â 764 Â Unrealized gain on marketable securities Â Â - Â Â Â - Â Â Â 1,049 Â Â Â - Â Â Â 1,049 Â Foreign currency translation adjustment Â Â - Â Â Â - Â Â Â - Â Â Â (1) Â Â - Â Â Â (1) Net loss Â Â - Â Â Â - Â Â Â - Â Â Â (76,616) Â Â (76,616) Balances at September 30, 2024 Â Â 41,041,216 Â Â $ 41 Â Â $ 660,041 Â Â $ 895 Â Â $ (396,278) Â $ 264,699 Â Â Â Â Â Â Â Â Â Â Â Â

connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.Marketable SecuritiesThe Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholdersâ€™ equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented.Â Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.In November 2023, the FASB issued ASU 2023-07, Segment Reporting â€“ Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the disclosure requirements related to the new standard but does not anticipate a material impact on its consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024. Adoption is permitted either prospectively or retrospectively, and the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s financial statements upon adoption. Note 4. Fair Value of Financial Instruments The carrying value of the Companyâ€™s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: â€¢Level I â€“ Unadjusted quoted prices in active markets for identical assets or liabilities; 9 Â â€¢Level II â€“ Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and â€¢Level III â€“ Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at September 30, 2024 (in thousands):Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury securities Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Total Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Â Â Â Â Â Â Â Â Â Â Â Â Â The following table sets forth the Companyâ€™s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Â Â Â Fair Value Measurements at September 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 26,400 Â Â $ 26,400 Â Â $ - Â Â $ - Â Total cash equivalents Â $ 26,400 Â Â $ 26,400 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â $ 236,308 Â Â $ â€” Â Â $ 236,308 Â Â $ â€” Â Total marketable securities Â $ 236,308 Â Â $ â€” Â Â $ 236,308 Â Â $ â€” Â Total assets Â $ 262,708 Â Â $ 26,400 Â Â $ 236,308 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Essentialis purchase price contingency liability Â $ 14,464 Â Â $ â€” Â Â $ â€” Â Â $ 14,464 Â Total liabilities Â $ 14,464 Â Â $ â€” Â Â $ â€” Â Â $ 14,464 Â Â Â Â Fair Value Measurements at December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Essentialis purchase price contingency liability Â $ 11,549 Â Â $ â€” Â Â $ â€” Â Â $ 11,549 Â Total liabilities Â $ 11,549 Â Â $ â€” Â Â $ â€” Â Â $ 11,549 Â Based on the terms of the Companyâ€™s completed merger with Essentialis on March 7, 2017, the Company is obligated to make cash earnout payments of up to a maximum of $21.2 million to the former Essentialis stockholders. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Companyâ€™s analysis of the likelihood of obtaining specified approvals from the U.S. Food and Drug Administration (FDA) as well as achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue. The Level 3 estimates are based, in part, on subjective assumptions. In determining the likelihood of this occurring, the analysis relied on published research relating to clinical development success rates. Based on managementâ€™s assessment, an 88% probability of achieving all three milestones was determined to be reasonable as of both September 30, 2024 and December 31, 2023. During the periods presented, the Company has not changed the manner in which it values its Essentialis purchase price contingent liability.The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between levels within the hierarchy during the periods presented. 10 Â The following table sets forth a summary of the changes in the fair value of the Companyâ€™s Level 3 liabilities for the nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Â Â Â Â Purchase Price Â Â Â Â Â Â Â Â Â ContingentLiability Â Balance at January 1, 2024 Â Â Â Â Â Â Â Â $ 11,549 Â Change in value of contingent liability Â Â Â Â Â Â Â 2,915 Â Balance at September 30, 2024 Â Â Â Â Â Â Â Â $ 14,464 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2018 PIPE Warrants Â Â Purchase Price Â Â Â Number ofWarrants Â Â Liability Â Â ContingentLiability Â Balance at January 1, 2023 Â Â 34,241 Â Â $ 1 Â Â $ 8,835 Â Change in value of 2018 PIPE Warrants Â Â â€” Â Â Â 652 Â Â Â â€” Â Change in value of contingent liability Â Â â€” Â Â Â â€” Â Â Â 1,633 Â Balance at September 30, 2023 Â Â 34,241 Â Â $ 653 Â Â $ 10,468 Â Â Note 5. WarrantsThe Company has issued multiple warrant series, of which the 2018 PIPE Warrants were determined to be liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging. Warrants Issued as Part of the Units in the 2018 PIPE Offering The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and prior to their expiration on December 21, 2023, entitled the holders to purchase 34,241 shares of the Companyâ€™s common stock at an exercise price equal to $30.00 per share, subject to adjustments. In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology. Since the Company may be obligated to settle the 2018 PIPE Warrants in cash, the Company classified the 2018 PIPE Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as Other income (expense) in the Companyâ€™s condensed consolidated statements of operations. The 2018 PIPE Warrants were either exercised prior to or expired on December 21, 2023. Â Note 6. Commitments and Contingencies Facility Leases On June 13, 2024, the Company entered into a new office lease in Redwood City, California for office space for its headquarters facility. The lease provides office space of approximately 18,026 square feet and for base monthly rent payments beginning at $57,400 that increase annually by approximately 3.0% over the term of five years from the date of occupancy. In addition to base rent, the Company has agreed to reimburse the landlord for certain operating expenses under the terms of the lease. The lease commencement date was September 1, 2024 when the premises became available for occupancy and the related operating lease ROU assets and liabilities were recorded in the Company's condensed consolidated balance sheet as of September 30, 2024. The Company's operating lease ROU assets, current operating lease liabilities and long-term operating lease liabilities each appear as a separate line within the Company's condensed consolidated balance sheets. In September 2024, the Company recorded an increase to its right-of-use assets by $2.8 million and an increase to its lease liability of $2.8 million as a result of the June 2024 office lease. As of September 30, 2024 and December 31, 2023, the Company's short-term liabilities were equal to $0.4 million and $0.3 million, respectively, and the long-term operating lease liabilities were equal to $2.6 million and $0.1 million, respectively. The Companyâ€™s prior operating lease for its predecessor headquarters facility office space in Redwood City, California began in June 2021 and expired in May 2023. In April 2023, the Company entered into a twenty-four month lease extension commencing on June 1, 2023. The term of the lease extension expires in May 2025. On February 8, 2024, the Company entered into a six-month office license agreement to license 4,141 square feet of additional space adjacent to its existing office where the Company was located and in 11 Â July 2024, the Company provided notice of early termination of the license agreement for the additional space effective September 17, 2024. As a result of the lease extension, in 2023, the Company recorded an increase to its right-of-use assets by $0.6 million and an increase to its lease liability by $0.6 million. The weighted average discount rate related to the Company's lease liabilities as of September 30, 2024 was 8.5% over a remaining term of 5 years. The weighted average discount rate related to the Company's lease liabilities as of December 31, 2023 was 8.25% over a remaining term of 17 months. The discount rate was determined based on estimates of the Companyâ€™s incremental borrowing rate, as the discount rate implicit in the lease cannot be readily determined. Due to the short-term nature of the February 2024 office license agreement, the license agreement obligations are not included in the Company's right-of-use assets and lease liabilities on the Company's condensed consolidated balance sheets.The components of lease expense during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Three Months EndedSeptember 30, Â Â Nine Months EndedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost: Â Â Â Â Â Â Â Â Â Â Â Â Operating lease cost $ 137 Â Â $ 76 Â Â $ 291 Â Â $ 235 Â Variable lease cost Â 4 Â Â Â Â â€” Â Â Â 12 Â Â Â â€” Â Short-term lease cost Â 54 Â Â Â 12 Â Â Â 147 Â Â Â 33 Â Total operating lease cost $ 195 Â Â $ 88 Â Â $ 450 Â Â $ 268 Â Â Â Â Â Â Â Â Â Â Â Â Supplemental cash flow information related to leases was as follows (in thousands):Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Operating cash flows from operating leases $ 248 Â Â $ 264 Â Â Â Â Â Â Â The following is a schedule by year of future maturities of the Company's operating lease liabilities as of September 30, 2024 (in thousands):Â Â Â Â 2024 (remainder of the year) $ 64 Â 2025 Â 526 Â 2026 Â 751 Â 2027 Â 861 Â 2028 Â 942 Â Thereafter Â 665 Â Total lease payments Â 3,809 Â Less interest Â (780) Total $ 3,029 Â Other CommitmentsThe Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies as well as other services and products for operating purposes, which are generally cancelable upon written notice. As of September 30, 2024, the Companyâ€™s non-cancelable other commitments aggregated $2.8 million.Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. 12 Â Note 7. Stockholdersâ€™ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of Preferred Stock. Public Offering of Common StockOn May 9, 2024, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million.Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded WarrantsOn October 2, 2023, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other offering expenses. Concurrently, the Company also completed the closing of 1,825,000 shares of its common stock and 1,175,000 pre-funded warrants in a private offering pursuant to a securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99, for total gross proceeds of approximately $60.0 million. In aggregate, the Company received $129.0 million of gross proceeds less offering costs of $8.2 million. The Company is not required under any circumstance to settle any of the pre-funded warrants for cash, and therefore classified the pre-funded warrants as permanent equity.Securities Purchase AgreementOn December 16, 2022, the Company entered into a Securities Purchase Agreement for a private placement (Private Placement) with certain entities and members of management (collectively, Purchasers). Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers warrants to purchase up to an aggregate of 22,598,870 shares of the Companyâ€™s common stock, at a purchase price of $0.4425 per warrant. The closing of the Private Placement occurred on May 8, 2023 (the Issue Date), following the satisfaction of certain closing conditions, including the completion of enrollment in the randomized withdrawal period of Study C602. The Company received gross proceeds of $10.0 million for the sale and issuance of warrants to purchase common stock.The warrants were separated into two tranches with 8,598,870 Tranche A Warrants with an exercise price of $1.75 per share and aggregate proceeds of up to approximately $15.0 million, and 14,000,000 Tranche B Warrants with an exercise price of $2.50 per share and aggregate proceeds of up to $35.0 million. The Tranche A warrants were immediately exercisable and were required to be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of Study C602. On September 26, 2023, the Company announced positive top-line data and subsequently received $15.0 million from the exercise of the Tranche A warrants. The Tranche B warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance or 30 days following receipt of FDA approval of DCCR for the treatment of PWS. Through September 30, 2024, certain investors had exercised their Tranche B warrants and the Company has received $22.7 million. The receipt of the aggregate exercise price of up to $12.3 million for the remaining Tranche B warrants is contingent upon the exercise of such warrants. Underwritten Public Offering On March 31, 2022, the Company sold 2,666,667 shares of its common stock at a public offering price of $3.75 per share, and for certain investors, in lieu of common stock, pre-funded warrants (the 2022 pre-funded warrants) to purchase 1,333,333 shares of its common stock at a public offering price $3.60 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.15 per share exercise price for each 2022 pre-funded warrant. The March 2022 pre-funded warrants are immediately exercisable and may be exercised at any time until all of the March 2022 pre-funded warrants are exercised in full. Each share of common stock or March 2022 pre-funded warrant was sold together with one, immediately exercisable, common warrant (the 2022 common warrants) with a five-year term to purchase one share of common stock at an exercise price of $4.50 per share. The net proceeds of the offering were $13.8 million, after deducting the underwriting discount and other offering expenses. The Company is not required under any circumstance to settle any of the 2022 pre-funded warrants or the 2022 common warrants for cash, and therefore classified both types of warrants as permanent equity.Through September 30, 2024, 2,145,073 of the March 2022 common warrants had been exercised for gross proceeds of $9.7 million and 581,850 warrants were exercised using the cashless exercise option with no proceeds to the Company. As of September 13 Â 30, 2024, 1,273,077 of the March 2022 common warrants remain outstanding. All 1,333,333 of the March 2022 pre-funded warrants were exercised in 2023 using the cashless exercise option with no additional proceeds received by the Company.At the Market Offering In July 2021, the Company entered into a Controlled Equity Offering Sales Agreement under which the Company was able to sell shares of its common stock having an aggregate offering price of up to $25.0 million from time to time in any method permitted by law deemed to be an "at-the-market" Rule 415 under the Securities Act of 1933, as amended. The Controlled Equity Offering Sales Agreement was terminated in connection with the October 2, 2023 financing. While active, the Company sold 1,877,170 shares of common stock through the at the market program, totaling $7.4 million in net proceeds.On July 19, 2024, the Company entered into the Sales Agreement with Jefferies, pursuant to which the Company may offer and sell up to $150.0 million of shares of its common stock, from time to time, through Jefferies.The Company will pay Jefferies a commission of 3.0% of the aggregate gross proceeds from the sale of shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any shares under the Sales Agreement. The offering of the shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by Jefferies or the Company, as

permitted therein. Common Stock Warrants As of September 30, 2024 and December 31, 2023, the following table summarizes the Company's outstanding common stock warrants:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Expiration Date Common stock warrants Â Â 7,904 Â Â $ 388.94 Â Â Â 7,904 Â Â $ 388.94 Â Â November 2024 March 2022 Common warrants Â Â 1,273,077 Â Â $ 4.50 Â Â Â 1,929,066 Â Â $ 4.50 Â Â March 2027 May 2023 Tranche A pre-funded warrants Â Â 1,250,647 Â Â $ 0.01 Â Â Â 2,758,281 Â Â $ 0.01 Â Â November 2026 May 2023 Tranche B warrants Â Â 4,935,305 Â Â $ 2.50 Â Â Â 6,750,000 Â Â $ 2.50 Â Â November 2026Â (1) May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â $ 0.01 Â Â Â 451,632 Â Â $ 0.01 Â Â November 2026 October 2023 pre-funded warrants Â Â 250,000 Â Â $ 0.01 Â Â Â 1,175,000 Â Â $ 0.01 Â Â N/A Total Â Â 8,168,565 Â Â Â Â Â Â 13,071,883 Â (1) Subject to earlier expiration as described above.Equity Incentive Plans 2014 PlanThe Company maintains the 2014 Equity Incentive Plan (the 2014 Plan). Under the 2014 Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the 2014 Plan may be incentive stock options (ISOs) or nonqualified stock options (NSOs). ISOs may be granted only to Company employees, including officers and directors. The Board has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Performance-based grants have vesting contingent upon the achievement of certain performance criteria related to the Companyâ€™s commercialization of its therapeutics. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board. On January 17, 2024, the Company filed a Registration Statement on Form S-8 which registered an additional 1,000,000 shares automatically available for issuance under the 2014 Plan as of December 31, 2023. On June 6, 2024, the stockholders approved the Amended and Restated 2014 Plan which included an increase of 2,000,000 shares, which became immediately available for grant and issuance. As of September 30, 2024, a total of 609,179 shares are available for future grant under the 2014 Plan. 14 Â Inducement PlanThe Company maintains the 2020 Inducement Equity Incentive Plan (the Inducement Plan). The Inducement Plan provides for the grant of equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2014 Plan.In accordance with Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individualsâ€™ bona fide period of non-employment with the Company), as an inducement material to the individualsâ€™ entry into employment with the Company, or, to the extent permitted by Rule 5635(c)(3) of the Nasdaq Listing Rules, in connection with a merger or acquisition. On January 31, 2024, the Company filed a Registration Statement on Form S-8 which registered 500,000 shares available for issuance under the Inducement Plan, which became available for issuance following approval of the Board of Directors on January 24, 2024.As of September 30, 2024, a total of 5,318 shares are available for future grant under the Inducement Plan. Stock-based compensation expenseThe Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements during any of the periods presented.Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development $ 18,516 Â Â $ 935 Â Â $ 23,682 Â Â $ 1,587 Â General and administrative Â 38,082 Â Â Â 1,266 Â Â Â 46,521 Â Â Â 2,449 Â Total $ 56,598 Â Â $ 2,201 Â Â $ 70,203 Â Â $ 4,036 Â Stock OptionsThe Company granted options to purchase 288,850 and 77,000 shares of the Companyâ€™s common stock to employees during the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company granted options to purchase 1,369,230 of the Company's common stock to employees and a consultant, and during the nine months ended September 30, 2023, the Company granted 1,663,454 of the Company's common stock to employees. There were no performance-based options granted during the three and nine months ended September 30, 2024 and 2023, respectively. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â 2024 Â 2023 Â 2024 Â 2023 Expected life (years) 6.1 Â 5.3-6.0 Â 5.8-6.1 Â 5.3-6.0 Risk-free interest rate 3.7%-3.8% Â 4.0%-4.4% Â 3.7%-4.6% Â 3.5%-4.4% Volatility 121% Â 98%-100% Â 121%-124% Â 98%-100% Dividend rate â€”Â Â % Â â€”Â Â % Â â€”Â Â % Â â€”Â Â % The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates: â€¢Expected life: The expected life of stock options represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected life of the Companyâ€™s service-based stock options has been determined utilizing the â€œsimplified methodâ€, based on the average of the contractual term of the options and the weighted-average vesting period. The expected life for the performance-based options was determined based on consideration of the contractual term of the stock options, an estimate of the date the performance criteria would be met and expectations of employee behavior.â€¢Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected life of the stock options. 15 Â â€¢Volatility: The estimated volatility rate is based on the volatilities of the Companyâ€™s common stock for a historical period equal to the expected life of the stock options.â€¢Dividend rate: The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The following table summarizes stock option transactions for the nine months ended September 30, 2024 which were for awards issued under the 2014 Plan and the Inducement Plan: Â Â Â Number ofOptions Â Â Weighted-AverageExercisePrice per Â Â WeightedAverageRemainingContractualTerm Â Â Aggregate Intrinsic Value Â Â Â Outstanding Â Â Share Â Â (in years) Â Â (in thousands) Â Balance at January 1, 2024 Â Â 2,369,665 Â Â $ 11.56 Â Â Â 8.72 Â Â $ 70,834 Â Options granted Â Â 1,369,230 Â Â Â 42.91 Â Â Â Â Â Â Â Options exercised Â Â (171,520) Â Â 7.59 Â Â Â Â Â Â Â Options canceled/forfeited Â Â (44,124) Â Â 42.30 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â Options exercisable at September 30, 2024 Â Â 1,116,184 Â Â $ 15.67 Â Â Â 7.40 Â Â $ 41,095 Â Options vested and expected to vest at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â The weighted-average grant date fair value of options granted was $37.84 and $3.80 per share for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to stock options that are likely to vest was $50.1 million, which is expected to be recognized over the weighted-average remaining vesting period of 2.7 years. Restricted Stock Units There were 1,239,375 performance-based restricted stock units and 366,625 restricted stock units granted to employees and a director during the three months ended September 30, 2024 and zero granted during the three months ended September 30, 2023. During the nine months ended September 30, 2024, there were 1,249,375 performance-based restricted stock units and 758,155 restricted stock units granted to employees and directors. During the nine months ended September 30, 2023, 414,710 restricted stock units were granted to employees. The shares were valued based on the Companyâ€™s common stock price on the grant date.The following table summarizes restricted stock unit transactions for the nine months ended September 30, 2024 as issued under the 2014 Plan: Â Â Number ofRestricted Stock Units Â Â Weighted-AverageGrant-Date Fair Value per Share Â Outstanding at January 1, 2024 Â Â 15,534 Â Â $ 43.92 Â Restricted stock units granted Â Â 2,007,530 Â Â $ 46.47 Â Restricted stock units vested Â Â (950,534) Â $ 45.81 Â Restricted stock units canceled/forfeited Â Â - Â Â $ 0.00 Â Outstanding at September 30, 2024 Â Â 1,072,530 Â Â $ 47.02 Â The weighted-average grant-date fair value of all restricted stock units granted during the nine months ended September 30, 2024 and 2023 was $46.47 and $5.25, respectively. The fair value of all restricted stock units vested during the nine months ended September 30, 2024 and 2023 was $44.67 million and $23,000, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to restricted stock units was $34.5 million, which is expected to be recognized over the weighted-average remaining vesting period of 0.4 years. 74,250 restricted stock units vested on September 30, 2024 and are included in the Restricted stock units vested line item above. The shares of common stock were subsequently issued after September 30, 2024 and therefore are not included in the outstanding common stock as of September 30, 2024.2014 Employee Stock Purchase Plan The Companyâ€™s board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan (ESPP). The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of 1,864 shares of the Companyâ€™s common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual 16 Â increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of: â€¢1.0% of the outstanding shares of the Companyâ€™s common stock on the first day of such year;â€¢3,729 shares; or â€¢such amount as determined by the board of directors. As of September 30, 2024, there were no purchases by employees under this plan. Â Note 8. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding during the period. Shares of common stock that are potentially issuable for little or no cash consideration at issuance, such as the Company's pre-funded warrants issued in March 2022 and October 2023 and in connection with the exercise of certain May 2023 Tranche A and Tranche B warrants, are considered outstanding common stock and are included in the calculation of basic and diluted net loss per share in connection with ASC 260 Earnings Per Shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the exercise or vesting of common stock awards and exercise of common stock warrants that are not pre-funded. The Company applies the two-class method to calculate basic and diluted earnings per share as its warrants issued in March 2022, May 2023 and October 2023 are participating securities. However, the two-class method does not impact the net loss per share of common stock as the March 2022, May 2023 and October 2023 common warrants issued do not participate in losses. For the three and nine months ended September 30, 2024 and 2023, the effect of issuing potential common stock is anti-dilutive due to the net losses in those periods and therefore the number of shares used to compute basic and diluted net loss per share are the same in each of those periods. The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock Â Â 39,360,966 Â Â Â 10,287,620 Â Â Â 35,824,742 Â Â Â 9,206,650 Â March 2022 pre-funded warrants Â Â - Â Â Â 1,122,819 Â Â Â - Â Â Â 1,227,670 Â May 2023 Tranche A pre-funded warrants Â Â 1,816,427 Â Â Â 26,309 Â Â Â 2,154,299 Â Â Â 8,866 Â May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â Â - Â Â Â 451,632 Â Â Â - Â October 2023 pre-funded warrants Â Â 250,000 Â Â Â - Â Â Â 486,496 Â Â Â - Â Total Â Â 41,879,025 Â Â Â 11,436,748 Â Â Â 38,917,169 Â Â Â 10,443,186 Â The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares): Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Warrants issued to 2010/2012 convertible noteÂ Â Â holders to purchase common stock Â Â 6,804 Â Â Â 6,804 Â Warrants issued to underwriter to purchase common stock Â Â 1,100 Â Â Â 1,100 Â 2018 PIPE warrants Â Â - Â Â Â 34,241 Â March 2022 common warrants Â Â 1,273,077 Â Â Â 2,130,656 Â May 2023 Tranche A warrants Â Â - Â Â Â 2,867,908 Â May 2023 Tranche B warrants Â Â 4,935,305 Â Â Â 14,000,000 Â Options to purchase common stock Â Â 3,523,251 Â Â Â 2,300,412 Â Outstanding restricted stock units Â Â 1,072,530 Â Â Â 424,244 Â Total Â Â 10,812,067 Â Â Â 21,765,365 Â Â 17 Â Note 9. Subsequent EventsÂ The Company has evaluated its subsequent events from September 30, 2024 through the date these condensed consolidated financial statements were issued and has determined that there are no subsequent events disclosure required. 18 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The interim consolidated financial statements included in this Quarterly Report on Form 10-Q and this Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2023, and the related Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, contained in our Form 10-K for the year ended December 31, 2023. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are subject to risks and uncertainties, including those set forth in Part II â€“ Other Information, Item 1A. Risk Factors below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results. Business Overview We are focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Our lead candidate is DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). We have Fast-Track and Breakthrough Therapy designations for DCCR for the treatment of PWS in the United States (U.S.) and orphan designation for the treatment of PWS in the U.S. as well as in the European Union (E.U.). DCCR has been evaluated in a Phase 3 study (C601 or DESTINY PWS), a 3-month randomized, double-blind placebo-controlled study, which completed enrollment in January 2020, with 127 patients at 29 sites in the U.S. and U.K. Participants who completed treatment in DESTINY PWS were eligible to receive DCCR in a long-term open-label extension period (C602). Top line results from DESTINY PWS were announced in June 2020. Although the trial did not meet its primary endpoint of change from baseline in hyperphagia, significant improvements were observed in two of three key secondary endpoints. In January 2022, the FDA recommended that additional controlled data be included in a New Drug Approval (NDA) submission and in October 2022, we initiated the RW period of Study C602. This was a multi-center, randomized, double-blind, placebo-controlled study of DCCR in 77 patients with PWS at 17 sites in the U.S. and 5 sites in the U.K. This RW period consisted only of patients enrolled in Study C602 and did not enroll any new patients. In September 2023, we announced positive statistically significant top-line results from the RW period of Study C602. In April 2024, the FDA granted Breakthrough Therapy Designation for DCCR, the first ever breakthrough designation for a drug being developed for PWS, in June 2024 we submitted an NDA for DCCR to the FDA, and on August 27, 2024, we announced the FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. Critical Accounting Policies and Significant Judgments and Estimates Our managementâ€™s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our critical accounting estimates and significant accounting policies are more fully described in Note 3 of our most recent Form 10-K and including the policy below. Marketable Securities The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholdersâ€™ equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented. 19 Â Results of Operations Comparison of the three months ended September 30, 2024 and 2023 Â Â Â Three Months Ended September 30, Â Â Increase (decrease) Â Â Â 2024 Â Â 2023 Â Â Amount Â Â Percentage Â Â Â (in thousands) Â Â Â Â Â Â Â Operating expenses Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 30,138 Â Â $ 6,043 Â Â $ 24,095 Â Â Â 399 % General and administrative Â Â 49,197 Â Â Â 3,318 Â Â Â 45,879 Â Â Â 1383 % Change in fair value of contingent consideration Â Â 877 Â Â Â 1,021 Â Â Â (144) Â Â 14 % Total operating expenses Â Â 80,212 Â Â Â 10,382 Â Â Â 69,830 Â Â Â 673 % Operating loss Â Â (80,212) Â Â (10,382) Â Â (69,830) Â Â 673 % Other income (expense), net Â Â Â Â Â Â Â Â Â Â Â Change in fair value of warrants liabilities Â Â - Â Â Â (653) Â Â 653 Â Â Â Â 100 % Interest income, net Â Â 3,596 Â Â Â 174 Â Â Â 3,422 Â Â Â 1967 % Total other income (expense), net Â Â 3,596 Â Â Â (479) Â Â 4,075 Â Â Â 851 % Net loss Â $ (76,616) Â $ (10,861) Â $ (65,755) Â Â 605 % Revenue To date, we have earned no revenue from the commercial development and sale of novel therapeutic products. Research and development expense Research and development expense was $30.1 million, which includes $18.5 million of non-cash stock-based compensation, for the three months ended

September 30, 2024, compared to $6.0 million, which includes $0.9 million of non-cash stock-based compensation, in the same period of 2023. Personnel and other associated costs increased $2.4 million as we hired additional employees in support of our research and development activities. Costs in support of our NDA submission increased $2.7 million and we invested $1.3 million in supply chain activities in preparation for commercial launch. The cadence of our research and development expenditures will fluctuate depending upon the state of our clinical programs, the timing of manufacturing and other projects necessary to support the submission of an NDA and prepare for commercial launch. The $17.6 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon the acceptance by the FDA of the NDA submission and fully vest upon the approval by the FDA. General and administrative expense General and administrative expense was $49.2 million, which includes $38.1 million of non-cash stock-based compensation, for the three months ended September 30, 2024, compared to $3.3 million, which includes $1.3 million of non-cash stock-based compensation, in the same period of 2023. Personnel and associated costs increased $3.0 million as we have hired additional employees in preparation for commercial launch and in support of our increased business activities. Professional services expenses and other program costs associated with preparation for commercial launch, including medical affairs activities, increased by $5.9 million. The $36.8 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon acceptance by the FDA of the NDA submission and fully vest upon approval by the FDA. Change in fair value of contingent consideration We are obligated to make cash payments up to a maximum of $21.2 million to the former Essentialis stockholders upon the achievement of certain future commercial milestones associated with the sales of DCCR in accordance with the terms of our merger agreement with Essentialis. The fair value of the liability for the contingent consideration payable by us achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue in future years was estimated to be $14.5 million as of September 30, 2024, a $0.9 million increase from the estimate as of June 30, 2024. During the three months ended September 30, 2023, the estimate increased by $1.1 million from the $9.4 million estimate as of June 30, 2023. Other income, net We had other income, net of approximately $3.6 million in the three months ended September 30, 2024, compared to other expense, net of approximately $479,000 during the three months ended September 30, 2023. The increase was primarily due to an 20 Â increase in interest income driven by higher cash and cash equivalents, marketable securities and long-term marketable securities during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Comparison of the nine months ended September 30, 2024 and 2023 Â Â Â Nine months ended September 30, Â Â Increase (decrease) Â Â Â 2024 Â Â 2023 Â Â Amount Â Â Percentage Â Â Â (in thousands) Â Â Â Â Â Â Â Operating expenses Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 57,082 Â Â Â 16,500 Â Â $ 40,582 Â Â Â 246 % General and administrative Â Â 68,558 Â Â Â 9,341 Â Â Â 59,217 Â Â Â 634 % Change in fair value of contingent consideration Â Â 2,915 Â Â Â 1,633 Â Â Â 1,282 Â Â Â 79 % Total operating expenses Â Â 128,555 Â Â Â 27,474 Â Â Â 101,081 Â Â Â 368 % Operating loss Â Â (128,555) Â Â (27,474) Â Â (101,081) Â Â 368 % Other income (expense), net Â Â Â Â Â Â Â Â Â Â Â Â Â Change in fair value of warrants liabilities Â Â - Â Â Â (652) Â Â 652 Â Â Â 100 % Interest income, net Â Â 8,687 Â Â Â 434 Â Â 8,253 Â Â Â 1902 % Total other income (expense), net Â Â 8,687 Â Â Â (218) Â Â 8,905 Â Â Â 4085 % Net loss Â $ (119,868) Â $ (27,692) Â $ (92,176) Â Â 333 % Revenue To date, we have earned no revenue from the commercial development and sale of novel therapeutic products. Research and development expense Research and development expense was $57.1 million, which includes $23.7 million of non-cash stock-based compensation, for the nine months ended September 30, 2024, compared to $16.5 million, which includes $1.6 million of non-cash stock-based compensation, in the same period of 2023. Personnel and associated costs increased $4.9 million as we hired additional employees in support of our research and development activities. Costs in support of our NDA submission increased $9.9 million and we invested $3.7 million in supply chain activities in preparation for commercial launch. The cadence of our research and development expenditures will fluctuate depending upon the state of our clinical programs, the timing of manufacturing and other projects necessary to support the submission of an NDA and prepare for commercial launch. The $22.1 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon the acceptance by the FDA of the NDA submission and fully vest upon the approval by the FDA. General and administrative expense General and administrative expense was $68.6 million, which includes $46.5 million of non-cash stock-based compensation, for the nine months ended September 30, 2024, compared to $9.3 million, which includes $2.4 million of non-cash stock-based compensation, in the same period of 2023. Personnel and associated costs increased $5.5 as we have hired additional employees in preparation for commercial launch and in support of our increased business activities. Professional services expenses and other program costs associated with preparation for commercial launch, including medical affairs activities, increased by $9.4 million. The $44.1 million of additional non-cash stock-based compensation being recognized in the period is predominantly due to performance-based RSU grants which partially vested upon the acceptance by the FDA of the NDA submission and fully vest upon the approval by the FDA. Change in fair value of contingent consideration We are obligated to make cash payments up to a maximum of $21.2 million to the former Essentialis stockholders upon the achievement of certain future commercial milestones associated with the sales of DCCR in accordance with the terms of our merger agreement with Essentialis. The fair value of the liability for the contingent consideration payable by us achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue in future years was estimated to be $14.5 million as of September 30, 2024, a $2.9 million increase from the estimate as of December 31, 2023. During the nine months ended September 30, 2023, the estimate increased by $1.6 million from the $8.9 million estimate as of December 31, 2022. 21 Â Other income, net We had other income, net of approximately $8.7 million in the nine months ended September 30, 2024, compared to other expense, net of approximately $0.2 million during the nine months ended September 30, 2023. The increase was primarily due to an increase in interest income driven by higher cash and cash equivalents, marketable securities and long-term marketable securities during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Liquidity and Capital Resources We used $45.1 million of cash in operating activities and had a net loss of $119.9 million during the nine months ended September 30, 2024. We had an accumulated deficit of $396.3 million at September 30, 2024 as a result of having incurred losses since our inception. We had $48.4 million in cash and cash equivalents, $208.4 million of marketable securities, $27.9 million of long-term marketable securities and $243.2 million of working capital on September 30, 2024. As of September 30, 2024, we had lease obligations totaling $3.0 million to be paid through August 2029, consisting of two operating leases for office space in Redwood City, California. We have financed our operations principally through issuances of equity securities. In May 2024, we closed an underwritten public offering of 3,450,000 shares of our common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses of $9.7 million. In July 2024, we entered into an Open Market Sale AgreementSM with Jefferies LLC, as sales agent ("Jefferies"), pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $150,000,000. Previously in October 2023, we announced the closing of the underwritten public offering of 3,450,000 shares of our common stock at a public offering of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other estimated offering expenses. We also announced the closing shares of our common stock and pre-funded warrants in a concurrent private offering pursuant to the securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99, for gross proceeds of approximately $60.0 million. In aggregate, we received $129.0 million of gross proceeds from this financing. In December 2022, we entered into a securities purchase agreement providing for the sale of up to $60.0 million in warrants and the common stock issuable upon the exercise thereof. Through September 30, 2024, we have received $10.0 million from the sale of these warrants and $37.7 million in proceeds from the exercise of certain of these warrants. Warrants with an aggregate exercise price of $12.3 million are still outstanding. We expect to continue incurring losses for the foreseeable future and may require additional capital to complete our clinical trials, pursue product development initiatives and penetrate markets for the sale of our products. We believe that we will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the access to such capital resources is uncertain and is not assured. In the future, if we are unable to secure additional capital, we may be required to curtail our clinical trials and development of new products and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in our efforts to complete clinical trials and commercialize our products, which is critical to the realization of our business plan and our future operations. Cash flows The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net cash used in operating activities Â $ (45,105) Â $ (18,626) Net cash used in investing activities Â Â (232,125) Â Â Â€" Â Net cash provided by financing activities Â Â 155,962 Â Â Â 56,461 Â Net (decrease) increase in cash and cash equivalents Â $ (121,268) Â $ 37,835 Â Â 22 Â Net cash used in operating activities During the nine months ended September 30, 2024, operating activities used net cash of $45.1 million, which was primarily due to the net loss of $119.9 million, less non-cash expense of $70.2 million for stock-based compensation, $1.5 million for depreciation and amortization, $0.3 million for non-cash lease expense, $2.9 million related to the change in fair value of contingent consideration, and $3.5 million added back for accretion of premium/discount on marketable securities. Additionally, usage of cash during the nine months ended September 30, 2024 increased by $3.4 million due to changes in operating assets and liabilities. During the nine months ended September 30, 2023, operating activities used net cash of $18.6 million, which was primarily due to the net loss of $27.7 million less non-cash expense of $4.0 million for stock-based compensation, $1.5 million for depreciation and amortization, $0.3 million for non-cash lease expense, and $2.3 million related to the change in fair value of common stock warrants and contingent consideration. Additionally, usage of cash during the nine months ended September 30, 2023 decreased by $1.0 million due to changes in operating assets and liabilities. Net cash used in investing activities During the nine months ended September 30, 2024, we used $308.9 million for purchases of marketable securities and $0.2 million for purchases of property and equipment. We received proceeds of $77.0 million from maturities of marketable securities. During the nine months ended September 30, 2023, there were no investing activities. Net cash provided by financing activities During the nine months ended September 30, 2024, we received $149.0 million from the sale of common stock, net of issuance costs and $5.7 million from the exercise of common stock and pre-funded stock warrants. We also received $1.3 million from the exercise of stock options. During the nine months ended September 30, 2023, we received $33.4 million from the sale and issuance of warrants pursuant to the Securities Purchase Agreement and $16.0 million prior to and for the issuance of common stock in conjunction with our October 2, 2023 financing. We also received net proceeds of $7.1 million from the sale of common stock through the at the market program. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements. Item 3. Quantitative and Qualitative Disclosures about Market Risk There have not been any material changes to our exposure to market risk during the nine months ended September 30, 2024. For additional information regarding market risk, refer to the Qualitative and Quantitative Disclosures About Market Risk section of the Form 10-K. Item 4. Controls and Procedures (a) Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (Exchange Act), is recorded, processed, summarized and reported within the time periods specified in U.S. Securities and Exchange Commission, or SEC, rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective. 23 Â (b) Changes in Internal Control over Financial Reporting There have been no changes to our internal control over financial reporting that occurred during the three months ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, even if determined effective and no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives to prevent or detect misstatements. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. 24 Â PART II â€" OTHER INFORMATION Item 1. Legal Proceedings We may, from time to time, be party to litigation and subject to claims that arise in the ordinary course of business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We currently believe that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Item 1A. Risk Factors An investment in our securities has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial conditions and/or operating results. If any of these risks actually occur, our business, operating results and financial condition could be harmed, and the value of our stock could go down. This means you could lose all or a part of your investment. We have included in Part I, Item 1A of our Form 10-K, a description of certain risks and uncertainties that could affect our business, future performance or financial condition (the Risk Factors). There have been no material changes from the disclosure provided in the Form 10-K with respect to the Risk Factors. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information We have social media posts at Twitter (X) - @SolenoTX and LinkedIn - Soleno Therapeutics, Inc. It is possible that information we post on social media channels could be deemed to be material information. The information on, or that may be accessed through, our website and social media channels is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q. (c) Insider Adoption or Termination of Trading Arrangements The following provides information regarding Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, each a "10b5-1 Plan") adopted in the third quarter of 2024 by any director or officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934 ("Section 16 Director or Officer"): Anish Bhatnagar, our Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors adopted a 10b5-1 Plan on September 6, 2024. Mr. Bhatnagar's 10b5-1 Plan provides for the potential sale of up to 300,000 shares of 25 Â our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Jim Mackaness, our Chief Financial Officer, adopted a 10b5-1 Plan on September 6, 2024. Mr. Mackaness' 10b5-1 Plan provides for the potential sale of up to 60,000 shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Patricia C. Hirano, our Senior Vice President, Regulatory Affairs, adopted a 10b5-1 Plan on September 13, 2024. Ms. Hirano's 10b5-1 Plan provides for the potential sale of up to 124,026 shares of our common stock, and expires on September 13, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest. Kristen Yen, our Senior Vice President, Clinical Operations, adopted a 10b5-1 Plan on September 13, 2024. Ms. Yen's 10b5-1 Plan provides for the potential sale of up to 95,089 shares of our common stock, and expires on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest.These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). Certain of our Section 16 Directors or Officers may participate in employee stock purchase plans, 401(k) plans or dividend investment plans of us that have been designed to comply with Rule 10b5-1(c). No non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) were adopted by any Section 16 Director or Officer during the third quarter of 2024. Additionally, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any Section 16 Director or Officer in the third quarter of 2024. Item 6. Exhibits See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated herein by reference. 26 Â EXHIBIT INDEX Â Â Â Â Incorporated by Reference from ExhibitNumber Â

Description of Document Â Registrantâ€™sForm Â Date Filedwith the SEC Â ExhibitNumber Â FiledHerewith Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10.1 Â Open Market Sale AgreementSM, dated July 19, 2024, by and between Soleno Therapeutics, Inc. and Jefferies LLC Â 8-K Â July 19, 2024 Â 10.1 Â 31.1 Â Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31.2 Â Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.1â€ Â Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. Â§1350 Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 32.2â€ Â Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. Â§1350 Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â 104 Â Cover Page formatted as Inline XBRL and contained in Exhibit 101.Â Â Â Â Â XÂ â€ The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Date: November 6, 2024 SOLENO THERAPEUTICS, INC. Â Â Â By: /s/ James Mackaness James MackanessChief Financial Officer(authorized officer and principal financial and accounting officer) Â 27 EX-31.1 2 slno-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A) I, Anish Bhatnagar, M.D., certify that: 1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â /s/ Anish Bhatnagar Anish Bhatnagar President, Chief Executive Officer (principal executive officer) Â Â EX-31.2 3 slno-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A) I, James Mackaness, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â /s/ James Mackaness James Mackaness Chief Financial Officer (principal financial and accounting officer) Â Â EX-32.1 4 slno-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission (the â€œReportâ€), Anish Bhatnagar, President, Chief Executive Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: â€¢The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and â€¢The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 6, 2024 Â /s/ Anish Bhatnagar Anish Bhatnagar President, Chief Executive Officer (principal executive officer) Â Â EX-32.2 5 slno-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the â€œCompanyâ€) on Form 10-Q for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission (the â€œReportâ€), James Mackaness, Chief Financial Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: â€¢The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and â€¢The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 6, 2024 Â /s/ James Mackaness James Mackaness Chief Financial Officer (principal financial and accounting officer) Â Â EX-101.SCH 6 slno-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) 3 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) 4 link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) 5 link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) 6 link:presentationLink link:calculationLink link:definitionLink 100110 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Overview link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Liquidity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Warrants - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Warrants - Fair Value of Convertible Preferred Stock Warrant Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Liabilities Liabilities, Fair Value Disclosure [Abstract] Debt Instrument Debt Instrument [Axis] Plan Name Plan Name [Domain] Tax withholding payments for net share-settled equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Summary of Outstanding Common Stock Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Issuance of restricted stock units under equity incentive plans (shares) Issuance Of Restricted Stock Units Shares Under Equity Incentive Plan Issuance of restricted stock units shares under equity incentive plan. Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Unpaid financing costs included in accounts payable and accrued liabilities Unpaid costs for issuing common stock and pre funded warrants. Unpaid Costs for Issuing Common Stock and Pre Funded Warrants Unrecognized stock based compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount May 2023 Tranche A Pre-funded Warrants [Member] Share-Based Payment Arrangement, Tranche One [Member] Tranche A [Member] Reverse stock split Stockholders' Equity, Reverse Stock Split Balances at beginning (shares) Balances at end (shares) Shares, Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Increase in right of use assets Operating Lease Right-Of-Use Asset Increase Operating lease right-of-use asset increase. Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Operating lease, description Lessee, Operating Lease, Description Area of operating lease Area of Real Estate Property 2024 (remainder of the year) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Summary of Changes in Fair Value of Level 3 Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Supplemental disclosure of non-cash operating and financing information Noncash Investing and Financing Items [Abstract] Employee Stock Purchase Plan [Member] Employee Stock [Member] Title and Position [Axis] Class of Warrant or Right Class of Warrant or Right [Axis] Sale of Stock Sale of Stock [Domain] 2018 PIPE Warrants [Member] 2018 PIPE Warrant Liability [Member] Two Thousand Eighteen P I P E Warrant Liability [Member] 2018 PIPE warrant liability. Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line

Items] Entity Central Index Key Entity Central Index Key Proceeds from offering after deducting underwriting discount and other estimated offering expenses Proceeds From Offering After Deducting Underwriting Discount And Other Estimated Offering Expenses Proceeds from offering after deducting underwriting discount and other estimated offering expenses. Accrued clinical trial site costs Increase Decrease In Accrued Clinical Trial Site Costs Increase decrease in accrued clinical trial site costs. Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Common stock, shares issued Common Stock, Shares, Issued Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Expected Dividend Yield [Member] Measurement Input, Expected Dividend Rate [Member] Prepaid expenses, other current assets and other assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregrate offering price. Aggregrate Offering Price Aggregrate Offering Price Overview Business Description and Basis of Presentation [Text Block] Income Statement [Abstract] Percentage of aggregate gross proceeds to pay commission. Percentage of Aggregate Gross Proceeds to Pay Commission Percentage of aggregate gross proceeds to pay commission Entity Address, State or Province Entity Address, State or Province Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Sale agreement amount Sale Of Stock Authorized Amount Sale of stock authorized amount. Liability Class Liability Class [Axis] Cover [Abstract] Earnings Per Share, Basic, Total Net loss per common share basic Earnings Per Share, Basic Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating expenses Operating Expenses [Abstract] Increase in lease liability Increase In Operating Lease Liability Increase in operating lease liability. Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Aggregate Intrinsic Value [Abstract] Share based compensation arrangement by share based payment award options non vested aggregate intrinsic value. Common stock purchase liability. Common Stock Purchase Liability Common stock purchase liability Weighted-Average Exercise Price per Share Sharebased Compensation Arrangementby Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward] Stock-based compensation expense Share-Based Payment Arrangement, Expense 2022 Pre-funded Warrants [Member] Two Thousand Twenty Two Pre Funded Warrants [Member] Two Thousand Twenty Two Pre Funded Warrants. Going Concern And Managements Plans [Text Block] Going concern and managementâ€™s plans. Liquidity Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets Assets, Current [Abstract] Asset Purchase Asset Purchase [Axis] Asset purchase. Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Restricted stock units canceled/forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options exercisable at end of period (shares) Accumulated other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Operating lease, term of contract Lessee, Operating Lease, Term of Contract Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Other non-cash reconciling items Other Operating Activities, Cash Flow Statement Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] May two thousand twenty three tranche b warrants. May Two Thousand Twenty Three Tranche B Warrants [Member] May 2023 Tranche B warrants May 2023 Tranche B Warrants [Member] Summary of Financial Instruments Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vesting [Axis] Vesting Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Stock Options [Member] Warrants expire term prior to anniversary date of issuance Warrants Expire Term Prior To Anniversary Date Of Issuance Warrants expire term prior to anniversary date of issuance Unrealized loss on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Input Type Measurement Input Type [Domain] Statement of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member] Convertible Debt Securities [Member] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Number of common stock purchased upon issuance of warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Employee-related Liabilities, Current, Total Accrued compensation Employee-related Liabilities, Current Stock units granted Restricted stock units granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Options exercisable at end of period Share based compensation arrangement by share based payment award options exercisable aggregate intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value Subsequent Event Type [Axis] Subsequent Event Type Options to Purchase Common Stock [Member] Equity Option [Member] Total other income (expense), net Nonoperating Income (Expense) Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Flag Amendment Flag Warrant issuance description Class Of Warrant Or Right Exercise Price Description Class of Warrant or Right, Exercise Price Description Long-term lease liabilities Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Text Block [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] Additional paid-in-capital Additional Paid in Capital, Common Stock Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Net loss Net loss Exercise of stock options (shares) Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options (shares) Per share exercise price for pre-funded warrant Per share exercise price for pre-funded warrant Per Share Exercise Price For Pre Funded Warrant Per share exercise price for Pre-funded warrant. Research and Development [Member] Research and Development Expense [Member] 2023 Tranche B Warrants [Member] 2023 Tranche B warrants [Member] Two Thousand Twenty Three Tranche B Warrants Member Two thousand twenty three tranche B warrants. Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and Administrative Expense, Total General and administrative General and Administrative Expense Contractual term of option Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred Stock, Shares Issued Preferred stock, shares issued Cash paid for amounts included in measurement of lease liabilities. Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases Operating Lease, Payments Proceeds from exercise of stock options Proceeds from Stock Options Exercised 2020 Inducement Equity Incentive Plan [Member] Two Thousand Twenty Inducement Equity Incentive Plan [Member] Two thousand twenty inducement equity incentive plan. Adjustments to Additional Paid in Capital, Warrant Issued Issuance of common stock warrants, net of issuance costs Number of shares purchases by employees Stock Issued During Period, Shares, Employee Stock Purchase Plans Ownership interest of voting rights of all classes of stock (percent) Ownership Interest Percentageof Voting Rightsof Stock Ownership interest, percentage of voting rights of stock. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Options exercisable at end of period (in dollars per share) Options canceled/forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Controlled Equity Offering Sales Agreement [Member] Controlled Equity Offering Sales Agreement [Member] Controlled equity offering sales agreement. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Number of shares available for issuance under the plan on the first day of each year Common stock, shares outstanding Common Stock, Shares, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Antidilutive Securities Antidilutive Securities [Axis] Schedule of weighted-average common shares outstanding [Table Text Block] Schedule of Weighted-Average Common Shares Outstanding Gross proceeds from common stock public offering Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Proceeds from issuance or sale of equity Summary of Restricted Stock Unit Transactions Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease, expiration date Lease Expiration Date Operating lease, extension expiration Lessee, Operating Lease, Extension Expiration, Month and Year Lessee, operating lease, extension expiration, month and year. Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Restricted stock units vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Restricted Stock units Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Statistical Measurement Statistical Measurement [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Operating lease cost Operating Lease, Cost Total assets Total assets Assets, Fair Value Disclosure Total operating lease cost Lease, Cost Derivative Financial Instruments, Liabilities [Member] Derivative Financial Instruments, Liabilities [Member] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease Director [Member] Board of Directors [Member] Underwritter discount and other offering expenses. Underwritter Discount and Other Offering Expenses Underwriter discount and other offering expenses Number of shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Weighted average grant-date fair value of all restricted stock units granted Restricted stock units granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Future stock-based compensation, requisite service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Offering costs Stock Issued Issuance Costs Stock issued issuance costs. Income Statement Location Statement of Income Location, Balance [Axis] Total assets Assets Expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted stock units vested 2014 Equity Incentive Plan [Member] Two Thousand And Fourteen Equity Incentive Plan [Member] 2014 equity incentive plan. Common stock warrant liability [Member] Common Stock Warrant Liability [Member] Common Stock Warrant Liability [Member] New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Equity [Abstract] Assets Assets, Fair Value Disclosure [Abstract] Less transaction costs Payments of Stock Issuance Costs Proceeds from sale of common stock and pre-funded warrants Proceeds From Sale Of Common Stock And Pre Funded Warrants Proceeds from sale of common stock and pre-funded warrants. Restricted stock units canceled/forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Essentialis, Inc. [Member] Essentialis Inc [Member] Essentialis, Inc. Stockholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] Weighted average remaining vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Options exercisable at end of period Fair value of restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Shares granted to date Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total Performance Based Options Operating lease, weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Fair Value Disclosures [Abstract] AT the market offering. AT the Market Offering [Member] At the Marrket Offering Stock Issued During Period, Value, New Issues Sale of common stock, net of issuance costs Jefferies LLC [Member] Jefferies LLC. Jefferies LLC [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Current liabilities Liabilities, Current [Abstract] Kristen Yen [Member] Kristen Yen [Member] Kristen yen. Document Type Document Type Accounting Standards Update [Axis] Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Schedule of Components of Lease Expense Lease, Cost [Table Text Block] Statement of Stockholders' Equity [Abstract] Balance at the beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development Research and Development Expense Income tax benefits recognized from stock-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Redwood City, California [Member] CALIFORNIA Options granted Number of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Percentage of outstanding stock maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Asset Class [Domain] Subsequent Event Type [Domain] Subsequent Event Type Contractual Term [Member] Measurement Input, Expected Term [Member] Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Patricia C. Hirano [Member] Patricia C. Hirano [Member] Patricia c. hirano. Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs Proceeds from Exercise of Common Stock Warrants and Pre-Funded Common Stock Warrants, Net of Costs Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs. Payments for Rent Rent payments Weighted Average Exercise Price, Balance at the end of period Weighted Average Exercise Price, Balance at the beginning of period Exercise price of warrants exercised Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted Average Exercise Price per Share Proceeds received prior to and for the issuance of common stock. Proceeds Received Prior To And For The Issuance Of Common Stock Proceeds received prior to and for the issuance of common stock Long-term assets Assets, Noncurrent [Abstract] Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Marketable Securities, Current Marketable securities Marketable securities current Warrants and rights immediately exercisable term. Warrants And Rights Immediately Exercisable Term Warrants and rights immediately exercisable term 2022 Common Warrants [Member] Two Thousand Twenty Two Common Warrants [Member] Two Thousand Twenty Two Common Warrants. Warrants and Rights Note Disclosure [Abstract] Underwritten Public Offering [Member] Underwritten Public Offering [Member] Underwritten public offering. 2023 Tranche A Warrants [Member] Two Thousand Twenty Three Tranche A Warrants [Member] Two thousand twenty three tranche A warrants. Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Entity Address, Address Line Two Entity Address, Address Line Two Expiration Date Expiration period Class Of Warrant Or Right Warrants Expiration Month And Year Class of warrant or right warrants expiration month and year. Liabilities and stockholdersâ€™ equity Liabilities and Equity [Abstract] Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Long-term liabilities Liabilities, Noncurrent [Abstract] Sales agreement. Sales Agreement [Member] Sales Agreement [Member] Antidilutive securities excluded from computations of diluted weighted-average shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Asset Purchase Asset Purchase [Domain] Asset purchase. APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Lessee, Operating Lease, Liability, to be Paid, after Year Five Thereafter May two thousand twenty three tranche a warrants. May Two Thousand Twenty Three Tranche A Warrants [Member]

May 2023 Tranche A warrants May 2023 Tranche A Warrants [Member] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Common stock, maximum aggregate purchase price Common Stock Maximum Aggregate Purchase Price Common stock, maximum aggregate value purchase price. Trading Symbol Trading Symbol Total stockholdersâ€™ equity Balances at beginning Balances at ending Equity, Attributable to Parent Issuance of restricted stock units under equity incentive plans Issuance Of Restricted Stock Units Value And Option Exercises Under Equity Incentive Plan Issuance of restricted stock units value and option exercises under equity incentive plan. Exercise of common stock warrants, net of issuance costs (shares) Class Of Warrant Or Right Exercised Class of warrant or right exercised. Warrants exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Warrants outstanding Balance at the end of period, in shares Balance at the beginning of period, in shares Number of Common Warrant Shares Number of Common Shares Outstanding Restricted Stock Units [Member] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Variable lease cost Variable Lease, Cost Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Operating lease, expiration Lessee Operating Lease Month And Year Of Expiration Lessee, operating lease month and year of expiration. Summary of Stock Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Capital stock, shares authorized Capital Units, Authorized Change in value of liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Measurement Input Type Measurement Input Type [Axis] Geographical Geographical [Axis] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Future stock-based compensation for unvested employee options granted and outstanding Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Purchase price contingent liability [Member] Purchase Price Contingent Liability [Member] Purchase price contingent liability. Use of Estimates Use of Estimates, Policy [Policy Text Block] Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Class of Stock [Line Items] Volatility [Member] Measurement Input, Price Volatility [Member] Non-cancelable other commitments Other Commitment Other Commitment, Total Expected dividend yield Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Marketable Securities Marketable Securities, Policy [Policy Text Block] Security Exchange Name Security Exchange Name Schedule of Marketable Securities Classified as Available-for-sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Counterparty Name Counterparty Name [Domain] Fair Value by Liability Class Fair Value by Liability Class [Domain] Total operating expenses Operating Expenses Risk-free Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Non-cash lease expense Noncash Lease Expense Noncash lease expense. Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Cantor [Member] Cantor Fitzgerald And Co [Member] Cantor Fitzgerald and Co. Weighted average grant date fair value per option granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event [Member] Subsequent Event [Member] Maximum [Member] Maximum [Member] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Right-of-use asset Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Operating lease beginning date Lessee Operating Lease Commencement Month And Year Lessee, operating lease commencement month and year. Earnings Per Share, Diluted, Total Net loss per common share diluted Earnings Per Share, Diluted Total liabilities Liabilities Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Issuance of common stock (shares) Stock Issued During Period, Shares, New Issues Sale of common stock, net of issuance costs (shares) Entity Filer Category Entity Filer Category Anish Bhatnagar [Member] Anish Bhatnagar [Member] Anish bhatnagar. Purchases of marketable securities Payments to Acquire Marketable Securities Other income (expense), net Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Less interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less interest Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Options outstanding at end of period Options outstanding at beginning of period Balance at March 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Options vested at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value Share based compensation arrangement by share based payment award options vested aggregate intrinsic value. Common Stock Warrants [Member] Common stock warrants. Common Stock Warrants [Member] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Earnings Per Share [Text Block] Net Loss per Share Entity Emerging Growth Company Entity Emerging Growth Company Accrued clinical trial site costs Accrued Clinical Trial Costs Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Shares issued from sale of common stock Shares Issued From Sale Of Common Stock Shares issued from sale of common stock. Accounting Standards Update 2016-13 [Member] ASU No. 2016-13 [Member] Money Market Funds [Member] Money Market Funds [Member] Other current liabilities Other Liabilities, Current Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average common shares outstanding used to calculate basic net loss per common share Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding used to calculate basic shares Vesting [Domain] Vesting Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Operating lease liabilities Common stock, shares authorized Common Stock, Shares Authorized Tax withholding payments for net share-settled equity awards (shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Proceeds from sale of common stock, net of costs Proceeds from Issuance of Common Stock Proceeds from the sale of common stock, net of issuance costs Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Cash and Cash Equivalents [Abstract] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Options vested and expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Public Offering [Member] Public Offering Options outstanding at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Proceeds received prior to and for the issuance of common stock and pre-funded warrants Proceeds received prior to for issuance of common stock and pre-funded warrants Proceeds received prior to for issuance of common stock and pre-funded warrants General and Administrative [Member] General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Proceeds from Issuance of Warrants Sale and issuance of warrants Estimated Fair Value Estimated Fair Value Debt Securities, Available-for-Sale Accounting Policies [Abstract] Summary of Stock Option and Restricted Stock Unit Transactions Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating lease annually increase percentage. Operating Lease Annually Increase Percentage Rent payments annual increase percentage Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Marketable Securities, Noncurrent Long-term marketable securities Stockholdersâ€™ equity Equity, Attributable to Parent [Abstract] Statement [Table] Statement [Table] Maximum potential cash earnout payments Asset Acquisition Contingent Consideration Arrangements Earn Out Payment Asset acquisition contingent consideration arrangements earn out payment, Options vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Shares issued from sale of pre-funded warrants Shares Issued From Sale Of Pre-Funded Warrants Shares issued from sale of pre-funded warrants. Exercise of common stock warrants and pre-funded common stock warrants Stock Issued During Period, Value, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants Stock issued during period, value, exercise of common stock warrants and pre-funded common stock warrants. Preferred stock, shares authorized Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Fair Value Adjustment of Warrants Change in fair value of stock warrants Change in fair value of warrants liabilities Change in fair value of warrants liabilities Entity File Number Securities Act File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash and cash equivalents Earnings Per Share [Abstract] Measurement term Warrants and Rights Outstanding, Term Statement of Financial Position [Abstract] Operating loss Operating Income (Loss) Price per unit Shares Issued, Price Per Share Price per share Performance-Based Restricted Stock Units [Member] Performance-based restricted stock units. Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Entity Shell Company Entity Shell Company Fair Value of Convertible Preferred Stock Warrant Liability Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Schedule of supplemental cash flow information related to leases. Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block] Schedule Of Supplemental Cash Flow Information Related To Leases Class of Warrant or Right Class of Warrant or Right [Domain] Public offering price per pre-funded warrant Public Offering Price Per Pre Funded Warrant Public offering price per pre-funded warrant. March two thousand twenty two pre funded warrants. March Two Thousand Twenty Two Pre Funded Warrants [Member] March 2022 pre-funded warrants March 2022 Pre-funded Warrants [Member] Entity Current Reporting Status Entity Current Reporting Status Exercise of common stock warrants, net of issuance costs Class Of Warrant Or Right Exercised Value Class of warrant or right exercised value. October 2023 Pre-funded Warrants [Member] Oct 2023 Pre-funded Warrants [Member] Oct 2023 Pre-funded warrants. October Two Thousand Twenty Three Pre-funded Warrants [Member] Contingent liability for Essentialis purchase price Asset Acquisition, Contingent Consideration, Liability, Noncurrent Subsequent Events [Abstract] Contingent receipt upon exerise of warrants and future performance of company Contingent Receipt Upon Exerise Of Warrants And Future Performance Of Company Contingent receipt upon exerise of warrants and future performance oF company. Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Change in Accounting Principle, Accounting Standards Update, Adoption Date May 2023 Tranche B Pre-funded Warrants [Member] Share-Based Payment Arrangement, Tranche Two [Member] Tranche B [Member] Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Options canceled/forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Purchases of property and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid City Area Code City Area Code Measurement input Warrants and Rights Outstanding, Measurement Input Total current liabilities Liabilities, Current Milestones payment Milestones Payment Milestones payment. Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase decrease in operating lease liabilities. Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2010 and 2012 Convertible Promissory Notes [Member] Two Thousand And Ten And Two Thousand And Twelve Convertible Promissory Notes [Member] Two Thousand and Ten and Two Thousand and Twelve Convertible Promissory Notes [Member] Exercise of common stock warrants and pre-funded common stock warrants (shares) Stock Issued During Period, Shares, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants Stock issued during period, shares, exercise of common stock warrants and pre-funded common stock warrants. Proceeds from exercise of common stock warrants Proceeds from Warrant Exercises Proceeds from warrant exercise Sale and issuance of warrants to purchase common stock Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Commitments and Contingencies Disclosure [Abstract] Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Operating lease liabilities Operating lease, short-term liability Operating Lease, Liability, Current Exercisable warrants maximum aggregate exercise price. ExercisableWarrants Maximum Aggregate Exercise price Exercisable warrants maximum aggregate exercise price Warrants to Purchase Stock [Member] Warrants To Purchase Common Stock [Member] Warrants To Purchase Stock [Member] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accumulated Deficit [Member] Retained Earnings [Member] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Document Transition Report Document Transition Report Percentage of fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Minimum [Member] Minimum [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Common Stock [Member] Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Options vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Percentage of probability of achieving milestone Percentage Of Probability Of Achieving Milestone Percentage of the probability of achieving the milestone. Two Thousand Twenty Three Tranche A Pre-funded Warrants [Member] 2023 Tranche A Pre-funded Warrants [Member] Two thousand twenty three tranche a pre funded warrants. Debt Securities, Available-for-Sale, Current Total marketable securities Warrants Issued to Underwriter to Purchase Common Stock [Member] Underwriter [Member] Underwriter [Member] Underwriter [Member] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss) Other comprehensive loss Income Statement Location Statement of Income Location, Balance [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other long-term assets Other Assets, Noncurrent Increase (Decrease) in Other Operating Liabilities, Total Other liabilities Increase (Decrease) in Other Operating Liabilities Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding 2014 Plan and Inducement Plan [Member] Two Thousand And Fourteen Equity Incentive Plan And Two Thousand Twenty Inducement Equity Incentive Plan [Member] Two thousand and fourteen equity incentive plan and two thousand twenty inducement equity incentive plan. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Liquidity disclosure. Liquidity Disclosure [Text Block] Liquidity Title and Position [Domain] Warrants and rights exercisable term from following receipt of U.S. Food and drug administration approval. Warrants And Rights Exercisable Term From Following Receipt of U.S. Food and Drug Administration Approval Warrants and rights exercisable term from following receipt of U.S. Food and drug administration approval Fair value of estimated warrants Warrants and Rights Outstanding Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs Proceeds from exercise of common stock and pre-funded stock warrants. Proceeds from Exercise of Common Stock and Pre-Funded Stock Warrants Common stock, $0.001 par value, 100,000,000 shares authorized, 41,041,216 and 31,678,159 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Increase (Decrease) in Employee Related Liabilities, Total Accrued compensation Increase (Decrease) in Employee Related Liabilities Interest income, net Investment Income, Interest Reverse Stock Split Reverse Stock Split Policy [Policy Text Block] Reverse stock split. Cash and Cash Equivalents, Fair Value Disclosure Total cash equivalents Schedule Of Cash And Cash Equivalents [Table] Cash and Cash Equivalent [Table] Total Total Right-of-use liability Operating Lease, Liability Measurement Frequency Measurement Frequency [Axis] Commitments and contingencies (Note 6) Commitments and Contingencies Weighted Average Remaining Term Warrants term Class Of Warrant Or Right Warrant Term Class Of Warrant

Or Right, Warrant Term 2018 PIPE Warrant Liability [Member] Two Thousand Eighteen P I P E Warrant Liability To Purchase Common Stock [Member] Two thousand eighteen PIPE warrant liability to purchase common stock. Weighted Average Number of Shares Outstanding, Diluted, Total Weighted-average common shares outstanding used to calculate diluted net loss per common share Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding used to calculate diluted shares Options vested and expected to vest at end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total lease payments Lessee, Operating Lease, Liability, to be Paid Jim Mackaness [Member] Jim Mackaness [Member] Jim Mackaness. Proceeds from sale of common stock and common stock warrants, net of issuance costs. Proceeds from Sale of Common Stock and Common Stock Warrants, Net of Issuance Costs Proceeds from the sale of common stock and common stock warrants, net of costs ISOs [Member] Incentive Stock Options [Member] Incentive Stock Options [Member] Entity Small Business Entity Small Business March two thousand twenty two common warrants. March Two Thousand Twenty Two Common Warrants [Member] March 2022 common warrants March 2022 Common Warrants [Member] Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio US Treasury Securities [Member] US Treasury Securities [Member] Warrant Liability Disclosure [Text Block] Warrant Liability Disclosure [Text Block] Warrants Accretion (Amortization) of Discounts and Premiums, Investments Accretion of premium/discount on marketable securities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Asset Class [Axis] Intangible Assets, Net (Excluding Goodwill), Total Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Increase in right of use assets Operating lease right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Measurement Frequency Measurement Frequency [Domain] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Operating lease remaining term Operating Lease, Weighted Average Remaining Lease Term Change in fair value of contingent consideration Asset Acquisition Contingent Consideration Change In Fair Value Asset acquisition contingent consideration change in fair value. Subsequent Events Subsequent Events [Text Block] Net unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Total liabilities Liabilities, Fair Value Disclosure Short-term lease cost Short-Term Lease, Cost XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Registrant Name SOLENO THERAPEUTICS INC Â Entity Central Index Key 0001484565 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Common Stock, Shares Outstanding Â 43,117,432 Entity File Number 001-36593 Â Entity Tax Identification Number 77-0523891 Â Entity Address, Address Line One 100 Marine Parkway Â Entity Address, Address Line Two Suite 400 Â Entity Address, City or Town Redwood City Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94065 Â City Area Code 650 Â Local Phone Number 213-8444 Â Entity Incorporation, State or Country Code DE Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current Yes Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol SLNO Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 48,413 $ 169,681 Marketable securities 208,363 Â Prepaid expenses and other current assets 1,423 1,677 Total current assets 258,199 171,358 Long-term assets Â Â Property and equipment, net 196 12 Operating lease right-of-use assets 2,992 407 Intangible assets, net 7,291 8,749 Long-term marketable securities 27,945 Â Other long-term assets 83 165 Total assets 296,706 180,691 Current liabilities Â Â Accounts payable 6,243 3,149 Accrued compensation 3,408 3,135 Accrued clinical trial site costs 1,762 3,393 Operating lease liabilities 448 273 Other current liabilities 3,101 1,555 Total current liabilities 14,962 11,505 Long-term liabilities Â Â Contingent liability for Essentialis purchase price 14,464 11,549 Long-term lease liabilities 2,581 130 Total liabilities 32,007 23,184 Commitments and contingencies (Note 6) Stockholdersâ€™ equity Â Â Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding Common stock, $0.001 par value, 100,000,000 shares authorized, 41,041,216 and 31,678,159 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 41 32 Additional paid-in-capital 660,041 433,885 Accumulated other comprehensive gain 895 Â Accumulated deficit (396,278) (276,410) Total stockholdersâ€™ equity 264,699 157,507 Total liabilities and stockholdersâ€™ equity $ 296,706 $ 180,691 X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: slno_AccruedClinicalTrialCostsCurrent Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-

gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 100,000,000 100,000,000 Common stock, shares issued 41,041,216 31,678,159 Common stock, shares outstanding 41,041,216 31,678,159 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses Â Â Â Â Research and development $ 30,138 $ 6,043 $ 57,082 $ 16,500 General and administrative 49,197 3,318 68,558 9,341 Change in fair value of contingent consideration 877 1,021 2,915 1,633 Total operating expenses 80,212 10,382 128,555 27,474 Operating loss (80,212) (10,382) (128,555) (27,474) Other income (expense), net Â Â Â Â Change in fair value of warrants liabilities 0 (653) 0 (652) Interest income, net 3,596 174 8,687 434 Total other income (expense), net 3,596 (479) 8,687 (218) Net loss (76,616) (10,861) (119,868) (27,692) Other comprehensive income (loss) Â Â Â Â Net unrealized gain on marketable securities 1,049 0 898 0 Foreign currency translation adjustment (1) (1) (3) (1) Total comprehensive loss $ (75,568) $ (10,862) $ (118,973) $ (27,693) Net loss per common share basic $ (1.83) $ (0.95) $ (3.08) $ (2.65) Net loss per common share diluted $ (1.83) $ (0.95) $ (3.08) $ (2.65) Weighted-average common shares outstanding used to calculate basic net loss per common share 41,879,025 11,436,748 38,917,169 10,443,186 Weighted-average common shares outstanding used to calculate diluted net loss per common share 41,879,025 11,436,748 38,917,169 10,443,186 X - DefinitionAsset acquisition contingent consideration change in fair value. + ReferencesNo definition available. + Details Name: slno_AssetAcquisitionContingentConsiderationChangeInFairValue Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income (Loss) [Member] Balances at beginning at Dec. 31, 2022 $ 10,348 $ 8 $ 247,762 $ (237,422) Â Balances at beginning (shares) at Dec. 31, 2022 Â 8,159,382 Â Â Â Stock-based compensation 495 Â 495 Â Â Issuance of restricted stock units under equity incentive plans 136 Â 136 Â Â Issuance of restricted stock units under equity incentive plans (shares) Â 9,534 Â Â Â Tax withholding payments for net share-settled equity awards (shares) Â (128) Â Â Â Foreign currency translation adjustment 16 Â Â Â $ 16 Net loss (8,356) Â Â (8,356) Â Balances at ending at Mar. 31, 2023 2,639 $ 8 248,393 (245,778) 16 Balances at end (shares) at Mar. 31, 2023 Â 8,168,788 Â Â Â Balances at beginning at Dec. 31, 2022 10,348 $ 8 247,762 (237,422) Â Balances at beginning (shares) at Dec. 31, 2022 Â 8,159,382 Â Â Â Foreign currency translation adjustment (1) Â Â Â Â Net loss (27,692) Â Â Â Â Balances at ending at Sep. 30, 2023 23,220 $ 15 288,320 (265,114) (1) Balances at end (shares) at Sep. 30, 2023 Â 15,467,229 Â Â Â Balances at beginning at Dec. 31, 2022 10,348 $ 8 247,762 (237,422) Â Balances at beginning (shares) at Dec. 31, 2022 Â 8,159,382 Â Â Â Balances at ending at Dec. 31, 2023 157,507 $ 32 433,885 (276,410) Â Balances at end (shares) at Dec. 31, 2023 Â 31,678,159 Â Â Â Balances at beginning at Mar. 31, 2023 2,639 $ 8 248,393 (245,778) 16 Balances at beginning (shares) at Mar. 31, 2023 Â 8,168,788 Â Â Â Stock-based compensation 1,204 Â 1,204 Â Â Issuance of common stock warrants, net of issuance costs 9,973 Â 9,973 Â Â Sale of common stock, net of issuance costs 7,101 $ 2 7,099 Â Â Sale of common stock, net of issuance costs (shares) Â 1,772,397 Â Â Â Foreign currency translation adjustment (16) Â Â Â (16) Net loss (8,475) Â Â (8,475) Â Balances at ending at Jun. 30, 2023 12,426 $ 10 266,669 (254,253) Â Balances at end (shares) at Jun. 30, 2023 Â 9,941,185 Â Â Â Stock-based compensation 2,201 Â 2,201 Â Â Exercise of common stock warrants, net of issuance costs (shares) Â 5,522,113 Â Â Â Exercise of common stock warrants, net of issuance costs 19,445 $ 5 19,440 Â Â Exercise of stock options 10 Â 10 Â Â Exercise of stock options (shares) Â 3,931 Â Â Â Foreign currency translation adjustment (1) Â Â Â (1) Net loss (10,861) Â Â (10,861) Â Balances at ending at Sep. 30, 2023 23,220 $ 15 288,320 (265,114) (1) Balances at end (shares) at Sep. 30, 2023 Â 15,467,229 Â Â Â Balances at beginning at Dec. 31, 2023 157,507 $ 32 433,885 (276,410) Â Balances at beginning (shares) at Dec. 31, 2023 Â 31,678,159 Â Â Â Stock-based compensation 6,445 Â 6,445 Â Â Issuance of restricted stock units under equity incentive plans (shares) Â 11,034 Â Â Â Exercise of common stock warrants and pre-funded common stock warrants 923 $ 1 922 Â Â Exercise of common stock warrants and pre-funded common stock warrants (shares) Â 1,644,886 Â Â Â Exercise of stock options 15 Â 15 Â Â Exercise of stock options (shares) Â 3,000 Â Â Â Unrealized loss on marketable securities (105) Â Â Â (105) Foreign currency translation adjustment (1) Â Â Â (1) Net loss (21,398) Â Â (21,398) Â Balances at ending at Mar. 31, 2024 143,386 $ 33 441,267 (297,808) (106) Balances at end (shares) at Mar. 31, 2024 Â 33,337,079 Â Â Â Balances at beginning at Dec. 31, 2023 157,507 $ 32 433,885 (276,410) Â Balances at beginning (shares) at Dec. 31, 2023 Â 31,678,159 Â Â Â Foreign currency translation adjustment (3) Â Â Â Â Net loss (119,868) Â Â Â Â Balances at ending at Sep. 30, 2024 264,699 $ 41 660,041 (396,278) 895 Balances at end (shares) at Sep. 30, 2024 Â 41,041,216 Â Â Â Balances at beginning at Mar. 31, 2024 143,386 $ 33 441,267 (297,808) (106) Balances at beginning (shares) at Mar. 31, 2024 Â 33,337,079 Â Â Â Stock-based compensation 7,160 Â 7,160 Â Â Issuance of restricted stock units under equity incentive plans (shares) Â 75,750 Â Â Â Sale of common stock, net of issuance costs 148,955 $ 4 148,951 Â Â Sale of common stock, net of issuance costs (shares) Â 3,450,000 Â Â Â Exercise of common stock warrants and pre-funded common stock warrants 2,620 $ 1 2,619 Â Â Exercise of common stock warrants and pre-funded common stock warrants (shares) Â 1,435,319 Â Â Â Exercise of stock options 537 Â 537 Â Â Exercise of stock options (shares) Â 88,631 Â Â Â Unrealized loss on marketable securities (46) Â Â Â (46) Foreign currency translation adjustment (1) Â Â Â (1) Net loss (21,854) Â Â (21,854) Â Balances at ending at Jun. 30, 2024 280,757 $ 38 600,534 (319,662) (153) Balances at end (shares) at Jun. 30, 2024 Â 38,386,779 Â Â Â Stock-based compensation 56,598 Â 56,598 Â Â Issuance of restricted stock units under equity incentive plans 1 $ 1 Â Â Â Issuance of restricted stock units under equity incentive plans (shares) Â 789,500 Â Â Â Exercise of common stock warrants and pre-funded common stock warrants 2,147 $ 2 2,145 Â Â Exercise of common stock warrants and pre-funded common stock warrants (shares) Â 1,782,048 Â Â Â Exercise of stock options 764 Â 764 Â Â Exercise of stock options (shares) Â 82,889 Â Â Â Unrealized loss on marketable securities 1,049 Â Â Â 1,049 Foreign currency translation adjustment (1) Â Â Â (1) Net loss (76,616) Â Â (76,616) Â Balances at ending at Sep. 30, 2024 $ 264,699 $ 41 $ 660,041 $ (396,278) $ 895 Balances at end (shares) at Sep. 30, 2024 Â 41,041,216 Â Â Â X - DefinitionClass of warrant or right exercised. + ReferencesNo definition available. + Details Name: slno_ClassOfWarrantOrRightExercised Namespace Prefix: slno_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or right exercised value. + ReferencesNo definition available. + Details Name: slno_ClassOfWarrantOrRightExercisedValue Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of restricted stock units shares under equity incentive plan. + ReferencesNo definition available. + Details Name: slno_IssuanceOfRestrictedStockUnitsSharesUnderEquityIncentivePlan Namespace Prefix: slno_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of restricted stock units value and option exercises under equity incentive plan. + ReferencesNo definition available. + Details Name: slno_IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, shares, exercise of common stock warrants and pre-funded common stock warrants. + ReferencesNo definition available. + Details Name: slno_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants Namespace Prefix: slno_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period, value, exercise of common stock warrants and pre-funded common stock warrants. + ReferencesNo definition available. + Details Name: slno_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) $ in Thousands 3 Months Ended Jun. 30, 2024 USD ($) Statement of Stockholders' Equity [Abstract] Â Less transaction costs $ 9,746 X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (119,868) $ (27,692) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 1,484 1,469 Accretion of premium/discount on

marketable securities (3,495) 0 Non-cash lease expense 250 254 Stock-based compensation expense 70,203 4,036 Change in fair value of stock warrants 0 652 Change in fair value of contingent consideration 2,915 1,633 Other non-cash reconciling items (3) (1) Change in operating assets and liabilities: Â Â Prepaid expenses, other current assets and other assets 279 (177) Accounts payable 3,094 1,338 Accrued compensation 273 (177) Accrued clinical trial site costs (1,631) 15 Operating lease liabilities (152) (242) Other liabilities 1,546 266 Net cash used in operating activities (45,105) (18,626) Cash flows from investing activities Â Â Purchases of property and equipment (210) 0 Purchases of marketable securities (308,915) 0 Maturities of marketable securities 77,000 0 Net cash used in investing activities (232,125) 0 Cash flows from financing activities: Â Â Proceeds from the sale of common stock, net of issuance costs 148,955 0 Proceeds from the sale of common stock and common stock warrants, net of costs 0 17,074 Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs 5,690 19,445 Proceeds received prior to and for the issuance of common stock and pre-funded warrants 0 19,932 Proceeds from exercise of stock options 1,317 10 Net cash provided by financing activities 155,962 56,461 Net (decrease) increase in cash and cash equivalents (121,268) 37,835 Cash and cash equivalents, beginning of period 169,681 14,602 Cash and cash equivalents, end of period 48,413 52,437 Supplemental disclosure of non-cash operating and financing information Â Â Operating lease right-of-use assets obtained in exchange for operating lease obligations 597 Unpaid financing costs included in accounts payable and accrued liabilities $ 199 X - DefinitionAsset acquisition contingent consideration change in fair value. + ReferencesNo definition available. + Details Name: slno_AssetAcquisitionContingentConsiderationChangeInFairValue Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in accrued clinical trial site costs. + ReferencesNo definition available. + Details Name: slno_IncreaseDecreaseInAccruedClinicalTrialSiteCosts Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in operating lease liabilities. + ReferencesNo definition available. + Details Name: slno_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash lease expense. + ReferencesNo definition available. + Details Name: slno_NoncashLeaseExpense Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs. + ReferencesNo definition available. + Details Name: slno_ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrantsNetOfCosts Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from sale of common stock and common stock warrants, net of issuance costs. + ReferencesNo definition available. + Details Name: slno_ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds received prior to for issuance of common stock and pre-funded warrants + ReferencesNo definition available. + Details Name: slno_ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnpaid costs for issuing common stock and pre funded warrants. + ReferencesNo definition available. + Details Name: slno_UnpaidCostsForIssuingCommonStockAndPreFundedWarrants Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ (76,616) $ (21,854) $ (21,398) $ (10,861) $ (8,475) $ (8,356) $ (119,868) $ (27,692) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement The following provides information regarding Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, each a "10b5-1 Plan") adopted in the third quarter of 2024 by any director or officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934 ("Section 16 Director or Officer"): Anish Bhatnagar, our Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors adopted a 10b5-1 Plan on September 6, 2024. Mr. Bhatnagar's 10b5-1 Plan provides for the potential sale of up to 300,000 shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Jim Mackaness, our Chief Financial Officer, adopted a 10b5-1 Plan on September 6, 2024. Mr. Mackaness' 10b5-1 Plan provides for the potential sale of up to 60,000 shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Patricia C. Hirano, our Senior Vice President, Regulatory Affairs, adopted a 10b5-1 Plan on September 13, 2024. Ms. Hirano's 10b5-1 Plan provides for the potential sale of up to 124,026 shares of our common stock, and expires on September 13, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest. Kristen Yen, our Senior Vice President, Clinical Operations, adopted a 10b5-1 Plan on September 13, 2024. Ms. Yen's 10b5-1 Plan provides for the potential sale of up to 95,089 shares of our common stock, and expires on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest.These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). Certain of our Section 16 Directors or Officers may participate in employee stock purchase plans, 401(k) plans or dividend investment plans of us that have been designed to comply with Rule 10b5-1(c). No non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) were adopted by any Section 16 Director or Officer during the third quarter of 2024. Additionally, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any Section 16 Director or Officer in the third quarter of 2024. Non-Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Terminated false Anish Bhatnagar [Member] Â Trading Arrangements, by Individual Â Name Anish Bhatnagar Title Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors Rule 10b5-1 Arrangement Adopted true Adoption Date September 6, 2024 Expiration Date September 6, 2025 Arrangement Duration 365 days Aggregate Available 300,000 Jim Mackaness [Member] Â Trading Arrangements, by Individual Â Name Jim

Mackaness Title Chief Financial Officer Rule 10b5-1 Arrangement Adopted true Adoption Date September 6, 2024 Expiration Date September 6, 2025 Arrangement Duration 365 days Aggregate Available 60,000 Patricia C. Hirano [Member] Â Trading Arrangements, by Individual Â Name Patricia C. Hirano Title Senior Vice President Rule 10b5-1 Arrangement Adopted true Adoption Date September 13, 2024 Expiration Date September 13, 2025 Arrangement Duration 365 days Aggregate Available 124,026 Kristen Yen [Member] Â Trading Arrangements, by Individual Â Name Kristen Yen Title Senior Vice President Rule 10b5-1 Arrangement Adopted true Adoption Date September 13, 2024 Expiration Date September 30, 2025 Arrangement Duration 365 days Aggregate Available 95,089 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=slno_AnishBhatnagarMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=slno_JimMackanessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=slno_PatriciaCHiranoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=slno_KristenYenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Overview 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Overview Note 1. Overview Soleno Therapeutics, Inc. (the Company or Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). DCCR has received Fast-Track and Breakthrough Therapy designations for the treatment of PWS in the United States (U.S.) and orphan designation for the treatment of PWS in the U.S. as well as in the European Union (E.U.). On June 28, 2024, the Company submitted a new drug application (NDA) to the FDA for DCCR for the treatment of PWS in individuals four years and older who have hyperphagia and on August 27, 2024 announced that the FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024.The Company incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. It initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs. During 2017, the Company merged with Essentialis, Inc (Essentialis) and subsequently received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from â€œCapnia, Inc.â€ to â€œSoleno Therapeutics, Inc.â€. Essentialis was a privately held clinical-stage company focused on the development of breakthrough medicines for the treatment of rare diseases where there is increased mortality and risk of cardiovascular and endocrine complications. After the merger, the Companyâ€™s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested all prior business efforts. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Liquidity Note 2. LiquidityThe Company used $45.1 million of cash in its operating activities and had a net loss of $119.9 million during the nine months ended September 30, 2024 and has an accumulated deficit of $396.3 million at September 30, 2024 resulting from having incurred losses since its inception. The Company had $48.4 million of cash and cash equivalents on hand, $208.4 million of marketable securities and $27.9 million of long-term marketable securities on September 30, 2024. The Company has financed its operations principally through issuance of equity securities. On May 9, 2024, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million. On July 19, 2024, the Company entered into an Open Market AgreementSM (the "Sales Agreement") with Jefferies LLC, as sales agent ("Jefferies"), pursuant to which the Company may offer and sell, from time to time, through Jefferies shares of its common stock having an aggregate offering price of up to $150,000,000. In December 2022, the Company entered into a Securities Purchase Agreement providing for the sale of up to $60.0 million in warrants (Tranche A and Tranche B) and the common stock issuable upon the exercise thereof. Cumulative to date through September 30, 2024, the Company has received $10.0 million from the sale of these warrants and $37.7 million in proceeds from the exercise of certain of these warrants. Warrants with an aggregate exercise price of $12.3 million are still outstanding.The Company expects to continue incurring losses for the foreseeable future. However, the Company expects that its current cash, cash equivalents and marketable securities balances will be sufficient to enable the Company to meet its obligations for at least the next twelve months from the date of this filing. X - DefinitionLiquidity disclosure. + ReferencesNo definition available. + Details Name: slno_LiquidityDisclosureTextBlock Namespace Prefix: slno_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation and Summary of Significant Accounting Policies Note 3. Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies There have been no material changes to the significant accounting policies during the three and nine months ended September 30, 2024 as compared to the significant accounting policies described in Note 3 of the â€œNotes to Consolidated Financial Statementsâ€ in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, except as noted below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2024. For further information, refer to the financial statements and footnotes included in the Companyâ€™s annual financial statements for the fiscal year ended December 31, 2023, which are included in the Companyâ€™s annual report on Form 10-K filed with the SEC on March 7, 2024.Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.Marketable SecuritiesThe Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholdersâ€™ equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented.Â Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.In November 2023, the FASB issued ASU 2023-07, Segment Reporting â€“ Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the disclosure requirements related to the new standard but does not anticipate a material impact on its consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024. Adoption is permitted either prospectively or retrospectively, and the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s financial statements upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments Note 4. Fair Value of Financial Instruments The carrying value of the Companyâ€™s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: â€¢Level I â€“ Unadjusted quoted prices in active markets for identical assets or liabilities; â€¢Level II â€“ Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and â€¢Level III â€“ Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at September 30, 2024 (in thousands):Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury securities Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Total Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Â Â

and $200 million in cumulative revenue. The Level 3 estimates are based, in part, on subjective assumptions. In determining the likelihood of this occurring, the analysis relied on published research relating to clinical development success rates. Based on managementâ€™s assessment, an 88% probability of achieving all three milestones was determined to be reasonable as of both September 30, 2024 and December 31, 2023. During the periods presented, the Company has not changed the manner in which it values its Essentialis purchase price contingent liability.The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between levels within the hierarchy during the periods presented. The following table sets forth a summary of the changes in the fair value of the Companyâ€™s Level 3 liabilities for the nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Â Â Â Â Purchase Price Â Â Â Â Â Â Â Â Â ContingentLiability Â Balance at January 1, 2024 Â Â Â Â Â Â Â $ 11,549 Â Change in value of contingent liability Â Â Â Â Â Â Â Â Â Â Â 2,915 Â Balance at September 30, 2024 Â Â Â Â Â Â Â Â Â $ 14,464 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2018 PIPE Warrants Â Â Purchase Price Â Â Â Number ofWarrants Â Â Liability Â Â ContingentLiability Â Balance at January 1, 2023 Â Â 34,241 Â Â $ 1 Â Â $ 8,835 Â Change in value of 2018 PIPE Warrants Â Â â€” Â Â Â 652 Â Â Â â€” Â Change in value of contingent liability Â Â â€” Â Â Â â€” Â Â Â 1,633 Â Balance at September 30, 2023 Â Â 34,241 Â Â $ 653 Â Â $ 10,468 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants 9 Months Ended Sep. 30, 2024 Text Block [Abstract] Â Warrants Note 5. WarrantsThe Company has issued multiple warrant series, of which the 2018 PIPE Warrants were determined to be liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging. Warrants Issued as Part of the Units in the 2018 PIPE Offering The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and prior to their expiration on December 21, 2023, entitled the holders to purchase 34,241 shares of the Companyâ€™s common stock at an exercise price equal to $30.00 per share, subject to adjustments. In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology. Since the Company may be obligated to settle the 2018 PIPE Warrants in cash, the Company classified the 2018 PIPE Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as Other income (expense) in the Companyâ€™s condensed consolidated statements of operations. The 2018 PIPE Warrants were either exercised prior to or expired on December 21, 2023. X - DefinitionWarrant Liability Disclosure [Text Block] + ReferencesNo definition available. + Details Name: slno_WarrantLiabilityDisclosureTextBlock Namespace Prefix: slno_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 6. Commitments and Contingencies Facility Leases On June 13, 2024, the Company entered into a new office lease in Redwood City, California for office space for its headquarters facility. The lease provides office space of approximately 18,026 square feet and for base monthly rent payments beginning at $57,400 that increase annually by approximately 3.0% over the term of five years from the date of occupancy. In addition to base rent, the Company has agreed to reimburse the landlord for certain operating expenses under the terms of the lease. The lease commencement date was September 1, 2024 when the premises became available for occupancy and the related operating lease ROU assets and liabilities were recorded in the Company's condensed consolidated balance sheet as of September 30, 2024. The Company's operating lease ROU assets, current operating lease liabilities and long-term operating lease liabilities each appear as a separate line within the Company's condensed consolidated balance sheets. In September 2024, the Company recorded an increase to its right-of-use assets by $2.8 million and an increase to its lease liability of $2.8 million as a result of the June 2024 office lease. As of September 30, 2024 and December 31, 2023, the Company's short-term liabilities were equal to $0.4 million and $0.3 million, respectively, and the long-term operating lease liabilities were equal to $2.6 million and $0.1 million, respectively. The Companyâ€™s prior operating lease for its predecessor headquarters facility office space in Redwood City, California began in June 2021 and expired in May 2023. In April 2023, the Company entered into a twenty-four month lease extension commencing on June 1, 2023. The term of the lease extension expires in May 2025. On February 8, 2024, the Company entered into a six-month office license agreement to license 4,141 square feet of additional space adjacent to its existing office where the Company was located and in July 2024, the Company provided notice of early termination of the license agreement for the additional space effective September 17, 2024. As a result of the lease extension, in 2023, the Company recorded an increase to its right-of-use assets by $0.6 million and an increase to its lease liability by $0.6 million. The weighted average discount rate related to the Company's lease liabilities as of September 30, 2024 was 8.5% over a remaining term of 5 years. The weighted average discount rate related to the Company's lease liabilities as of December 31, 2023 was 8.25% over a remaining term of 17 months. The discount rate was determined based on estimates of the Companyâ€™s incremental borrowing rate, as the discount rate implicit in the lease cannot be readily determined. Due to the short-term nature of the February 2024 office license agreement, the license agreement obligations are not included in the Company's right-of-use assets and lease liabilities on the Company's condensed consolidated balance sheets.The components of lease expense during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Three Months EndedSeptember 30, Â Â Nine Months EndedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost: Â Â Â Â Â Â Â Â Â Â Operating lease cost $ 137 Â Â $ 76 Â Â $ 291 Â Â $ 235 Â Variable lease cost Â 4 Â Â Â â€” Â Â Â 12 Â Â Â â€” Â Short-term lease cost Â 54 Â Â Â 12 Â Â Â 147 Â Â Â 33 Â Total operating lease cost $ 195 Â Â $ 88 Â Â $ 450 Â Â $ 268 Â Â Â Â Â Â Â Â Â Â Â Â Supplemental cash flow information related to leases was as follows (in thousands):Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Operating cash flows from operating leases $ 248 Â Â $ 264 Â Â Â Â Â Â Â Â The following is a schedule by year of future maturities of the Company's operating lease liabilities as of September 30, 2024 (in thousands):Â Â Â Â 2024 (remainder of the year) $ 64 Â 2025 Â 526 Â 2026 Â 751 Â 2027 Â 861 Â 2028 Â 942 Â Thereafter Â 665 Â Total lease payments Â 3,809 Â Less interest Â (780) Total $ 3,029 Â Other CommitmentsThe Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies as well as other services and products for operating purposes, which are generally cancelable upon written notice. As of September 30, 2024, the Companyâ€™s non-cancelable other commitments aggregated $2.8 million.Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Equity Note 7. Stockholdersâ€™ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of Preferred Stock. Public Offering of Common StockOn May 9, 2024, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million.Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded WarrantsOn October 2, 2023, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other offering expenses. Concurrently, the Company also completed the closing of 1,825,000 shares of its common stock and 1,175,000 pre-funded warrants in a private offering pursuant to a securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99, for total gross proceeds of approximately $60.0 million. In aggregate, the Company received $129.0 million of gross proceeds less offering costs of $8.2 million. The Company is not required under any circumstance to settle any of the pre-funded warrants for cash, and therefore classified the pre-funded warrants as permanent equity.Securities Purchase AgreementOn December 16, 2022, the Company entered into a Securities Purchase Agreement for a private placement (Private Placement) with certain entities and members of management (collectively, Purchasers). Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers warrants to purchase up to an aggregate of 22,598,870 shares of the Companyâ€™s common stock, at a purchase price of $0.4425 per warrant. The closing of the Private Placement occurred on May 8, 2023 (the Issue Date), following the satisfaction of certain closing conditions, including the completion of enrollment in the randomized withdrawal period of Study C602. The Company received gross proceeds of $10.0 million for the sale and issuance of warrants to purchase common stock.The warrants were separated into two tranches with 8,598,870 Tranche A Warrants with an exercise price of $1.75 per share and aggregate proceeds of up to approximately $15.0 million, and 14,000,000 Tranche B Warrants with an exercise price of $2.50 per share and aggregate proceeds of up to $35.0 million. The Tranche A warrants were immediately exercisable and were required to be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of Study C602. On September 26, 2023, the Company announced positive top-line data and subsequently received $15.0 million from the exercise of the Tranche A warrants. The Tranche B warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance or 30 days following receipt of FDA approval of DCCR for the treatment of PWS. Through September 30, 2024, certain investors had exercised their Tranche B warrants and the Company has received $22.7 million. The receipt of the aggregate exercise price of up to $12.3 million for the remaining Tranche B warrants is contingent upon the exercise of such warrants. Underwritten Public Offering On March 31, 2022, the Company sold 2,666,667 shares of its common stock at a public offering price of $3.75 per share, and for certain investors, in lieu of common stock, pre-funded warrants (the 2022 pre-funded warrants) to purchase 1,333,333 shares of its common stock at a public offering price $3.60 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.15 per share exercise price for each 2022 pre-funded warrant. The March 2022 pre-funded warrants are immediately exercisable and may be exercised at any time until all of the March 2022 pre-funded warrants are exercised in full. Each share of common stock or March 2022 pre-funded warrant was sold together with one, immediately exercisable, common warrant (the 2022 common warrants) with a five-year term to purchase one share of common stock at an exercise price of $4.50 per share. The net proceeds of the offering were $13.8 million, after deducting the underwriting discount and other offering expenses. The Company is not required under any circumstance to settle any of the 2022 pre-funded warrants or the 2022 common warrants for cash, and therefore classified both types of warrants as permanent equity.Through September 30, 2024, 2,145,073 of the March 2022 common warrants had been exercised for gross proceeds of $9.7 million and 581,850 warrants were exercised using the cashless exercise option with no proceeds to the Company. As of September 30, 2024, 1,273,077 of the March 2022 common warrants remain outstanding. All 1,333,333 of the March 2022 pre-funded warrants were exercised in 2023 using the cashless exercise option with no additional proceeds received by the Company.At the Market Offering In July 2021, the Company entered into a Controlled Equity Offering Sales Agreement under which the Company was able to sell shares of its common stock having an aggregate offering price of up to $25.0 million from time to time in any method permitted by law deemed to be an "at-the-market" Rule 415 under the Securities Act of 1933, as amended. The Controlled Equity Offering Sales Agreement was terminated in connection with the October 2, 2023 financing. While active, the Company sold 1,877,170 shares of common stock through the at the market program, totaling $7.4 million in net proceeds.On July 19, 2024, the Company entered into the Sales Agreement

with Jefferies, pursuant to which the Company may offer and sell up to $150.0 million of shares of its common stock, from time to time, through Jefferies.The Company will pay Jefferies a commission of 3.0% of the aggregate gross proceeds from the sale of shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any shares under the Sales Agreement. The offering of the shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by Jefferies or the Company, as permitted therein. Common Stock Warrants As of September 30, 2024 and December 31, 2023, the following table summarizes the Company's outstanding common stock warrants:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Expiration Date Common stock warrants Â Â 7,904 Â Â $ 388.94 Â Â Â 7,904 Â Â $ 388.94 Â Â November 2024 March 2022 Common warrants Â Â 1,273,077 Â Â $ 4.50 Â Â Â 1,929,066 Â Â $ 4.50 Â Â March 2027 May 2023 Tranche A pre-funded warrants Â Â 1,250,647 Â Â $ 0.01 Â Â Â 2,758,281 Â Â $ 0.01 Â Â November 2026 May 2023 Tranche B warrants Â Â 4,935,305 Â Â $ 2.50 Â Â Â 6,750,000 Â Â $ 2.50 Â Â November 2026Â (1) May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â $ 0.01 Â Â Â 451,632 Â Â $ 0.01 Â Â November 2026 October 2023 pre-funded warrants Â Â 250,000 Â Â $ 0.01 Â Â Â 1,175,000 Â Â $ 0.01 Â Â N/A Total Â Â 8,168,565 Â Â Â Â Â Â Â 13,071,883 Â (1) Subject to earlier expiration as described above.Equity Incentive Plans 2014 PlanThe Company maintains the 2014 Equity Incentive Plan (the 2014 Plan). Under the 2014 Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the 2014 Plan may be incentive stock options (ISOs) or nonqualified stock options (NSOs). ISOs may be granted only to Company employees, including officers and directors. The Board has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Performance-based grants have vesting contingent upon the achievement of certain performance criteria related to the Companyâ€™s commercialization of its therapeutics. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board. On January 17, 2024, the Company filed a Registration Statement on Form S-8 which registered an additional 1,000,000 shares automatically available for issuance under the 2014 Plan as of December 31, 2023. On June 6, 2024, the stockholders approved the Amended and Restated 2014 Plan which included an increase of 2,000,000 shares, which became immediately available for grant and issuance. As of September 30, 2024, a total of 609,179 shares are available for future grant under the 2014 Plan. Inducement PlanThe Company maintains the 2020 Inducement Equity Incentive Plan (the Inducement Plan). The Inducement Plan provides for the grant of equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2014 Plan.In accordance with Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individualsâ€™ bona fide period of non-employment with the Company), as an inducement material to the individualsâ€™ entry into employment with the Company, or, to the extent permitted by Rule 5635(c)(3) of the Nasdaq Listing Rules, in connection with a merger or acquisition. On January 31, 2024, the Company filed a Registration Statement on Form S-8 which registered 500,000 shares available for issuance under the Inducement Plan, which became available for issuance following approval of the Board of Directors on January 24, 2024.As of September 30, 2024, a total of 5,318 shares are available for future grant under the Inducement Plan. Stock-based compensation expenseThe Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements during any of the periods presented.Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development $ 18,516 Â Â $ 935 Â Â $ 23,682 Â Â $ 1,587 Â General and administrative Â 38,082 Â Â Â 1,266 Â Â Â 46,521 Â Â Â 2,449 Â Total $ 56,598 Â Â $ 2,201 Â Â $ 70,203 Â Â $ 4,036 Â Stock OptionsThe Company granted options to purchase 288,850 and 77,000 shares of the Companyâ€™s common stock to employees during the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company granted options to purchase 1,369,230 of the Company's common stock to employees and a consultant, and during the nine months ended September 30, 2023, the Company granted 1,663,454 of the Company's common stock to employees. There were no performance-based options granted during the three and nine months ended September 30, 2024 and 2023, respectively. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â 2024 Â 2023 Â 2024 Â 2023 Expected life (years) 6.1 Â 5.3-6.0 Â 5.8-6.1 Â 5.3-6.0 Risk-free interest rate 3.7%-3.8% Â 4.0%-4.4% Â 3.7%-4.6% Â 3.5%-4.4% Volatility 121% Â 98%-100% Â 121%-124% Â 98%-100% Dividend rate â€”Â Â % Â â€”Â Â % Â â€”Â Â % Â â€”Â Â % The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates: â€¢Expected life: The expected life of stock options represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected life of the Companyâ€™s service-based stock options has been determined utilizing the â€œsimplified methodâ€, based on the average of the contractual term of the options and the weighted-average vesting period. The expected life for the performance-based options was determined based on consideration of the contractual term of the stock options, an estimate of the date the performance criteria would be met and expectations of employee behavior.â€¢Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected life of the stock options.â€¢Volatility: The estimated volatility rate is based on the volatilities of the Companyâ€™s common stock for a historical period equal to the expected life of the stock options.â€¢Dividend rate: The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The following table summarizes stock option transactions for the nine months ended September 30, 2024 which were for awards issued under the 2014 Plan and the Inducement Plan: Â Â Â Number ofOptions Â Â Weighted-AverageExercisePrice per Â Â WeightedAverageRemainingContractualTerm Â Â Aggregate Intrinsic Value Â Â Â Outstanding Â Â Share Â Â (in years) Â Â (in thousands) Â Balance at January 1, 2024 Â Â 2,369,665 Â Â $ 11.56 Â Â Â 8.72 Â Â $ 70,834 Â Options granted Â Â 1,369,230 Â Â Â 42.91 Â Â Â Â Â Â Â Options exercised Â Â (171,520) Â Â 7.59 Â Â Â Â Â Â Â Options canceled/forfeited Â Â (44,124) Â Â 42.30 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â Options exercisable at September 30, 2024 Â Â 1,116,184 Â Â $ 15.67 Â Â Â 7.40 Â Â $ 41,095 Â Options vested and expected to vest at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â The weighted-average grant date fair value of options granted was $37.84 and $3.80 per share for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to stock options that are likely to vest was $50.1 million, which is expected to be recognized over the weighted-average remaining vesting period of 2.7 years. Restricted Stock Units There were 1,239,375 performance-based restricted stock units and 366,625 restricted stock units granted to employees and a director during the three months ended September 30, 2024 and zero granted during the three months ended September 30, 2023. During the nine months ended September 30, 2024, there were 1,249,375 performance-based restricted stock units and 758,155 restricted stock units granted to employees and directors. During the nine months ended September 30, 2023, 414,710 restricted stock units were granted to employees. The shares were valued based on the Companyâ€™s common stock price on the grant date.The following table summarizes restricted stock unit transactions for the nine months ended September 30, 2024 as issued under the 2014 Plan: Â Â Number ofRestricted Stock Units Â Â Weighted-AverageGrant-Date Fair Value per Share Â Outstanding at January 1, 2024 Â Â 15,534 Â Â $ 43.92 Â Restricted stock units granted Â Â 2,007,530 Â Â $ 46.47 Â Restricted stock units vested Â Â (950,534) Â $ 45.81 Â Restricted stock units canceled/forfeited Â Â - Â Â $ 0.00 Â Outstanding at September 30, 2024 Â Â 1,072,530 Â Â $ 47.02 Â The weighted-average grant-date fair value of all restricted stock units granted during the nine months ended September 30, 2024 and 2023 was $46.47 and $5.25, respectively. The fair value of all restricted stock units vested during the nine months ended September 30, 2024 and 2023 was $44.67 million and $23,000, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to restricted stock units was $34.5 million, which is expected to be recognized over the weighted-average remaining vesting period of 0.4 years. 74,250 restricted stock units vested on September 30, 2024 and are included in the Restricted stock units vested line item above. The shares of common stock were subsequently issued after September 30, 2024 and therefore are not included in the outstanding common stock as of September 30, 2024.2014 Employee Stock Purchase Plan The Companyâ€™s board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan (ESPP). The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of 1,864 shares of the Companyâ€™s common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of: â€¢1.0% of the outstanding shares of the Companyâ€™s common stock on the first day of such year;â€¢3,729 shares; or â€¢such amount as determined by the board of directors. As of September 30, 2024, there were no purchases by employees under this plan. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss per Share Note 8. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding during the period. Shares of common stock that are potentially issuable for little or no cash consideration at issuance, such as the Company's pre-funded warrants issued in March 2022 and October 2023 and in connection with the exercise of certain May 2023 Tranche A and Tranche B warrants, are considered outstanding common stock and are included in the calculation of basic and diluted net loss per share in connection with ASC 260 Earnings Per Shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the exercise or vesting of common stock awards and exercise of common stock warrants that are not pre-funded. The Company applies the two-class method to calculate basic and diluted earnings per share as its warrants issued in March 2022, May 2023 and October 2023 are participating securities. However, the two-class method does not impact the net loss per share of common stock as the March 2022, May 2023 and October 2023 common warrants issued do not participate in losses. For the three and nine months ended September 30, 2024 and 2023, the effect of issuing potential common stock is anti-dilutive due to the net losses in those periods and therefore the number of shares used to compute basic and diluted net loss per share are the same in each of those periods. The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock Â Â 39,360,966 Â Â Â 10,287,620 Â Â Â 35,824,742 Â Â Â 9,206,650 Â March 2022 pre-funded warrants Â Â - Â Â Â 1,122,819 Â Â Â - Â Â Â 1,227,670 Â May 2023 Tranche A pre-funded warrants Â Â 1,816,427 Â Â Â 26,309 Â Â Â 2,154,299 Â Â Â 8,866 Â May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â Â - Â Â Â 451,632 Â Â Â - Â October 2023 pre-funded warrants Â Â 250,000 Â Â Â - Â Â Â 486,496 Â Â Â - Â Total Â Â 41,879,025 Â Â Â 11,436,748 Â Â Â 38,917,169 Â Â Â 10,443,186 Â The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares): Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Warrants issued to 2010/2012 convertible noteÂ Â Â holders to purchase common stock Â Â 6,804 Â Â Â 6,804 Â Warrants issued to underwriter to purchase common stock Â Â 1,100 Â Â Â 1,100 Â 2018 PIPE warrants Â Â - Â Â Â 34,241 Â March 2022 common warrants Â Â 1,273,077 Â Â Â 2,130,656 Â May 2023 Tranche A warrants Â Â - Â Â Â 2,867,908 Â May 2023 Tranche B warrants Â Â 4,935,305 Â Â Â 14,000,000 Â Options to purchase common stock Â Â 3,523,251 Â Â Â 2,300,412 Â Outstanding restricted stock units Â Â 1,072,530 Â Â Â 424,244 Â Total Â Â 10,812,067 Â Â Â 21,765,365 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events Note 9. Subsequent EventsÂ The Company has evaluated its subsequent events from September 30, 2024 through the date these condensed consolidated financial statements were issued and has determined that there are no subsequent events disclosure required. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2024. For further information, refer to the financial statements and footnotes included in the Companyâ€™s annual financial statements for the fiscal year ended December 31, 2023, which are included in the Companyâ€™s annual report on Form 10-K filed with the SEC on March 7, 2024. Use of Estimates Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results

could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition. Marketable Securities Marketable SecuritiesThe Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholdersâ€™ equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented. Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.In November 2023, the FASB issued ASU 2023-07, Segment Reporting â€“ Improvements to Reportable Segment Disclosures, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the disclosure requirements related to the new standard but does not anticipate a material impact on its consolidated financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024. Adoption is permitted either prospectively or retrospectively, and the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s financial statements upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Marketable Securities Classified as Available-for-sale Securities Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at September 30, 2024 (in thousands):Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â U.S. Treasury securities Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Total Â $ 235,410 Â Â $ 903 Â Â $ (5) Â $ 236,308 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Summary of Financial Instruments Measured at Fair Value on Recurring Basis The following table sets forth the Companyâ€™s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Â Â Â Fair Value Measurements at September 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 26,400 Â Â $ 26,400 Â Â $ - Â Â $ - Â Total cash equivalents Â $ 26,400 Â Â $ 26,400 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â $ 236,308 Â Â $ â€” Â Â $ 236,308 Â Â $ â€” Â Total marketable securities Â $ 236,308 Â Â $ â€” Â Â $ 236,308 Â Â $ â€” Â Total assets Â $ 262,708 Â Â $ 26,400 Â Â $ 236,308 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Essentialis purchase price contingency liability Â $ 14,464 Â Â $ â€” Â Â $ â€” Â Â $ 14,464 Â Total liabilities Â $ 14,464 Â Â $ â€” Â Â $ â€” Â Â $ 14,464 Â Â Â Â Â Fair Value Measurements at December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Essentialis purchase price contingency liability Â $ 11,549 Â Â $ â€” Â Â $ â€” Â Â $ 11,549 Â Total liabilities Â $ 11,549 Â Â $ â€” Â Â $ â€” Â Â $ 11,549 Â Summary of Changes in Fair Value of Level 3 Financial Instruments The following table sets forth a summary of the changes in the fair value of the Companyâ€™s Level 3 liabilities for the nine months ended September 30, 2024 and 2023 (dollars in thousands): Â Â Â Â Â Â Purchase Price Â Â Â Â Â Â Â Â Â ContingentLiability Â Balance at January 1, 2024 Â Â Â Â Â Â Â Â $ 11,549 Â Change in value of contingent liability Â Â Â Â Â Â Â Â Â 2,915 Â Balance at September 30, 2024 Â Â Â Â Â Â Â Â Â $ 14,464 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2018 PIPE Warrants Â Â Purchase Price Â Â Â Number ofWarrants Â Â Liability Â Â ContingentLiability Â Balance at January 1, 2023 Â Â 34,241 Â Â $ 1 Â Â $ 8,835 Â Change in value of 2018 PIPE Warrants Â Â â€” Â Â Â 652 Â Â Â â€” Â Change in value of contingent liability Â Â â€” Â Â Â â€” Â Â Â 1,633 Â Balance at September 30, 2023 Â Â 34,241 Â Â $ 653 Â Â $ 10,468 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Components of Lease Expense The components of lease expense during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Three Months EndedSeptember 30, Â Â Nine Months EndedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost: Â Â Â Â Â Â Â Â Â Â Operating lease cost $ 137 Â Â $ 76 Â Â $ 291 Â Â $ 235 Â Variable lease cost Â 4 Â Â Â â€” Â Â Â 12 Â Â Â â€” Â Short-term lease cost Â 54 Â Â Â 12 Â Â Â 147 Â Â Â 33 Â Total operating lease cost $ 195 Â Â $ 88 Â Â $ 450 Â Â $ 268 Â Â Â Â Â Â Â Â Â Â Â Â Â Schedule Of Supplemental Cash Flow Information Related To Leases Supplemental cash flow information related to leases was as follows (in thousands):Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Operating cash flows from operating leases $ 248 Â Â $ 264 Â Â Â Â Â Â Â Â Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease The following is a schedule by year of future maturities of the Company's operating lease liabilities as of September 30, 2024 (in thousands):Â Â Â Â 2024 (remainder of the year) $ 64 Â 2025 Â 526 Â 2026 Â 751 Â 2027 Â 861 Â 2028 Â 942 Â Thereafter Â 665 Â Total lease payments Â 3,809 Â Less interest Â (780) Total $ 3,029 Â X - DefinitionSchedule of supplemental cash flow information related to leases. + ReferencesNo definition available. + Details Name: slno_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock Namespace Prefix: slno_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Summary of Outstanding Common Stock Warrants As of September 30, 2024 and December 31, 2023, the following table summarizes the Company's outstanding common stock warrants:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Number of Common Warrant Shares Â Â Weighted Average Exercise Price per Share Â Â Expiration Date Common stock warrants Â Â 7,904 Â Â $ 388.94 Â Â Â 7,904 Â Â $ 388.94 Â Â November 2024 March 2022 Common warrants Â Â 1,273,077 Â Â $ 4.50 Â Â Â 1,929,066 Â Â $ 4.50 Â Â March 2027 May 2023 Tranche A pre-funded warrants Â Â 1,250,647 Â Â $ 0.01 Â Â Â 2,758,281 Â Â $ 0.01 Â Â November 2026 May 2023 Tranche B warrants Â Â 4,935,305 Â Â $ 2.50 Â Â Â 6,750,000 Â Â $ 2.50 Â Â November 2026Â (1) May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â $ 0.01 Â Â Â 451,632 Â Â $ 0.01 Â Â November 2026 October 2023 pre-funded warrants Â Â 250,000 Â Â $ 0.01 Â Â Â 1,175,000 Â Â $ 0.01 Â Â N/A Total Â Â 8,168,565 Â Â Â Â Â Â Â 13,071,883 Â (1) Subject to earlier expiration as described above. Summary of Stock Based Compensation Expense Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development $ 18,516 Â Â $ 935 Â Â $ 23,682 Â Â $ 1,587 Â General and administrative Â 38,082 Â Â Â 1,266 Â Â Â 46,521 Â Â Â 2,449 Â Total $ 56,598 Â Â $ 2,201 Â Â $ 70,203 Â Â $ 4,036 Â Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â 2024 Â 2023 Â 2024 Â 2023 Expected life (years) 6.1 Â 5.3-6.0 Â 5.8-6.1 Â 5.3-6.0 Risk-free interest rate 3.7%-3.8% Â 4.0%-4.4% Â 3.7%-4.6% Â 3.5%-4.4% Volatility 121% Â 98%-100% Â 121%-124% Â 98%-100% Dividend rate â€”Â Â % Â â€”Â Â % Â â€”Â Â % Â â€”Â Â % Summary of Stock Option and Restricted Stock Unit Transactions The following table summarizes stock option transactions for the nine months ended September 30, 2024 which were for awards issued under the 2014 Plan and the Inducement Plan: Â Â Â Number ofOptions Â Â Weighted-AverageExercisePrice per Â Â WeightedAverageRemainingContractualTerm Â Â Aggregate Intrinsic Value Â Â Â Outstanding Â Â Share Â Â (in years) Â Â (in thousands) Â Balance at January 1, 2024 Â Â 2,369,665 Â Â $ 11.56 Â Â Â 8.72 Â Â $ 70,834 Â Options granted Â Â 1,369,230 Â Â Â 42.91 Â Â Â Â Â Â Â Â Options exercised Â Â (171,520) Â Â 7.59 Â Â Â Â Â Â Â Â Options canceled/forfeited Â Â (44,124) Â Â 42.30 Â Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â Options exercisable at September 30, 2024 Â Â 1,116,184 Â Â $ 15.67 Â Â Â 7.40 Â Â $ 41,095 Â Options vested and expected to vest at September 30, 2024 Â Â 3,523,251 Â Â $ 23.55 Â Â Â 8.55 Â Â $ 97,143 Â Summary of Restricted Stock Unit Transactions The following table summarizes restricted stock unit transactions for the nine months ended September 30, 2024 as issued under the 2014 Plan: Â Â Number ofRestricted Stock Units Â Â Weighted-AverageGrant-Date Fair Value per Share Â Outstanding at January 1, 2024 Â Â 15,534 Â Â $ 43.92 Â Restricted stock units granted Â Â 2,007,530 Â Â $ 46.47 Â Restricted stock units vested Â Â (950,534) Â $ 45.81 Â Restricted stock units canceled/forfeited Â Â - Â Â $ 0.00 Â Outstanding at September 30, 2024 Â Â 1,072,530 Â Â $ 47.02 Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na

Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Weighted-Average Common Shares Outstanding The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock Â Â 39,360,966 Â Â Â 10,287,620 Â Â Â 35,824,742 Â Â Â 9,206,650 Â March 2022 pre-funded warrants Â Â - Â Â Â 1,122,819 Â Â Â - Â Â Â 1,227,670 Â May 2023 Tranche A pre-funded warrants Â Â 1,816,427 Â Â Â 26,309 Â Â Â 2,154,299 Â Â Â 8,866 Â May 2023 Tranche B pre-funded warrants Â Â 451,632 Â Â Â - Â Â Â 451,632 Â Â Â - Â October 2023 pre-funded warrants Â Â 250,000 Â Â Â - Â Â Â 486,496 Â Â Â - Â Total Â Â 41,879,025 Â Â Â 11,436,748 Â Â Â 38,917,169 Â Â Â 10,443,186 Â Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares): Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Warrants issued to 2010/2012 convertible noteÂ Â Â holders to purchase common stock Â Â 6,804 Â Â Â 6,804 Â Warrants issued to underwriter to purchase common stock Â Â 1,100 Â Â Â 1,100 Â 2018 PIPE warrants Â Â - Â Â Â 34,241 Â March 2022 common warrants Â Â 1,273,077 Â Â Â 2,130,656 Â May 2023 Tranche A warrants Â Â - Â Â Â 2,867,908 Â May 2023 Tranche B warrants Â Â 4,935,305 Â Â Â 14,000,000 Â Options to purchase common stock Â Â 3,523,251 Â Â Â 2,300,412 Â Outstanding restricted stock units Â Â 1,072,530 Â Â Â 424,244 Â Total Â Â 10,812,067 Â Â Â 21,765,365 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended May 09, 2024 Oct. 02, 2023 Mar. 31, 2022 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Jul. 19, 2024 Dec. 31, 2023 Cash And Cash Equivalents [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â Â Â $ (76,616,000) $ (21,854,000) $ (21,398,000) $ (10,861,000) $ (8,475,000) $ (8,356,000) $ (119,868,000) $ (27,692,000) Â Â Â Accumulated deficit Â Â Â (396,278,000) Â Â Â Â Â (396,278,000) Â Â Â $ (276,410,000) Cash and cash equivalents Â Â Â 48,413,000 Â Â Â Â Â 48,413,000 Â Â Â $ 169,681,000 Marketable securities current Â Â Â 208,363,000 Â Â Â Â Â 208,363,000 Â Â Â Â Long-term marketable securities Â Â Â 27,945,000 Â Â Â Â Â 27,945,000 Â Â Â Net cash used in operating activities Â Â Â Â Â Â Â Â (45,105,000) (18,626,000) Â Â Â Proceeds from sale of common stock, net of costs Â Â Â Â Â Â Â Â 148,955,000 $ 0 Â Â Â Securities Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Sale and issuance of warrants Â Â Â Â Â Â Â Â Â 10,000,000 Â Â Â Â Proceeds from warrant exercise Â Â Â Â Â Â Â 37,700,000 Â Â Â Â Exercisable warrants maximum aggregate exercise price Â Â Â $ 12,300,000 Â Â Â Â Â 12,300,000 Â Â Â Â Jefferies LLC [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate Offering Price Â Â Â Â Â Â Â Â Â Â Â Â Â $ 150,000,000 Â Underwritten Public Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock (shares) 3,450,000 3,450,000 2,666,667 Â Â Â Â Â Â Â Â Â Proceeds from offering after deducting underwriting discount and other estimated offering expenses $ 158,700,000 $ 69,000,000 $ 13,800,000 Â Â Â Â Â Â Â Â Â Underwriter discount and other offering expenses $ 9,700,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Price per unit $ 46.00 $ 20.00 $ 3.75 Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from warrant exercise Â Â Â Â Â Â Â Â Â $ 0 Â Â Â Underwritten Public Offering [Member] | Securities Purchase Agreement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Cash And Cash Equivalents [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from sale of common stock, net of costs Â Â Â Â Â Â Â Â Â Â Â Â Â $ 60,000,000 Â Â X - DefinitionAggregate offering price. + ReferencesNo definition available. + Details Name: slno_AggregrateOfferingPrice Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionExercisable warrants maximum aggregate exercise price. + ReferencesNo definition available. + Details Name: slno_ExercisablewarrantsMaximumAggregateExercisePrice Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionProceeds from offering after deducting underwriting discount and other estimated offering expenses. + ReferencesNo definition available. + Details Name: slno_ProceedsFromOfferingAfterDeductingUnderwritingDiscountAndOtherEstimatedOfferingExpenses Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnderwritter discount and other offering expenses. + ReferencesNo definition available. + Details Name: slno_UnderwritterDiscountAndOtherOfferingExpenses Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=slno_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=slno_JefferiesLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=slno_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details) $ in Thousands Sep. 30, 2024 USD ($) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Amortized Cost $ 235,410 Unrealized Gains 903 Unrealized Losses (5) Estimated Fair Value 236,308 US Treasury Securities [Member] Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Amortized Cost 235,410 Unrealized Gains 903 Unrealized Losses (5) Estimated Fair Value $ 236,308 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Liabilities Â Â Contingent liability for Essentialis purchase price $ 14,464 $ 11,549 Fair Value, Measurements, Recurring [Member] Â Â Assets Â Â Total cash equivalents 26,400 Â Total marketable securities 236,308 Â Total assets 262,708 Â Liabilities Â Â Total liabilities 14,464 11,549 Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] Â Â Assets Â Â Total cash equivalents 26,400 Â Fair Value, Measurements, Recurring [Member] | US Treasury Securities [Member] Â Â Assets Â Â Total marketable securities 236,308 Â Essentialis, Inc. [Member] | Fair Value, Measurements, Recurring [Member] Â Â Liabilities Â Â Contingent liability for Essentialis purchase price 14,464 11,549 Level 1 [Member] | Fair Value, Measurements, Recurring [Member] Â Â Assets Â Â Total cash equivalents 26,400 Â Total assets 26,400 Â Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] Â Â Assets Â Â Total cash equivalents 26,400 Â Level 2 [Member] | Fair Value, Measurements, Recurring [Member] Â Â Assets Â Â Total marketable securities 236,308 Â Total assets 236,308 Â Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | US Treasury Securities [Member] Â Â Assets Â Â Total marketable securities 236,308 Â Level 3 [Member] | Fair Value, Measurements, Recurring [Member] Â Â Liabilities Â Â Total liabilities 14,464 11,549 Level 3 [Member] | Essentialis, Inc. [Member] | Fair Value, Measurements, Recurring [Member] Â Â Liabilities Â Â Contingent liability for Essentialis purchase price $ 14,464 $ 11,549 X - DefinitionAmount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with

banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: slno_AssetPurchaseAxis=slno_EssentialisIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Mar. 07, 2017 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Â Milestones payment $ 100.0 $ 200.0 Â Percentage of probability of achieving milestone 88.00% 88.00% Â Essentialis, Inc. [Member] Â Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Â Maximum potential cash earnout payments Â Â $ 21.2 X - DefinitionAsset acquisition contingent consideration arrangements earn out payment, + ReferencesNo definition available. + Details Name: slno_AssetAcquisitionContingentConsiderationArrangementsEarnOutPayment Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMilestones payment. + ReferencesNo definition available. + Details Name: slno_MilestonesPayment Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of the probability of achieving the milestone. + ReferencesNo definition available. + Details Name: slno_PercentageOfProbabilityOfAchievingMilestone Namespace Prefix: slno_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: slno_AssetPurchaseAxis=slno_EssentialisIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) - USD ($) $ in Thousands 6 Months Ended 9 Months Ended Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Â Balance at the beginning of period, in shares Â 13,071,883 Â Balance at the end of period, in shares Â 8,168,565 Â Purchase price contingent liability [Member] Â Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Â Balance at the beginning of period $ 8,835 $ 11,549 $ 8,835 Change in value of liabilities Â 2,915 1,633 Balance at end of period Â $ 14,464 10,468 2018 PIPE Warrant Liability [Member] | Common stock warrant liability [Member] Â Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Â Balance at the beginning of period $ 1 Â $ 1 Balance at the beginning of period, in shares 34,241 Â 34,241 Change in value of liabilities Â Â $ 652 Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value Adjustment of Warrants Â Â Balance at end of period Â Â $ 653 Balance at the end of period, in shares Â Â 34,241 X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByLiabilityClassAxis=slno_PurchasePriceContingentLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=slno_CommonStockWarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants - Additional Information (Detail) - 2018 PIPE Warrant Liability [Member] - $ / shares 9 Months Ended Sep. 30, 2024 Dec. 19, 2018 Class Of Warrant Or Right [Line Items] Â Â Number of common stock purchased upon issuance of warrants Â 34,241 Weighted Average Exercise Price per Share Â $ 30 Warrant issuance description The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and prior to their expiration on December 21, 2023, entitled the holders to purchase 34,241 shares of the Companyâ€™s common stock at an exercise price equal to $30.00 per share, subject to adjustments. Â X - DefinitionClass of Warrant or Right, Exercise Price Description + ReferencesNo definition available. + Details Name: slno_ClassOfWarrantOrRightExercisePriceDescription Namespace Prefix: slno_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) 1 Months Ended 9 Months Ended 12 Months Ended Jun. 13, 2024 USD ($) ftÂ² Feb. 08, 2024 ftÂ² Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Commitments And Contingencies [Line Items] Â Â Â Â Â Operating lease, extension expiration Â Â Â 2025-05 Â Increase in right of use assets Â Â $ 2,800,000 Â $ 600,000 Operating lease, short-term liability Â Â $ 448,000 $ 448,000 $ 273,000 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Â Â Operating lease, short-term liability Operating lease, short-term liability Operating lease, short-term liability Long-term operating lease liabilities Â Â $ 2,581,000 $ 2,581,000 $ 130,000 Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Â Â Long-term operating lease liabilities Long-term operating lease liabilities Long-term operating lease liabilities Increase in lease liability Â Â $ 2,800,000 Â $ 600,000 Operating lease, weighted average discount rate Â Â 8.50% 8.50% 8.25% Operating lease remaining term Â Â 5 years 5 years 17 months Non-cancelable other commitments Â Â $ 2,800,000 $ 2,800,000 Â Redwood City, California [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Operating lease, description Â Â Â began in June 2021 and expired in May 2023 Â Operating lease beginning date Â Â Â 2021-06 Â Operating lease, expiration Â Â Â 2023-05 Â Operating lease, term of contract 5 years 6 months 24 months 24 months Â Operating lease, expiration date Â Sep. 17, 2024 Â Â Â Area of operating lease | ftÂ² 18,026 4,141 Â Â Â Rent payments $ 57,400 Â Â Â Â Rent payments annual increase percentage 3.00% Â Â Â Â Â X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: slno_CommitmentsAndContingenciesLineItems Namespace Prefix: slno_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncrease in operating lease liability. + ReferencesNo definition available. + Details Name: slno_IncreaseInOperatingLeaseLiability Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLessee, operating lease commencement month and year. + ReferencesNo definition available. + Details Name: slno_LesseeOperatingLeaseCommencementMonthAndYear Namespace Prefix: slno_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLessee, operating lease, extension expiration, month and year. + ReferencesNo definition available. + Details Name: slno_LesseeOperatingLeaseExtensionExpirationMonthAndYear Namespace Prefix: slno_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLessee, operating lease month and year of expiration. + ReferencesNo definition available. + Details Name: slno_LesseeOperatingLeaseMonthAndYearOfExpiration Namespace Prefix: slno_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionOperating lease annually increase percentage. + ReferencesNo definition available. + Details Name: slno_OperatingLeaseAnnuallyIncreasePercentage Namespace Prefix: slno_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionOperating lease right-of-use asset increase. + ReferencesNo definition available. + Details Name: slno_OperatingLeaseRightOfUseAssetIncrease Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of lessee's operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes current operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=stpr_CA Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease cost $ 137 $ 76 $ 291 $ 235 Variable lease cost 4 Â 12 Â Short-term lease cost 54 12 147 33 Total operating lease cost $ 195 $ 88 $ 450 $ 268 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Â Â Operating cash flows from operating leases $ 248 $ 264 X - DefinitionCash paid for amounts included in measurement of lease liabilities. + ReferencesNo definition available. + Details Name: slno_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract Namespace Prefix: slno_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) $ in Thousands Sep. 30, 2024 USD ($) Operating lease liabilities Â 2024 (remainder of the year) $ 64 2025 526 2026 751 2027 861 2028 942 Thereafter 665 Total lease payments 3,809 Less interest (780) Total $ 3,029 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended May 09, 2024 Oct. 02, 2023 Sep. 26, 2023 Dec. 16, 2022 Oct. 31, 2023 Mar. 31, 2022 Jul. 31, 2021 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Jul. 19, 2024 Jun. 06, 2024 Jan. 24, 2024 Jan. 17, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â

Offering Sales Agreement [Member] | Cantor [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Issuance of common stock (shares) Â Â Â Â Â Â Â Â Â Â Â 1,877,170 Â Â Â Â Â Proceeds from the sale of common stock, net of issuance costs Â Â Â Â Â Â Â $ 7,400,000 Â Â Â Â Â Â Â Â Â Â Â Common stock, maximum aggregate purchase price Â Â Â Â Â Â $ 25,000,000 Â Â Â Â Â Â Â Â Â Â Securities Purchase Agreement [Member] Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Sale and issuance of warrants to purchase common stock Â Â Â Â Â Â Â Â Â Â Â $ 10,000,000 Â Â Â Â Â Â Â Â Â Â Shares issued from sale of common stock Â 1,825,000 Â Shares issued from sale of pre-funded warrants Â 1,175,000 Â Proceeds from sale of common stock and pre-funded warrants Â $ 60,000,000 Â Number of common stock purchased upon issuance of warrants Â Â Â 22,598,870 Â Proceeds from warrant exercise Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of preferred stock and warrants for common stock issued. + ReferencesNo definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=slno_TwoThousandTwentyInducementEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=slno_TwoThousandAndFourteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=slno_IncentiveStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=slno_PerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MarchTwoThousandTwentyTwoCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=slno_ControlledEquityOfferingSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=slno_CantorFitzgeraldAndCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=slno_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=slno_SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=slno_JefferiesLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=slno_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MarchTwoThousandTwentyTwoPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_SubsidiarySaleOfStockAxis=slno_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details) - $ / shares 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 8,168,565 13,071,883 Common Stock Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 7,904 7,904 Weighted Average Exercise Price per Share $ 388.94 $ 388.94 Expiration Date 2024-11 Â March 2022 Common Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 1,273,077 1,929,066 Weighted Average Exercise Price per Share $ 4.5 $ 4.5 Expiration Date 2027-03 Â May 2023 Tranche A Pre-funded Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 1,250,647 2,758,281 Weighted Average Exercise Price per Share $ 0.01 $ 0.01 Expiration Date 2026-11 Â May 2023 Tranche B Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 4,935,305 6,750,000 Weighted Average Exercise Price per Share $ 2.5 $ 2.5 Expiration Date 2026-11 Â May 2023 Tranche B Pre-funded Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 451,632 451,632 Weighted Average Exercise Price per Share $ 0.01 $ 0.01 Expiration Date 2026-11 Â October 2023 Pre-funded Warrants [Member] Â Â Class of Warrant or Right [Line Items] Â Â Number of Common Warrant Shares 250,000 1,175,000 Weighted Average Exercise Price per Share $ 0.01 $ 0.01 X - DefinitionClass of warrant or right warrants expiration month and year. + ReferencesNo definition available. + Details Name: slno_ClassOfWarrantOrRightWarrantsExpirationMonthAndYear Namespace Prefix: slno_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MarchTwoThousandTwentyTwoCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MayTwoThousandTwentyThreeTrancheBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_OctoberTwoThousandTwentyThreePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Stock-based compensation expense $ 56,598 $ 2,201 $ 70,203 $ 4,036 Research and Development [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Stock-based compensation expense 18,516 935 23,682 1,587 General and Administrative [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Stock-based compensation expense $ 38,082 $ 1,266 $ 46,521 $ 2,449 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Expected life (years) 6 years 1 month 6 days Â Â Â Volatility 121.00% Â Â Â Dividend rate 0.00% 0.00% 0.00% 0.00% Minimum [Member] Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Expected life (years) Â 5 years 3 months 18 days 5 years 9 months 18 days 5 years 3 months 18 days Risk-free interest rate 3.70% 4.00% 3.70% 3.50% Volatility Â 98.00% 121.00% 98.00% Maximum [Member] Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Expected life (years) Â 6 years 6 years 1 month 6 days 6 years Risk-free interest rate 3.80% 4.40% 4.60% 4.40% Volatility Â 100.00% 124.00% 100.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Â Â Â Â Â Options granted 288,850 77,000 1,369,230 1,663,454 Â 2014 Plan and Inducement Plan [Member] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Â Â Â Â Â Beginning balance Â Â 2,369,665 Â Â Options granted Â Â 1,369,230 Â Â Options exercised Â Â (171,520) Â Â Options canceled/forfeited Â Â (44,124) Â Â Ending balance 3,523,251 Â 3,523,251 Â 2,369,665 Options exercisable at end of period (shares) 1,116,184 Â 1,116,184 Â Â Options vested and expected to vest at end of period (shares) 3,523,251 Â 3,523,251 Â Â Weighted-Average Exercise Price per Share Â Â Â Â Â Beginning balance (in dollars per share) Â Â $ 11.56 Â Â Options granted (in dollars per share) Â Â 42.91 Â Â Options exercised (in dollars per share) Â Â 7.59 Â Â Options canceled/forfeited (in dollars per share) Â Â 42.30 Â Â Ending balance (in dollars per share) $ 23.55 Â 23.55 Â $ 11.56 Options exercisable at end of period (in dollars per share) 15.67 Â 15.67 Â Â Options vested and expected to vest at end of period (in dollars per share) $ 23.55 Â $ 23.55 Â Â Weighted Average Remaining Contractual Term Â Â Â Â Â Options outstanding at end of period Â Â 8 years 6 months 18 days Â 8 years 8 months 19 days Options exercisable at end of period Â Â 7 years 4 months 24 days Â Â Options vested and expected to vest at end of period Â Â 8 years 6 months 18 days Â Â Aggregate Intrinsic Value Â Â Â Â Â Options outstanding at beginning of period Â Â $ 70,834 Â Â Options outstanding at end of period $ 97,143 Â 97,143 Â $ 70,834 Options exercisable at end of period 41,095 Â 41,095 Â Â Options vested and expected to vest at end of period $ 97,143 Â $ 97,143 Â Â X - DefinitionShare based compensation arrangement by share based payment award options exercisable aggregate intrinsic value. + ReferencesNo definition available. + Details Name: slno_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue Namespace Prefix: slno_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionShare based compensation arrangement by share based payment award options non vested aggregate intrinsic value. + ReferencesNo definition available. + Details Name: slno_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValueAbstract Namespace Prefix: slno_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward] + ReferencesNo definition available. + Details Name:

slno_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: slno_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=slno_TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) - Restricted Stock Units [Member] - $ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Â Â Â Restricted stock units granted 366,625 0 758,155 414,710 Restricted stock units vested Â Â (74,250) Â Weighted-average grant date fair value Â Â Â Â Restricted stock units granted (in dollars per share) Â Â $ 46.47 $ 5.25 2014 Equity Incentive Plan [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Â Â Â Beginning balance Â Â 15,534 Â Restricted stock units granted Â Â 2,007,530 Â Restricted stock units vested Â Â (950,534) Â Ending balance 1,072,530 Â 1,072,530 Â Weighted-average grant date fair value Â Â Â Â Beginning balance (in dollars per share) Â Â $ 43.92 Â Restricted stock units granted (in dollars per share) Â Â 46.47 Â Restricted stock units vested (in dollars per share) Â Â 45.81 Â Restricted stock units canceled/forfeited (in dollars per share) Â Â 0 Â Ending balance (in dollars per share) $ 47.02 Â $ 47.02 Â X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=slno_TwoThousandAndFourteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares 41,879,025 11,436,748 38,917,169 10,443,186 Weighted-average common shares outstanding used to calculate diluted shares 41,879,025 11,436,748 38,917,169 10,443,186 March 2022 Pre-funded Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares Â 1,122,819 Â 1,227,670 Weighted-average common shares outstanding used to calculate diluted shares Â 1,122,819 Â 1,227,670 May 2023 Tranche A Pre-funded Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares 1,816,427 26,309 2,154,299 8,866 Weighted-average common shares outstanding used to calculate diluted shares 1,816,427 26,309 2,154,299 8,866 May 2023 Tranche B Pre-funded Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares 451,632 Â 451,632 Â Weighted-average common shares outstanding used to calculate diluted shares 451,632 Â 451,632 Â October 2023 Pre-funded Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares 250,000 Â 486,496 Â Weighted-average common shares outstanding used to calculate diluted shares 250,000 Â 486,496 Â Common Stock [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Weighted-average common shares outstanding used to calculate basic shares 39,360,966 10,287,620 35,824,742 9,206,650 Weighted-average common shares outstanding used to calculate diluted shares 39,360,966 10,287,620 35,824,742 9,206,650 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MarchTwoThousandTwentyTwoPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_OctoberTwoThousandTwentyThreePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 10,812,067 21,765,365 Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 6,804 6,804 Options to Purchase Common Stock [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 3,523,251 2,300,412 Outstanding Restricted Stock Units [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 1,072,530 424,244 Warrants Issued to Underwriter to Purchase Common Stock [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 1,100 1,100 2018 PIPE Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding Â 34,241 March 2022 Common Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 1,273,077 2,130,656 May 2023 Tranche A Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding Â 2,867,908 May 2023 Tranche B Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 4,935,305 14,000,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_UnderwriterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MarchTwoThousandTwentyTwoCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MayTwoThousandTwentyThreeTrancheAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=slno_MayTwoThousandTwentyThreeTrancheBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

H]U2M=R3;R*GR%.C?+%Q6EXM-ZI'^?:L4=U>['++">0ZB%,4TI64FA>7 M[XW/'.SY'ZNR>BUNYH52![T5>RO/91JGJS6(ATPTMB#SE
M%2WUFQ47!5'Z5JP7LA*49(U2D2^0YX6+@K!RMCQKGEV)Y1FO5B6 K(N" MB(?W-.?WYS,X>WSPF:TWRCQ8+,\JLJ;75'VMKH2^6^RL9*R@I62\!(*NSF?O MX)L+C(U"(_$/H_>R=PV,*S>^.7M \-Y8TCF^M MT=EN3*/8OWZT_D?CO';FADAZP?-_6:8VY[-X!C*Z(G6N/O/[/VGK4&#LI3R7 MS2^X;V6]&4AKJ7C1*FL$!2NW_\GW-A]!>A/**!6 1VK@%N%)G*++;+&K4NB
MR/),\'L@C+2V9BZ:V#3:VAM6FFF\5D*_95I/+2]XF2>E)H1G05Y+G+"-*W[PG M.2E3"JZ-80E.P-?K2_#]Q6OP K 2?-GP6I(RDV<+I3$82XNT'>_]+CPT,=XU MK4X!]N8 >]+D^4504#H#1.1L?R"--W${] M-/EC:K?25*KFH*3*YG<\CG@2#F;%(H/L,Y+L0"9.D)\T1*)8N08YU\E.S M$.9'%')K:"^RPY70(@/#8"+X'6M"-VUNUT(',FQ)WS#RAN5FD8.Q%R839 D[MMH3^42U,SL@-RZ"R$V"^\W> :1H MS'"Z6D;3;Q.#@3>%M6-"!(_L^0[A?"9B:]WY%32)>GM4-TWJG;G)^?[T/(5 M%^!WS4KZ%P>Z+8E# ,?;3XR\7E/:(K3L4C&,_0F,'04B M-P5>*)@RNP"MIO*]#%)4HT7O/J;ZT4\?&T%[C1LSV9@+8N?-[3O?$>O*'2N M]>*I[<;GF=4R)>_Q0A&;OM2Y=D7JP.NSDZA]>#]}VK[K'6DC-VE?";JB>JW. M@#1!F(,7WJGG0=T)"7!*\]J^!=";>U[S!^2&"'/J4*L-%^P_FND=#G]\RJ0T M]-\<2=1*ZKU0IC/(&L$G['WM*?/SAO;CUK4.R-TZF'KAY530YCIHSJCY<.[I M/P3#)EX8SL,HGL,@<0<3$ 6N::5H<:/;@<=SST;JDJ;MT_8XJZ&>3N9MYE&3,MK%X5S7'6"2M/4E(QO4I:88X;E3#T MO#%4RZ8>XSB>:!-PU])@=TNC&]NZJ//F)+L];--]N* ;_GACH(U8=9N'%OV M[\EPS^P>^ZF'N%T+A-V' 7W?,KIB*;,>6.#Q <)UHU:-&Q_;8(H"GTXP:*X
M:UNPNVW9LJC\H:4:CYL/%/KAZ$C1(@>#*)@Z$L*]0)CMOL]ZF']]0>=&)^+ M6X\$+'+6O(X%%[_.^;;VD8@U*T2NHU9:T3N-=!C$]G/5]D;QJOGB<\.5XD5S MN:%$@S<"^OV*Z^Z@O3$?D78?#9?_ U!+ P04 " #/@&99ZJ4S_?H" " M"@ & 'AL+W=O0#"-!!I)9JVBXFH:)M%],NW.1 K#IV9AOH]NMWG*09H>&K&A=@.^=]_1SG M&'N\D>I1IP"&/&5>!^[9,C5VP(W&.5W" M',S7?*:PŸ]8N"J82KY=Y:8=.(,'9+ M@JZXN9>;3U ET0+=^L>2Z^-"!:2.S2HP$&\I,E+WVJ%F)+X/?V"(* M$)PJZ%:";I%H25:D=4<-C<9*B[KR7>AF&\'7:%&K,A@G[&N=&X5.&-A--I4CPMI4!"L*4E9PDUV+FEG(H8R-P::W(QHPJ$2<&PF/)+\IZ\)2[1*8[JL6N0P[JY M<37G;3EGL&?..>0=TO6N2. %O1;Y]+#\#F*4^X6\VY2[F'V]!$&]!$'AU]V' M8S!EK$Q#Y()\9 (39Y23F=2LJ+0?-P_:**RWGVVIEMZ]=F^[":]U3F.8.+C+ M-*@\U.-&[-W[H?6A+_#^9-9:A6R]#]Y!{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
MO7QQ@UZ@M$?MJP4*DS,IE)-6 \[C>O)W1\G9_=,SD%O62&W JW4)!,@?CD< M'PW$3Y51C5OVDUOOW]B#A]U-D&.]0K9EN\!\%I>'.Y"<'QM]]=VCM\QPFM1Q M*CZGAZ_.BF*#Z)>=SB%PA8\<+LRAR^"MV)&8WHU42@G*]W0T__DG[%N_0/9> MDVQY3;+5EZB?,MUVJ!E%^0%5FBW4:LN"ON>936HEF*O4>P-*OZ-%BKWLDHP
M25193(74N;BGD.8CEW;$FQH;]@KDG*T9YD)=6U.5853MV#:KGUH4B3NE1#1OB=>86!:4,7@RT; M&S9T07:$/<,%@,EW'-B%H!$A&'3A Y-JV=E%E2?HJE5*C/Q<=%'8M1"2L/.L&-
(*@"#M$(P2"R &U ;-6JC MX:>*W%*NTCQF.44OZ_6]>84*"M:SZ)JEVN2+:])MKH266M%L'7J$:WOJCT' MPCG1/6*6DL)5C"1#2?*QI6H\1+_)-M5T4/KMQ:K%=4.B'@:FWBW*=GGL0VR>Y]B5U]MON MQ9KS.>U=U-@-(E-\%P6)![CLLX=V6_VIL<6#[=K\3_6"WE=KZ]#6D('OXXY, M (>MT#68A64 X79G,/A#$X3
*.LH!H*Y,/;T^/C6^>+C5?:K#:'C_]0*X\&^;D!_ MDF:E!+?$[FO.9QT 8) # QR (#U.V"?.D)[N/\5&WTTF1,]NHE2/6@YRX(MQ$H!)"D2_7)4ZDU,R5!,LKA4U:%.$MVLP"9"YMG=[M'%81!9MF',
D!B[#1^ MX)I[!@#2"2,<8-^HPBN(TW)=!X=^CY&G_M4>[E]_R,@ZV[[12] Q[;$2Z(9[MK 2ZZQXK 4[8RNG9YGE.^:;Z:B&4O+*0Q\W0YFKS9>37ZGN WRXP<'V) M;U?'[QXG^N-GF+>$;])"O3[1M1K*F@1JNOSX9>-X(MFNVKI_9%*RO#K<4I)0 MK@'J_VO&Y-.)'J#YOC3_'U!+ P04 " #/@&99M6MTRKL. #)C@ & M 'AL+W=O-1\2*P;?DOL(
M$.]A05T_U+KGO\83QN9XMR5;1OZL=RK7YS7S>KHE,? MFX=Q^]B4Q7Q[T&HY9F$HQJNB6E =7F_[UUS>UUONF6U+M\U0;M9K8KFZT_E MLGZZN8JNOOW'K]7#HNO_8WQ[_5@\E. +[L/CNT9]&N]1YM6J7+=5O0Z:\O[F MZL?H!YF)_H!MBW]4Y5-[\'/07\K'NO[4?W@[O[D*^S.JE^6LZR$*]<_G\]Y< M+GLD=1Z_[T"O]C'[P]__H8NMQ>O+N9CT99W]?*?U;Q;W%QE5\&\O"\VR^[7
M^NGGU=O9ZK^Z2SLNF_5.0_[ZINJ_!]\VZV,PKU?IU M, H^O)\&K[Y['7P75.O@MT6]:8OUO+T>=^H<^TCCV>Y\?GH^'W;D?'ZKNV() M"\:''W97KU;J/MV>:/"O7\K5Q[+Y-P
SQ6%^G*L+4C=\L0S>%=5\]'8=W!6/ ME3HE##0_ 3};:5;:Y3:OT. *^FE4=AB:'H_V]6Y2-(FZE!I5%W]L_E\';]:Q> ME<&KO]9M^_I(G+&Z2?9W"MO?*6P;.#X2^*=B6:QG91L47?"Q?*C6ZVK]T^8
MEK,W 8^^#UC(&,3X,Z[8XO8CW>?;*.1Q=CW^?$BPV\J[,75;L#A-!3.;Y6ZS M$>-IS*QV$KWOUH*RB 8:?_G/RG\&2P^1'R81G5LZFE$%S2C!)!&:P&>_9C%$VM\/J'_
MS0/5^]13ORWZ802B+78R'4\2JRN@T3P3,QT0,*<,*(G #":2/1),RL3;MMWT M':M .:BGTKJEF_4#9;I\+FW6EGF<;]$0A9D[V-F#*QK;=W"E!,LIP63FSI)U)@Q:)GM: M)B@M?U:-=:ZED
)3WB7NW9SRQ4X_B^Z:>$BP?=/Z2*"21_2C4TCHPX*Y-B;XQ*)FUPK32Q!0G/$)MR830+L1BY,TM0 ET/#8/1H= M&!"13Y8,$70Z5RBV[R-@AV;*()&EF9-9RK Y*9]D0C/IU"Y!="F;8 =LW%V
M3Q"=-@H)- I -K!5@%^S>?F5)L%T<7= CR"=T<9ZA>0ALU)T205FDF]J@PB MW#1XP:0I*B:()*S5SCU)]=G:/9#XD$ASP&*.,D3<+47N1T53NW MV0&P8LZSS%ZT
=KUDXLXLAXE$K_DONB.>12/M>8I- MJO!)T205FLGG01W F0K_I%O# %WN.EML0"4)/ !9PMH!SM;0,-CSA;3LIV] M5+:?SABI;&>0;(?\+=*P.2F:I$(S2=6RG=&M]3-
7IT.GHFF*===^OUUE5+^MOK6BWM&2[M/5*/+K[C8;P?38#*3U/&)ZG-&*G()T635&@FLUKDLXLM MPS- %$V>2(?)CS8,V/GK\0Q:T(Y3NS(0C^!- :D/,.P2 M)%50L^Y6"WQ^CL#_RV:-
>YH<$/@L9G87X:Z^M^7X%(!B0OVQGSI NQ%+8I98 M,P.)7_&Y&=7ZGI^O[T_GE53?R90T;$Z*)JG03#JUO.>XO/<1 M.!S0XM03%STIB2"LVDY&"S &XDY%_*9E:UW@('G; A,;U[GFLM M)
EC4<3MGD>[A8!V#\$EK 6NK06.6POGT@RR"]@ DSBVYQ.[9H?/*V>HA)'L M]4K\VKR9N(2CP+6CP'%'X9")9PKJQWX,A%,-%S;*\-X/.\A\'3$G#2BI$(S M^=!V 0;@$@19-4":):)VGC@N/'P GG*H>)\
MNXM12ODI*5I.BB;Q;)CL:/. X^8!)DXY)(?#3#@4D!H$I&CYP&N05%%-&K1' MP(<7%7@4*'%7>T,%2KMF:($2! 45* 'MX (EJ.&1VS76,C[VDO%^!4HXMN^#
M(8;6_L$")=*X.2F:I$(S^=0F0CS<1#A:H 23Z6I^L/1BUPXMO0"PP-(+H!U< M>H%?];E9U5H^/F>IWJL X_@W5=<\7ZD (,T;DZ*JG03%:U'1#C=H#7=G-7 MEPM7!N(!O7>
<#XF9D\:45&@F0.AO7L@(.?[@DZ[^U$&S4G1 M)!6:R;4V!^+AY@!HTP2%FI"HT*/[GO,YW AD&B@8$'MP:Z1,8>SR8-P[#); M_"JJ.;F$01!K@R >;A"#4G=A-AU$R(U2&:9L+DD-11(T205FDFZ-
A1B MW%#P1#6P@Q;B&2I?)BO.-+>1X)['R\P4A.@IL!V?#HOOR0HN6D M:!+/ALF.=C(2W,G C-0$\@TB/K%W4^$AO"D@+788> V2*JI)@[8^DN'6!_SR MC1AD"-@(T%M SAN_W$T*W%
[]!K#B.&+")7?6Y6#]XLB,M^ B\5C^#=5UR5?\1+)8V;DZ)) M*C2356T<)+AQ\)*Y%+#QWC9K\.C>#W)2+X 435*AF3QJ+R#!O0!TU@6MET>3 M3#C3+E+]3XJ6DZ)*C23+>T4),-?1P"O -
B(6]GZ=N\1]&4%L>Z0 MEA!A:+?+@78C/A',V4(*-,PFQ[2>EN).5SW T75N.%^DKQ=(7#6K'M)J0FMO M%)F2QLU)72O5FOFV6ZW=Q?"ZA:.;IT$R!5!F "D3 ;QBP%8F !:H3(!VL#*!
M&AY5)D)K:7%.58"7/L$C^/8! ;Q -8GI'%S4C1)A6:RJJ6YH-MA(%S)FZH3 ML>]YTAT&@V+F!#$E%9I)B;8 !&X!7/0UW*0.@7 =@K27J';W((]4'2-$D%9K) MM;8'!&X/O'#OM0 \@EC-
=&R7[@>@?.Z]"-0]AP,OR#O]%_"1Q#:1Q"XCT"U M_QH/X]VM #,A3D)WZ8PT;$Z*)JG03&8/OLK@_U&$ '(-O#10.-6] GC]H,T> M!!39.T_QZ_1FY1+.@-#.@!A>)7"ATA#\#+R[(E W$/.$VS1-24\P!
(7/2D)(*S61$&QD"-S+.*P[!0;U[%O"" MQ$PX>[A(@^:D:)(*S?PB%V!^&K1'A]\9+JD!3P"&+;O<#C^W8S4K2<%$V>2(= MD'9,4MPQ><%Z1@HL[-NU(7AT;WI(/1)2-(EGPV1'.QX)H@[JQ0I5 4098G]
MNC@\A#<%I-LL!EZ#I(IJTJ#=CM2KX %X!PQH)::N]<"R,$WLJ<*NG>' .E\D M!>R1"$/G&\5RH-U(S02%_=9D"36,#EX58Z9*FP7I\%H"[.4N<,(H=?M=ZKH%
M/..92!WOE31N3HHFJ=!,/K7[D)YP'SR\U]3U!!*1.,5J>$3O 6E0T)PTJ*1" M,TG1QD%ZT2]!!+D#]A?8O)VV"_#S]NY(I+8"%9K)V<%W&N*VPB4=_@9>/=$UW^(THR%]K=I3$G#YJ1HD@K-_*91[4!D
MN /AY>QEKL9.A2VH(\"\YM"F!I,=#.*2T&VH^QE4 [N+08:'BT MM#C3KD/F]5V(?7+,;WX]MU*XZ4%I/&S4G1)!7:,Y_C=E&6W;3HBMOKQ^*A M_*5H'BHUJ5J6]PH^?--[5DWUL-
A_Z.K'FRLUB?A8=UV]VOZX*(MYV?0-U._O MZ[K[]F&L\)_JYM,VQNW_%!+ P04 " #/@&99#XD33D\" #O! & M 'AL+W=O$]N#8 M5D)IG:=B; MVRPUC5-2P]PR;*I*V)<9*+..=\G.^\[B7Z]+YC2A+:
[&&!;B'>F[)BWJ60E:@ M41K-+*RF_.I\,AOY^!#P4\(6]VSF*UD:\^B=K\64QUX0*,B=9Q"T;. :E/)$ M)..IX^1]2@_BX\7VX4 MAB_;=K$Q9WF#SE0=F!144K>K>.[ZL =(D@. I
,D07>;**B\$4YDJ35;9GTT ML7DCE!K0)$YJ_U,6SM*!)S+KHTNJ,50,++0*%D(1\["T4*]=\C,BCR3/Y9& M%6#Q';M:J1[8:>-%DTA*?J,G 2G,R%.F,G3&KVHS0-!UE@&CE2ZO-%
M>:=JUJI*#]@:LCM#=,AN25WQ/SZB"OLRDUV9L^0HX;=&#]@P?L^2.!FQA\4- M.STY.\([[-LW#+$# [Q]GPZVZ??5$IVER_?GM3:T[*/7V?U 3K 6.4PY31R" MW0#/WKXY'\>?CF@?]=I'Q]BS[X#
(2)I&T4Y(;M"]^K-:GG'@\5.^R3Y>CL9I MM-G/'NU=P@KL.HP:$FFC77L?^]U~FJ_:2_POO'T*[H1=2XU,P8J@\>#R@C/; MCE?K.%.'*[TTC@8DF"6]2&!])VOC'$[QR?HW[CL+U!+ P04 " #/@&99 MS
ZB&G<' +:(& 'AL+W=O9UJB8UXET4M*3GJ__H:4+=DB MQ20+?XGU,AP],\.99TCF]DFJ[WK'>8V>RZ+2+Y=-7+)O9C. MV4I5LAINU>-.[Q5GN1U4%C,21G![\)AYWM7DP6]WNV2-
_X/6W_;V"NUFQ)1S?YA& 6M=&D&6(D_!' 29]?(F+*1\KNY^7=^-XD,(E[PK#8J&/P<^)H7A=$$./X*IUT MWS0#SZ]/VG^VQH,Q&Z;Y6A;_$7F]NYLL)RCG6]84]6_RZ5_\:-#U?
M]'24C28H:W0MR^-@0%"*]OUEST='G T /?X!Y#B # ?$(P/H<0"UAK;(K%E? M6,U6MTH^(66D09NYL+ZQH\$:49DP/M0*W@H85Z_6LLHA*#Q'<*5E(7)6P\U# M#3\0K5HCN45KIG?
H9XBX1N^:BC6Y)GW:(J^/7Q![WYZCWY"HD*_[V2C697K MVUD-R(S^679$\;E%0490I.BKK.J=1O\$-/GE^!E8U)E%3F9])D&%#WS_$=\H M R(1B3UXUJ\?3@-P:..=E:O71,2\;!VZM
[=*E@BR4+%:5(_M-!:UX/K&Y[96 M;>Q7:U+\1N]9QN\FD,.:JP.?K/[^-YQ$__#9?"5E%QZ(.P_$(>VK7Z B%5)[MYT8[,K$C3=DYK*88I\MD>3L[G./WR)%%DI).[+9O$,V#\;F4_Y?2+-VKM<2
M2E,FJTP4'%5'R.:IN"5E%WY*.C\EP0A^X: T$ZRM MOE6.6"E5+?YG'_@L;]7-S*%XV4\B*E/*$G]$5UT2!=!I)^R3'$+$VH?@"Y% M4\YRH3/95#6"QT!8WWG->A!DS;-
&V>CY3%@XZ*8T3N<#&URIR&_ LC-@&4X6 M64WM;"LX,!3BSWM3HGT E\ZGR3P:P(//)Q'Z :09+ V\ M=EX$H*8.C$5(CH ZTK%$4W\:"4DUP4Q+O>L>J1F[S=,J'0@14--Y-#&SO0 M$U.*0?
I[>2L*!+>%[!%)YB-%"9_Q,OY+D*$ZF;(#Y+/+XJ3U]+VZ4O>J;&8:J^5WS/1'[*9?T! M21M**)3*3+LSO[0OV@=>O\3N!%RDPX"Z0E.\6(R$M*=U'&1#PP*FWFNT9S], MJ??BFSN?
IE$ZY"B/%*9T.0*PU/A,<)E1#4\V@@'I!NAQ)%DY6N$(!) 9,BE^F M4HL17HB,%A6 OYJR&# K4>B[]%-J"AX"-D5.ZM-EX![YL1AZORU2]<&\)R MUPO5)<*1Z0>*1*/E?
B>1'&81=L^1)"EQ'Q/$Z&"%TIDHS0)NEIDX1I M\Y?7=+T^T,2EQ&D!QJ&0>GQR>)F0,>0]>Q+I@67J YW2 M"3T#DS #WS;P^\! LP<.NQR,UTO62GH5) MD-DN
;^Z23\JO6P:HJ7;Z'@$QR#W9$G"9/F5U4=H;\LK<<&EP2BC!Q/&S*SB&NB=+DKPIH;>B8M!.OKS^)D$2?G-&?TG; MI1=Z.B9A.KY7,N,\/_H_Z -I5AR7!64)ZR^[H/E@MRO@H="Z 2\%]IX.#A>
MIG,GI*]>XY*>]DF8JE]GC*U7%P].R(7.S'K7-YV,LP5P8MH,;(^)CVWDS"W M7QK'G[G*A'=:.,JEBK80I,JTV9@?T+QOLM@'S)'5L]K04:1R/H?UHQ (ZZY5OI$?G ,W9))HQN:,Z7N9?$MSVD>F5#4Z8&KCPY| M
(:U'A<';BP24IG],V/>UEQ"E+M9Z8OTF0"RW+Z\K+<(X+3E(YT;;1O+6AX M83X>V=8*N3>-O!^U9Z5-\6((W",UDFRT[P5HN!?HJC[T 0=AW+OYX2VB7MPN MU^/Y/$V&?;)';I[$R@SM!
[3ACZ*J3"Q,L\8A<7*O M"6Y'@),T60X75SZY.(G&9G_?/=!PJQ"P@)L-@2!VMR^(ES$>+F4]8G,2TY&U M+.U;"!IN(1Z:_;ZPAUJP@C7;P874C;*9V^U2G2UP3,7J\D-4[8GIR!*=7K7) MN):V2S_U308--
QG#);0R)Z%3N9U"PWC:_)&;FL$PVS_RYZS=/3,%7@X&RTTA M'MEX10Q"\9N^O#YS&Y1Y.C9E^A:%AEN4;Y7="^OG@65>4X"%F^M9X-MIO9H MY+AM\L+:/OSUMUB_=
([&@.L&UL_.3HE+KA[MX;E&%GY[LMH][0[H/]ECZ<'S MS_AFW1ZS]VK:4_^O3$$5TQ#[+:.B,/BX@'JH]2&Q:KFW9J$;6=>RM)<[SG^N MC "|WTI9GV[,!{I_9UC]'U!+ P04 " #/@&99.57_O^D" !2"P
& M 'AL+W=O+(B-(-<3.E:9SE%,"JA+-4MP_#T#"98"_KE MVH(&?5+P-,%H00$KL@S2]R%*R7:@F=INX2E9QUPNZ$$_AVNT1/PY7U QTQN5 M*,D09@G!@*+50+LW>W-'VI<&OQ*T97MC(#-
Y(>153N;10#-D0"A%(9<*4-PV MZ &EJ1028?RI-;7&I03WQSOU29FIR.4%,O1 TMJ)Q..!YFL@0BM8I/R);&>H MSL>5>B%)67D%V\6@+340%HR3K(9%!%F"JSM\]J_#'F"> JP:L(X!YP1@UX#=
M%G!JP&D+N#7@M@6\&O#: IT:Z+1]2WX-^&T]=&N@6Y9#M7_EYH\@AT&?DBV@ MTEJHR4%9024MJCS!LM:7G(JGB>!XL(#O8,/ M'RN\$A J.$A2EA!47@%CPO
M1^#ZZ@9<@02#GS$I&,01Z^M<^)8*>EC[&59^K!-^,;!(,()&.,(10I^=I[O MGN%UD7.3N+5+?&B=%5RB_[8QA=@&9:CB.?A//ZMP&?QT7G\$5*!FR?QO9'O@!5H5=RCEI.GDT]EL,0
M#31Q^#'$-T@+/G\R/>.KJLHN*3:ZI-CXDF*32XI-+RDVNZ38_$)B!W7L-'7L MG%,/?HC&:(Y#DB%P_9TP=J,JW4K"*R5D&{0};CN>9WI]?;-?E0HSR_1=Y]I. MI#2SN_ZAV5AA9AJ^9QZ:311FOM-
Q#ZVF*BO;/4I@IG)I=GWO*+2Y*H..U[4: MLVHK]+T#-D-T779G#(2DP+SZTS2K30-X7_8]1^M#LSLST3!6`=T_^:K; M%#_;=8(92-%*N#+N.J*1H%4'5TTXR*6]8N9!P !R8 !@
!X;"]W;WKKGG'MZ1SYUHG=X)>:,2QC3Y MDJ6Y.ALD6A>OQF,5)2RC:B0*EL.5E9 9U7 HUV-52$9C:Y2EX\#S9N.,\GPP M/[7GKN3|5)0ZY3F[DD2564;EYIREXNYLX ^\)S[R=:+-
B?'\M*!K=LWT+\65 MA*-Q@Q+SC.6*BYQ(MCH;+/Q7YY/ &-@[?N7L3K4^$S.41 WYN!J?#;P#"-6 MLD@;" K ;MD%2U.#!#P^UZ"#QJHK^U@X?!+*EB%R+J<D<DN1O0S <[5&L-
Y'ANLG*M)5SE8*?G[R& ^,9/D MDZ0QS]=D(27-UPSBKM7I6(,'<]\JM'.*[1@!UI(+D6N$T7>Y#&+[]N/@5E# M+]C2.P]0P&M6C$CH##4G@!1.B$BJ90F##9M2AA0UWP':-=DB6&_(^C_DMCTN:
M=@V^ IUT@YKU\TH5-&)G U@@BLE;-IA__YT_ |WY *$|:RA,,?7-9.:J91B;>L6'{D:W+M *|?O$C*7,SZS1XOV91*;GF MX/7-
ER@Q8&01:6/CGX23(6$T2@@E@]KQ54KSP1&AL2ATY<:@Z(3+F'PNJ80P M&5L[82"C--^0F$L0 0'GS:45C^"6NT00KD"-EG_!-:*%A5GQU Q*LL\EV%2# M K#K6D\/F3G:@S5Y/FC9O&
[Y_[GR/SAZ118Y5PDY3ZC.*828#(DH);E(.%L! M*#@P@K4U&)(KF%20G%S#F.+ZMI\+)B&H0+FYS5RD)&/9L@J$P5P*R* YV$9" M-?&CI!578K+#X+PUGM7+;D0NY5Z_B+;,5(9!EXI:&+;BKR[$O!
[0T/N4Q-CO"3@B2KKC,J4,PM2I,R& M&V!IFA):ZD1(C>,$&9JKJA-AC)6DMG)-R)V[G.IM)W,#)07#', !28P@N3!% M-4_)'IYK#I-H0?UHQ (ZZY5OI$?G ,W9))HQN:,Z7N9?$MSVD>F5#4Z8&KCPY| M
_WLL+C/_J=AOZ):<@@NN1B1=QR\B3KVURSG0/=7"'AKT0RW$B0 =K%:4:"P M5S;\T*5#;5T=N@C\8#+T@MEAVB:9?,-T!#NS\;/D"H9,?H=?/ T7(+$\,FNB M$B\@=$@>P-&A23B9#KWCD|
R4#[@U4;VBY;.Q:U?YY=#0B%TQJ:/,W\>JH;ZI5X!1TJ1M20#V&-5I M|VQ-8/@B UC591)44HHG>"M@/3!))AX_O.;H^K(0-E>#"B#Z2T,T(QD>Q%2
M:4(((4@HT%XRF':0>5[.]_!9/&P@#IY,)"?!,0V?_$%NDC<@=9;V9[W9_@ MK0*) 1&X[6QS1F01QJP@P'S;#&%P]SHU0-IKN)89P,)3!MV?'-9_C9^^=]KT MO5.T0?WT*^JM;A>&;3^J1$LHL?
CMO'[V7#[R6* M\W6'^<>E%;$_NQBA2 <^W!PW//(^?XGGL^ DHGS243_#4TXQU<<*MODH(PL/W MW!.\AS_"<9UV4NFQ^W<>-+ AMC8I?)3[0+0@ZAEB2TP/W#4 CRCAH+1Q]>P
MU#N)X/8/NGZ,E=O?\-&]B/D;TI10G!>.\. 9 /E-C%\?+NAG;S79<6PDQP. M$\ZF)*8;='*Y N/CQ6"Q7LM#NA0%K>4IW2Y8S55*%. +8C8[;^?P1 L_I^/; M+O^NAOBXV-]_?,0D&@ UX #A+4'L4=8
Z?Y :!OO<+:8_\880VX M7.\AK#T(CQ'6P E^@,OUOL+: [.'L 9.[(,>L=]/6&N4MK#.=NMJX'0]P'6] W#(\U<<[4'9"EP5*&9/(:[!4Y2$P6)$ ' V"6N/68/4X.Q<5(?X)]4V%[
M[#IWJC!&3O,#7+L/T5<RIL#\P>"ANVOL;L4?W]%+9&:2NL'TR\8-8ML%3^!!7^;/:F M+Z:M.,R!*A6Z2A!.G^3KWJ>H"*&K"&'/YM(.;>TQ: ^4$H^$D/L2U>]>H]M@]
M5E1#) _A+M<'B&H/8I^H.KT/>_ 9W>D45MW^4]$ZF#U$=>*$?M(C]/N):HW2%M63J7=||\6FCEOOYF1,KNT;2(|$ MHLQU]9I.<[9YRVE1O=OC;J]>D;JDV <-.]^S?\!4$L#!!0 (, ^ 9EFCW9,'; 4 M
/\+ 9 >&PO=V]R:W-H965TF3DSŸ,72ND>?,P=Z+@OC+SMY"-6G7L\G.92*=VW%!BL+ZTH5,'19UO>. M51J-RJ(W|<_]DJE3>?|(LY-W=6%K4.A=#4|=>;HLE5M=
M9*)W=5&IC.!Y/%13AU%0@Y+JDHW7UI#CQ65G-/AT?2S[XX8_-"_]UC>))W-K M'V5PEUYV^D*("TZ"("CV?Z%8BT* 0.-'B]G9"F&V]]K]-OH.WR9*\]C6WS7 M:<@O.Z<=2GFAZB+,
[/(W;OWY('B)+7S\I66S]P@G)K4/MFR-,2ZU:?[5DEK>=U8#M^P/*//UH37SRE4KXL@/]>\2-.U?OWPT^]L]WL#W>L#W>A;XS$;LMO]C -.C2&H'N M;<'&TK>B?*M:379"QV"3;-^< QD7[@
X1HC7V.>6]#VC?'R7 M[H*G @V$$B#K5(§^"$S&XQGM3;3Z:9]U"]JY%4 WZ>8YL$CL<(9:!@(%-2\|V"<%M@D?IDH7XHXJV]7764R=2MD=?M=%HUHQ-(0Q M;5#+'3B&7(4-2B!?SS[J3"
(PJ$6,F893 C]D%!"EQ@NB)%P#$H_BU^[^W]2B+ M7LK3TU-\DS3OL|WLYG4[:AYUO[8W3^//:$;:R*6Y@&F_>_*A@[#'YV8S"+:* M3[RY#7@PQD\4.;0O&["^L'@CM ,Y8//FO_H;4$L#!!0 (, ^
9ED@8?^W MA04 .(9 >&PO=V]R:W-H965T. M9!&%*CT<9]GQL)+*)+/SN'?K9N>V"5H9NG7"-U4EW>,5:;N^2$;)=N.;6I:! M-X:S\UHNZ8["W_6MP]>P0RE41<8K:X2CQ45R.7I[->7[\
<(_BM:^MQ;LR=S: M>_[X5%PD&1M$FO+ "!(.*[HFK1D(9OS<8":=2A;LK[?H'Z+O\&4N/5U;_4,5 MH;Q(3A-1T$(V.GRXSC^T]>>(\7*K??PKUNW=R4DB\L8'6VV$84&E3/LK'S94 M<9K)(C#
<"XVAWJRA:^4X&.3MW=BT0:OTODVB7B3%_"NI2^%-(6(B_=P="4UF>#%OY=S'QP8\=|^ MMUO4Z7Y4KI*WOI8Y720H T]N1=C9/#Z$?SL=AT;]L(#%. M10"6F1 ^D(/-*:2\(N1,ZA448H1
65[F109MG6B@]* M?(Q?*0LAA4&+T-9[%GLE1J.S]*Q#*AK'<@$*## MRNC0E3=5HV7 3923RE5H-4S.CM-)IT&&?3A(,J/52^>,<|-A< M^. "Q0=%%7M3<#M(GP6$'89O3=/HL-FQI7%"//S@O<3"
T#C[10]|9Z"G&L2 MGF#'+HRX?-*+&>YJ:Y9_!'+5"U*XM%$C*[FJI=-/ MR(NC0E3=5HV7 3923RE5H-4S.CM-)IT&&?3A(,J/52^>,<|-A< M^. "Q0=%%7M3<#M(GP6$'89O3=/HL-FQI7%"//S@O<3"
0H&V19)GPI'47.L&VYK4 -@;;6WW-*Y3-AF-S:AGP< MIP" -RW(0*Q+E3-;<]TPK]@T>B"7*T_,X46CM9@_QOW.0')1.?:40VCB* @6 M:EV.R)&0!4H%FU)O3&VCNW3,]-
K9G*C8(CPS=DV.N!:..3M:3;5X'8DX8E@0R M%TT>MF71,T@4RN>V,2&RPN+f2J#1 ?,6I$7D;9 Z5F,-.QX41A ACZ_$V4Y9 MS-?G!MNCO1D#6XD+01GXC+Q]!3CRRUP3ETM'A/F*POHB7K-
4<@=^^]U!\@;3 M*)3B,T7K<'1S+2I>NXE2YB^1)SV*FI&9Z3%8D9R9F*3T:\H[PM M,(1O?"A|J,6N,F^W -E%$4E:H>]R+/(NPG"4^JJ/LS3KRA^$74OG)/>3U]_Q MB_>6N(QAV7Y=O8F?
#/7$X5C"W"]:FMG<+P,F$]E%*J[;IHHG#^LN.";;H#YO M*4^]YH[B$!3(VVQR47NB&/A%$QI'J?AHU[0B]PMKMJ@E.EQD*T\C,(3GR.#Y-.&8 M[>_ W=6Y);Q=X!?]F^ M6W?7V]<_ >M)2P4Y-
"XAFZ36=AJ)2M0P3URB+)ROG:QEQZ=?3T'@E2R:JS?1X-GLVK:6V MHXLSOG?M+|Y<&XVVZMJ+T-:U]/>7RKB[\]'1J+MQH]=5!!O3B[-&KM5"Q0 - MMG=)X/_%.KNS#X+)=>3Z:D4++* MJ"
(2!XE_M^I*&4.,H,:GS'/4BR3"X> ^. ^UNV';8L95!7SORARUB=CUZ,1*E6 MLC7QQMW]765[GA*_PIG ?\5=.OOLY4@4;8BNSL30H-8V_9>?LQ\&!"]F>PB.
M,|$QZYT$L9:_R"@OSKR[$YY.@QOJ8%.9&LII2T%91(^G&G3QXE(&'81;B6NO M@K)1)E_94BQ2F.C90J^M7NE"VBCF1>%:&[5=BVMG=*%5.)M&:.$+\ID66>IFD
M'N^1 ^E+|YFRL@GAC2U5NTT]A06_&<6?&Y?$7&2Y4,Q$GL[$XGAV??H'22> ^6 M$^9WLH??#BO%O^?+$#U@])]=!B=^[IOY46J]"HTLU/FH(4?[6S6Z^/FGHV>S MUU_0]K37]O1+W/]O0?
RRU-]=5.)D(GZ$]*| ^?U\IKT0E;Y58*F6%=1_OS3B^/CV6NZR;I?.1M 5L*L4KS5 M5MJ"K%O H0IE, 8F.'I-G(C^BE2Q]W3WZ/GK(.;6MCA_HQKGHT (J&R)HJGA MKP+%FTGNE?
39O%]4D:T[8NM.QD)]+F S66D=Z;"DDKTOO@@(&\PZD,FME6VI MB:YPD&!#^K4Q:=6;%'J3.E]D6P8!1IHD1VO+[AR MW9ID[N+P7V-QTQI%#IT=31BDO@2AN1^3"?>B=.0WR"A,6\
(YQG36:9NZ9Y<7 M^>BY; /I9&:K"4YU2A 99?)N)=`K]KM"6&D%%+BP9*C\%:VGM'C",=.E{J4L,!('93"I)<5*:B^:(0IZ M Q_Z=6CR]2C\>5$_ %'U,2;5=F(#D8:,.AN0CN2H)6*]6F 28-@6=
%,37AB%.*]B& NCY5(;'9&|8QR|5;:E M7^IS0Y .V5N&5WJ4!@76D_W$VN">N>5W>&;%[%EX 4,#E106D.&E"AT"L80F ?{^Z /2.V8]%E]_=6,X9 [*.LD4K:EJAE-"AU1G1"V(>U MO$<@V1D%IS3!
D%P.+G)+BBH72GPK--L!4?!YJ[\D/((/Z_IA.J56+4^|^KQ M0V$@Y^2*NQ.JVUG5P6Q?I92I4N[DM$?EW15SDTO?*-+O*L[:@([A392+

*UPK"3E,#^ ^O;9IOY"#[C>HB_\#4$L#!!0 M (,^ 9EDSEF/JX 0 "(. 9 >&PO=V]R:W-H965T'F!*7!N@)#&CPRS680T MCN7['/W&YHZY+*B"]>#?V5*'HV:_29:PH@G7#V+[&V3Y= U>(+BR_V2;VIZA M<9 H+:+,&1E$+$ZO]&)9W&LBRO**:CH=2;(DTUHAF;FRJ MUAO)L=@LREQ+?,O03X]O*)/D&^4)$+$B-RRF<< H)[>QTC+!V=>*'#W2!0=U M/&QKC&C|VD&&?IFB>^^@GY-[$>M0D>MX"AZ.=U+KQ9P#IM3XCLM MXCE>IP;/+]+W+9[_KI5F6.4XL!=%X^ET?DH>T11U ML2N1)K\0S^^V.JZ#=^>.C_]'1$N.[7BOY3O]QJ/06$3D30S?4EQ#:H$41N[6NV/!VN8RP6)X/+KT"[Q5$0; M&N^^?NE[[MD%OBF(LQ)Q'2+C+:"@HE(**Y/"2YX"Q6]#GL3")$$6.|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|> M!.8+I Z+4R>*(V!T\,)O)TV""M.&^7?P+'Q/0$@1OR@++=B2B-FD@DWC>M36]E2R+G%,P84+ 4!=T[@%K"7L:2F3 M< B^$6MZXK<"2]D4G:+--PI.#+)L%2Y5I^>34W4CQ-'[\BR1?,#MC"0/4>->2F/' M \)5#']RCH$@\; 46T MXP4QC @G[H43CPL'XRU6,5WCL?_.BP8^|[(UO6N,B1S^H+# (_]D*%W?E!PO M'6TDOOOP<6,NG/(>3;Z7N2B'U#7.X(^>#O*|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|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| M=;C(?NXO;]/DE:3E^,(K+U3'7%5?'"5A7,;#4YX6_QL6=?G2#O_:AZLP_T$^ MDOM5<:$X9OTM,>)#\I1'|>9YGZX_:48\>5))A_^_)\TU&E'A%5XQZA5_?J_>XM)(G#"VYX%?[07Y#1F)5?F8M3O>FSRJ(6.A*A=9>X-?_D1W1?GH MXL:K_')S'W/+M?X;SRK7^V\|ZZ$S^F\|JSLO_&L._^]!M;XAP^3GO]9]S#D"QZ?H&U?>^(+W6X<.,66T?0;'2S_\R]!&OV7=:. C M,1F)*4A,16(:$M.1F('$3"1F(3$;B3E(S$5B'@AKQ=/D%$\3GKYTB[7A-LDR M5@!Q*Z\-("0F(S'E@$D55JYSORT_SB2I&#T:W0Z_G:<+8Z0HS*>3SDB-.7*| MF'=&ZHN1PF@N"9V1!F/D?#*;=@::K('C:??^6*RVA<56 M3<^?3>.%),ZZ3SP5.:^&Q'0D9BQ$XE9_?>5C9S706(N$O.FS"R93X1Q-RF0LVI(M3$=B!A(SD9C5=T_9R%D=).8B,4_JY(0@+:2Y<#$F9]>8F'%CPO'3KS3WG[>4 M9#38IV$>THP4%](B*UA1P>6NC0HD)B,Q9=9YHJC^5AD9Z4C,0&(F M$K-Z[RH;.:V#Q%PPXBP5I[,3WDRY^:)G<3KCSE-(Q*QDH65*%SPVD1!8C(2 M4^;=I^EL,>FNN57DK!H2TY&8@<1,)&;UW5,VY)MQ6H%L_HBH0Q278T]?,P7A|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|=5TUHM\ENK$=__R)_BZN""=EQ#-06JJ5!-@VHZ5#.@F@G5+**AF M0S5'|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|&)03+7)[&$^>QJ/=#A=XF0)I M#/#[3 C].#'G>WT]B_X 4$L#!!0 (, ^ 9EGIP,YM4P4 ,$F 9 M>&PO=V]R:W-H965T"DGEF M%(4]Y/O#7D18[$W&V7?W8C+FB0I93.\%D$D4$?%Z14. ^N?2@]_;% WM>JO2+ MWF2\(L]T2M73ZE[HJU[A9"1"H>Y<:Z!Q&+ MM__)CWP@2@:PWV" <@/4U@#G!C@3NN0)NN&*#(9"[X!(FVMO:4?LK')K+4: M%]=IG"JA?V7:3DUN"1/@&PD3"O@"W+*8Q $C(?@22R42G2\EP6](@NDUR5R7A=:T@H/^>=&JHJ!?*.A;%9A*/7FKX*R< M3TI5^_<=C694_%/7=:OW?5/IR%EE(;%0 RL)?M99TS55NO I41'SBH2AX7$ MH377CUSI-2L@<@GH]X2M29AFND[RUL^@5&IHV/?]GPK2&JVCEK-"RUD++7I% M?M%KZ2RD0*;EVKCBG+T7A(?8'_VDR!JSHZ)1H6C40A%I+,-134[0V3L)UB = M)9P7$LX/6?;/74XD1\XJ.J%OD,%OD:S0KC?W,=BQKM?&:5Y3G%E;>J3$,KT(ZKX M[6\ N:-==P!{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`]>(SM"K$W0IQ_^/B3HTU3K$RG!3/>7=E=,]AG-,L,3*\0\(BH2C$*BH M?41!PCFF2W -!18=\$397""^AG."E/]7B=1CF%H/!$,=Z!TP@21(2-H SX^, M$* "> -Y^%?5$LAT=*WQ54QJQ@@$:&RGIZ8F2,?_[)LQ?J_AO$\QO":SD M&[?PC5N'/KZ&1,48 E "&2$P1TMJ,7:#BL,5XIB%'1U<(H)[BI::^&;TIJ! MJ5(PO<^LQY9C7ECJOEJ&ZWW*6IJU1%FOH*S7A#}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|^3/N.-$*A^6%;H%17:+15"<, ^K6.7 SR(<*>)]??SEL?C@2/VV M!M#GV:M2:+^E\;6$K]NL@L !V? MP/'?ORP*>?/%,%^-^4G.!K_JFCA3,|+ M\VP"8..2I^%X>LX37E^@=5LERKA9C"!'N/AD&.@Q S4F$;V!U4''DCNX(0. M?'W0@;_?\>+@EN$T_UO1YIN'[:O8E;_DJ]1B*JZ?-K.,7W&O2F78V@I934) M\TS"?).PP!"LH;93J>WHZ-,_UI@BH2](,%/S@!^B>4RAU_6,9SDTIH+;:K MT"9AGDF8K||>'WKNN>6J1#74BH:H;B6JVW6;192H2:(^69%[0 68 -/T9Y MCEFNDE,+["JG29A7P(82)K9USU-[;(G/I/^\JY3)2H/#2H?-.ANZ#"M=AMT& M6[XBE)TS3%.0Q&@>)S%[5:FCQ795QR3,&QXDRG'&A^*<5BPX+&:/!JUI'U5I M'YV8]KLB[7=ON3X#LPVE?*D[T\,\46-?Q5C)8@SQ-<[OD=[(+GK6/_V/P0;&L8WN,ZZZSUA;SQW)E@65 M-&NL:N$;(U4WT&*[=@.3,&]\,,[<,3P6"P[+P4'[='E9)?[RW>/V=*]LY^B3,\C6+^?O M'$%7U?L[?\QV, XMM&#H%7?C5LG;X6:-2@76CVMJ_Y&:5Y) M.[X3,EIMH*A6MQ>".T8)[#9_;Z5KA2. GOF9)091G(=DP\5\8D25T^2[(X,CD7 $4FF?Z::[VKN!6K-@RI?%|Y"O?SA!8K4C M;(4I"&M'1RF84<_&*,TK:2?,>2<6#$RUKRE0;;= O6/PB*,M(1&8%7TW!+,CD4/E_4 IF#[4=MIC M_?\1&^ACWRF079LXMM[$T0RYUIE4C^PZ[HXT4#[2AZ,S()_I*]\,-D!['F&(G1MF\%_JM[5>.FA+]GO/8LH?-V[V9HI@#G3W_Q-.W ML+,Z)FF!*5I3G=H LO7^Q*/PU=?HM=4^*.-WJ[S=D;-_WSW35]-UY3)*\XW2 M E.TIF"U!63K+:"&8'RSG&U0PO?)10W.QUC(3Z"E>M(LT)=-&W&P+Z51B\4WTKD M?*9<\%#K8L0G.%7|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

&7#I:OBPFHZY82SZ4Q5%;=4%FN R1QF2EHN M5R@SC@;>PX+:)F\$PDT!BZ:N!3I?)F#&3 D7U 1P=MF&$61?TM TZ?B'H3W!- M898&OL@<\Z?XD 3H58BW*DSC5PD76!_#('H'<10G>^*9_3M|\$HX@[XH ||W M>*DH3MLYXSE0J*D4HTKSZ7,1$/YT@*N2=Q&^UJXRGBMX8JS)1?R)4DFO5/(:*

M>W13HV:N82%SFA74CP8*K2I0_8GPC;A/A19[Z+G=N%NG<7(Z"M>[V>WQ&2:] M3QMTN//^*M0K/Y8,9*YN;1/VN_WDF_@'_VQ_2A.Q'6!_:=IQ>LWTBDM#R11$*

M&1U_I'FBVQ'5&E;5_I4OE:69X9 @ "0@ !D !X;*]W;W)K&ULA95A;]HP$(;_BI554RNM30@D0 >1UE;5)K&:@G;I;)*#6$WLS':@_?<[M.VG*AH$OQ'9\[_/>!9\G6R%75 Z@R6M9<#7UB*

HYO5D*6 M5.-4KGU52:"9#2H+/PR"V"\IXUXRL6LSF4Q$K0O&82:)]LN2RK<;*,1VZO6\ M]X4Y6^?:+/C)I*)K6(!^KF829WZGDK$2N&*"$PFKJ?>M=WW3LP%VQR\&6[4S M)B:5I1*

O9O(CFWJ!<00%I-I(4'QLX1:*PBBACS^MJ-#N^%WJWB:/R2RI M@EM1_&:9SJ?>R",9K&A=Z+G8?HB@9+QY MTM>V$#L!87@@(&P#0NN[

5F7=U339'+%EDBS&J7,P*9JH]$@20_*Y*4R+<;&F$!] 4U:H"W)&&"=/ MN:@5FE 37V-JQJ"?MFG<-&F$!])80'5%^L5?$@;A@#PO[LCYV<6_,CY6IBM/ MV)4GM+K] [H?*

C@OK&.NPQ&)H+([+9",V<(N9 W:M*IK"U,,31$!NP$L^?^K% MP=:ACUW*BX0\6G4$,7*MY#C>(#J&&' M&IY"C5RHX1YJ/ C=]%&'&AU%/>6 37RE0:]

HSU@'$=NX+@#CH\#A:9%>XJJ MMD&XT.,]=\4C-WL7O#1Y8*C] =0"EL,I@M*.]M+L,>]'(Z"]R=[MH[G;63 MU]L[?OT@_#]/?Z>QFTORD MU2#-!GR_$D*_3\SUT=W^R5]02P,$%@ SX!F6?I"FGW()@ %,, " !D M !X;*]W;W)K&ULQ=U;<]M&PN;QKX+R;NUFJA*9 M ,]9QU6V<3X#WFPNIO8")B&)%1XT(.C#U/OA7P D!8"$FF3RGU(N8EHF?DV) MUF.H@:?[W;=-

]N?V,4USZ?MJN=]8QSY]^??MV.WM,5\GV;O.4LH_N=]D MJR0O?IL]O-T^96DRKPY:+=\]O=[H[2I9K-\^!?U=]+,S>)OI\N5BG8:9M-VM

M5DGVXV.ZW'S[[8W\YOB!>/'PF)/O^W5/RD'Y.\]^?PJSXW=MG9;Y8I>OM M8K.6LO3^MSN5+2I?I M+*^-I/CE:_HI72Y+]G@A_SJH;YX'+0]L/C[]>O79%Y_-EV2;?MHL_UC,||??

MWDS>2//T/MDM\WCSS4P/G]&P]&:;Y;;ZO_3M\-S>&VFVV^:;U>'@XA6L%NO] MK\GWPU>B<8 \>.$ Y7" , '[A@.'A@.'I <,7#A@= M#AA=^Y+&AP/&UQXP.1PPN?

8E30\'3*!=0>X=W[G>R2*2V/(SV_VU>^V?'R[MY;/W>_32(<;/[E\]IZ_>,CQ39?/WO47#SF^[?+5[(M\?./EJ]Y M^2C6R]5[_W;_K5A]'ZM)GKQ_EVV^25GY_,

(K'U1A4!U??/LNUF5P?,;OGU7II_ YCW=O(^)5E-;;V6%$?3^B\L*(LN1MUOGC5M+6\W3><;PE M/KY_Z7A'?/STTO'>A=>O"("WQ9?_^3U0CN_!1T4H>LD/[3?]65)ZRJ#C]7P2

M'QW,\CNIIU2']SL.5\6'?TZ?[B1E].+AFOAP-9W=2?+^<*7K+\,5+[XOOSBZ M<>DKEST?WC6Z*3[[_B9>|:7K]UY\X^SK#^_ZW)V_-[K[]T;WKGC?

M!6^.QO=?,N,7CP\NG!X4ARN#%X\/+[B<'G<=7@K M/OK/$=ZOO/Y+[^1CDJ72Q^+D;2Y]VJR*4]KM/JT_9%FR?DB+T\Q<^OA#:CXO M3'Y4'_[P+_SRU/K7[5,R2W][4YP[;]/L

M:_KF_?_Z'_*H]W^ZTHS$5!+32$PG,8/$3!*S2,PF,8?$7!+S2,PGL8#$0A*+ M2"R&L%9:#Y[3>B#2WX?99I:F\ZUTGVO64OZ82MMDF4J;>VFV6:V*U-Z69^0_

M2^LT+S^XV&YWR7J6%G^ZS;==X2P<[M9P)C&5Q#02TTG,(#&3Q"P2LTG,V6.C M"BOGUKZ^EP>3Z7#8Z_7>O?W:3-[S9YX\PR-?F$]B 8F%)!:16 QAK3@=/L?I M\(8X?4[+3?

85'%8C,9W$#!(S2@[9D3AD=U^6BUD1IO=IME@_2$_9 MHLC8IS0K'J6_W.._*>5+I6U).-^1=02O4;PW:/.39I!NWT;CH]"5ER2(W$=!(S M2,PD,8O$;!)S2,PE,8_$?!

(+2"PDL8C$8@AKA>SX.63'PI -CNGZXD_ZPN-O MC5$24TE,(S%]?'9:/E$Z3LH-7%C^CSQ=?%/%W/I1^+=-EUZ]-'(71K$)*8

M2F(:B>DD9I"826+6'IN^?"'&OO@,Y^(SW(O/\,A/RB>Q@,1"$HM(+(:P5I3) MO>Y*ETGRPRZ6NRW.TG)S=/U6U0 MU1.*

WY:K*7Y9KE,LFWUQJOR=++#K!M:/SI=A:PRBFHIJ&JKIJ&:@FHEJ%JK9 MJ.87]\-QF<).WA:>4O]?/N)B=IB]XT'J4"5 M1+4*UF-+:F=OH",A7 M_D1=9>:VR-YDL4R^+(O(W63U5??

R0E!6W=/TM$S64I&]Y>/[1;8M _I'=34^ MF3U*/](DZ\Q=XT0KGM,Y1H$V]>LG1Y> !7@I*:BFH9J.JH9J&:BFH5J-JHY MJ.:BFH=]/JH%]!:B6H1J,:6U [QN3LGBZM3GLB"5K.>-

UM3]\2[^K91OI*== M-GLLJOFH M%]!:B&H1JL64U@[ANEDEBZM5?^%F5;%X<[J2FHIJVD%KW0KZ5]\/A M5EYMG[^I%#XO,%"=!G?F,-

K90C45U;2#UEKQX&V\/#T%1OM8J&:BFH5J-JHY MJ.:BFH=]/JH%]!:B6H1J,:6U,[>N@LF7NF#U*>[S7.\J^;Y8[592\O"0I0]E MDR()G&UU$MG_J)5,51344T[:)=GD'5T7

/53%2S4,U&-0?57%3S4,U'M0#5 M0E2+4"VFM/9J_W4VCT4WKXF1FX-6%1344U#-1W5#%0S4T 5^H O]BJ^E^>R:E*YXL_L<+ _;K(C^-9-VY/+AX_)OS&RW6H9J&

M:CJJ&:AFHIJ%:C:J.0>MO2!]OZM\AX[KH9J/:@&JA:@6H5I,:>ULK@MZBKB@ M]Q?N:A.+-ZV@M>JI@\[Y9'1<]5,5+-0S4&U!]5<5/-0S4>U -5"

M5(M0+::T=MK63;SBH2AMVWO@'$YZGR_A=8:M$+PY;$E-134-U714,U#-1#4+ MU6Q4(6W//]Q"GWY\6 MV?X^X?(NB4U65N:2]7KQ-F;YHI0[53%2S4,U&-0?

57%3S4,U'M0#50E2+4"VFM'9"UY4Z15RI MZVIYG+8[]J?*]YOEU@X1CW-S_*+M/%33 M#EIS,K+?W0YIQS50S40U"]5L5'-0S44U#]5\5 M0+42U"-5B2FMG<-W04\0- M/6^QKN)6V

U!RW>HIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQ MI;4BN%\7|/K[[LGK=4/Z:+D/U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 MU4)4BU MIK1V@-?EOKYXP[K@VSK-

MH^+)VFQSM-BA.K*WM=-7EWKVU\2++#Z0 M+)?2;)EMLVGUVVI]8^FGIS2;%4G>N3.H>-R;JCFHU] :B&J1:@64UH[994Z9<4-/*6G]"1K/=_ - M]F?$VK]VB_Q'\9$R/A=?

4RDL=P$5S6.(!['Q*3M&*':IJ]*:CFH^J+JIYJ.:C6H!J{:I%J!936CN@ZQI>O_ :\QAH:P_55%334$U'-0/53%2S M4,U&-0?57%3S4,U'M0#50E2+4"VFM':

U\V^XJ'H#+ON41^W@OZ:+);5[1GW MFTQZ*&_0Z(QE(7MS+).:BFH:JNFH9J":B6K606N6T(=]>7(Z3T&.Z5PUIHN. MZ:&:CVH!JH6H%G6]5QTW-<74J.V K-M5X_0M[V%53ML%3>5:

[%4\UH$T[5%-1 M34,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*UF-+:05R7[OJCUYYJ0)MU MJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:6U [QNV_7%;3MK

M/=NL4BE/ODM?TG5ZO\BW92MZ\|\>_+O(ZJHO7=T@|'"85]@C6==^8;VG!#-175-%334,1OW!<' :>FC=#-4"5 M1+4*UF-+: MH5??ZKBNIF^7Q;!I5.

[ZCK3;OTUW98K,:2KI^7F1YJ>!F2U5,YFEV_SXL%B M_ = 9F&AG#=545--034/*<8_+#PS6+3>5(J'NO6 MC$4U%=4T5--1S4 U$]4L5+-1S;GPG:(:CFHUJ M:B&J1:@64UH[J.M.V4#

<*>N^U4#Z+TGIR8,_T'T0#W=S5]-5,E334$U'-0/5 M3%2S4,U&-0?57%3S4,U'M0#50E2+4"VFM'9<*W5<*Z]\0\(+:^AFHIJ&JKI MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-

8.\+J\-KAV#[G:N@]BIN98 M1BMJI*:AFHYJ\IJ9J&8-SC?@&_6F\GAZ.LN,CNI<.:J+CNJAFHIJ :J%'5I? MI6L=U@=-NX85CX9MAV =?FK>/B?FG HGG7-.1+B5W!S5I:BFH:JNFH9J":

MB6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64UD[PNITV&+[V' 3::D,U%=4T5--1 MS4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LIK1W@=:MM(-[$+-PO!5EN/K2Y ME^Z312:MDNS/-

)>^)LM=Y\X78O'F1$9K:JBFH9J.:@:JF:AFH9J-:LY!:RXE M*9\M)8D.Z:&:CVH!JH6H%]%:3&GMH*W;9P-Q^^SOSG4H

MIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI;4#O"X"#L1%P$^; M=9XELWR7+*4\S59U#[HSC-$V'ZJIJ*:AFHYJ!JJ9J&:AFHUJSH50!;FWKYIT M)B]: 40U'14"5

M1+4*UF-):R3NL*X1#<;')^AS\A^8\Q /?FM*HIJ*:AFHZ MJAFH9J*:AVH^J@6H%J):A&HQI:6#NZX$#N57GO.8HB5!5%-1 M34,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5

M1+4*UF-+: :[4 2[>P>ZV.0\Q M=G,8HX4_5--034+6:ETG'[6S]^7Y<+#@OG,M!>'ZIJ*:AFHYJ!JJ9J&:A MFHUJ#JJYJ.:AFHJJ :J%J!:A6DQI[42NVX;%PU>>RQB@ 4YJ*JIJ*:CFH%J

M)JI9J&:CFH-J+JIYJ.:C6H!J{:I%J!936CO Z[+A4+P5WN_KQG8=U7*B4L=R MSNGW\G%GF)]OY034,U'=4, M5#-1S3IHS95B^J/12!F>9N?Y\T[W NEXRG@XD8?#TS@\?]Y

'HSET^\7_4 M1[4 U\4)4BU MIK1VT-4=O*&X@Z>7]>:JUQ>!LOJ&=IM(P'W&X%T!B#:KT,U M%=4T5--1S4 U$]4L5+-1S1F>]%G[W&(S&7:>8Y\]4^F=/\|"7YZ-:@&HAJD6H M%E-

:.U+K4MQ0O*/<'^GBX;':'^EKFI6K2%0GD+_,DSS=KR;Q'+?)]CFHUJ :B&J1:@64UH[:.L]VDB\.IV%&VK_^C9UXG%O#F2T@89J&IKIJ&:@

MFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-:.,:7.[=?>IFZ$MM90344U#=5T M5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B2FL'>-UD&XF:;%?>'B96;DYA

MM+V&:AJJZ:AFH0J):A:JV:CFC#KW5AL/^V"G10#]5\5 M0 M+42U"-5B2FOGM>0H\ M'?:&_<%IT](--%3S42U M1#5(E2+*:V=M'4#;?1Q%[KI3;9*UK/TE_T.\(6K M?

9WIB_;34$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIK9W1= MGAN-7_LZ'MJ00S45U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BRFM

M'>!U56\DKNI=>QT/:=RAFHIJ&JKIJ&:@FHEJUD%K3A3(2G_;'Y^N\]#QQ--U M'C]MP;GEHI^"AVH^J@6H%J):A&HQI;4#L>[2C<2-(2_)9H^2TE.4\H1V59S*

M_I&4Y[*7YAG0%AV]I:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5I, M::U4'M>%NG'OE>=9QF@##]545--034U -5' M5(M0+::T=H#71;VQN*CG[\3I9_)VM?

99]3ZQNWKY'\7BS8F,5O!034,U'=4, M5#-1S3IH[7F"<;\W/KD/S$;'=:X=UD6']:J&G2K3WFC4'M9'APU0+42U"-5B M2FM'I%)'I'@KN<[?C\<[OC5OJ?9;+%-I3!;S-

)R"9]!6G:&)5IW0S45U314 MTU'-0#43U:R#)O<:.^3&X.YV=1<=TKAK31UBVTXJ'H;UNU4_!FN2S.2@]KZ_3W

M]T7PKA^DVS\DRW4H?'K)T/_O:6'/G4_&#_2837B\3CWMS1I:.BFH:JNFH9J":.MB6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64UL[MNJ4V'K[V]3*TUH9J*JIJ*:C MFH%J)JI9J&:CFH-

J+JIYJ.:C6H!J{:I%J!936CO Z_+;6%Q^LJ;;7=E*Z^8 MS?97S/9UXY^VU06S?W1F,EIV0S45U314TU'-0#43U2Q4LU'-0347U;SQ^8YR

M\F0\EL>]TWEEM,>&:B&J1:@64UH[:NL>VUB\"5R8;69LM]*]]EF)>6/J:1- MEF?A^LT3O/R@XMC.L\VVIS[Y@6TMH9J*JIJ*:CFH%JYOA\"[3QH&,I7@L= MUD8U!]5<5/-0S4>U

-5"5(M0+::T=A37C:2(QN\'VJ16XJ^3[8K5;2VRV6.R+1Z4=T5T9B]:5D,U%=4T5--1S4 U]Z"UMI_<;X5^%K[HUF^H MJ*:BVH>]OFH%J!:B&H1JL64U@[?NOTV%K?Z/]>S7:;

(%^E6"H\Y>WZ)KS-T MT0(U -5"5(M0+::T=H#7 M!;B)N !7WBXG)>MY/7>\N9> ^`9>6R#?UO$9SQKDS]-%>'*JJ*:AFHYJ!JJ9 MJ&:AFHUJSD%K3N3(O:Z)'!<=UT,U'14"5 M1+4*UF-

+:(:S4(2RNV.W+QE4$ M%^?'U;6^KNM\G:F+%NP.6OMZ?/OX*MR9O6BA;W*^ M]YWLK?M[MQMYB2NS6'A8#?G\.#L)\%1YT^'"CJNAFHZJAFH9J*:A6HVJCFH

MYJ*:AVH^J@6H%J):A&HQI;6#N"[D3<3;QM7KG[7"]SCI.Y=V3\4'N^:&.X,8 M+=^AFHIJVN1_S%%&4XGD],[/W5T7 /53%2S4,U&-0?57%3S4,U'M0#50E2+

M4"VFM'80U\6ZR85=Y5IGQ(>0E=++#4FN=88NVZE!-134-U714,U#-1#4+U6Q4 M-QYO0UMS*&:CVH!JH6H%]%:3&GML*UK=1-QK>YO+6DIMF_,7:1"

MAVK:09.5QC=I[VXP4(:GY[AH.P[53%2S4,U&-0?57%3S4,U'M0#50E2+4"VF MM';LUA6ZB;A"=TC9Y.LRK6|Q.V_2'4]Z7V[2B<>Y.8+1)AVJ::BFHYJ!:B;] M69/S7IZL]#M.+VUT7&?

2N=U(=034,U M'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*UF-+:V5R7YZ;]UY[?0,MU]*:B MFH9J.JH9J&:BFH5J-JHYJ.:BFH=]/JH%]!:B6H1J,:6U [QNX!4/12?7'ZH9

MC:R.B\]Z7X+L75S%L.:BFH:JNFH9J":BVH>JOFH%ART MUCTTP\XF;(@.'*%:3&GMH*T;=E-QP^[W]3S-OF6+/$_74KC!LES,ZL05SF"@

M93I44U%-0S4=U0Q4,U'-0C4;U1Q4G!:-5.!\/SGV@^7?M$5?PJ;TY2=-G(8CVV5#-1C4'U5Q4\U#-1[4 U4)4 MBU MIK1V"-;]N*FX%_<\!5O$XRQ6UVQ<_PY?J2F_RQ6OSL.!N;?BIG

=+. MI=TM J':CJJ&:AFHIJ%:C:J.:CFHJ':CZJ!:@6 MHEJ$:C&EM=)7[M5=N/*Q*'_9128OC';KO"K+J2RGL9S.V6,YF.8?E7);S6,YGN8#E0I:+6"[&N)-HEAO1?*'FMK\AX?D4^.EYON#I

M;.WU[C!&NVTLI[*]. M/ITC9D>U6,YF.8?E7);S6,YGN8#E0I:+6"[&N),PIC?"6+PUG)!!(X$'%^Y;:&Z'\3P]D=Q7U_#2^6Z6E[_?':_LE;_IN+27

M;O/%*BE7>K_J(M_Q5;4K+Y/.ZWQ=SQU-_>)N_#)WA[&)*>SG-'Y->Q/.KXN M)CNRO7(VRSDLY[*QG,YR1N+7U4N+&>QG,URSI%K_MMUNFX],Z3'SG,-R+LMY+.>S M7,!R(XD<2>-

Q!6WU*Y:(Z=:_M^#>;/4I*3U'*)1O*.XF?LUJTDLZ%X6^/:G3#.);36$YG.8/E3):S6,YF.8?E M7);S6,YGN8#E0I:+6"[&N)- GS8"?=\I>;W%=8ZO ,MTM+;'*3KVWQM<^]]R'>?3^%F+PY

MI%%.93F-Y726,UC.9#GKR+7W31[W>^.3M85L=F#GZH%==F'/Y7R6"U@N9+F(MY6*,.XG61@M/OM#"N_V&*[%X>[*RO3N4TUA.9SF#Y4R6LUC.9CGGR%U<5L5E

M!_98SF>Y@.5"EHM8+L:XD_A5&O$K[MY=><%/K-P>N6R]#N4TEM-9SF YD^4L MEK-9SCERK64]V<&P-^Z?12[;L$,YG^4"E@M9+F*Y&.-.(K?1L)/%E:R_<,4O

MK$O0UUWU$[^$V_:+>BAG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+|>R7,1R M,<:=A']CM%<\|?N6K?H=7@&4ZR:DLI[&R7,1R,<:=|&^C"RA?Z)>.2G-EOY03F4YC>5TEC-

8SF0YB^5L MEG..W,6%!%UV8(,E')8+6"YDN8CE8HP[B=Q&\4\6%_^NG93^G,YVY9I#Z;9X MUGX->^G#0Y;N)SA:L]??%ZO=ZL(T=-LC1#F5Y326TUG.8#F3Y2R6LUG.83F7

MY3R6\UDN8+F0Y2*6BS'N).8;;4-Y\NK3U&SA$.54EM-83FY@.5"EHM8+L:XDTQO% YE\19_[6G]_#&5MLGR;&OHGZ5UFIBG,9R.LL9+&>RG,5R-LLY+.>RG,=R_I%K+-0F7R5H\.R*&

M;XYAE%-93F,YG>4,EC-9SF(YF^4QG,YR!LN9+&>QG,UR#LNY+.>QG,]R Q7(QQ)YFN M-#)=7'"LE^ZHMAC<2LG79+%,OBSWVPL^O+BCH-B]/:G9RB/*:2RGLYS!N=?

_&9#0X7;P#'=6Y;E27'=5C.9_E I8+62YBN1CC3I*UT6-4Q#W&,,UF MQ9EON59_D:Z;7;[-D_6\O%^DFG"65OLI0+K#E>TGHIS*_"B!-

)D]5KN%=B>V\'72:)Z;IL3(),QTF1W6N&]5E1_58SF>Y@.5"EHM8+L:XDR1NM 45<5OP M+(F?#E?ZMM*7'U)ZN K8?<.%F+X]7-G:(,II+*>SG,%R)LM9+&>SG'/DFB%\

M5AM$A_18SF>Y@.5"EHM8+L:XDP1NU 85<6WPI=I*=^2RY4&44UE.8SF=Y0R6 M,UG.8CF;Y1R6XDTQMU0D6\>6&]-?=NO7CA M-

@JV#GC@FK>Y*R<_8ZKLF!K+Z2QGL)S)3YWY0# M?-MD?U:?_OQ_!E!+ P04 " #/@&99QH_E:P,% #Y'@ &0 'AL+W=O M7AT?24_0>$O9(U\1

M(L!SFF1\XJR$6)^[+H)6),6\1!F8;D029^2. ;Y}4\Q>+DE"MQ.'.]O?(V7*Z%>:<*?C-5Z2&1' MK,^8O'-+E7F?YQ/&4

M(Y*02"@)+/\\D2N2)$I)^OA>B#KE9ZK$W>M7]4]Z\'(P#YB3*YK)^$]W?Y!B0 .E%|&$Z]]@6\1Z#H@V7-"T2)8.TCC+_^+GHA ["5*G M.0$5"6@_H7\DP2\2=.7UC46>#IF=

N8BI9JZD+71F?+T<29>HPSP>2[ML.*)G/"^,_@YOLF%B_@#,SRIPKH GS9""YP-H^S);BB;2IKKY/ M/68,9X*#7ZZ)P""?Y6)/P(7\!5FA(]=(?VI3W&CPLME[@4=\3("MS03*PYN

MLCF9U_-=.:YR<.AU<)?(*#@CZQ[PO=\ \E" P<^5.?V:1#(=ZG3?8,]J&, @'P6#L/NT.ZS .^KM0A]%?!M8L#TK+ Z/EY[I_=DO42!]?EE'OU*=*E M2:PV]*

<>M!1PP8V2V!)K%:"85F"H>V&'1XTXG#D]?>ZM26HYC4LO89&K_=Z MSR)SU^4NUNC/+* 6^#,(F[K'F/C.[H%>M:UZ1F.WF$4KH8&@O08R M+R%FU5,GD"VU>@UV$ -

VM(P4PK;*8$FM7@94E0'97DH*Q=]FAH9R6QON34'0/#%AQ2S0R ,?6U0*;=5_I:]^;W_G;HNJ.Z]0 YI9XPV+2HN"G+;# M.\]O["5CYGM[J6(2:(;26_RBJ13\+3M(_FL'+N3C(&>+C2+G-

RXQ5C'%EE]I M'A6HP*Y(!5I%%5M]]3)4L *MTPH)!&(]E[0/UAB#@/1Y145!3N+@"+8 8_]92Z@B%1I&+GM+S.7:UA6S M[*D3RI9:O0@5N"NT 5911=;:O4R5.B"K*,+.B22_L@?^-

[^[M\0& P'GOQI MGIVH0A?4(;]@!BA!!^C2%E5W7]$+^C"ZM"@8UA5SYGMJ]4(7="*Z7)Z,+N9/ M.'EN=8NJ(7U!6Z(*OH8DNM7H8*79!U=$&'1-(?P,!'^Y.T-:]NN0(7U"&X

MH#>|2UM4W7D%+NC#X-*B8%I@N@ 7OP(7WPPN7R)52OI1>;4I<6L??)7[5W0 MBU_1B]\5O?A6Z<666KT,%:WXUNG%X025&>28F0-WIM 32_-,]3?,2O]$%X*

M[9:UI2T]=^[N'''ZFA"WUF2L'$=UD(C]G+%MSW4O&FF6X7GA]*WF"WCC(,$ M+&2]UQO*NK'\G#6_$72MCRH?]! TU9$0#Y_H2\7JC/[\[9[^#U!+ M P04 " #/@&99 [T],*P# 8$0

&0 'AL+W=O3)I!!TUT_]5LYWS?N>;@P_1(Z#U+ 3AZ*/*2S8R4[^K:-%F< M0H'9%:F@%$^VA!:8BRW=F:RB@!,%*G+3L:S +'!6&O.I.KNE\RG9\SPKX98B MMB*3!^7D)/CS+"-IX.

[;)=R>6#.IQ7>P1KXU^]6BIW9LB19 27+2(DH;&?& MPKZ,;$L"E,1?&1Q99XVD*QM"]N7F2S(S+&D1Y!!S28'%UP%6D.>22=CQO2$U M6IT2V%T_L7]4S@MG-IC!BN1_9PE/9\;80

EL\3[G=^3X&1]'?,D7DYRI3W1L M9"T#Q7O&2=&^A05%5M;?^^$)1 <@>(8!3@-P3@'>,P"W ;@OU> U . ^F&OP&

MH%PW:]I5X$+,\7Q*R1%1*2W8Y$)%7Z%%O+)2%L]4_TS@>7W,2WZK>NZ062+E 1:BF0D:$4*4:$,JOQ'#W(-Z$T('&?Y6P'IN@[1 MFU=OT2N4E>C/E.P9+A.V-

;FP5.HSX\;J96V5\XQ5+KHA)4\9BLH$D@%\>!D_ MN8 W183:,#E/85HZ%PG74%TAUWJ",OQ!NQ9O1SN#KGS_[1'_UE[+QAN6S.N MXG.?XTLQA?

>;\XI84(K+'8@^PM'F$77E;O&C.EX<,4W>]6$KPCCZ]H?0@KYP M*-@_0P53F^0-FR3;Z36K< PS0_1+!O0 QOSU;W9@?1C*EDZR4"=9I(FLEU>O

MS:MWB;WN!4V^XFZ"H'[3A|)2,P:*4?XH'>9^X$_&4_/0C?>YE.-8=E\H/!<:.M68[EJ6BXWSKN7W3\3HO2TSA%HENA$ [BY[-2U?KM!HH-T,&^

MO$CYLP6IDRS4219I(NOE)6CS$OQZC2:0F5>=9*%.LD@362^OHS:O(^V-IE;T M.^^|/?:MX*31G$M-7/^DSYS+.&XP=DIZS(_^?SP:IC/CUN_Q1:_00D4YZK-

M+!)QF\L8IUC>E"!VFHND/UN1.LE"G621)K)>9B9M9B;_7J>9Z,RK3K)0)UFD MB:R75]OZ,=]8VGM-0[F]9+ACZ[1%K ;$;"G*^M*]7]L!Y*,=^-5G^H*__,IC!

M=)>5#.6P%G;JL]Y'HC;0>P^L-)Y6:,S>$BZE5+5/ 8K"4 N+AF#^M)8*00 $#4 M YO\"4$L#!!0 (,^ 9EF76'7H8000)$8 9 >&PO=\]R:W-D4R5 M]\$E UAU8M8VI?

S[,O8@$@T5M*,S%T M%E(N;UQ73!>08M%B2\C4FQGC*99JR.>N6'+ B0:EU T\K^NFF&3.:*#G'OAH MP%:2D@P>,!*K-,5\,P;*UD/'=]XG'LE\(?,)=S18XCE,0'Y9/G

U4;Z59|9>|L'G9.AXN4= 82IS"JQ^O<(= M4)HS*3^^E:1.M68.W'U^9_^H-Z\V\XP%W#'Z+TGD8NCT')3 #*^H?&3KOZ#< M4"?GFS(]$^T+FT]!TU70K*T!"L/4I(5O_%;*<0.(B/

((2$.P#.D< 80D(MSP6T2T#[7$"G!.BNM\7>M7 1EG@TX&R>&ZMV(/'K;Y&*!U(EA^4B>3]+5$X M.9I(-GU9.)H %[^A^-N*R VZ0A-U().5!<1FZ",F'#UANM*CVS7F"?K$<28A

M05\$R>9H3/'TY4IA& 6!_EGJ(_# R31_><\2H.A#!!(3^OO E%>I54D6O$LV#MBB$UBV4.C]@0(O:#?X M2W G_@ONX*:US@4F%MDL66RK6=BMANT9A(_)*$L@2Q+&$)FV[

M!|IZ>|*>M(A.6L0FB]|^KJM|71OW=4|RDJY2|/4>TF?@C>G3R'!I^K1)%MDD MBRV1U<+0]\+0^\DUL&;26)AJZI0%-2P* MJJJLO6,E-

3J/]7^:*;A4RT$OK=M1CPC^2,1+UR]YG\D6'[/K-"=R?Z<-\W^@]IO!EQZZD]TN2;^W+\FA MU>$?'/$IKKHGM5[%FN_9!'3MBU]U/VR?YZGO?

=EJ^N=4Z4<>,X(MU%6#Y>_KT6#2"MK[M:IB("B'90!1F:BFO=:LSQOOO[V(@V5)?\#XS*5FJ'Q> $^"Y@7H_8TR^ M#_(%]O]"C/X'4$L#!!0 (,^ 9EG $(8.P< .PW 9 >&PO=V]R

M;W-H965T=:6PD+K;SB6>2 +-] MZ&PFZ>6ATP<%9)LI!E?(N?S[%1>#A8D"S7G8EP2$SG>D\^G"^2S.'U/^,ULS M)M#3)DZRB]%:B.W99)(%:

[;A3C=LD0^6:9\0X6\Y;M)MN6,AH71)IX0PW F M&QHEH)5Y47;#%^?I3L11PFXXRG:;#>7/5RQ.'R[&>+0ONU6:Y$73!;G6[IB M=TQ\V=*P>3>I4<)HPY(L2A($V?)B=(G/?-

/(#8H:7R/VF!U_,Y(,O=RXZ>?<>O4,3E*TI9QF*D@(K^R +Y?7G=;&+ MI,?L?")D5 ,&3X*J6U=EM\@+W3+1IS01ZPQY2/ ME(YT?7]"W;976W*]]%SK(M#=C%2&X3

M&>,/;+3X\P_L&']W,0X)YD*">9!@/A"8,E*L>J18.O3%?MU:R7$A.A>"IQ+ M+@#R??OA06:SF6V<3QX.R3JN-IT:1JN6>UP+F\Z M_6;L[#IVMC9VQ,

6NHEIN6M\3,)=4,ZLHFR_$W2%5(L[=)9 @KF08!XDF \$ MIC#MU$P[_]UU($<*9!@+B28!PGF

X$I(V5:CY2I=DVX8JLH27)N[ZE2^VV!/C091U\ZN/G

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
*KP_GVRK;9L/E@#V?;M$:/V#^<7M'Q9M=H<1)AG.6D!Q0O0)I9U_]@A,IH&;\D^ # M;SP#:FG).:;F36V0(Q7:)?R>W+X"Y<&!1)O25*F_H)#.=>QP'+',E* M8;&"+,F+7_2M)* (A("'Z!=Q2P#T5)\I\$H:[Z4;_%+ ?ZF&H!10IMN%[8JX M$'$TGU)R %3.%FCR0;&OI 5?22X#Y8%3\341\PX398#H#G7 #7OUMXBPZMBR5-X MWG-XTJN7.%5;XW5;(S'S%MFB)9Y9(O0S3/:;FO_T"A\X?70XV"1::!(L,@;5"P:]" MP=>ASQMI@*DTL%-I8"WB@'=NW$6!%R@\>;KMY]YP.'2#];UOTGT^S6G/", JG MC((Q#$Z HO-*
I/O1'L$9KV1U4=@>OL;L(UBZSM7!]8]$D6!B<$70Y\MW@A.[(MD,X6V\.*[:$VX7Q290".+]$>4U'6%/$%8L0Q6&$@CU*=[B+|]%)VDV"A2;! M(D-@+>>,*N>,?B %@#=)#F*1J1%E8"L2N"H)WG;Y2]NFKZ],@H4%V+B90X8# M?W2R0\YG!8-&7FN1.Z[('6O)=1WHUX?E4AR4HMP&=ZDX)(^E5A>56M"^5)H$ M"TV"18; 6IZ95)Z9_"^*H(G)4#)%IH$BPR!M4(!.G5SY6BWZ0*ODSQ/\K5H M9L7>7':>17J.OJXPBA:6;.TJ0)12GG^2XDPI=-/IM2V67=KUEVSM:X>KS?)M'"$JU5|DX"IR/4#:EMDUZWV%#; MMLVC//Y>.O'.MZPS!+U0:F5+:)K!N3*'_DWH&J&UY>X>O2;30 M*%ID"JWMHK]'AQHF^NS4[-$LZ*%[.\EH1UVBM?H%;S!Q3S?(SVBI8=U30VU7 M:*YOT^OI[0JC77:)!KWO]&ZFM+9]4;?0\%4]=''$]G&%T1[:*%I8HK5=$0S& M\-05AK2V75$WW%#?<3_CBJ7,3RF.[16A*YST=(O1?MPH6EBB:?[3&IE2V/9(MW6A#;?-V4@KUH7URGH=`|<]K8^,=4O4QJ94EIP:C6\ MN->1!JM;WVMUUWDROH!7-(!C/)2WQ.HBLH8OKIAO$6;.,I7@E5SF D(HD6 MM[;%"R=;=2WY2#@GF7K<8!1C*B> ([RM"^/%%*]CNSN?_5!+ P04 " #/ M@&9965A,,5 % =)P &0 'AL+W=OT:R4-L2?>>2YY+7NJ8G#!S\;E>,2;1E[*HZLO92LKUA675Z8J5M'[+ MUZQ23Y9L3N!ZDU9 M4O'UFA7\^7*&9R\W/N:/*]G&+A'B-0VOQ9\Z>ZZWOJ.G* ^>?FXMWV>7,;EK$"I;*!H*JCR=VPXJB05+M M^*<'G0TQ&\?
*M]R_HO|2=5YUYH#6[X<6G/).KRUDX0QE;TDA/ +G7UG?H;:! M*2_]C|Z[FWM&4HWM>1E!ZQ:4.95!TF_]$1L.2@D=G&,C MN+V#>VP$KW=HNVYU?
*6^)BZFDB[G@ST@TU@JM^=*RWWHKOO*J&2CW4JBGN?*3 MB]_46'S/ZQ]MF4#W*RH8>H/NU7#,-@5#?(D^M52S[,W5$Q-JZ* ;7I8JPZUM MC3YL9"UIE>75(_HA9I+FQ8*H6Z? SBVIFM@$LM*^,===<\B!YCCHEE=R5:.D MREBF\8_- I'!WU+4#/R0%WZNB1'PGJW?(L?^"1&;N)KVW!SO[NBZ_^B)_\Y M^H0,9Q@L3HOG','[*:@:*6I0W$N>?
*D9_O5?/T3O)ROIO7:HI,%MK.S;XA MQJIC!VXX-8SW#9TPP@'VHZEAHD&T?=?!H3\83OCR!KZ_&5Y<5&^1H8\XYE M:_ P &/[A@<8TR
*:&?,'QGPC8[=4I*NF@!!T]B;Y:8IK.@3%8)6LD9_W;+R M@0GM_#<"GSK_(<%B2+ $"&R2G6#(3@!9D0/(C$""Q9!@"1#8)"/AD)'P]2JR M,?2I^0LU-8B0$.]4EA@R:*()2DC@!
*[:^2D4#Z]%KUG5C\%-YCX[D'3)HH@EJ MXAW;HWZPO[$^?&U?+]'O:D%0N@%=G;Q.F",.<2B\H6@R*ED"A37.UI?4PY&K1 MHT'E!1(M!D5+H-"F>2%C7LCKK1E]I,G4#
['ODF#GG51C2'S'WBU+.C/LN23: M?2/5&(:A?^!U%(;%!L%U;E+?1_]+KV#;5T:GTV1CBY#D"BQ:!H"13:-%>C.,4>:'TV:MV3\P)%H.B)5!HT[R,$AB;-?!Y MZ]_ _Z.!AWV'[-8;4 5\9-
*0$*NJ4^5'>8J-6.WNQ#X[D'E3K'ADU@8HZY7X4 MLMBL9#^DDJLEH5L]3EXS0*4J*%H,BI9 H4VS- I?'(&N&:!2%A0M!D5+H-"F MVT:C+B9F77S6-:.//7FI]&SUMU.WS&T]-3^:J&
[HNY&_4[>@HDZ9'U4N.;JU M&PO=V]R M;W-H965TKTE"UZ,.I&PN/,2+I5 7G/%PA1=D1L3C M:LKDF5.C1'%,A[3## R'W6NX.4$]56'HL4_,5GSK6.@4GFF]$6=W$6CCJLB
M(@D)A8+ \N.53$B2*"09QW\5:*=^INJX?;Q!_ZM(7B;SC#F9T.0ICL1RU.EW M0$3F.$_$ UU_)E5"OL(+:<+OV!=M74[(,RYH&G564:0QEGYB=\J(K8Z2)SV M#JC]@'8[=
*]T\H.7I%H&5F1U@76>#QD= V8:BW1U$']3=%;9A-G:AAG@LF[MS>PGQE]EI7RAG(,586"VQ(R 3V FBR7*$P+H'$RI()F(<9*|@YLXR17K8$;" MG,4B)AQ\RP47.(OB; %NW]
(DCT@$YHRF8$+352ZP&BVND(K>\N9302V)/EV] M$B9+I7RLCO3;#1$X3GZ7P?#B[M 1,EL5LQ-6F5V7F:$#F0W /5@6@_W]R\2&-P)DO)_VU@NH^BV1Z'>,I=\A4,RZLC7""?L ME73&O_X" _?/-HHL@6F$=6O"NB9TG3#>$$8TPL=]HV]JEUOJA9755O6):!- MU;:Q5X;D%R&I5^KK&+I]B-R@-W1>MYG9;XA@+_"]P*\;:EG[==:^,>LGS!C. M! =WG.)0
*M)52*Y3&+Y>QDDHP9_=@2L(6F@5I11(D:THT?;$I]>>^-58?!\)&+5V-I"TTEKK"TT&L$32<2]TZW0--LG MYR38KB74>%AD]K#W6,XX:@T+;>:<#VG*C'IL\32;JF+2)A34\]S>
[O):2T.$/3?P@P."::PK.GO7>_Q>+/F"OZ5 MPB4!5Q]4C-6%5UMH.@F-DT7=!U",57=K"TTGK7&WR+QT>QK%6+6Z%9HF]W!0 M&[C]]7"PRN]@]65U_4%96%UUMH>DD-,86]+
*[G^KL3T7Y#V'6+GQW).%N[OBEABV(SG,O \TR4NYKUU7K#_:K8 M9MZY?@TO)^6V>0-3[N)+L[>(9?X)F4M(]Z(GPV+EQGAY(NBJV%M^ID+0M#A< M$AP1IAK(^W-
*Q>9$/:#^]X3Q_U!+ P04 " #/@&99$BS6K$D# #P% M#0 'AL+W-T>6QE2D M]7!^O6L_L\!Y&'E)KPX@O6BU<&(_?+D,/)]W!AU=YO:+C\U1,]Q%'/K':1H MCR"../7H,?
*+7DF"",':=;!Q9A?Q6 MU0P$,LX;@9W0&8;]DFA-E;@Q$[O8&E] 03V^7Y9&X5219;MS%X:[,4$&4N5 M4=6$;8]<#03BCG=_ 0^)5O M<2_RC:X-VDO7\4;E.Q1Z]]SLQUAY]
*N]%;1G"WL M?)$W C#V-LY.RI(OOW V%05UFS\XX+!/5G[!3"KV9*)!JTR,@:HP>*1*L\FF MY8\BY3U=Z%4[+7)<<^<(-?_;/$^IH(KP3=&F]]!|SEE^M..Z^E63[5-D5I-58 MO]G?
*N\BK8Q"9'((H^C)WC&(3(] 9/?-GI]'BXS?9R*C^B2T<=S:.FPUU@ . MM8/P)QRB^3IH,)XSKIFH9S.6952\.',9>DW&YL^Y+7ZS/J.YF7-]WX"#<#W^
*M03,V+!)FU2TDHEZU'G^'[;63YD1M8C&1T07-1O543<=V&)B\B5I_P&$7N;$? M/X+Y.,R/ (;%P11@/LX+B_,_[:>'[L=AF+:>%^FA/CW4QWGYD)']8G\/JGY M^'>:IG&
*<)%A&1R.O@A&6MR2!'S\;1@T\L#@0Z>]RC5<;[Y#]?8#5=%^'8#O% M.Q';*9YK0/QY X\T]5<;BP,>6!6PWH'X_CC04WZ?.(;]8MJP.QA'TA1#H!?] M/9HD2'82^/KK@]TE<9RF?
*@0POX(XQA"X&W$$4P :,"2.[7MPYWT4K=Y3T?I_MG,-G4$L#!!0 (, ^ 9EF7BKL"

*-8?20$3;8T.P6BP^0"X9 M9K>]9!:GQ!]8F:-D$<+RL-?S MQ4*6W'^S2VG@RMRZD@GW*5LJKF=(JO(R3YEC+A)7*]%*]2C%.^@GS"_O\PSKU M:DW@>EHXJ_4X2=L+]]
*(%57OHGM:0=WSFFY; 9S\]Q@(R341\&G"OG0].C&9\# MXTI"Y ;L"O92Z2#=.0_RN[/54I2'>AAXBE[T&$TJD.>V MJ$IU0AM')W4-;/O"+7W"#"_E.%EW8=P(=F$"!
*(E=F78HZ%L_*=SZ2K1/'0 W MBJ$[5'#!78D&G [RS!HAC9>"P9&W6@G@$.R4:VX*R2+(#(',M@CY.XL@P^+<^U>JJ4)O$0*A"B!URRKWRS.[9Q$D/79L>C?6F
*M55GR&!.32$ILD4NN'+OGNI(UZZ4RD ^*:W"R#ZXJ8TQ.(RFQ1WIQ.@,Z?_X4 M,T9*KHRR5*')Q^8WA7(7(%$E!$]V(#%CI,3*F 9;/"ZLADKBO[+2)!N>F"B M2(E-
*<0/C7EOOV1+*W3!.Y4WQ>R0$NMA6LV\?*KJ.>%KvZI^"FV).2(FE@%:4 MSC0EQ<20$IL!K2@=$ P31D8L##2#V4Z,B6DD(];(IAQF.["PT])_C2'1E0BQ M1#XF\T93$"
*9L4#>Y@=LEYT(.(.S9^R'2W&Q+R2$7L%3YYXEI]A9LF(S8)C MQO/\#)-,1BP9'',88V+&R8B-@V..8DS,/QFQ?]9SL,T9I&),S#\|9L7_PPKX; M[XM@_LFWZ9_N]@WFGYQ*PS#C
*M2CADH]I\,PS#C@I2CNV'$%MIH_=TBC$Q M"^7$%OH$LUFXNI=X_S('+)1O87WSAME-(&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/-V4V.@D 0AN&K& Y@6U7X-
*U%7LW$[\0)$6S&"$+HGH[PS,H8VP_GPK;T=1&& M3>O/MS/[IJN+>%MV!]<6VU-Q\$Y'HXGK7F=D]]?KS,'FVOK_3&SV^^/62S;; M[!]?XQ^#W4_3G4+I?0]"W
*MHMY*H+>BWDJ@M_9>M@GT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT M5M1;"?0VU-L(]#;4VPCT-M3;"/2VWL<2 KT-]38"O0WU-@*]#?4V KT-]38" MO0WU-@*]#?4V
*KUSU#LGT#M'O?-WZAWBM?+AV?-8X_W?276\7>N?M[\O'YN] MAW#'V<$OC=4O4$L#!!0 (,^ 9EF(C*DWI0$ "\9 3 6T-O;G1E M;G1?5'EP97-
*=+GAM;,V9S6Z#,!"$7P5QC8)C.TU_E.32]MKFT!=P80DH@"W; M29.WKR$_4JL4-4JES@4+O#LS>*7O -.WG2$7;>NJ<;.X\-X\,.;2@FKE$FVH
*M"3NYMK7RX=8NF5'12BV)B=%HPE+=>&K\T+<;:\7SZ1+E:5SYZWH;'KM3-++94 MN3AZW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZNQA6E<8-0$+.S#NW.SP;'OM<-
*M65MF%"V4]2^]#E5L6S'G=Q6YI%_B3$:=YV5*F4[7=6A)G+&D,E<0^;I*]I*# M?FH?C_=!VUM5W_]";]=DUJ5S=&?=?])YI]02P$"% ,4 " #/@&99 M!T%-8H$ "Q $ @ $
9&]C4')O<',O87!P+GAM M;%]+ 0(4 Q0 (,^ 9EEMO+'[@ "L" 1 " :\ M !D;V-0&UL4$L! A0# M% @ SX!F63T:HS3S!0 RA\ !@ ("!#0@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F69&1]83E M!0 :QH !@ ("!!!@ 'AL+W=O !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F6&PO=V]R:W-H965T&UL4$L! A0# M% @ SX!F6:/=DP=L!0 _PL !D
*("!,$(,'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F6069 MBW,E"0 ZQ@ !D ("!&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F6&PO M=V]R:W-H965T.+
*!X;"]W;W)K&UL4$L! A0#% @ SX!F64#(*&AS"0 CQH !D ("! MBHX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ SX!F6= Z1L;M!@ I1(!D ("!GZ$ 'AL+W=O&PO=V]R:W-
*H965T&UL4$L! A0#% @ SX!F66LTM88/ M P]@D !D ("!_K< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F66!Z>Z+E!)QD !D M ("!9,0 'AL+W=O&PO=V]R M:W-
*H965T&UL M4$L! A0#% @ SX!F68RYY8PM P " L !D ("!TM, M 'AL+W=O&PO=V]R:W-H965T&RW@(D(9 M " @1[: !X;"]W;W)K&UL4$L! A0#% @ MSX!F6?I"FGW()@ %,, " !D
*("!,]T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F69=8)>AA! MD1@ !D ("!3PT! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ SX!F65E83#%0!0 '2< !D M ("!]!X!
'AL+W=O&PO=V]R:W-H M965T7!E&UL4$L%!@ Q #$ 3@T % U 0 $\! end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 230 273 1 false 52 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.soleno.life/20240930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 100070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 100090 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) Statements 6 false false R7.htm 100110 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Overview Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureOverview Overview Notes 10 false false R11.htm 995465 - Disclosure - Liquidity Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidity Liquidity Notes 11 false false R12.htm 995475 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 12 false false R13.htm 995485 - Disclosure - Fair Value of Financial Instruments Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 995495 - Disclosure - Warrants Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrants1 Warrants Notes 14 false false R15.htm 995505 - Disclosure - Commitments and Contingencies Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995515 - Disclosure - Stockholders' Equity Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 995525 - Disclosure - Net Loss per Share Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShare1 Net Loss per Share Notes 17 false false R18.htm 995535 - Disclosure - Subsequent Events Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 995555 - Disclosure -*

Fair Value of Financial Instruments (Tables) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments 20 false false R21.htm 995575 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 21 false false R22.htm 995585 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquity 22 false false R23.htm 995595 - Disclosure - Net Loss per Share (Tables) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShare1 23 false false R24.htm 995605 - Disclosure - Liquidity - Additional Information (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail Liquidity - Additional Information (Detail) Details 24 false false R25.htm 995625 - Disclosure - Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details) Details 25 false false R26.htm 995635 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) Details 26 false false R27.htm 995645 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail Fair Value of Financial Instruments - Additional Information (Detail) Details 27 false false R28.htm 995655 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) Details 28 false false R29.htm 995665 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail Warrants - Additional Information (Detail) Details 29 false false R30.htm 995685 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 30 false false R31.htm 995695 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) Details 31 false false R32.htm 995705 - Disclosure - Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details) Details 32 false false R33.htm 995715 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOperat Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details) Details 33 false false R34.htm 995725 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 34 false false R35.htm 995735 - Disclosure - Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details) Details 35 false false R36.htm 995745 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) Details 36 false false R37.htm 995755 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) Details 37 false false R38.htm 995765 - Disclosure - Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail) Details 38 false false R39.htm 995775 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) Details 39 false false R40.htm 995785 - Disclosure - Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail) Details 40 false false R41.htm 995795 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) Sheet http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighteda Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) Details 41 false false All Reports Book All Reports slno-20240930.htm slno-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false

JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT


```
{ "version": "2.2", "instance": { "slno-20240930.htm": { "nsprefix": "slno", "nsuri": "http://www.soleno.life/20240930", "dts": { "inline": { "local": [ "slno-20240930.htm" ] }, "schema": { "local": [ "slno-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 226, "keyCustom": 47, "axisStandard": 17, "axisCustom": 1, "memberStandard": 22, "memberCustom": 27, "hidden": { "total": 20, "http://fasb.org/us-gaap/2024": 10, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 5, "http://www.soleno.life/20240930": 1 }, "contextCount": 230, "entityCount": 1, "segmentCount": 52, "elementCount": 564, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 612, "http://xbrl.sec.gov/ecd/2024": 31, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R3": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "100070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_b65c92db-1db0-4fbe-94ae-799538ccc46f", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5a102da9-a625-4537-ac35-2e388f9779ce", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R6": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "longName": "100090 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_01b97620-1ed6-4a1f-b4b0-f50295b1ea65", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_01b97620-1ed6-4a1f-b4b0-f50295b1ea65", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100110 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm",
```

```
"first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureOverview", "longName": "995455 - Disclosure - Overview", "shortName": "Overview", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidity", "longName": "995465 - Disclosure - Liquidity", "shortName": "Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:LiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:LiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "995475 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments", "longName": "995485 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrants1", "longName": "995495 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:WarrantLiabilityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:WarrantLiabilityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995515 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShare1", "longName": "995525 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureSubsequentEvents", "longName": "995535 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995545 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995555 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995575 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "995585 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995595 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "longName": "995605 - Disclosure - Liquidity - Additional Information (Detail)", "shortName": "Liquidity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1e5e516f-65ce-4250-966d-f1cc553f8f71", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "slno:LiquidityDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R25": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "longName": "995625 - Disclosure - Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta
"longName": "995635 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)",
```

"shortName": "Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1494ba3f-ba32-4750-9888-514978f6caeb", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R27": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "longName": "995645 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)", "shortName": "Fair Value of Financial Instruments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:MilestonesPayment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:MilestonesPayment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "longName": "995655 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail)", "shortName": "Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_1dd7bcf0-b57c-410f-8e7a-7e1808c3fc83", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_75100528-ccdd-4686-b0c1-22374464cd91", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R29": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "longName": "995665 - Disclosure - Warrants - Additional Information (Detail)", "shortName": "Warrants - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_0f061a6e-4ff6-4626-bf57-e24019c88478", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "slno:ClassOfWarrantOrRightExercisePriceDescription", "span", "p", "slno:WarrantLiabilityDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0f061a6e-4ff6-4626-bf57-e24019c88478", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "slno:ClassOfWarrantOrRightExercisePriceDescription", "span", "p", "slno:WarrantLiabilityDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995685 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:LesseeOperatingLeaseExtensionExpirationMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "slno:LesseeOperatingLeaseExtensionExpirationMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail", "longName": "995695 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail)", "shortName": "Commitments and Contingencies - Schedule of Components of Lease Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "longName": "995705 - Disclosure - Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details)", "shortName": "Commitments and Contingencies - Schedule Of Supplemental Cash Flow Information Related To Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "slno:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "slno:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera "longName": "995715 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details)", "shortName": "Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "longName": "995725 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "shortName": "Stockholders' Equity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9a702919-c36f-473f-a7e4-cf26df3be746", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R35": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "longName": "995735 - Disclosure - Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details)", "shortName": "Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_29ea4adf-efec-411d-be05-cc74cae6af7b", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1c55d4df-7bc7-46a7-ae3b-4b6dfa8c4c69", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R36": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail", "longName": "995745 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail)", "shortName": "Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail", "longName": "995755 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail)", "shortName": "Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "longName": "995765 - Disclosure - Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail)", "shortName": "Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_eb6ccb76-cafe-4c5c-90db-ac14a5291c09", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2539e12f-afaa-49d5-8f00-e9050dd37b71", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R39": { "role": "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail", "longName": "995775 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail)", "shortName": "Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_95c910a8-6da8-

484a-b23c-e3cc54432fbc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_09bd42fa-b2c2-40f2-9a09-34f1bd94a32e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R40": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "longName": "995785 - Disclosure - Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail)", "shortName": "Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_3b92e3d4-77a4-499d-aa76-14e99700820e", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_01e49438-dd3c-4302-9c14-6a145b1fd93d", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "unique": true } }, "R41": { "role": "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "longName": "995795 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail)", "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c45c3dd8-1029-4bd6-97da-2ffdb5f177bb", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "slno-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201613Member", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU No. 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": ["r171"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r37", "r590"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of premium/discount on marketable securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r59"] }, "slno_AccruedClinicalTrialCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AccruedClinicalTrialCostsCurrent", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical trial site costs", "label": "Accrued Clinical Trial Costs Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive gain", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r15", "r16", "r52", "r100", "r441", "r462", "r466"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r9", "r16", "r310", "r313", "r383", "r457", "r458", "r702", "r703", "r704", "r710", "r711", "r712", "r713"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r648"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r47"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r475", "r710", "r711", "r712", "r713", "r764", "r819"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r661"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r661"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r661"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r661"] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r85", "r86", "r87", "r88", "r89", "r90", "r125", "r126", "r127", "r128", "r139", "r161", "r162", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r190", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r349", "r350", "r359", "r360", "r361", "r378", "r379", "r380", "r381", "r382", "r383", "r396", "r397", "r398", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466"] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Tax withholding payments for net share-settled equity awards", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r33", "r34", "r241"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of common stock warrants, net of issuance costs", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r10", "r29", "r65"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "slno_AggregrateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AggregrateOfferingPrice", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Aggregrate offering price.", "label": "Aggregrate Offering Price", "terseLabel": "Aggregrate Offering Price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate

Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r694"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r620", "r630", "r640", "r672"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r623", "r633", "r643", "r675"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r695"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r661"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r668"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r624", "r634", "r644", "r668", "r676", "r680", "r688"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r686"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r269", "r271"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "slno_AnishBhatnagarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AnishBhatnagarMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Anish Bhatnagar [Member]", "label": "Anish Bhatnagar [Member]", "documentation": "Anish bhatnagar." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computations of diluted weighted-average shares outstanding", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r148"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Area of operating lease", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r296"] }, "slno_AssetAcquisitionContingentConsiderationArrangementsEarnOutPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AssetAcquisitionContingentConsiderationArrangementsEarnOutPayment", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Maximum potential cash earnout payments", "label": "Asset Acquisition Contingent Consideration Arrangements Earn Out Payment", "documentation": "Asset acquisition contingent consideration arrangements earn out payment," } } }, "auth_ref": [] }, "slno_AssetAcquisitionContingentConsiderationChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AssetAcquisitionContingentConsiderationChangeInFairValue", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "label": "Asset Acquisition Contingent Consideration Change In Fair Value", "documentation": "Asset acquisition contingent consideration change in fair value." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta" "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability for Essentialis purchase price", "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent." } } }, "auth_ref": ["r763"] }, "slno_AssetPurchaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AssetPurchaseAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Asset Purchase", "label": "Asset Purchase [Axis]", "documentation": "Asset purchase." } } }, "auth_ref": [] }, "slno_AssetPurchaseDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AssetPurchaseDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Asset Purchase", "label": "Asset Purchase [Domain]", "documentation": "Asset purchase." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r71", "r78", "r96", "r117", "r152", "r155", "r157", "r158", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r298", "r302", "r351", "r437", "r502", "r564", "r565", "r590", "r611", "r731", "r732", "r778"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r92", "r101", "r117", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r298", "r302", "r351", "r590", "r731", "r732", "r778"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r328", "r329", "r581"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Long-term assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "slno_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "AtTheMarketOfferingMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "AT the market offering.", "label": "AT the Market Offering [Member]", "terseLabel": "At the Marrket Offering" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r167"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails" ],
"lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with
change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r168" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation":
"Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } },
"auth_ref": [ "r165", "r184", "r436" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Estimated Fair Value", "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation":
"Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [
"r166", "r184", "r328", "r430", "r581", "r584", "r720", "r767", "r768", "r769" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Total marketable securities", "documentation": "Amount of investment in
debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r164",
"r184" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r683" ]
}, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } },
"auth_ref": [ "r684" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang":
{ "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r679" ] },
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]",
"terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r679" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role":
{ "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r679" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r679" ] },
"ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI
Disclosure" } } }, "auth_ref": [ "r679" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined
[Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r679" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by
type of award under share-based payment arrangement." } } }, "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254",
"r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r682" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r681" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI
Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r680" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r680" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or
basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
} } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
"documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used
to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe
all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureOverview" ], "lang": { "en-us": { "role": { "terseLabel": "Overview", "label": "Business Description and Basis of
Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature
and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business
divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying
basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref":
[ "r36", "r60", "r61" ] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Redwood City, California [Member]", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "slno_CantorFitzgeraldAndCoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.soleno.life/20240930", "localname": "CantorFitzgeraldAndCoMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor
[Member]", "label": "Cantor Fitzgerald And Co [Member]", "documentation": "Cantor Fitzgerald and Co." } } }, "auth_ref": [] }, "us-
gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Purchases of property and equipment included in accounts payable", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay
for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us-gaap_CapitalUnitsAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CapitalUnitsAuthorized", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Capital stock, shares authorized", "label": "Capital Units, Authorized", "documentation": "Number of authorized capital units or capital shares. This
element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash
Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash
Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of
currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.
Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk
of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r19",
"r94", "r556" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai
], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents", "documentation": "Fair value portion of
currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.
Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk
of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r765", "r766" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents
[Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash,
Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash
and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash
equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not
limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents
```

include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r19", "r57", "r116"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r57"] }, "slno_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": ["r83", "r84", "r90", "r124", "r161", "r172", "r173", "r174", "r180", "r181", "r186", "r190", "r276", "r279", "r280", "r288", "r289", "r291", "r305", "r306", "r316", "r317", "r349", "r350", "r360", "r378", "r379", "r396", "r397", "r455", "r456"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": ["r83", "r84", "r90", "r161", "r172", "r173", "r174", "r180", "r181", "r182", "r186", "r190", "r276", "r279", "r280", "r288", "r289", "r290", "r291", "r292", "r304", "r305", "r306", "r307", "r316", "r317", "r318", "r321", "r349", "r350", "r360", "r378", "r379", "r396", "r397", "r455", "r456", "r699"] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": ["r125", "r138", "r177"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r659"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r656"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r654"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r97", "r98", "r99", "r154", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r469", "r470", "r471", "r472", "r572", "r698", "r707"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r30"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "slno_ClassOfWarrantOrRightExercisePriceDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ClassOfWarrantOrRightExercisePriceDescription", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Warrant issuance description", "label": "Class Of Warrant Or Right Exercise Price Description", "documentation": "Class of Warrant or Right, Exercise Price Description" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Balance at the end of period", "periodStartLabel": "Weighted Average Exercise Price, Balance at the beginning of period", "verboseLabel": "Exercise price of warrants exercised", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Weighted Average Exercise Price per Share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r230"] }, "slno_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants, net of issuance costs (shares)", "label": "Class Of Warrant Or Right Exercised", "documentation": "Class of warrant or right exercised.", "verboseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "slno_ClassOfWarrantOrRightExercisedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ClassOfWarrantOrRightExercisedValue", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants, net of issuance costs", "label": "Class Of Warrant Or Right Exercised Value", "documentation": "Class of warrant or right exercised value." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of common stock purchased upon issuance of warrants", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r230"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Warrants outstanding", "periodEndLabel": "Balance at the end of period, in shares", "periodStartLabel": "Balance at the beginning of period, in shares", "terseLabel": "Number of Common Warrant Shares", "verboseLabel": "Number of Common Shares", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails",

"http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r30"] }, "slno_ClassOfWarrantOrRightWarrantTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ClassOfWarrantOrRightWarrantTerm", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Term", "terseLabel": "Warrants term", "label": "Class Of Warrant Or Right Warrant Term", "documentation": "Class Of Warrant Or Right, Warrant Term" } } }, "auth_ref": [] }, "slno_ClassOfWarrantOrRightWarrantsExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ClassOfWarrantOrRightWarrantsExpirationMonthAndYear", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Expiration Date", "terseLabel": "Expiration period", "label": "Class Of Warrant Or Right Warrants Expiration Month And Year", "documentation": "Class of warrant or right warrants expiration month and year." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r660"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r660"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r43", "r74", "r438", "r489"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r63", "r192", "r193", "r542", "r725", "r730"] }, "slno_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and contingencies." } } }, "auth_ref": [] }, "slno_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments and contingencies." } } }, "auth_ref": [] }, "slno_CommonStockMaximumAggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommonStockMaximumAggregatePurchasePrice", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, maximum aggregate purchase price", "label": "Common Stock Maximum Aggregate Purchase Price", "documentation": "Common stock, maximum aggregate value purchase price." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r601", "r602", "r603", "r605", "r606", "r607", "r608", "r710", "r711", "r713", "r764", "r817", "r819"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r46"] }, "slno_CommonStockPurchaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommonStockPurchaseLiability", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Common stock purchase liability.", "label": "Common Stock Purchase Liability", "terseLabel": "Common stock purchase liability" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r46", "r490"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r46"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "verboseLabel": "Number of shares available for issuance under the plan on the first day of each year", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r46", "r490", "r508", "r819", "r820"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized, 41,041,216 and 31,678,159 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r46", "r440", "r590"] },
"slno_CommonStockWarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommonStockWarrantLiabilityMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Common stock warrant liability [Member]", "label": "Common Stock Warrant Liability [Member]", "documentation": "Common Stock Warrant Liability [Member]" } } }, "auth_ref": [] }, "slno_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "CommonStockWarrantsMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Common stock warrants.", "terseLabel": "Common Stock Warrants [Member]" } } }, "auth_ref": [] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r665"] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r664"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r666"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r663"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r106", "r108", "r112", "r431", "r448", "r449"] },
"slno_ContingentReceiptUponExeriseOfWarrantsAndFuturePerformanceOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ContingentReceiptUponExeriseOfWarrantsAndFuturePerformanceOfCompany", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Contingent receipt upon exerise of warrants and future performance of company", "label": "Contingent Receipt Upon Exerise Of Warrants And Future Performance Of Company", "documentation": "Contingent receipt upon exerise of warrants and future performance oF company." } } }, "auth_ref": [] },
"slno_ControlledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ControlledEquityOfferingSalesAgreementMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Controlled Equity Offering Sales Agreement [Member]", "label": "Controlled Equity Offering Sales Agreement [Member]", "documentation": "Controlled equity offering sales agreement." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member]", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": ["r735"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r118", "r119", "r210", "r225", "r384", "r393", "r435", "r557", "r559"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page."

```
} } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r38", "r39", "r72", "r73", "r120", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r567", "r568", "r569", "r570", "r571", "r588", "r708", "r726", "r727", "r728", "r772", "r773" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r14", "r120", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r567", "r568", "r569", "r570", "r571", "r588", "r708", "r726", "r727", "r728", "r772", "r773" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r28" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments, Liabilities [Member]", "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [ "r343" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Board of Directors [Member]" } } }, "auth_ref": [ "r719", "r818" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r615" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r647" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r658" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Net loss per common share basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r113", "r129", "r130", "r131", "r132", "r133", "r134", "r141", "r143", "r145", "r146", "r147", "r151", "r286", "r295", "r325", "r326", "r432", "r450", "r561" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Net loss per common share diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r113", "r129", "r130", "r131", "r132", "r133", "r134", "r143", "r145", "r146", "r147", "r151", "r286", "r295", "r325", "r326", "r432", "r450", "r561" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShare1" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r140", "r148", "r149", "r150" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Future stock-based compensation, requisite service period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r270" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r762" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Future stock-based compensation for unvested employee options granted and outstanding", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r762" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefits recognized from stock-based compensation", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r269" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options [Member]", "documentation":
```

```
"Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r613" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r613" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r613" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r697" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r613" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r613" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r613" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r613" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r652" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r693" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r693" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r693" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r87", "r109", "r110", "r111", "r121", "r122", "r123", "r126", "r133", "r135", "r137", "r153", "r176", "r183", "r187", "r231", "r274", "r275", "r282", "r283", "r284", "r287", "r294", "r295", "r308", "r310", "r311", "r312", "r313", "r315", "r324", "r352", "r353", "r354", "r355", "r356", "r357", "r360", "r362", "r383", "r447", "r457", "r458", "r459", "r475", "r528" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r662" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r620", "r630", "r640", "r672" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r617", "r627", "r637", "r669" ] }, "slno_EssentialisIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "EssentialisIncMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Essentialis, Inc. [Member]", "label": "Essentialis Inc [Member]", "documentation": "Essentialis, Inc." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r668" ] }, "slno_ExercisablewarrantsMaximumAggregateExercisePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ExercisablewarrantsMaximumAggregateExercisePrice", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Exercisable warrants maximum aggregate exercise price.", "label": "ExercisableWarrants Maximum Aggregate Exercise price", "terseLabel": "Exercisable warrants maximum aggregate exercise price" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of stock warrants", "verboseLabel": "Change in fair value of warrants liabilities", "negatedTerseLabel": "Change in fair value of warrants liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r7" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r328", "r329", "r342", "r581" ] }, "us-
```

gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r328", "r329", "r342", "r581"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r330", "r331", "r332", "r584"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r330", "r331", "r332", "r584"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Convertible Preferred Stock Warrant Liability", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r330", "r331", "r584"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338", "r343", "r582"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338", "r343", "r582"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r215", "r233", "r234", "r235", "r236", "r237", "r238", "r327", "r329", "r330", "r331", "r332", "r341", "r342", "r344", "r388", "r389", "r390", "r568", "r569", "r574", "r575", "r576", "r581", "r584"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338", "r343"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r328", "r329", "r330", "r332", "r581", "r768", "r770"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r337", "r339", "r340", "r341", "r344", "r345", "r346", "r347", "r348", "r429", "r581", "r585"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r215", "r233", "r238", "r329", "r342", "r388", "r574", "r575", "r576", "r581"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r215", "r233", "r238", "r329", "r330", "r342", "r389", "r568", "r569", "r574", "r575", "r576", "r581"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r215", "r233", "r234", "r235", "r236", "r237", "r238", "r329", "r330", "r331", "r332", "r342", "r390", "r568", "r569", "r574", "r575", "r576", "r581", "r584"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338", "r343"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r333", "r334", "r335", "r336", "r337", "r338", "r343"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Fair Value of Level 3 Financial Instruments", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included

in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r333", "r338", "r343"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r328", "r329", "r330", "r332", "r581", "r768", "r770"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Change in value of liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r334", "r343"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of period", "periodEndLabel": "Balance at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r333", "r343"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r215", "r233", "r234", "r235", "r236", "r237", "r238", "r327", "r329", "r330", "r331", "r332", "r341", "r342", "r344", "r388", "r389", "r390", "r568", "r569", "r574", "r575", "r576", "r581", "r584"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r581", "r765", "r766", "r767", "r768", "r769", "r770"] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": ["r334", "r343"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r624", "r634", "r644", "r676"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r624", "r634", "r644", "r676"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r624", "r634", "r644", "r676"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r624", "r634", "r644", "r676"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r624", "r634", "r644", "r676"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r657"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r54", "r512"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r54"] }, "slno_GoingConcernAndManagementsPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "GoingConcernAndManagementsPlansTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidity"], "lang": { "en-us": { "role": { "label": "Going Concern And Managements Plans [Text Block]", "documentation": "Going concern and management\u2019s plans.", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "slno_IncentiveStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IncentiveStockOptionsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "ISOs [Member]", "label": "Incentive Stock Options [Member]", "documentation": "Incentive Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r188", "r189", "r191", "r334", "r338", "r343", "r452", "r454", "r513", "r554", "r583", "r789"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r189", "r191", "r334", "r338", "r343", "r452", "r454", "r513", "r554", "r583", "r789"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "slno_IncreaseDecreaseInAccruedClinicalTrialSiteCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IncreaseDecreaseInAccruedClinicalTrialSiteCosts", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical trial site costs", "label": "Increase Decrease In Accrued Clinical Trial Site Costs", "documentation": "Increase decrease in accrued clinical trial site costs." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "slno_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase decrease in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, other current assets and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "slno_IncreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IncreaseInOperatingLeaseLiability", "crdr": "credit", "presentation": [

```
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in lease liability", "label": "Increase In Operating Lease Liability", "documentation": "Increase in operating lease liability." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r624", "r634", "r644", "r668", "r676", "r680", "r688" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r686" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r616", "r692" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r616", "r692" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r616", "r692" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r185", "r723", "r724" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r152", "r156", "r158", "r564", "r705" ] }, "slno_IssuanceOfRestrictedStockUnitsSharesUnderEquityIncentivePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IssuanceOfRestrictedStockUnitsSharesUnderEquityIncentivePlan", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock units under equity incentive plans (shares)", "label": "Issuance Of Restricted Stock Units Shares Under Equity Incentive Plan", "documentation": "Issuance of restricted stock units shares under equity incentive plan." } } }, "auth_ref": [] }, "slno_IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock units under equity incentive plans", "label": "Issuance Of Restricted Stock Units Value And Option Exercises Under Equity Incentive Plan", "documentation": "Issuance of restricted stock units value and option exercises under equity incentive plan." } } }, "auth_ref": [] }, "slno_JefferiesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "JefferiesLlcMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Jefferies LLC [Member]", "documentation": "Jefferies LLC.", "label": "Jefferies LLC [Member]" } } }, "auth_ref": [] }, "slno_JimMackanessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "JimMackanessMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Jim Mackaness [Member]", "label": "Jim Mackaness [Member]", "documentation": "Jim Mackaness." } } }, "auth_ref": [] }, "slno_KristenYenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "KristenYenMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Kristen Yen [Member]", "label": "Kristen Yen [Member]", "documentation": "Kristen yen." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r368", "r589" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r775" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "slno_LesseeOperatingLeaseCommencementMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "LesseeOperatingLeaseCommencementMonthAndYear", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease beginning date", "label": "Lessee Operating Lease Commencement Month And Year", "documentation": "Lessee, operating lease commencement month and year." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, description", "label": "Lessee, Operating Lease, Description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r367" ] }, "slno_LesseeOperatingLeaseExtensionExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "LesseeOperatingLeaseExtensionExpirationMonthAndYear", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, extension expiration", "label": "Lessee, Operating Lease, Extension Expiration, Month and Year", "documentation": "Lessee, operating lease, extension expiration, month and year." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r776" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r376" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of the year)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r776" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "terseLabel": "Less interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref":
```

["r376"] }, "slno_LesseeOperatingLeaseMonthAndYearOfExpiration": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "LesseeOperatingLeaseMonthAndYearOfExpiration", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, expiration", "label": "Lessee Operating Lease Month And Year Of Expiration", "documentation": "Lessee, operating lease month and year of expiration." } } }, "auth_ref": [] } }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r774"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r38", "r39", "r40", "r41", "r42", "r43", "r44", "r117", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r299", "r302", "r303", "r351", "r488", "r562", "r611", "r731", "r778", "r779"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r51", "r75", "r443", "r590", "r709", "r722", "r771"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r40", "r93", "r117", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r299", "r302", "r303", "r351", "r590", "r731", "r778", "r779"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r329", "r765"] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "slno_LiquidityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "LiquidityDisclosureTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidity"], "lang": { "en-us": { "role": { "documentation": "Liquidity disclosure.", "label": "Liquidity Disclosure [Text Block]", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "slno_MarchTwoThousandTwentyTwoCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "MarchTwoThousandTwentyTwoCommonWarrantsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty two common warrants.", "label": "March Two Thousand Twenty Two Common Warrants [Member]", "terseLabel": "March 2022 common warrants", "verboseLabel": "March 2022 Common Warrants [Member]" } } }, "auth_ref": [] }, "slno_MarchTwoThousandTwentyTwoPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "MarchTwoThousandTwentyTwoPreFundedWarrantsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty two pre funded warrants.", "label": "March Two Thousand Twenty Two Pre Funded Warrants [Member]", "terseLabel": "March 2022 pre-funded warrants", "verboseLabel": "March 2022 Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "verboseLabel": "Marketable securities current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r700"] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": ["r700"] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r35"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r194", "r195", "r196", "r197", "r239", "r272", "r332", "r394", "r451", "r453", "r467", "r480", "r481", "r531", "r533", "r535", "r536", "r538", "r552", "r553", "r566", "r572", "r577", "r584", "r585", "r586", "r587", "r599", "r733", "r780", "r781", "r782", "r783", "r784", "r785"] }, "slno_MayTwoThousandTwentyThreeTrancheAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "MayTwoThousandTwentyThreeTrancheAWarrantsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty three tranche a warrants.", "label": "May Two Thousand Twenty Three Tranche A Warrants [Member]", "terseLabel": "May 2023 Tranche A warrants", "verboseLabel": "May 2023 Tranche A Warrants [Member]" } } }, "auth_ref": [] }, "slno_MayTwoThousandTwentyThreeTrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "MayTwoThousandTwentyThreeTrancheBWarrantsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty three tranche b warrants.", "label": "May Two Thousand Twenty Three Tranche B Warrants [Member]", "terseLabel": "May 2023 Tranche B warrants", "verboseLabel": "May 2023 Tranche B Warrants [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r660"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r660"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Expected Dividend Yield [Member]", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r767", "r768", "r769"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Contractual Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r767", "r768", "r769"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r584", "r767", "r768", "r769"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r767", "r768", "r769"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r330", "r331", "r332", "r584"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r330", "r331", "r332", "r584"] }, "slno_MilestonesPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "MilestonesPayment", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Milestones payment", "label": "Milestones Payment", "documentation": "Milestones payment." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType",

```
"nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r239", "r272", "r332",
"r394", "r451", "r453", "r467", "r480", "r481", "r531", "r533", "r535", "r536", "r538", "r552", "r553", "r566", "r572", "r577", "r584", "r585", "r586", "r599", "r733", "r780",
"r781", "r782", "r783", "r784", "r785" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for
Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r679" ] }, "us-gaap_MoneyMarketFundsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetai
], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term
money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit,
and other highly liquid securities." } } }, "auth_ref": [ "r735" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r687" ] },
"ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named
Executive Officers, Footnote" } } }, "auth_ref": [ "r661" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing
activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of,
their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-
term credit." } } }, "auth_ref": [ "r115" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net
cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities,
including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property,
plant, and equipment and other productive assets." } } }, "auth_ref": [ "r115" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net
cash used in operating activities", "terseLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation":
"Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in
value not defined as investing or financing activities." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash
flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss",
"totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r53", "r59",
"r76", "r91", "r105", "r107", "r111", "r117", "r125", "r129", "r130", "r131", "r132", "r133", "r136", "r137", "r144", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204",
"r205", "r206", "r286", "r295", "r326", "r351", "r446", "r510", "r526", "r527", "r609", "r731" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected
or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description
[Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r660" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-
NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r624", "r634", "r644", "r668", "r676" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO
Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r651" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r650" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r668" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule
10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r687" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule
10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r687" ] }, "us-
gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Supplemental disclosure of non-cash operating and financing information", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] },
"slno_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "NoncashLeaseExpense", "crdr": "debit",
"presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-cash lease expense", "label": "Noncash Lease Expense", "documentation": "Noncash lease expense." } } }, "auth_ref": [] }, "us-
gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit",
"presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang":
{ "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or
expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r55"
] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] },
"slno_OctoberTwoThousandTwentyThreePreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname":
"OctoberTwoThousandTwentyThreePreFundedWarrantsMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail",
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "October 2023 Pre-funded Warrants [Member]", "terseLabel": "Oct 2023 Pre-funded Warrants [Member]", "documentation": "Oct 2023 Pre-funded warrants.",
"label": "October Two Thousand Twenty Three Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the
portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } },
"auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract",
"presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang":
{ "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": {
"role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating
revenues." } } }, "auth_ref": [ "r77", "r563", "r714", "r715", "r716", "r717", "r718" ] }, "slno_OperatingLeaseAnnuallyIncreasePercentage": { "xbrltype": "percentItemType",
"nsuri": "http://www.soleno.life/20240930", "localname": "OperatingLeaseAnnuallyIncreasePercentage", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Operating lease annually increase percentage.", "label": "Operating Lease Annually Increase Percentage", "terseLabel": "Rent payments annual increase percentage" } } },
"auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit",
"presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining
cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-
```

```
of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r369", "r589" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating lease liabilities" } } }, "auth_ref": [] } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesReconciliationOfUndiscountedFutureMinimumLeasePaymentsRemainingUnderOpera ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "totalLabel": "Total", "terseLabel": "Right-of-use liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r364" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease, short-term liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r364" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r365" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term lease liabilities", "terseLabel": "Long-term operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r364" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r365" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r366", "r372" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use asset", "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r363" ] }, "slno_OperatingLeaseRightOfUseAssetIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "OperatingLeaseRightOfUseAssetIncrease", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in right of use assets", "label": "Operating Lease Right-Of-Use Asset Increase", "documentation": "Operating lease right-of-use asset increase." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r375", "r589" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease remaining term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r374", "r589" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r95" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cancelable other commitments", "label": "Other Commitment", "totalLabel": "Other Commitment, Total", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r102", "r103", "r104", "r447" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r447" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized loss on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r102", "r104", "r169" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39", "r590" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash reconciling items", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r660" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r622", "r632", "r642", "r674" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r625", "r635", "r645", "r677" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r625", "r635", "r645", "r677" ] }, "slno_OwnershipInterestPercentageofVotingRightsofStock": { "xbrltype": "percentItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "OwnershipInterestPercentageofVotingRightsofStock", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest of voting rights of all classes of stock (percent)", "label": "Ownership Interest Percentageof Voting Rightsof Stock", "documentation": "Ownership interest, percentage of voting rights of stock." } } }, "auth_ref": [] }, "slno_PatriciaCHiranoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PatriciaCHiranoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Patricia C. Hirano [Member]", "label": "Patricia C. Hirano [Member]", "documentation": "Patricia c. hirano." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r649" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Rent payments", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r5" ] }, "us-
```

gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Less transaction costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r18"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r721"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r56"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r659"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r659"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r651"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r668"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r661"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r650"] }, "slno_PerShareExercisePriceForPreFundedWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PerShareExercisePriceForPreFundedWarrant", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Per share exercise price for pre-funded warrant", "terseLabel": "Per share exercise price for pre-funded warrant", "label": "Per Share Exercise Price For Pre Funded Warrant", "documentation": "Per share exercise price for Pre-funded warrant." } } }, "auth_ref": [] }, "slno_PercentageOfAggregateGrossProceedsToPayCommission": { "xbrltype": "percentItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PercentageOfAggregateGrossProceedsToPayCommission", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate gross proceeds to pay commission." } } }, "auth_ref": [] }, "slno_PercentageOfProbabilityOfAchievingMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PercentageOfProbabilityOfAchievingMilestone", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of probability of achieving milestone", "label": "Percentage Of Probability Of Achieving Milestone", "documentation": "Percentage of the probability of achieving the milestone." } } }, "auth_ref": [] }, "slno_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Performance-Based Restricted Stock Units [Member]", "documentation": "Performance-based restricted stock units." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r652"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r696"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r651"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r45", "r223"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Convertible preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r45", "r490"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r45", "r223"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r45", "r490", "r508", "r819", "r820"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r45", "r439", "r590"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r701"] }, "slno_ProceedsFromExerciseOfCommonStockAndPreFundedStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsFromExerciseOfCommonStockAndPreFundedStockWarrants", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs", "documentation": "Proceeds from exercise of common stock and pre-funded stock warrants.", "label": "Proceeds from Exercise of Common Stock and Pre-Funded Stock Warrants" } } }, "auth_ref": [] }, "slno_ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrantsNetOfCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrantsNetOfCosts", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs", "label": "Proceeds from Exercise of Common Stock Warrants and Pre-Funded Common Stock Warrants, Net of Costs", "documentation": "Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock, net of costs", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from the sale of common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Sale and issuance of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds from common stock public offering", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity",

```
"terseLabel": "Proceeds from issuance or sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r4", "r469" ] }, "slno_ProceedsFromOfferingAfterDeductingUnderwritingDiscountAndOtherEstimatedOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsFromOfferingAfterDeductingUnderwritingDiscountAndOtherEstimatedOfferingExpenses", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from offering after deducting underwriting discount and other estimated offering expenses", "label": "Proceeds From Offering After Deducting Underwriting Discount And Other Estimated Offering Expenses", "documentation": "Proceeds from offering after deducting underwriting discount and other estimated offering expenses." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "slno_ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of common stock and common stock warrants, net of issuance costs.", "label": "Proceeds from Sale of Common Stock and Common Stock Warrants, Net of Issuance Costs", "terseLabel": "Proceeds from the sale of common stock and common stock warrants, net of costs" } } }, "auth_ref": [] }, "slno_ProceedsFromSaleOfCommonStockAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsFromSaleOfCommonStockAndPreFundedWarrants", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock and pre-funded warrants", "label": "Proceeds From Sale Of Common Stock And Pre Funded Warrants", "documentation": "Proceeds from sale of common stock and pre-funded warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r13" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of common stock warrants", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from warrant exercise", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r706" ] }, "slno_ProceedsReceivedPriorToAndForTheIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsReceivedPriorToAndForTheIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds received prior to and for the issuance of common stock.", "label": "Proceeds Received Prior To And For The Issuance Of Common Stock", "terseLabel": "Proceeds received prior to and for the issuance of common stock" } } }, "auth_ref": [] }, "slno_ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received prior to and for the issuance of common stock and pre-funded warrants", "label": "Proceeds received prior to for issuance of common stock and pre-funded warrants", "documentation": "Proceeds received prior to for issuance of common stock and pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r91", "r105", "r107", "r114", "r117", "r125", "r133", "r136", "r137", "r170", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r286", "r295", "r297", "r300", "r301", "r326", "r351", "r433", "r445", "r474", "r510", "r526", "r527", "r579", "r580", "r610", "r704", "r731" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Net, Total", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r377", "r434", "r444", "r590" ] }, "slno_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PublicOfferingMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "documentation": "Public Offering" } } }, "auth_ref": [] }, "slno_PublicOfferingPricePerPreFundedWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PublicOfferingPricePerPreFundedWarrant", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Public offering price per pre-funded warrant", "label": "Public Offering Price Per Pre Funded Warrant", "documentation": "Public offering price per pre-funded warrant." } } }, "auth_ref": [] }, "slno_PurchasePriceContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "PurchasePriceContingentLiabilityMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price contingent liability [Member]", "label": "Purchase Price Contingent Liability [Member]", "documentation": "Purchase price contingent liability." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r649" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r649" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r232", "r239", "r265", "r266", "r267", "r272", "r332", "r391", "r392", "r394", "r451", "r453", "r467", "r480", "r481", "r531", "r533", "r535", "r536", "r538", "r552", "r553", "r566", "r572", "r577", "r584", "r585", "r586", "r587", "r599", "r603", "r729", "r733", "r768", "r781", "r782", "r783", "r784", "r785" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r232", "r239", "r265", "r266", "r267", "r272", "r332", "r391", "r392", "r394", "r451", "r453", "r467", "r480", "r481", "r531", "r533", "r535", "r536", "r538", "r552", "r553", "r566", "r572", "r577", "r584", "r585", "r586", "r587", "r599", "r603", "r729", "r733", "r768", "r781", "r782", "r783", "r784", "r785" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r617", "r627", "r637", "r669" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r118", "r119", "r210", "r225", "r384", "r393", "r435", "r558", "r559" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r273", "r554", "r564", "r786" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r618", "r628", "r638", "r670" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r619", "r629", "r639", "r671" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r626", "r636", "r646", "r678" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Units [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r48", "r65", "r442", "r461", "r466", "r473", "r491", "r590"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r87", "r121", "r122", "r123", "r126", "r133", "r135", "r137", "r176", "r183", "r187", "r274", "r275", "r282", "r283", "r284", "r287", "r294", "r295", "r308", "r311", "r312", "r315", "r324", "r360", "r362", "r457", "r459", "r475", "r819"] }, "slno_ReverseStockSplitPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ReverseStockSplitPolicyPolicyTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Split", "label": "Reverse Stock Split Policy [Policy Text Block]", "documentation": "Reverse stock split." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Increase in right of use assets", "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r373", "r589"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r687"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r687"] }, "slno_SaleOfStockAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "SaleOfStockAuthorizedAmount", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale agreement amount", "label": "Sale Of Stock Authorized Amount", "documentation": "Sale of stock authorized amount." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "slno_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "SalesAgreementMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities Classified as Available-for-sale Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]", "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Instruments Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r765", "r766"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r240", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Unit Transactions", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r68"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option and Restricted Stock Unit Transactions", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r68"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r70"] }, "slno_ScheduleOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ScheduleOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Significant Accounting Policies [Line Items]", "label": "Schedule Of Significant Accounting Policies [Line Items]", "documentation": "Schedule Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "slno_ScheduleOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ScheduleOfSignificantAccountingPoliciesTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Significant Accounting Policies [Table]", "label": "Schedule Of Significant Accounting Policies [Table]", "documentation": "Schedule Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Outstanding Common Stock Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often

measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r30"] }, "slno_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Schedule Of Supplemental Cash Flow Information Related To Leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average common shares outstanding [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Common Shares Outstanding", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r23"] }, "slno_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r612"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r614"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r159", "r160", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r477", "r478", "r479", "r532", "r534", "r537", "r539", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r555", "r573", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r603", "r734", "r788", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Restricted stock units canceled/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock units canceled/forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Stock units granted", "terseLabel": "Restricted stock units granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r257"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant-date fair value of all restricted stock units granted", "terseLabel": "Restricted stock units granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r257"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r254", "r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r254", "r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Restricted stock units vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r258"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r261"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Restricted Stock units", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r258"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail"],

```
"lang": { "en-us": { "role": { "verboseLabel": "Expected dividend yield", "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r267" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r240", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] },
"slno_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable at end of period", "documentation": "Share based compensation arrangement by share based payment award options exercisable aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "negatedLabel": "Options canceled/forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r742" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Options granted", "terseLabel": "Number of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r250" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value per option granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r260" ] },
"slno_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValueAbstract", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Aggregate Intrinsic Value [Abstract]", "documentation": "Share based compensation arrangement by share based payment award options non vested aggregate intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options outstanding at end of period", "periodStartLabel": "Options outstanding at beginning of period", "terseLabel": "Balance at March 31, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r246", "r247" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r246", "r247" ] },
"slno_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested at end of period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value", "documentation": "Share based compensation arrangement by share based payment award options vested aggregate intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options exercisable at end of period (shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r263" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable at end of period (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [
```

"r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest at end of period (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding stock maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r251"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options canceled/forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r252"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r250"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "May 2023 Tranche A Pre-funded Warrants [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche A [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "May 2023 Tranche B Pre-funded Warrants [Member]", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche B [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Contractual term of option", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r578"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail"], "lang": { "en-us": { "role": { "terseLabel": "Expected life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r264"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r69"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Options exercisable at end of period", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r263"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r262"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair market value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "slno_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.soleno.life/20240930", "localname":

"SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price per Share", "label": "Sharebased Compensation Arrangementby Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Roll Forward", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": ["r64", "r67"] }, "slno_SharesIssuedFromSaleOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "SharesIssuedFromSaleOfCommonStock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued from sale of common stock", "label": "Shares Issued From Sale Of Common Stock", "documentation": "Shares issued from sale of common stock." } } }, "auth_ref": [] }, "slno_SharesIssuedFromSaleOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "SharesIssuedFromSaleOfPreFundedWarrants", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued from sale of pre-funded warrants", "label": "Shares Issued From Sale Of Pre-Funded Warrants", "documentation": "Shares issued from sale of pre-funded warrants." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Price per unit", "label": "Shares Issued, Price Per Share", "verboseLabel": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Balances at beginning (shares)", "periodEndLabel": "Balances at end (shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Tax withholding payments for net share-settled equity awards (shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r370", "r589"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r46", "r49", "r50", "r87", "r109", "r110", "r111", "r121", "r122", "r123", "r126", "r133", "r135", "r137", "r153", "r176", "r183", "r187", "r231", "r274", "r275", "r282", "r283", "r284", "r287", "r294", "r295", "r308", "r310", "r311", "r312", "r313", "r315", "r324", "r352", "r353", "r354", "r355", "r356", "r357", "r360", "r362", "r383", "r447", "r457", "r458", "r459", "r475", "r528"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": ["r159", "r160", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r477", "r478", "r479", "r532", "r534", "r537", "r539", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r555", "r573", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r600", "r603", "r734", "r788", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r121", "r122", "r123", "r153", "r362", "r395", "r468", "r476", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r509", "r511", "r512", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r604"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r121", "r122", "r123", "r153", "r163", "r362", "r395", "r468", "r476", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r509", "r511", "r512", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r604"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r621", "r631", "r641", "r673"] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale and issuance of warrants to purchase common stock", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares purchases by employees", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r45", "r46", "r65"] }, "slno_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants and pre-funded common stock warrants (shares)", "label": "Stock Issued During Period, Shares, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants", "documentation": "Stock issued during period, shares, exercise of common stock warrants and pre-funded common stock warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock (shares)", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Sale of common stock, net of issuance costs (shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r45", "r46", "r65", "r469", "r528", "r540"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares granted to date", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total", "verboseLabel": "Performance Based Options", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r10", "r45", "r46", "r65"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise of stock options (shares)", "negatedLabel": "Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r45", "r46", "r65", "r251"] }, "slno_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants and pre-funded common stock warrants", "label": "Stock Issued During Period, Value, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants", "documentation": "Stock issued during period, value, exercise of common stock warrants and pre-funded common stock warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of common stock, net of issuance costs", "documentation": "Equity impact of the value of new stock

issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r45", "r46", "r65", "r475", "r528", "r540", "r610"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r46", "r49", "r50", "r65"] }, "slno_StockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "StockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Offering costs", "label": "Stock Issued Issuance Costs", "documentation": "Stock issued issuance costs." } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted], "lang": { "en-us": { "role": { "terseLabel": "Options to Purchase Common Stock [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r603"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balances at beginning", "periodEndLabel": "Balances at ending", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r46", "r49", "r50", "r62", "r492", "r508", "r529", "r530", "r590", "r611", "r709", "r722", "r771", "r819"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r66"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r66"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r358", "r386"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r358", "r386"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r358", "r386"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r385", "r387"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r667"] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r719", "r777"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r659"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r666"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r686"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r688"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r689"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r690"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r690"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r688"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r688"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r691"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r689"] }, "slno_TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionAndRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "2014 Plan and Inducement Plan [Member]", "label": "Two Thousand And Fourteen Equity Incentive Plan And Two Thousand Twenty Inducement Equity Incentive Plan [Member]", "documentation": "Two thousand and fourteen equity incentive plan and two thousand twenty inducement equity incentive plan." } } }, "auth_ref": [] }, "slno_TwoThousandAndFourteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "2014 Equity Incentive Plan [Member]", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "documentation": "2014 equity incentive plan." } } }, "auth_ref": [] }, "slno_TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2010 and 2012 Convertible Promissory Notes [Member]", "label": "Two Thousand And Ten And Two Thousand And Twelve Convertible Promissory Notes [Member]", "documentation": "Two Thousand and Ten and Two Thousand and Twelve Convertible Promissory Notes [Member]" } } }, "auth_ref": [] }, "slno_TwoThousandEighteenPIPEWarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandEighteenPIPEWarrantLiabilityMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "2018 PIPE Warrants [Member]", "terseLabel": "2018 PIPE Warrant Liability [Member]", "label": "Two Thousand Eighteen P I P E Warrant Liability [Member]", "documentation": "2018 PIPE warrant liability." } } }, "auth_ref": [] }, "slno_TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember", "presentation": ["http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail"], "lang": { "en-us": { "role": { "terseLabel":

```
"2018 PIPE Warrant Liability [Member]", "label": "Two Thousand Eighteen P I P E Warrant Liability To Purchase Common Stock [Member]", "documentation": "Two thousand eighteen PIPE warrant liability to purchase common stock." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyInducementEquityIncentivePlanMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Inducement Equity Incentive Plan [Member]", "label": "Two Thousand Twenty Inducement Equity Incentive Plan [Member]", "documentation": "Two thousand twenty inducement equity incentive plan." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyThreeTrancheAPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyThreeTrancheAPreFundedWarrantsMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Three Tranche A Pre-funded Warrants [Member]", "terseLabel": "2023 Tranche A Pre-funded Warrants [Member]", "documentation": "Two thousand twenty three tranche a pre funded warrants." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyThreeTrancheAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyThreeTrancheAWarrantsMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Tranche A Warrants [Member]", "label": "Two Thousand Twenty Three Tranche A Warrants [Member]", "documentation": "Two thousand twenty three tranche A warrants." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyThreeTrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyThreeTrancheBWarrantsMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2023 Tranche B Warrants [Member]", "terseLabel": "2023 Tranche B warrants [Member]", "label": "Two Thousand Twenty Three Tranche B Warrants Member", "documentation": "Two thousand twenty three tranche B warrants." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyTwoCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyTwoCommonWarrantsMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Common Warrants [Member]", "label": "Two Thousand Twenty Two Common Warrants [Member]", "documentation": "Two Thousand Twenty Two Common Warrants." } } }, "auth_ref": [] }, "slno_TwoThousandTwentyTwoPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "TwoThousandTwentyTwoPreFundedWarrantsMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureStockholdersEquitySummaryOfOutstandingCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Pre-funded Warrants [Member]", "label": "Two Thousand Twenty Two Pre Funded Warrants [Member]", "documentation": "Two Thousand Twenty Two Pre Funded Warrants." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r85", "r86", "r87", "r88", "r89", "r90", "r125", "r126", "r127", "r128", "r139", "r161", "r162", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r190", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r349", "r350", "r359", "r360", "r361", "r378", "r379", "r380", "r381", "r382", "r383", "r396", "r397", "r398", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r296" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfMarketableSecuritiesClassifiedAsAvailableforsaleSecuritiesDetails", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDeta ], "lang": { "en-us": { "role": { "terseLabel": "US Treasury Securities [Member]", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r560", "r574", "r576", "r581", "r787" ] }, "slno_UnderwriterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "UnderwriterMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeighted "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants Issued to Underwriter to Purchase Common Stock [Member]", "terseLabel": "Underwriter [Member]", "label": "Underwriter [Member]", "documentation": "Underwriter [Member]" } } }, "auth_ref": [] }, "slno_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "UnderwrittenPublicOfferingMember", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Underwritten Public Offering [Member]", "label": "Underwritten Public Offering [Member]", "documentation": "Underwritten public offering." } } }, "auth_ref": [] }, "slno_UnderwriterDiscountAndOtherOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "UnderwriterDiscountAndOtherOfferingExpenses", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Underwriter discount and other offering expenses.", "label": "Underwriter Discount and Other Offering Expenses", "terseLabel": "Underwriter discount and other offering expenses" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r685" ] }, "slno_UnpaidCostsForIssuingCommonStockAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "UnpaidCostsForIssuingCommonStockAndPreFundedWarrants", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid financing costs included in accounts payable and accrued liabilities", "documentation": "Unpaid costs for issuing common stock and pre funded warrants.", "label": "Unpaid Costs for Issuing Common Stock and Pre Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r79", "r80", "r81", "r82" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r371", "r589" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "terseLabel": "Vesting", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "terseLabel": "Vesting", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r655" ] }, "slno_WarrantLiabilityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "WarrantLiabilityDisclosureTextBlock", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrants1" ], "lang": { "en-us": { "role": { "label": "Warrant Liability Disclosure [Text Block]", "documentation": "Warrant Liability Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "slno_WarrantsAndRightsExercisableTermFromFollowingReceiptOfUSFoodAndDrugAdministrationApproval": { "xbrltype": "durationItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "WarrantsAndRightsExercisableTermFromFollowingReceiptOfUSFoodAndDrugAdministrationApproval", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights exercisable term from following receipt of U.S. Food and drug administration approval.", "label": "Warrants And Rights Exercisable Term From Following Receipt of U.S. Food and Drug Administration Approval", "terseLabel": "Warrants and rights exercisable term from following receipt of U.S. Food and drug administration approval" } } }, "auth_ref": [] }, "slno_WarrantsAndRightsImmediatelyExercisableTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.soleno.life/20240930", "localname": "WarrantsAndRightsImmediatelyExercisableTerm", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights immediately exercisable term.", "label": "Warrants And Rights Immediately Exercisable Term", "terseLabel": "Warrants and rights immediately exercisable term" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of estimated warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r767", "r768", "r769" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r767", "r768", "r769" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"WarrantsAndRightsOutstandingTerm", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureWarrantsFairValueOfConvertiblePreferredStockWarrantLiabilityDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r767", "r768", "r769" ] },
"slno_WarrantsExpireTermPriorToAnniversaryDateOfIssuance": { "xbrltype": "durationItemType", "nsuri": "http://www.soleno.life/20240930", "localname":
"WarrantsExpireTermPriorToAnniversaryDateOfIssuance", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Warrants expire term prior to anniversary date of issuance", "label": "Warrants Expire Term Prior To Anniversary Date Of Issuance", "terseLabel": "Warrants expire term prior to anniversary date of issuance" } } }, "auth_ref": [] }, "slno_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.soleno.life/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to Purchase Stock [Member]", "label": "Warrants To Purchase Common Stock [Member]", "documentation": "Warrants To Purchase Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Weighted-average common shares outstanding used to calculate diluted net loss per common share", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted-average common shares outstanding used to calculate diluted shares", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r142", "r147" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.soleno.life/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedaverageCommonSharesOutstandingDetail",
"http://www.soleno.life/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average common shares outstanding used to calculate basic net loss per common share", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average common shares outstanding used to calculate basic shares", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } },
"auth_ref": [ "r141", "r147" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r653" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10",
"Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r16": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r18":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-
1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r30": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-
2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph":
"2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r35": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
```

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r180": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r368": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

"Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":

"F", "Paragraph": "1", "Subparagraph": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r698": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r709": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r769": { "role":
```

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 57 0000950170-24-122276-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-122276-xbrl.zip M4$L#!!0 (,^ 9ED9_>3V(JT! '|2&@ 1 NCFGRG8;^|S3[XM7C$:G MA$1+HFSZU|=*7__'3_P1H7KS;>=V\3I^;[3 ;_)%>#*9A M.)X>3E+SP^YO/S8[H^%@E)K_^LN[7YL7XW"XGT:S!IJ|V>Q@Z^G3SY_/XEY M,)}J.AX0+4+,_&Q\<#09?-J;-3^$'YOR*WSV:)2&PW34O!J,W"@,W+#9/7GJ8UQF M>-)L#X?-N_*S:?,N3=/DCQ2?S&^Z-\/SP#,937]^=&;IG_F3\>334V]M??JE M7/-H?M'6%S\9QL'IM>5M>R4C1#V=?WGNTMFEE\KYL;.SEP[.+>#LU?PIGN,. MMY9.KL>3__T[EY>OO9N>7O[EPO7G]E>^/;ET\.6J^]*RC +R O&3RT?CT6N$ M_&00+O]9G$V>SHX.TE.\$$;S*T]7-1UG5V4]|^XOB+V0QP#>=^=[*FKR? V=#9QHVD>3_9;O"\'*H&8,_=)(<+TT%^^N>,O MSRUY.IE=W!M^>/X09I,K,<4^Q6]/#R -+G\T?G'NCH/16#"JOX>N\RO.:.S* M39V[A[#T?@\%,:#-!H_&0YR M"S=!+"=GH';Y#KX'L@)Z!E0]^N5_-#_M1?QW^:GV6 V3+)0 G__Z>G\=?ET M/\U-1,9T?#|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

|>UQ58>RPQSYS"J;/F[7@Z$?V_0.Y$=/Y_H%\?VDW M$[^<)!EU I0)2!"A:+J(-*@W9,VO9P3BM\|JI.Y$8\;>DGPK36U!$D3Q\140,] M:#T<0 M'07SCG^UB59P+LM#EN^-3:('R M_*,A+!&D4D!"1?+U!@T,B30<6&")-AE)<>T<_S2UJO/)NT$L[_@39IVV>E2 M=]_SG?\X;SE]^^.3VTW3IP+'^=N(#_MR.!R$P>RWM._Q$7&P7X Y'GU%COI, MTW+XVU\&TT>_G'RXN^510IF[?X_:87/)F^1S^-"WW\>S^_YT]+ M'_7+R1I/5_3TLNT?M'Z0T]7/W&16#)Y?6I<8+2ZQT_NBJ+WTQ:;7 . MV%:+^LT=(=<> [XT/IVX4WW_&NQ^]1T)(QS#]RXD4[QZR9LE!2()6]TB&50A*:IAR6EOD#]3ZVL#UG0RVSKEMW!-XT\3=[W0'Q_M&%"S@\|G6\^VE494 .L=%;T)5>*D%3CJA*HKV>7 "HM"H\;G' (+D4:-J@!Y4$ M$61BX)$HT"R.$<4.5Z"BB58%U"7,TMG9;4^*WYR??,/K[W123!J2O0 98U$[M70!CBRUK#"KD1#.966W(O %2>G'(=D<#S[":8@)M!;*I' FR*6E HV!'CJPL MVA6U0O94K+ |YV$Q=U%U'H]:9^TYY?I=FGOE7KK)"#7O96M;1'4E0936(08! MBD57PG$.#%,&'Q"E0V@1I,H*V-.R-A^Y=4D]R4@]3B:|+K$59D47BJ'2DQU M&LPM\7([QM;B1!U]=?+.Z+DI&,S<!*@&C-/;,"B7CLL;@B9! M(GGC^4A3.CU85F#09@'FLY2<&"}=E%W+]U.:|Z/E*,W+,54L80Y9K0--2FH% MS0:\M %LR,0JER3GH;93OR6O/1.[6C94>$=FR]>CUV)*6!18%I>"8B2"\5N 3FDE)4)E]##*+6!NT;JNOA'"X?SC$:^,; MV5Z:E.LF:;_<[8\T#X9N#,>C(3&7 I!0 N(EE.!3B79) (RSW)$52'6V=@&%^ MTJ:7*3L+>-*)W^2,/Q00O?+R6VL 0H54& B:7$"3#]2]#. M%FL)[2;)D4]Z&YBVU1+@:8C_+T>_)5=*,]]LRDGZYV$:A;/SH#V]^.RET].D MADT))92V>CP]Q&Y,#Q.FCDH1W M1L8]Q[,83UX-9O_ZE"9N&-N4L6O@<6,4*B[:5HBU9|!S3=Y '<" MC;3,6C:?IK\.P[() M4 .UW4 Y6$]< 17Q#T("]6[&T4KB(4@A.,N^6D_#/!L' 7)!TYY-!F%VG+;\ M831 QKC[X7]V$K&I'C!AHS@4[0DD*W6"K[KPH!G8H ORU0:GDU'0F8J9^Z1%=>$C7]GA-WL1Y=>K>3HDRI+2M!@W&8L@:,2GPW1K%I58/?03P=QX"9' M4GC39YW5?G*HC^,8I|G@QF,Q07AQ[O=I+4L633MSM%S?/2C@#5,U\2(AT: MP<[[",$()GE&,WCY2>_WCLK$ZIU>SB>F$\T0!2FID]773L2[9TD=FD+14;_I MW')5R>$=ED>YX$1I*HC$2E#_42* B\% RIJ7'B'2I50K5&Z4P/K7-"I)=-NC MN!WW!Z.V[5UQ7-SG%%9?FA*9TC&+EK8FCCMP7#@@3&9/@]%95FL&U5;SMAQ_ M+D+ (1Y*0&1(C2C]+ LY1"4$)0E,B@=8+H6H;SZPGY\%3]9VB"6''/0AF$$AA M,Q"?%>%6V4QMK#J1#LLY!$4]{$52==H5=Y)3WF9.B-WX=)8U M\%'1G? KBA40K+0A@I3.H|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|IM6U306N EXQ*,(\4%<:',@@P'BT0B5]IYQI*9.K5HO? E*FK:W(M,$:3 MEPZ41)DGA)?-5D_5/B^]IE44HDRN++_VPK0)1[NTRB<"2 MY$EZ*BI,\NQUC2!U!905D((=GH(W!;B)X|!<:,"($G+[B,0L5JZV+J;%VW MG!R>$*EV:"."M$R5?ML$? &D/*JQ. AFTB+;:U-;51*%72G_="=U$2DZC!>84 MJK_).'#MA&EE9,R". 1RK7"M9OI/!5W>0Q(B9V8A4Y3)0J+RY#0Q^">(* C1 MWE;+1[==VU<#&>;HK'4;HDM2GA2EUU@AP0E"XX+7F]V=_79-6L,)/F&X*Z MB\"+Q#(6C8:8;'&4.HJ,.?A2TY8TRD EZNV7T8D:;BDI;I;CAHO$:\DT _R' M@\C$%6\.;T= <4$N"8J':BK=JA-B20$.%8 %OE[,I42 1P!!A@5+.A8^,A'H3 M/ZK)$;Z#@.JJ&#$R2C((I;67+-.P4@3+20)%K7914.)TE M@K;,L)GP:GW>]TLTNG9)\Q!)2;8Z%:=?4>PE?HZ;=T]- FAG1&|HU8& MYT!:&D'08C=P'U'\$I F M90;9!(>HJYW92"6SGN2D#E*&AY;,4%2)"BA(%1U^8BCX!4A MFV6!*E/I$MY.T%*N*$DV8O?BBJ^3ZC*A6IS_JKQDBPGSR%1;P-#)]\$:5MB M$W!<2:0G8P)#-NA4M5WIJDOQ6|^TCB2(D7G!YRG] T4-L)04E/]"0.(+H\AM\HX0L*$$R(27DK: <=4C1 M/(#W2-NHQ%@C#/%&5%L=6EN4H IP1C06HH;LN !AG 2GE('(%5-H!2=JJ\U* M6 FK?CX>_9FLX?IA?)SVY&@(M[.0+3(3QX$4L/#]:';/)E%?;2*WBFI;EA-P26AGP), RQ| 'S9E1-(94+7I5W<MPZS0 ME(/07E&4GD(5Z1G 9+1WO)642I6=Z0A 7D70^::O(N$W'FT5&P MKB H%=[;$VM!L,R4M1JUI6J]@O6&LBKH-98I&GA1"&"IE"HIC@+:,82S%$HE M9[,B 8RRV^E.7?6VR(P;;8@#E&T4A&?:9E%|ZO M1S')7')O.(=,=021@@*;/9I ,:,@F11!5)MD7[5O;ST>@2PH,8J5;MTNE4P. M!RX@JXR6(!TJD22OEDL^T%DEURZIE@37#C,CLHC$4(IR(I=JXT1*-R3O07EN MM==">%YM@NOWYR;.72$[HW@8SK"FVPQ/K,8EDDL#WM1.W%#%?U4RC7CVJ'$I MU,-"CK3>D&[?HKSFD$/6G/(4$UABVBXCB%1'$!!"YQA]E(Y46W944\AA';"S MTN32&X8D;TK(P8#1)\)7LMI@])]+K:NWK=4Z]7;@S>(^8-T1,ISFW].Z6O)B M99F-0F2& ()VQ20MI:74=WZK-Z%M/O]_LHQ$!)8)D$7F+E1Q.H!DL=3($H5VF MU1HO%4_37@D'6)(*ZG,HM@*P7/K;9AO!I<)=O-?>Q*1IKM9.Z P:*\'|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|LV_LM%DAR-$BMMMS75_A[I2?V/R8HWM+H'^E^ M-BRF02#"9I!SI10TS@.9BE>[W7 MYQ*G22:)(AR4# GMH*(M*Q4ATX ,AV>3=;7%,-5,B]!B9.RQ9"Q()"@5: M9MN)""X;Y8D5E-?;%]P&/K2K!$*0B4H1H:O;?UNF(J=I9U'*D8,3YFE)!& M^]:?C0]HCQRB22@A):7"55MS=X.Z^O^[[R>M'^5HF? &EY2BAC**D5H:"9KG8 M<=2"=[)$D#@+7(E0<39'-2&C\Q*@.]!D+861H#6JE,*G#%X7!:&=9$XB0\Y6 M&VC6GT*L@/(;A^N^7GHG 8148ETR@.IPF3B+1K:5.4$6A$4$F97+ [\2|/BR5 MW"*,JJ+Q8JU4:*>0@@D2R2)D6M?KQ70-XO:/&N%R8RV"O+"(]U%8G-MX"V@ MYJD"*A)6Y;AT;>_Y>G$9FG)#O1@O[:;3 ;/)"1?QI'QS@D:P2HTGXA#"(,0004.P" ;!IT#IR887K%S;4,FDJS'F&^S0%X911FS[Q=O4Y3NN 8^;)Z!*RE;'.0^4"/'<)+*,A*VN9 MLM4%D#9AQR2GG_7&#$2G99F#0L&7NEX5K4J:F.S# M)N#.&GNM/AQ.T3[(DH"D$@%1LI DU)# FHLB6*+Z#L:3B4$ _!K'N M)A)=Z@N2&I0]!B0O$Q>"4N)VB>6.^^|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|LD",2)\':I,1:I-=8$GY* M09,)0CCE](RJN@$5Z]@5C%.@(L02YSB)=2$DCB% 8(L02YSB)%D$5?3!+ 5Y: 8%8HW42* 67'(@&])>:[=A| [9.:MW@HXC3'%1 M@CT9H:-U ,=4@)@Y%RQ1%*UOH4S%;JG0U//=+F8*ZC'!;-O42M-SW'K")NT MHB&KG5*1HX1%9TM_<3D?;>P"E\ 2-R9;K6VH+D_|=FH?|ZCCI/11<^.0R\BB MGMMB-WO4_:1WQI4^;VKCYX^N+'6Q@@()F9"C"NN!A5(HK:U !H7@C)2&G*U- ML;[^&U?.>/KWP?YO+OSN1FFZ,3%FB<>//">5U.0BO|L29"= ,<5RD"2G>INS MU^Y]7LZD X16%+XXE#U%6>%0<$.!.QY!U<#I5&65<9_(_V(Z.7MA(M7) M@D^EWW&,]%5*^R)98$[4VL=WIG:$#=43S>7- LY1^MW$8]*:6JTE2^"1NR!/R:FX*!A(+2,KPSREKK9,MB:7Z#=X M? X^U^A?9R^]"QYKZK@N#;H$+]:Q5@]%-?(J2:VR.0@=:;49V)6%K3]".I(1(1)L0(B*0,J57)II&C'$M!)]YT59+S=7' MJ#KT.VI%0G ('>F5*45[R'69Y2"EY]8ZY@*OTE1Z/C[$;4P.4&$X^L8;]1S/ M8CQY-9C]ZU.I9B\NJ>?7=>&Y,6Y\;_YW08/)>#A,<2Z<3Y2HHG1-ES@*_ QF MT&(8=(09VL@4&0.? :3$@67F M^/+D!B??G+PO=[CD;M-_YMF%NQW.)EOEB]O>]Q2;3ZJ8V_S+6]ZQF.[%BL># MFJ+ZMX]G%-P+U/7<9-]6MI|^K,T@26=O\?H0+W>HDGZ[GL%T+!C56QIV7WQO M.1=^7SY\D4;C_<'HLMO>=)OG;O'T ,JO.8W=%Q<.]X:;P3>#+UNXLC'22YK. MW^XE%ULBP,? |C^:YB?|MYG.CH9(Z0<.E;31)YB-#[;($SD8/?L7#$8Q?=D" M_@R7#WNI)(@N;'7V Z^!?>8LN/)_@8P$^>X?(/3IZ0 M$C??=Z,1"/YI- MQOMX;2$3<,/!I'6,.59><;TP(U.'O-Y#U$().0ME#*

>).WCVS;._^SA| MUN=!G.UMY<$,6K(E]>A4=X<.88E[G%$J1/D]MNLJL]WG!W MXKKGW79_83P<3[;^1- K_GEV]V\ISI/3C83R[?;/@_C^\WGG_\D6S^W\[_TR'LOGS^X=W. ^YV7N\WVZQ?-R_|Z_K?MUW]]V3Q_\]MO.[N[.V]> MGYQ.!8MM-AU;,&-_] MW;_MO/[K^S>O'S,2&&7)=%EWHV8S&HU9|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|\45X53P[G/9QLGW6:5[C\2;GB8U/ M%_[-3T|GDVI?=9Q<:?'0+X7+9]PQ^$EROV^U?Z%\< F$OUW3'VDR*\TMC]]" M)%IV2N9U@M<^D0>S]U1>ZE&ZIC+^QO)(C)-9!C]8U'NY*?U[K&4=]:RE_&%R M<&QPM_G&;:7;Y.CY.*:+_K%IN>)@,OZCW*>3T,)\B#=UG5[*ZKW-;(Q[% M30.+ <|!_MY|V3DN49BW4NK,X+D* MDEH#D8P;2V\!R^\P![.VYF"]4[6NU]:4F[&DV9<*IZ:_SZ<#*9Q$%K7W3B? M/?%NI\UGTEY7N='"6@;4;GGQRH\&_VO<_=L8F- @CT.T_>/=E]TASWTYK<(UB? M9US-Z_&32P%)PCOPWZ) 56!ESWG_(KXO:8WT08!@&JUK+3T89A,D*1VQ(A!^_M]^C87"YLQSA)T^GQ/[\.1HEV:@I>? P17)W.2YC93,YZSSM%NN>EG<7D_?ASM|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|VB^=?U4=5^;Q7O;96)%L>" MJ!S%]2AN3JCI?,,]PNA@="*Y6MEW]2_;KT]^\@U\YJ?YK8IQ'R>CMS25OH2]TI*_004";XN??-4R>C;I#49<885=>,)- M,&9EP7+SO7Q-*X*D3E/@7L,..VQ[JE8UV4QC#+)*@R%DEX$L! [ST!2 M(FV6DDM]YS2,8_$TETX=FF,_OGZS8L1:E_R[AWAGK5+*&^"BS-@,1(C24!* M,AB5(HEWK] JX78OCP5KD;;=H=_K[=T7V]>UA+QQ#NE9C\BJVZ_7"5GBO)^H#|\V>V[:Y,$PQ<8-A_AE M:;!2?"__!P4S\MLW/AT? '>\]3YPDO.]KPCR+$+YHSGY@09BENF?%TZ@C3Q ML PY;B_%+8?4;M.4-6WS]VGS !XOX__30U3*IGOC4AEXT]UBMN=FWZ|!LSN_ MRK+$^8^/|_#CX\:-8O.#F^_1IX3 ./3_C3LHU[>7XH_**H[OTXY0:Q?1+M)- M9XTE371'TR=7- 3&X#5.QI.BB0V/FH1:V5&S4_0: M%II\O1=NYN8=2;X1.U_O<38 \.YP6++(99$I!F3G,B&]B*1=>-_|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`>(:4!"D8 Q%YZ>R4#3@::9:6FJ0N-%,Q6G//K{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||\R.>E'SZ!?94\+=1D12EI-)ZEZ7EYLB[;^W592DFTO8*B+K/)>SGR MZ!?3.YONXFSZR#[BS]RG8^$1!|- P.)TBRG[$3X='T\'T8UZ9ZXD]:7X[7:@40FU/(G#:;_/U3D9WTPXBG8\VPR'DY;C#^8C$.*!;E6AO#B26'K(1):9'][NH0> MF_MX](WBT8./XY+=7TDT^B0<_::DN%T5BGY0^+Q>+]!& <^:=6-:$?A^D3VJHM M=VZ;[JXT4/QK>?B<+||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|Z_I?BBM<"(FGD%2FT&D M*.!/[P\ P2PV-4I&LOQU*RVQRPL4,*:< @E]D/XE("$&+X))R69_.>SZ:VYX]=Y-)&7#_GV46Z[G9M!]V7Z"T0SC@7?C9$;7 KYM0 M:QX+R[^<3KN)^-X=)?>L]V==]X-U*2--E<&/>,K#M]MR6\[4*>]YZU7873>.KC" 7!/;UN]]X_GR%(DF-\4H8 M"-(Q5 JC 6>=!*,\\9QJ;7+H0I$\IN"7'L6VY=8|SZU;A9(^%FR)ZN3B M&9SW@U)ZMMBSQ?O/%@/)+EK%(5"60&@1P5C/(=*H3&"<&&*Z<-&NDBTJK7NV M6)<+5W2AT8M-U.C?CV=NV"OO#\E6?JB.DPGZ WMO]=7=/MUN1='7\0%N\;B-NI;"DX/2E/)Q,TSWBZZUWID;Q>=M8&+E+]T#Y M2$#DP_RP4!S5)Z9R2%WRFVV1M2$#OY;X=N--L>Q92SUT M4-Y3+A6BUSH;"8PKY%))!7#2! @^I.+9221>R.A8+'2Y?'[%'CB3ZM,+5Z+@ MOD%$=K/!Z%,S3&Z;FI90899SA$-_TL"8$V!LU$* !I!457>BZJV!4@BPQ/6\C<+MWYZY$V]T9S=SH MTZ!43\|UV]Z3>_I]JY<;9^4&Y5YK$@/8$!@(HC*^8A0?@G#PS) ^*_C.BCO*;\R)!F!C G) MO30[,P$YEW44A'2*N6*;.]N%GKM"? F4>;_'0,XA[|^Z*T_KV^\9!O21YT)(D M&R](E D2)O9$(D,5P;5WY2DT,1HEI;5..CU>!2ZK4/1CZV0#UR(I*$HD-R MXUD5/"PP|W[.U43UV_Y PUO6=/0LM&^%T;?"_.- NMV%F>8PQ@:*8@HB%@D[?@ M?0Y",*]4H)TD WSM?-&YHFCZAD"(MESP9X++LP%HS**Q>!!%58H@B7@,_4@ MB36.T&2%EYUD&BR1"U*U1%OYWK#!E3IE'WH#H%XG[Y+JV!-6R"Z,#XN'>XWR M:/6C0FYR$/=5-!D=N7$.",T:1-(1C'0*O##6YQR8$)THZ'.IU)7KUJK'FBRQ M".VI"+%9$JEGA3TK[%GA35@A%RJ(\DDX3D(2Q.X$O5%.+E3H+MZY MJ"NUW)#';IFY6_>(%?8#M:1++>W3/L_/PX^'\>]4B(C$@V$:E6VI.DQGX_#[M'OXB3;;M(?]K.WT,#OJN\=|;Y]U\-&^>TS? ZG'XH>)Q7VKO\6F:1]WGAY^ M%80]CW@P1// >$2/Q0\4K/=JNWW:U$HDXW8(>(:S:7/@CDK^;N^1W*!DQ'Y& M>T>>1"]9J1#5N$!G0'#/2H!$@_,A.VLTY41U$E0YIK:WLQ$/UFW M9U55@K)G55T5L^?H*#<$J'4$! D!C%81$G(=XD3D.G32!&6IK(H_IGTY:%\.*

>).WCVS;._^SA| MUN=!G.UMY<$,6K(E]>A4=X<.88E[G%$J1/D]MNLJL]WG!W MXKKGW79_83P<3[;^1- K_GEV]V\ISI/3C83R[?;/@_C^\WGG_\D6S^W\[_TR'LOGS^X=W. ^YV7N\WVZQ?-R_|Z_K?MUW]]V3Q_\]MO.[N[.V]> MGYQ.!8MM-AU;,&-_] MW;_MO/[K^S>O'S,2&&7)=%EWHV8S&HU9|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|\45X53P[G/9QLGW6:5[C\2;GB8U/ M%_[-3T|GDVI?=9Q<:?'0+X7+9]PQ^$EROV^U?Z%\< F$OUW3'VDR*\TMC]]" M)%IV2N9U@M<^D0>S]U1>ZE&ZIC+^QO)(C)-9!C]8U'NY*?U[K&4=]:RE_&%R M<&QPM_G&;:7;Y.CY.*:+_K%IN>)@,OZCW*>3T,)\B#=UG5[*ZKW-;(Q[% M30.+ <|!_MY|V3DN49BW4NK,X+D* MDEH#D8P;2V\!R^\P![.VYF"]4[6NU]:4F[&DV9<*IZ:_SZ<#*9Q$%K7W3B? M/?%NI\UGTEY7N='"6@;4;GGQRH\&_VO<_=L8F- @CT.T_>/=E]TASWTYK<(UB? M9US-Z_&32P%)PCOPWZ) 56!ESWG_(KXO:8WT08!@&JUK+3T89A,D*1VQ(A!^_M]^C87"YLQSA)T^GQ/[\.1HEV:@I>? P17)W.2YC93,YZSSM%NN>EG<7D_?ASM|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|VB^=?U4=5^;Q7O;96)%L>" MJ!S%]2AN3JCI?,,]PNA@="*Y6MEW]2_;KT]^\@U\YJ?YK8IQ'R>CMS25OH2]TI*_004";XN??-4R>C;I#49<885=>,)- M,&9EP7+SO7Q-*X*D3E/@7L,..VQ[JE8UV4QC#+)*@R%DEX$L! [ST!2 M(FV6DDM]YS2,8_$TETX=FF,_OGZS8L1:E_R[AWAGK5+*&^"BS-@,1(C24!* M,AB5(HEWK] JX78OCP5KD;;=H=_K[=T7V]>UA+QQ#NE9C\BJVZ_7"5GBO)^H#|\V>V[:Y,$PQ<8-A_AE M:;!2?"__!P4S\MLW/AT? '>\]3YPDO.]KPCR+$+YHSGY@09BENF?%TZ@C3Q ML PY;B_%+8?4;M.4-6WS]VGS

*MNB(%=W*8BM&X7Z;NN8)IO>2XUY35"XQS H-)5&BE FN- I'QCQ6: "':)I>&;I;BF9ACU|)#D(< ^|:=G5@|=E/>46:DHC',!M=N@ M* @?&1B'W(?*%'A4REAVP1!?*
1+M=';.B_*&7K/>>W-4]NL/!J.RSF4T&^'>* MMT""F?9Y]_>U\([GDAM:Z'N6O5-[7N&=7#!N4]952"BI22#Y!2L&7,E('2RVW]^FN0LMMFQJ&VU>O
M]+*C[^C5=_0Z*W^2C=0]"CFGA'HRJL@N.@6,16Y3$(|)3C)\6XI=9CB1K*QU MP 9W]>I98<*>U9XU7@9R70*,D%6W((UH/1-(D3B:B)0_\0FALX>:&2V.% M]+&4?8/#ROS1#
[W!8-^]UZ>A^SE84YR95%,B$0B""<|>.|Y<)-1Y"2;N8I= M:-G+DRKBL>US+7KVI,!!>4_9D[7*"!$XN- .$)<2C-44!.=:(I<)C%PŒBVB M^2Z//:'62_I\XKXKX (D\74N8M\%|#>|:
TV^WQ^+["=9[M=T^FW U_0'QU6#T MZ:SKYJAH8LW+Z10_'.!#I|W!X23LE5S#@\D@](V2[K>2V1M.9PTG8EF(WE @ MOO7K^(B&4PB [Y@T1EA_T7!:>.C$=OCGX6 Z*(__2I?
X:C](6[/>'2:UM/] MT"3Q6"CQP VLGHT]=%#>4S86]'4YAP0VF B"$ |..@.*B2 LT=:S3B*?ZV=C M]+'L&RSU.8HK]BOUE3A]:DZ?FG.77DV$^IA0+!'C'0]H)%#%+O+*$"&9*5\M
MLYJG)=\1>N<G'QWA)C@.,D#J2/P&*3T1)(.^D) MM2JF2#GI66)=GN^'GK?8Z^R]>.K%TX(#F:V)C%,)W..?H2+[!"(90&W<9Z)2 MB+H3G?U.4E%7U43L,2&ZET6>M[SOY[_+ ZZ51
M*>&E<)VHY]WS/\8?4[/$8-^]X7\/,>/R_)G|%.7TX OL#2*J]ENO/MI$E+?: M(P8'Q.#H\)65$:)+G/@@#"7VVX. <)/(&'/64,AE=KG@F8$+3H%141&\FTU!
M=IKELK_F.VG,NZKC($.)V&I4 9#__!Z/$N-^O$4 2[|I\ ^PJS9&\G*:2)))5MHNA[W)Q.W%RJC\AQKD5B%CQU$43B M!BS)%%((3N:@F+*R"Q_YZ?9:P?
[63=Y,=F=EP,]_NN%A>ILFNWMNDLZ[C_!E MN1ZOFK|)V_MI@@!^,1X.W61Z?/57E]+.ZU?7^)2N2CPE0J5DP;%(<2\F@'.: M@.)1$)'+].%.NE^N?__D";FT0]D5/K:.L&
[,)?P[JBU0IMN:L[WQ!%E-/ ?-:?ME%RAK]$V) M4@W9&8 19JR.8HWB?]>LEH"RG6^.DL<(I?+_FI!RONC&G6[I\6]0,V5* MB4D*E"(US)0P/X#V)0+U26@B>O;@
OZZ0>*UWHLI%%7M>$QKA+T6B'NE7PR.85 M\^ =M4 4B33Y:)FY$%^[$Q$91MFSVP6]>BS[&<)] F75#$%3G3.U$G2@[$+8 MR.!KA:\T.|YHDE%#Z!G"1F5@WT\76\FR&
(]6ZU\+@E"CI4,3'>UT$=#B03MGLTZ>2<4[1M8E^-3J(0M2PM<<2M^:R3Q Y;O;_9^_;EMLX MDK1?!3'_S(8G JFI\T&*O9!E>U<;LZ;#DG135O\GN/E&N[.+
MOAQD$^18@!A:AB@N+!I5+)8;8E4>:1+3)1C'1M'8M#P;TR(HP=>MA8NM-F' (M)< SEPWRR*S:SZKZW(223XUU4Z/OZL+RS0."D["Z09@W?[I \Q6^B;B<2#:=
M"":4^MH?,%W^E:__*]>3^NGG6!?P%N=?/"U%\80C6NY(X@E[8UVNC?8L:Q R M,U#5.@4G) >3; GHC]F(J:]B'*@Q%1=9,NL
MMB"B$Z"@GS'8ROE)13YV@Z%YT:V,6(3>GBS<6\RRA/%MW@Y+KSW]2K M7F/3SM[BY%68-:0>!HT<4@\?J0>F#YLYNP>]Y4%.+2%VW[,ZI.RLOPKB==X?S8|001U!A%>?
+$!>,2,X4G M'VS992RS-%L1'U^/2>HQ>>8EYB7F_8;.FRLY)5L!>B.$ 169]2R]-02!S[KB8\F]5((CQP%-=-Z M;\2]M>@[X$'W._^,CW:G7(2E%4HHC58]?
J%!P7A=D'GAU&$!UJLEK MY8#ER 7ZS+/LI?CG9GO2'[=0[:OSO5%3X_,W!*'Y!<6X9%2A&V*B%V,>;WQH/U/]>:1B =0_"?3/4/IOJ-<7SK MZCLRW?>MLL0CT4$S+R[B'+^ETKJ?-
WGO6FONQ$0/47 1AV\-0EX8 Z49A%\ M<0YB5P6?'-=!]I(C\\;HJJ=-WT]5[\W4LKNJW@^!F=/29T221))$DO>*V*=D M*DMVY[0+@E(,(:I8|2]HDTL03@G;\WR_?
9)DO8&I\7NL*AD025X9_?6_H=[^ M^M>CH+\/WVWJ5W_VV^Z[Z'VO[0.E?"5;:]W+Y[Y^\|:NDQ]W0OZS].G!1XB3 MD+HCY]%VSX4$:1;K^E&K10?
DZBVUN!X\N'95UR>7RJP)39JM\PCU#^LA@CLF M#/>RH,DM4>;9VTF:A[92PGEXA= L,EZ]Q_GRCO]O[1^^>PSR29GC.\BS M):XIX7%=R\6;YDF>M>?S\/YQ]^J3\Y"[!BHW//K99I-
=.L.;/_SO1;N:E?=7 M7[B^%+#)3\X7[;H8Y?$2YZ'KG5+IXEWW.,IG/KYFCG?WI(QSF?X3W[9,__>UZ0UQ^\I4,UWA>R^O&'MB29;\B.R0WW:M1I[=5",OKI7'9%$F9^?UX7;8VH2Y/B]I
MF'15%R>CGWM^>M]=-.$8-^U# __H0)=OS7=W6L<G'1UFU: M<0#?)>P"^5V+M?7.K?OX\E]UFX<'R6$?AM%@=<52WN+6;\3^ZMF%][!0Y:7..96VT/I;Z/05]E,:R4RR-
_15;#,OT>GW@*N-; MG" .NY.$1]R$]?"%3 ,M4K):H(M=:5:+*!90{$GS("H*/(;N8-&Z//I/1"Y3U M3=:&=?>"#"%8 URA]Y8Q)QANMQ7;;,*G3?[APQ:|<>.^]34'C4VYW&,'QY,H
M/:+ZS",5)5%63Y3%M?8B^@A9HP'%6 :7N <4PF9=E$ULJZZR)"&2%96R(U[XJO\!SEDR +*I4&\QHB#PR ML"8H*TRR:GM0Q2Y!N,/PFG%3K8G8R 8;MR@'RE6Z:.&$0]
NRR[ZYL$S(8!5 M&XQ9E97,J8_HVV&XRD^EVF.3V9/8WW0P[B#AMV>O0_,*)[-F4L)L.7D:YA?8 M==?KWC&KKS2K=2O76;YLMD=3?WJAX=%. 4G):>ZK6:A$UJ""TN"XMF B4YDY
ME9)_T%F[=MXL'C]M6UP]3?^ZF&VZKSZ[WLS/;N[ES=Y_WOQ4=_[_=!N_)_IV MEH8"D2U*-$(HWO?A=_+[_@%]L44ZH87/6P=@=N>]_]I0Y:7..96VT/I;Z/05]E,:R4RR-
(J!6=5)$Y5CNOKY6U(/(1UX9Q(8)45&XT(26R,GOR:B M>0RL*$!;>:V)5,C^)*(DH=R5*D7/ARA=P.G-0&CEXSSC(PC!5QN3&/2B<>@Q$ MR:=&[K'L9#!$>=!SD&,?WKNX?
UB0:+!G6G0IQPY MMP]$2M5_%IW_S"LK>I$"EI1*L%N6XRXG2_=%@\).E57$@M_^P.DNUN?QQRT_ M]"&??SQSF=B6V/8S^^:['><TW9%JI2](N5DLW.0U*
M!0E.&0U"\IB9MBIM.^V#{JS[8]!1EL/R+0#F M!-$LT^PUH5J28BRL1G,< M*AL+0:$!YVPL IE"C;U&9?=(LR,-T0)%2U1+5'0\5&N8M1%%@
M!6QP/'CGF6=;U0(/BOSNCVI'&@1^ -/25,K=HL&KU[B?+=Y1G6OTXG M#7YZU,Z]\U@=!V\=;*C5R)9[XD8*[>)Q+W< (0W:PK1<(N*ABG50RZ7N8- ^T M.]@?8;D,S:J=S&.
X3I)_]$CCE'#LH[!DJB@FB#)Y\ MB$+75W [5++#,8OK&N"G^7\OVE4W^>2L_.-R, ^YV8*[,WF&&_\/EHA.W$UP|
M&7GG10HRCUV4)|2APD0*:E#2EWSPL!U5U1FNP!Q@BB4\#SH:+3OX\C#'EAO MNSVV'M8(SIZ2; ,R XDLB2R_QJ13*=AL(YA4+3/%"H?H48#DKBBI94ZX=9YK MEX,&9-(=
[]8FDVXPHCQEZJ,25>R52+[#,S9;O!PMN Y<]6;M<)B\LJH7G+^ MAS'IAC5U^)MD\RE<^!68>MX1"[:KRP, GT_[TZDN.M5UKU:$//E1C4A$WH4) MM>[.NHIJ8EH?
L#K@II_ ^5<^;MI@AXLTQK*N]W-M8/>W-Z Y@D:5*)UR)"_L+ M.-]L4&$$);3K?/+.,%411'+*&(9!|:V6++L$'/?,A7R$1U&I[3_1)M'FMZ'- M$*H[KJO-:)(.H'01$+#^,[.BF$O5A-
P^R+]+*'//M.FFQM%@*3(AB0N)"WW!M^A M](E{FTC|/CT(M4NXGFYM"@=57(+(L=0?3#,G@O!*]1$#_7G1+#XN1NUWKC4% M0@=EH?$@^Y'S|"-P>S$P5W(V.8X_Y M".L1]VU]
)A^QM4^!Q.(1Z+;6GEQ$>?X+0G]?COKSWMC]KL?!"[_:836"<]9&-U1KHH)H@XSJ3.<*'>?E#N MOG[$%M]2WWYQO%79'%A2PA!R4=1P,:!N7>%2O^]%G?TQ]80.V#]7TP-
<&F74R[F(AXN#(=YW)I%P]2K(-:[NYU M=]=O>S]X6%AU'.L[7V/3S M|B=?U<=V;CT^$D0A4MEW3#4,4ZEN62D3X\F8YS MN;2+!RG602V7>@ ?[,#U15.?T[S>99Z\"K-
FLF@FI09^QU7HLBHMIHLEC0P; M3>?VNY.3%C6Z^*Q(IP0HYQ@XSC)XM,I&HZ79/H"WRYGGM9/YI*:/^2%7^21M ME.V(/?G38ODBS/%[<I(T):]
]N>S\C*\ZZOWY92I/99G#QD()VYDD"@'SVG% M&..+K(14K.H.7"2(S@10EAN3I4&Z-0]SEB. ^1673.[_% \)!A0/;<8$0Y4$:36*+C M+@&7WH&24D$L3(#010@,
(42S5;2PRP%:LN>."P4'[9M[XD;B T!7=W1]J,VD M;N@E-NG]9+4,33L/:P2&Z]U-G7CV4%A!G7AVU@J.H_#,,:G/6=^3R$CK/+I'SL@/.YB;?-OGE!Q@1]$?
M/C]>YI$C,J,@KT>F:8$0C&00M3)1I!R8Z:7% _'TH'EZ0+8ZD3J1^HF3.@H= MC6894,P95+6;P7D7P4G1-7+/Z&0O/89/@]0ED3H9W\33Q--'Q],JN6I>%P?*
M=V/:A=[5{I:ZBZ27(KA5.6X'27H.G1\3Y/Q39V.]QU-WTRA^[B:CCH?4XNB MHU83]'5QVBLHDLMJFM<62:{]LT M)P(F N|AR'*0^JA8"9AUOQIF#D)2'#ZXF'BHE%]VCKCL$B0_(
&ONR)3QSC] MBDSL2^Q[W.R;)8]..P$:70:E/(.H# *7V6 2W GR7$+,458^R^B,-Y:[!0#$#G'] S+PNE.R M$3!U3#X0C5/W%%KNZ1LCM(O'O5PBXN')=)S+I5T\2+$,:KE[K[\XB!V#]LL
M)^>;QLEOJA ;O@Y+G$YB:&=I$IH\R;/YQ0HSA5TH['*T81>+WHO@,["H.2BE M/40K??VG*#'G4ESJI8;RQ[!L9LVK]A=,PG D].%&%5?0*ZL+J:'*&N0D!64LFB MLHC)[>,)?-
_QQ$'7SQ^YNZ)1%)ZB _#E!TA1';>B2B5K)G6"&^HYJZ@"!&XB M")$MLYY;IV,?YV..5U&I7&Q&S\"&5%?C.$)(P8'+TLJ/H?+T/2QO,XO*B
MC[PF147GB$A+D98Z+2T5K98:BP;,7(.23(#C.H!1UG)>T%;.[>,$QU9%%8* 6&R %$405FGF62|=-8]74:GBA39: =.VKD:S5%56C)!R MTK)RI=(Q[^,)'%Y1B4>&W*G^CZ51*?
07N>$&4)=2GB%'Z7*VLGB8M6N M0LK/"87+>;):C&IRTT\PJ%[43:I/E4UFWHJO8;M=T8J(;11 E(K,J HX6J M%U5U0JI2B RKXX(H?77GE->\CSS0%2:>;B#Q\\6;B,NS: M8H.:FT]
[>:DA[6!#1L&] %DD@BI>=T.W"DB57? ^%!^WW(==\A['H!TBKTMES#.BH%2 M*,#)ZA2XI&W,P8C$MX],L;C6O6@'Z::>VRDW=PV%)>U [@.I"%(0#$K IGU0
M,EOPU0ZNYK%2W5$¥#C;%8BHGLAQ[*7 _!@5A30@R*@>6ZI6G>I:)?/ C?.\ MWGD*V\]PQ[7NQWU@4Z7DE#M#"[*O66X']>P?AJ:Y=S7>B:.^3UG:::Z/|26L[MYK71_J2U'?/::'^>]-
JNK-OZWVY&|/K7HUC*C>)6];L_^W7W7?6^%_?![?]* MC_S6O7SNZS=O[3[Y\6Q5OS9]>?U#-|^DW?%0YUX6-+DERCQ[.TGST%8G^+QZ MT=
L,EZ]Q_GRCO[O2GOW6.03\H+7'M\3ZN:[EXTSS)L_9\'MX_ M[EYI[&^C/M/F_[7;\E*S41V1317'YLY;/ZVL_^O+F9U]\ MUM2[6(7EZG&X6"Vz>?/Q"?;J;/Z_%O/&A0ZEK>QSE?
X3W[9,__>UZ0UQ^\I4, MUWA>R^O&'MB29;\B.TUR_""?8Z?('5<|>0B7_;'9+G$QSWW X\5BCLUB|O(U MUF_ BVI2M-/)\R8].[)IO$VWA]@6ZSCLM7KZYTWU],\/2JG^NDB_O]YQ$_7|
MF)Y=*]-G-Y7IB\W='I$\ZX.;+$]|L>[9U<_$9?MO_\|);I],?OS7Q6SU_F0L MI9X?S$^+Y63U&BL:EYW)U.3)SU7K3/Z|ON%U._FQBK>*$|^K.",N)Y)-)X() MM7YC_44>D8B_!62/8N'?
733A(G?E*\E<1R!|?=K*F06ERT%215L^&[A-U8 MP2YY-:G\)&|XDI7WI%<=FXO7I_QF|W0F!W\F-]^OC1UNUOI+-]ZY|W;H7I& MBXO|X87ZR^2K.V"/A£$LH+ET==
[BXQ;/P[{JQ]M'L$Y1;$[!3[>3:&]G M[2S.YE?Q/+ZZ_]X"H_7722]{&_>7FV;YY4(W=OG?/G$=/\@E]I$RA_FFPUQB M'GEWM#='ZZ'U'/EZ["F]O%-GZGF|)_M>=K_]80[5-
H=:M/OU:CYQN']OA9W_ML R-N7_Y.'+=%2+'<@&WBW%>"K+I*6=XM)VZ3;_S0AGESC(IY|+TY0NWIP[M'GRQ4_CO/A#:Y.;Y&1"T 8F$V) 2R.WES8,Z2S26:-?+&WIT2^6./DTG>6<
MUP<,PYSV..WQXY%IGWO\;/4:E[2|:7N/4*:C6BQMX)/DYY>+%9D?%$PBTMCG M&8[/&Y^P1UW?DW51P%UM@@9!*\\V_$ M7\(LP_-F["]6-
O@4R;1GJ|\7O<:FG;W]XNR*XWTDM,UIF(/))MKDH[[D=Y0! MCWZS4VR *&2/%#*^V,"FH2U%!0@EA)+/V)MOJDY9$4H()822SP0?POELYP06
MP81@,@Z8/&_2X@U.OOO[HFV_,+N>P$)@&3-8?L R2S,RO0@F!)//P&2K/2"A MI+<08JI/H*1!1PL?-L!RGUA\P."I[\,|*E^>5A- BLT%V'Y?L(W71;W/K+M M5.CICH_\[
2FPZ_V8,/8[L3RP0>M??Q0>Q^[YA)3,EH'Q2&"DJZ =VA 91E*MCN@B,UNS*FVID"D1')<%E# "/#,*&.,F95T2:GY[%-G7#E9[_O-/7YI(R:?& MNBG7=TVDI-U--
/5M5_LQ4C^US#\37WT=7W$C,2B=(!AWH***$%UE(K@TG+&V"+<'VI$V-KQHML1;)QI- M=W<-KMBS(6.SLMQ*!MFB!H7<@=D_!@=!9>Y>S.WHK%!25=9K) Z=)59=;("-M-
\"4J^-/<F>G^C1DVOKHZV!?L&B$-5/%V9 LFOLAZHN9>,+(HUGM6#ERSRRF ME.:!)0_%.UX926>(5G H!8NK_E@QV=]E.9ZSC:DPB-HFJ,Q1*L_9 !:Y8Rf)
MDIP\F#O&M9UJ9H=$7@Z{)#POG\)ZKM'Z0VY^*KNM MZ8\O'[K>PA###9D+OFW-LVM!M-5(B-T86N<4DY.-9&J&5T$IH);2.6I"C\,LL
M2Y(QKX'9;$!4X!G9NO=NUQ0QHC9W2;+G,G2!U0@(Q>@C$3P-EG00]NH3,T; M,F[!94_S_UZT]_7\]H>+#_UPNZ8YSYO+XI[U8;2UW?OLAMG[*U8WKJT+?8'+
MMI.$O^!RMLB_8E]\:M:?\CIA?H$]>7EFJA2EW(CV1BQ(E3&(&1"ZT $26@= M@9)K0.1Y"A<"H_<%<$B!(:V2SY+'"%HA:,T",U+Q)/*62^&8.4P+\%IT"6L3
MP7GE0'E=K,G5"XGD4IPL6O9=%D=IH_HYS]OVIHJNCFRS*9(GM:CE+*^P>T2+] MOMD);?V9<3G!=5IT,FLZ"IJQ3"5:.%DIVI2DIJ M4,$'\,H7",.IJIY0.(H3;ZJH4HW3] .)T4;-
@$5PHNBM\;%^-#/X?;K2SIO% MXRMPGI5?KZ&YSO/^U@%S4X7W6X?.S9F%V)*8_*5"\|$E>9Q/F53C5D%9>,6 M/@)(Q RH74@@B2TCD#(A-.!")+0.@(A$UH'(DA"ZPB$3&@=B"
)K;F^VQC0TY41E0V7D&. M@LID2B9+4[U$Y1,HIS5$Y 6D5D+(I#W?;F?X-75:1T)E7E"35B*S$0N2XGTC M$##*A=2"")+2.0,BUH(!H()F$+PWD&.(*#&RF.-#JJ^.
MQE&0XW84]*;JP*G&3?IP<=¥M-#AE:I%X^DSV44CHF$I2B)2B4$J)*")JA M2*((QL76H) ^O":E_U,?U4PG$|8MG&R1>033?)S-XOS[51^#E M'G"]]=P_\7R^NWHT!PSK1 P\F)#
L6!!>>FIWS$(PM&(H)-26|?GQ-?8M+,W^+Q)BS?XP1^^S\4 MSVT{Q=K2WS6O+CV@I\N9VU!Z68\Z&=GJV5HVOEZMMPD7(^E(^5W M,H@L.N5'IN0.A!!$E\'(&1"ZT
$26@=@9)K0,1)(6!"M|KAPE3!,L@ MA.TR8B6"US*#43$GIZ4.9;!9L2[B<^D+//[MTA5]VGO#F]I\V^>4'Q_C#M/;= M@T##ZG1,"2_B3K)T2,C'LS1"*UDZQVGIH'-):\TABNIL3X@!
(C]$4C"+O%UP M.NPSX75H2^<+Z2XR@ZC^ZU#)KK{)UX5?I-EVA%2LFPN7UI?Z2)^O)NUB/LN3 M*WD,6/=|>?%DR|[C66V(B\DA;Q5B!6(%8@5B!6(%8@5B!6(%8@5B!6(%8@5B M!6*%(;("1=T_&77G(|!|H$S|$"9;OQHL@C,E\"%T=!05!=FET9U M,¥V,.O:/?_0XI3R+?8R+??=?0[9+!//H4Y?=A M'IH4OSRL)O\=ENGU1/+I1#"A2+^=S#F D1W'V;/V4%5#
(',>BE58^1\-A)($ M.)EC02>K5MBJ$/=,A(J@&5H0?'BK(.IJ_?M4F#M#:V<6J786F MJP2_SQBVST]?DU.I[919/Z13+A0#(9HBFMH^U\>C+2V9\(I7FC)\1;EI.LR2 M%DYX%
[$7FNK.L.]>S*NQV/[XKXO9ZOW1IPW+D4\;)B(.MR#'043!!>NK@>2>25 MJ*12+(?(NMBE*S&.RBPA;)52<1F0)\X@Z.A!8.W0A5C ?- M)[7X5!A+5$54-5Y"\@=5G738T0LL6 2K/F-
,H#+SX-$[8,9&ES G9[<&?*<@ M.$8=P.AU"U$C42-1X3/ZK1AT,2@],JPS*!80H M6MJB,$M(QE=[KVC5!=(4).:=K73'(9YJW$1,QX5-PB,*06*10N.F0C%8_(L^!#UEE_VH>E0^W+Q
M-.=9=P]A_DN8Y>?-LW ^6X7Y^]S6VNY]=L/L_16K&]?6A,[Y=M9PLVDCE\Q M+5XUZT|9S|/ORV-6Y!D|(Q R(36@0B2T#H"(1-.:I&+(4;@4 M4?CHDXB
'C,HK2UX;5G]47{JW!KOXY9+P:.W1C#@F VHP M$%1D4S837D6,P MFER*4T4++#?T[0-KH>=M>=%6&DT69+++%=+6=IA=TC6]3?USNYK3\S+B>X3HM. M9DU'0;.W.#F?
AX;:IPX9@*2N/JVN2K*R<(Q01!%57:$"UYVM4K*DG*SEV;'. MZJH$*Z7W 2)/ME[C-$2F"R0=G$>KM.?7ZJ=-XO'5^.*[}>0W.=Y_VM^:F
M2/&W#IV;,PO/KI#Y2X7F@RL6K9Y;/7(51%0V;D&2GSP"(1-:I(N0M(2)\@N@@":TC$##*A=2"")+2.0,B$UH$(DM:Z2D(>5GU,/Y*=3,=]RO%?1'FZYQ'M6KQYLV@V^8HI,%5]\?
955(D+=I5Y_WES]^B3I4TN63EP#$NO46.$$(2H)P-MQ@56HK1|9$1_">_7Z=*SLHXM7P6=GW5K[RF;Z:=6/:P(CC37B9$;)8\^<|8A M)A%3*9"C2;"2KC2N, ,WB,*Y4@3?
*FO[FN311V6M'9XQ_W"QG#6O-D<6-HFC M^G36+[4/[VTY59I-Z[.A9!%1UW@%.0KJ4C9R;X0!9TLU2E1P$",R2,5+%,)/ M8=LHZ9&ZUD>L[F:N!S29(]XBWA]O($?!6RDSE!@Y<-
NY4(5)B*ZZ5;E$EKC/ MG&7>1\7;(7F+*S?UFA-[$7N-5Y 4ZAR@I FM Q$DH74$0B;T#D20H_,6[NXT3*9\ X).7S:>432DF"%0;!==VYL2H? MAZ3 J,PG9H7FW#RXC.RS:< K
)^59VMDKM_\CTM XJ{ M$2'R^AO/AH?ZDF"H'I*7/!$_0HR\JF18Q:$GD.7<9"87YIU6H\3DD*%%VN?3 MVL=-'&5GQ&0DJW=3T$* HIT%[A:A2$"+JO9E^V/#[KU-
[/_M#2DO%!=#9>09+Q.0(A$UH'(DA"ZPB$3&@=B"|'X2IH M9QS7GD\RP8#*)4,,(4"T(;&LE)1.[KMVCUR%HTR#43'?UX/LMZ8^HGF]P3R9 M+]IV4G%6Q_QW7(4XQTF+]>
{!U0PI*S9DI)%U2$(^GJ416@FMA%9"ZZ@%26@=@ M@9)K0,1Y"%$7G;E/'=-QA|H:7,&\(#'KI.3)(<$DS\"IXK[4)&K?:8B3K MF U/%@=I#=-<0%)%#GN1XY9M84[XV_'=9,6;_"# M(_R?
BWF>-;_^(\R:OU>7^*QY<>T%/UW.VOK2S8#0S[@Z*R_#N[!#/P\56,H9"M']QDNLH1.S!*RNK,#),1^6BSK(VTF=:,OL4GO)ZME:-IY6 ,T MY/^]:%?=Z#S2?2>#N*/3?
62IGK"0"\T#$22A=01")K0.1)"$UA$(F= Z$$%2 M%.CA4;""DBEIP 3G0/DNMR6Y!]>U0.YS]GFK%U"?^; NX'/!"S^!=(5?=I!P MYB.?-OGE!|_XZ,5;O*\8T*!:-E RC(B5S"
2\OS!LC=!*9M!QFD"9%N63X)"P M&S%Y?H@>OF0(NO.:_A"V:?TF0PC_^@8S2 J#3M)PQ%K@&-&&FV^2$5Z^;"MY76M/M+G]TFIF(_R%$H>]9!7UX\Y,+W>%:,%#Z30\JQ K$"L0*0
K$"L0*Q K$"L0*Q K$"GND!8]Z?S+]GJU1.,J#P,3J.@%;$4?*4\BWV,BWWT7 M]^V2P3SZ%.7W81Z.5+!|K",_==\@1++I1#"A2+V=S#& D9W5:/,/RL :Q.)W
M!NZ]%;X"1.D29.920,M\BEOMD;7GIJH:!Y^%_B]) DY+ 5(7@UX(*\66Y;Z9 MUG9VL6I?H>F*Q.\SH^VS&D.ZJ?1F;JT?TB$?"H$031%-;0<8,FFZVQ=)';A-WL7%2F>N_<*0@V>"@IF.B+
M9.SS@[&486R]Y1[=|`O<**J@0CR.*CJ!$.2@D>?44JPG%4B]+&2&]__$%(.M7K:;B^,OWOHSHY$>,|*"BV'Q(:4
MI2%;)%K)K0HA3;3>!LC&)5!2YLIN24#.%H/(!G,NMVFQ\%$_K!0(%-7S-=) M"-65]5H9@\$?P^X>6[Q76I3<3XT11(U$C<:2PQ%J0(S,J0;1.7-"X&%S5P$PNH6
QX'@HXQ4.T7$B\!6#.K7!L:C4- M2:1*V'VGF==:&&)H.5= O#G'IET?7)/N&#"R]$,+"?EXED9H);026@FMHQ;D M*/PR%9Y/B1G (!VHG"-
X*P,8I43PV7L3W59026H9G910N,V@,%6_K$0!O!21-MK-_J*7';+_O0K:A]N7B:\ZR[AS#_)-E/MZ; %\=Z(!4E6R@B$3&@= MB")K2,0,J%U(((&.J\.&8"DKSZMKXIDGJNJH!P3 M70D\%^
D@W-=:,WMPZ8FP+'WSI!;DXM/+_ "YB\5F@^N=K3.3X6%9!Q&7C M%N0HN$RJ6%!)"ZQ@ 9555^JH<]?8 UG1Q?FT+4BT9RY;V\Y/FWQVWMW7C^]P MF6;M/W\FA0;N?
G'B0DJP#I'NU]+W=Y MM+1X\V;17.,0_@C+96A6[20T>=+)}3.GR:?GN-Y%N&C .,23=]6CLW_^.2EU5E_;+$G!;(O>/E!^?;^-0Z,65JY"<^B.K&+D>T!B!>(YX;KR"'-7/BG+4_CZ V MDE0-
>,@LYB8SN5AGZBDQ.61HD?;Y3&)2*Q.T8^"9#57[F @.DP6FN/2F>!&2 M>DBT_J,>Q)_*3:Y?W)R9N_76MV)]7.TTY#(;,2"),=W!$(FM Y$
MD*,P(>Q*23.9H/[RO)H>VH(W&$]?@EPI*YG9FD"Z2YO-S_F^7[8>ACM8@W- M_R_Z&$?@8@9)K0,1)^%U!$(FM Y$P<0IW5N3D0:))U>SG!6(WX5N5
M]#&ZA%'X@KIDQOPK5% Q7P'2{/|UM1'-*\WF'>OPJR95)S5+_|=5R',<=)B MJGM_-4/*B@T9;60=DI"/9VF$5D(KH970.FI!$EI'(&1"ZT $.8K(BW(N98X(
M.:*GGC=>+6@1")@3*&@3,R@-;&!L(,?7-7_7,SSK'GU']5A_?NB;<:,%]=^ZM/E MK*TOW0S9 (RKL_(RO.NKQ=*4*3I!1G0W8D&2<3(^(1-:!R+(41@GV7]#"3G$ MHA"44@9\#
$,2Z%H481TMH^T$!DGQXX2JHXZ0-KH\6R/M)F4G?V$!OT^K). MAJ:=KZ<'3L+UX$%21P,&&AF/).3C61JAE=!*,"6TCEJ0A-81")G0.A!!D=@ MYAYPO?7,$@##BHL_
<<,6EG'"%4'Q_CIM5O\]4&?^QT9'M3TCX_WRJ>VQ5^)6$]& MHD=`K&0&G;"0":T#$22900\W>G+D,GWDL.P;Jf!@5=39ID/#A=JGVCK#9LJW53 MG]DQ.H,.T0RB
JH#9,+)DI,Z_8GS;8CI&+=7+B\OM5'^GPU:1?S69YCK2{YO76S.5=4IY$OL=$OOLN[MLE@WGT*X/D*WT1<3B2,3@03BG1<+^ 2CT2'KKRXZ!GCD[+W;W\X|!S>]9$R<5N M^H@
G4/IM(H%'YT%A;'HF+4P8FMXB2B.0.9+'=.[%>DZHF8M&C",9Z^[?< M@\.V M+.+5;L*35=B?I^Q:)15/ZHK%^=3<3@5=&N;4-2%2/+(X_$KOSN>Y>??{ M-)@#KI&_AX1?
PBS#\V;T*I8V^!')M&>JKQ>]QJ:= MO47:YK3-CT>F=-R)-CEM\[_8Y#>;4/[;_W.\6PI[46R*&2/%#*^V,!F[\"%% M!0@EA)+/V)MOJDY9$4H()822SP0?

POELYP06P81@,@Z8/&_2X@U:OOO{HFV_M.!NP)@&3-8?L R2S,RO0@F!)//P&0SI{90\K 0XQJ4_G8,,=5'4-]PX7W*

*M&>QTNV#M0)4"#QC(]'V8AR;5+P^KR7^%YB(LWT_X="*8D'N?;W8RU1-W?.1G MIS5]@^4>;'CH<=3]]#^"+'B7M"L0,7E0+@B(SB,XF9 G&9A#W!HJCD8PSCT4 M9A,H&P,$EJ*C#P5,I3DVV,,UX'9LXM5NPI-UTGTHPED[?K5FZ/'GQ_\TY=F MY4ZYJE/IQ/ZFCPUY/Q,U'58|'6*PXD Y*H@2BLL)(E<;5,D"@L "BM5154B MU_UPU-[&>A-*

%&44=HRB)HGJB,\T/WNZF'LUV9Q4?$0;'61L@*E/ .G X>B.F.F.DL&PVV;A,%VFG2@S=>+>D?;+Z8<"Y^F0Y5A>M1 2O H+U7DN7 M4ZE*F,S=XEJPU=C#0E^?NKPI?!BUS^8NN*

<>B4^RV5_8T=[.BW]1; M.5\N/C2ZI;KA/&\NJW;6YXW6-N^S&R;OKUB=N+8N] 4NW\X2_H++V2+_BFGQ MJEE_RO^$^07VY,,IKT?NX!'3C5V4)\|T9)L08H]AN8180BPAED0Y1,3>

*[4V@ MCS(Q]! <(E1C6H!+P8%'F33W*3?RO'HP)G(H5YCA :EI860I .!'TKGBK?4) MR9LX47CLO=*_TD7K>OZVO>A*XR:+,EEBNUK.T@J[9[1(OZ^W]"A*IN;-4WR4,LBH.22D2!*

M1IF@:NLH[XM.78@+B_,@E$((/B5(B5O465E:D)6.:N?-XO$5(,_*K|=P7,=.T M^>O N"FL^ZU#Y.:$PO.K(/Y2X?C@<CL_U5-7/$0?8U=E"=/7^04$V*/8;F$ MV*

*>FV)3*5O#8'=*N9D90$4)@ 8RN[JTO4A>UY11_38KM'@;'VJE\VN2S\^Z^ M?GR'RS1K[VF!/.# 1#1DA1"GC5J4)\|H9(408H]AN8180BPAED0Y1,3>[3=P MAS:4I$*

9F4%9+.#JGR!PGU5VGBN]=33O:Y)IY#<<+1"HRNH@;;.7X=WDC|GJ M=53<[#^W5.N=N>DP97DW7T'5I:8KY)GX8^PS)0S&S8"QZ[#M3& M0"8,/&F(G4)3/G%P&*

P4Q[CB40C+_$-RPW0L8180BR)DA [5C$38@KU[CL MSO,L\34V[>PM/F_2X@W^?=&VE|[JLTMG]67GJVYN\FF37W[P7#^TE_D95V?E M97C7U\G6L1]L)7H;NRA/GM{{("'$'L-R";$;/TBDR+&$HL%DJ&);I4$;Q<(M++1CTK-J<_31JXX.DF/&%;"'1/5+?M9%XW/&F87=$4Z_;'Y?6M/M+GJTFI ME_RY&$W"07]Y=6?O);JSZ|\S_;D!>3@IXLQ S$#.0,0 S$#.0,0 S$ M#.0,Q S$#,0,Q S$#.0,A^GPH8(M66D.";OF54$A.!DS!&X-CX5Q@^YV=#US M41IB'DIQ!910"1Q3'CB74L4L6 KR=G3|9UQ!"??/RC>UB=;?_M"=-Q-I=YC M@/Q(F97Z?*

*1#%$L4>/\5R;7W$Y"JQ6@VJ2 3OG 8=K?2Q9!$DZR.!211[3!2[M|*V7?*3QY^__#[,NS:7[22L)O\=ENGU1/+I1# A28\.L%/AUX^:KSG6#)<*

*M&\"V.U,2@:O>2074UL496AFV/>Z=H_',9P&2908]<@;^[&K%W%VNN!(.HB;AI34ZV$6B%1[$!5I$.T M68%1+%@6G&&TO5!3U]VZ%*P**RW;3P[JGLW3$3,1,XQ;E0)FI&*

*(=6L6HT"6,K M,Z4 WK,"Q5=G*_]D?,';S"31Y>]>1Q"FFRU:B0H"3P:T2]*(RE8Z;#G;>V,F MH:J;]27Q$,_'3]$4Y4'YB/&FE4H00'8*]+AS$[#M[*.5(Z\&TM9$8^T99\$E MB$Q4:XMQ#\YQ OZ59A%UY;O#\=/HJQ"(FL8NRI.GH/D/#*K']9%!E%V\2N, ME<"ZX:C6&9T,>BG%EBD6I-):\@"LZ'J-+P6<=AY*3$%6D\X4R?JDNOLE/H32 M4VN'Y3-2YI@8<+P, ^(F#,.*

*![(*KSZ*+]CGK %%%5A!QE$7+,736P=ABHY9 M.4EJ=0VQ A%YP25*V$D,<)G<36 6JD'Q1-497HD29IUWL88C>1J2+BPT@F M4AB#1M=8%09UB''L-R";&6(LB7*

*(B+W;*8N1N>)X!AU$!N6=@Y"%A904 MFJ)0B;0=,8_92A>Z U,J=&$D"2%R#SH&%X+.RN!6&.E#WY[VV>)ISK/N'L*\ M&TCZO'D6SF>K,%)?E8JWIY#^V@T;,NM"7^=#R[2SA+[B<+?*

OF!:OFO6GK$=S M]Q5_GPJF1N]B$=>-.790GSW5DG1!BCV&YA%A"+"&61#E$Q-[M3V!FV;20(CO M0*%F$$+RD(LM.3 TD6_Y$[P$Q9B,() ;4)HG<$5'D#]@]RJRK"+Y$R<+$!I

M=Y"4T?.VO>@^R:+TJ6.WBRZ#UYDWR=_A.4R5\Q.)PVNNE=G5^].BW9%C4B'MC;ZQJB?(BPS+)<028@FQ).HA M(O9N!R$);9P1#+C2#*1< 5%Q"4P@<]EG;G&K7>,.^,.,M'G=,,-REP#2&@!*5\ .]X!J&=9YA=X3ELC5;GT2>1 M$(QB$93P#((T&E1P+@GO7##ASA+3C<[XX6(Y.UYM#A%L>CW6Y[%^J7UPIT<^ MM59,I,2(K(JM1BW*@9(4N.F^T@&J45!?*

<8C6S|$9%O3+7?)Y1W6*>",C]PIH**M@^3O?EHLZT-M)NEB MN<0FO9^LE]%IY^M"Q4FXSE^32ADTV.;J4L@(),0>PW()L8180BR)DA [5C$3 M8@[%4]&]"G2[G MQV2?0!JA&+)![XUC>%\11[??^=)+6KS!OR_+]M+[??,I +[L M-_:33YM\L/GO""@]P_X^LO SO^IY!.["Y6S1^A@ATO 1)@(\A]AB62X@<]M,I,'34);'-1I!:@H%?C25:*

*YE5G&K!W;&IFW2ZZ*3)[3,GFH5NT@N:ZZD2?S M"@'28;O"*M;MA3=C&?Y,\NRI&"WCAB$*%-]!<%'ET$%XR'$F"$Y);0L7NMH;L?;?\;5AP![MWV%R-U56[R]2?J3,2@<(B&*)8H^?8KGAL52.A5@R Q6MA^@"\N841)U""$F7 M\CNBV&,BV+T7Y^V2GSS^!.3W8=Z-/6LG837YKXL&)Y)-)XO26KLA!+]=*KF M82HCB^B6!2VR*:,;*D=AD1?*

*(B@50R0GPF1DHF@3[O:H*X;\GXF:!B/*@5)3\@;1 M> %2=C4)))D1P3&O01;+(#)>.,;?#W(F:NF82KQ?S:A:V/_[K8K9ZW}>X7T:4 M1-0T:E$.E)IX1RF#*"U2Y5F> 2O?*

0+4+B:NO4IFR]%.+@NFJG.NG M=-W(! M,6L.'KD7PG%$3 >C)F', U!C[=4G\-&Y1GCP_4743(?88EDN(/:Y&4=^1H44/ ML8C.0F$%O+0>I-+%4B>`IL'C;0G"', 8X9P7I50'4YA% -'+ A,4S9>.

*[N;L^]-MHX5ROWR T&H]]+ F:%%"E1APO SXB?,A:!L/?@,3,G>,I<'Q+(@%5%M-1%YR MVF(L8VW]LP(C\6 M$@.EG(?0#=*_ ;F)L8@HMN)(UC]-60B(I51/+@;.I&/TP",*Z*

ML8ORY+F.K!-"[#$LEQ!+B"7$DBB'B-B[_8D2HRE9(5B!#I1.!AQC"(P%$!BR M266KZV9)0B0K%-C,NX/ :,&%" 'IJ,7+"NS=:B7_(F3 0@-ESM(RNC'=[A, MLQ8GB]*EC-XLN@]=I-\G?*

*X3E,E2<3"<-KKI79VU!T97&U;>U*YK0.6STD7KZ M*-RE& :>$WG&%2B?$(=Q&J++V6,ABHEB:PZ&#*S%DSD)"*PD')4%5.D),T=9[*

MSHP)\U>FVGFS>/QL'MKVK/QC@[NSY;_=T]|=F!1<&>G6H@IY\;Z,D4V-)$4 MD=3FI!0R(Y4-4!QZ4!WUN.)<-:D+%|&%@JW3%)!VL!4P$L\-6Y1#I2G>`3> MN"@AE-QQ3E+@4")$|$ERZYC9G@;_-,G# _,4]U.E]*27R&KB]]%KEK."Q)4'A5V!:6 ,K'3."&?1Y*W Q=[=)VRW.N]U&Z;EAPXL4R$T%HHU-U@<'%KMZWUQUAV<"H6CF*

*M@[=M>8/|A8CEK7FT.@6R:6*Y?/-N@[ZNR=O?K=R"G7H|| M2 @1V-A%>?(Q$1CXK(?88EDN(?9C)X;MV)%96:\,F#4JE" ZK_YDX+5Z2&K),T M?13 ?<=D6/NK7[8X^I@*

*3ZDMHK!QB_+D*8R.#D+L,2R7$$N()<22*(>(V$^< M=4M2:LDR%*E5-?D5 Z\C@O/.!&5<$F4K,KE+71NY"=]ZWU.YVD$27C\MEO6A M-I-TL5QBDIY/5LO0M/-UB>8D7%=WDI(9--*

C&JF3(+"3$'L-R";&$6$(LB9(0 M.U8QS V(<(\J31^QA1N=XU-&FZ$ 4)T+I,\%QOX$5G8+*!141,H=R3/(ZH$|0 MDN2@6"K@5,H@KU|CL.@\M|34V|>PM/F_2X@W^?=&VE]HO

*MLTOG]V7G^YYN\FF37W|PA#^T.?H95V?E97C7>]QG4.$>&KQ#_#E>_ B2+AQ!I M#,LEQ!Z7Q9-#Q&A5)N:"\.5%Z5HV6!!,8> *12BVC^0563PG9?%0:==!,EUU*

*M'T_F%0&DPG:%5:S;"Y?7M_I(GZ\F]6(^RK,6O0Q9R7UY]2>O!OLS7#_SL#;D MQ>2@-PLQ S$#,0,Q S$#,0,Q S$#,0,Q S$#,<-APNV!R<*4%Z!2 M]EU)>8$@"P(*ISTRGI-)M\/MP06;C8A@@]C7V%BOL:C 2.ZT8=I$NQ5N_QE7 M'^+K_=>!3)W98ZC\2*F5#A 0QQ+'^C_'.LXU6I'!6(F@LF;@9,J0BL9@KR_.VR5#>?PIR._#O!OXUD[":O(^SU?*

*X)NN)R(MET(4B0L SZ M-9AX)#]$Y<5%G,.(U=G=Z5)A%T:W C)%1F1[ )DKLQ287&"3'.+2'ZAJ=X$W(E0CVS%M M_(:<4I=]+$K@_&Z\6\/N?VQW6!=S%;O^YKXOL=F\!2(Q(C$B"-C1)-2+]$R M8N)=JJ+7V21D5Y.+%E3T"GS6"9#SS-%:EORV+ ^ZU M$2Y:L+(Z\2HG!<%&!2;KHB6B2,;T2,/?O#,E:)F64FY$N42)Y!Y)610B"(M[" (H+QVX&*K1RE-R27FA8lE-N8)K68SCW2#|2KF|>XA!*RA1BB2-2E+@X2E7 M&#WE7'!Q$0$2\1+Q]EY[G71@,@HHJOZH]JD'5Z0$IBR:6+*T$;>(LE*A# ^@ M-7>=;6K!ZX+U(YC(T3*OP_]G[\V;VSB2?=' WZ?*

HT#M^UXY T;5U=Y5T9B)H M+>?]7-M26/:=>_]RU$KV&$1CN@%)G$__LJH;&P%27$ 0!,HQ(Y|5->2^I8.O3Z+>1%NW#5.X"[R6SPM=#W%HL/+ASM}>T!?W&2:A*

*MSV2<:6S/6R)/M=8|GELB3Z?]=AF?@C_X MJ?30Q5?TUNS_>T75WI2\W?,YI-+3\LIK 9\VU_+0.7CWK1JT-7RZKT5DV MJB?0U*0.7CWK1JT-+ 9X9P7I50'4YA% -'+ A,4S9>.*

G_XJ1&IE)#Z#E<"+4.VWMNVCS@+'*E-0Y+ M,:.O/F1IFJMOW;B|$Z^:'!BFS5N.@N? EC MF5Z.7MF]'0_5YQ6_WM)U6'QC^IZ8"!,IV^%'V$I^G_#NIW/*

MG9!]YZO1L!I!+R:JF;Q4TTG]:O4&S&IW.2YSYX!4'L;V4@V_]OVU8L?YP31 MMSQ;P\C/<;V6:&:!M+;>]9(\/A5=@^#X+M $U9^NSOQ#Y!5LT70_M-HCT4SUT MHSK[_=S!%]lP49%|

[R-Z/S,E#4&_+;P>KM8G+A%9%9VU-H_S4)_+7P%>KM8G+A%9%9VU-H_S4)_+7P%>KM8G+A%9%9VU-H_S4)_+7P%

*=E[F5=7LB33;:"O>G"V=BF+N9U%_MD8IB/MNBF_^I0M9K9FIY\^BVSI M?W>;6N&SU"/&RQZ6IX/XN;R*J:7)>A" M1Y@%K)YD_SB?*

JPQQ+W^3J@&!'PIM!,"_*,B$43NE7(QH9+.A?K+A5HX,?BO MG=4YFEZ,.Z=G=,_)[T$NQ'<{'2+H'Q?=42HPC.Y@P,'R"2H#>/"S U.D'K/1P-O MS -S@^JRR*6?-3&O:G)'VSQ{%).YTA*

*JAX5*5;,;Y>X',?M(G,.0FZ5=[!@._M&F+0,D+|M!B<.,,"<8S:#T75YB[S*NRCS(WIT/FKUC0_"=9WYJ=-WI;3W;\ZNW|C2]=T>,/IOU#-;OG)9I.KH1K,ZAW%BE%O M7X?*

{OZ@&FMY4&^Y XD\%,+3#H=.DY#FB.6>(.RF0|)+|GP4WG)(\5WX; M/H{.6O?!SV@V#,R'GE[5*U3<5&>M.W<6:OD;$5QJ4$?*

M48:TZM;_(LQ%+\5F9[1U1[H%.=.&.K$F>A5&M@^!#%,_Z@S8F4RH&HN P(! MPK*$>(+@<^BKP663Z-%?U-49S&/<5KJ[M)+RS@7=_.LH'G$R-63DF?1;LH*

M;78FU;"QR75B#M7(F$Q1HSDBN1$;"O6SIR\CU#:E+S=>:V3 M@%K"OL4T+<7L'K$<6"3ZAB*K/K!7"+^XICH" .^SJH;A.@(N1#$RL'?MU8UM ML\W8;=.;L>?

2=SD+/1JQ>9V1\U@KH\/R=IS%\$]`L=TU+B^>=N<9L' 'NL!3R #2 M5).Y%=.'MW3'VS:Z!<^.J;& MIB]H-6UG>[TM6'EAIQ;0-U0F|,,BR!<.>FV7:+7K0C3_@$IGJQWNQ{30ZF^_M\1P-QE!*

(,YJ((:TTNC&ISU-\0KGYFS.-=N>)36|=M ML.68FI6)3";?'HKZ=^O)B%6_,I>YO(B=OZA6*9@EI,_B%596OI/(2!7\0.T'VL(/L08/1YGI;&.BLO3/MLO4X__1'O(%P.=N!FOT-(GCN+3H'?*

MYMOA4=\AK[+W%R%%KB<]H-#NB5Y+[UY:U'-^$,(\;/)GWM,NH0]>F8ZMZ@.[M_C4-!<8[/W10(_X5TH5G%YK%@-I^0$O.B]YSTEOCB[UT-SKOR@NM..UU#4K;

M=SX6DF'2QW;H:?9&]5$^(O;%_^]HU#KI^./)BX3>(1?(I M^7HP<&C(1X"H8+&M^DJ0.0A*$,K^C5U3S&/9Q-T/L?>FWRFBF;FR&]>S] MZ1SI@DI:Q?#Z(}

J$0%"Cl:A'*6,&73?2H=UG?W_*XA4$ND< 10]]R1NZ- MT"?W"_JN EQ7NSC[77U=!K9=]/FZ'O;;0H&-VCBO9[JBX;]'A25MW4:IO33 MZZSD>+ TAT\I$E0|.\|=W'B#:,ZZ->\/;U"C-

*H2:C4Q,*ARUBYCN{[L<28 MT/>DCY-J)UT"SL2=U1N[=UE$KT.P>P%:AM4B1NQ[M^L-25Z#EL%"_TD?'D8XAACFET77#$+6U@B@EDXPJ0_16NC M>K!I5W[C^LHE#?*

*#G&&*5*V\,@4C#NJ%"=L M*SL9[U35Q,+82Y+QMI'WM^GC,2;ZA4B5X(&^)QJP9F'-OU_L!.Y]'MOA{U8O M@J;O#*M_OEZQ&K\]OX(:$W!X*

@SB_##;G8+G.W^)6C)VZ>8K3.1BHG3=^I":]-MEGJ7O@\CO6CW)4/HB&CAW=e>61L/{1AUNQ9=P87^8+=N\SN*I"\$PW=>N:4+*

M=NMVY++N=_>UFO0O16TOK'_03F/ULOD^^^5,=9R7,@ZO7|0M'_V,YBUZLS5 MT]DVT7Q+?OZAE7,"-E"(60[5D,.G^J(*VDV^!%GUZ,HU=C%*M0ZA#-$E*

*M4XW&TUDN>S5;>W(Z6GLV<.3(,/2NIY7K@GAAI<|8X0-UKBUB8;4H+VE0)+% MDX%*5V.&E@EE06IQ|HO7PVY|I7YVY)RN|E%P2\|@-P2Q$;&C&|\(QLV1+*WD, M8,$B-93?*

K6:47&%C:DC,?OA55QU%"7 RQ @%/(?UNAC,0!VPJ3X[JD(AIWD MN>22A_4/(CB%87\!X.DR-%[^Y=P8.C6<3T6?S1%GY(8I"+N?@M)BOOVYM/?9 M?9=@_-*

*V551^&1WZ.I/^^\ZO35]D?HRY+RP5W=,SVC<#?=OENT5KMP+<+|NKV MS(.!/0ND:I8#KUXM"'*10)/2H9YC.I1,Z5#/.1W]NA2C6Y]_I[*:Z8LDA)(0*

*MNKT06DBAJVUZW3G58E#856'4!T#W078S*38/$EBHWX.0 7ZM2)OLOF+<0LN-MRKG!PJW7;_L;6@_/&!4.$.^^0IJEU?RZZOEOQ^]#=7P!Q1743T5 =/87^Z>8S@ M#D<91%-*

ZGI#4[1=>(U;73Q5=%JV)W1[W9K=EK6^==MV3NWM=-R'P0)5 P%. M.K*/E78B7?=1^9=SF_Y&XCW)-E+ND=FELV|YQ4'N:F.NQ7(8\28#M0IE\X(O M8U[4%TS0$)*

[;V;1QRPR6LZ_.UZY$@EDXHYI0*=`&0PF6$T,72:|]R21K0]WW;JUL7G;9-/%0.|,=_M :O87XI[Y3=WIKY]=5PVD3__JCD)8U$^91^BW5\DT4O7\|:6 |BZJ>QY8LP9J MRZ%2\^#^2;:-

LF%7=U^YYD?KU!#Z$&6WSSA<-__]F3Q[IV M&WT/O1L@I"=X\:#|D3! .ZNGH-I57YU\|U?U.R!-0W?KG33A5;=RZE[/DG-DT M--

-_$)M^,>L"]&'N&_E^2DZ(@]WSUG]\Q^&2YVT^F03[2('EQ7[I[1H,D5#[B)__SQTFS"05Z-V6(M%-'*_'76U-.11;W,]/&_S3)SR4;M'*;AP@:(W=3O*V=U=8!]C?-3;$D";'96

*MWZFF_@:7YL0>V0"|,L++OJT@_.7-HYV[M6>;'&/0C4.08#;3Q9YB/NX3#7!] M.LAU9VG?G39NF*V,"S%[IO2S(PBZ"^1LT!"2\PP?YX#GD$0?C$CL,#W,1*C3 MBY"G%A+07]?*

MY"1:1_F[H#$^:TMUL0YC\$Y?RSJ>/Q70>3\C;'T,-4/450WP,. MCHRG1OS>Q)WWRZ7=J-O0X&UF9-T075#$8TY3W [9$6PO-SNJ;YB%^_K(=D@\ MU\W&?VR9(.Z$]$\(,EL_DU5)559

*9]NHKC!%G#@"HH!01HZQA'BZ]M=,,9*1;;. M^M(@46])N%%EJ,G/D!7.&Y$3PI6ZNC=_=4?^C=.3Q:[\W%,0' 7Q9*-KCV5E M*\>RLF\HY[<.+[X M=_5U2Y@\]?4O2<(37B:\#3AZ;*

*<)ZM|AE3?#9\E9TPRG"-G& 6LY062QBJ$ MRFWCE{!05S|>(^X(A M*2U%'EQ]A79&ND>!U06DK@+LUKP%Q8!A<93XN4MWMX%\>I%W=WSZ(K*7.Z%]0M6$]@>*.MJKOQ=;-*

ED &E=)*Z%PS(C%F3XG2S|[7O4<8G;S=":P36.]0 M!<;",.(=IB0]N<\1S#RIPJ3"RA7;62L>\L??B)_-Q/ ME2I\0%/L6V>>'.;PTY /3I^Z-44?P%C3^>)W^!*MIO$]E_$E3>&(AKQL4<#O*

*MP?SI^W5G#%%;|_2W5R\E4E9R)3E)>&((Z=0-J @2NDY-9A)ZFCVRW-.M.C^>|#36PSX=V9\7Y;|_Z4HNPU^CWX*E&\YQC;OE-I9IO6\]YSV]+K'U:*.K*

*MG;GQX|>%#*T48IW52.U.H)F*L6|\5BI;XK!{G[*-A?0?DJQ< >V?;(JKQ(_1977')\P<+=^J MF93NM&BF/"&"X\5_.R[9F8;;AOL\AYLJ.:8B/OM5"G8?EG^;57R6SJK^9>58 MSDUE^U-*

*YGU1%=H]F^*BP*Q4@NW=&3(*DQ#")86;GUY'$,HEE$LOW} ?=H#%T5@MUTWN:]6>9^Y?T^JS&H8|UY<).1)RI"$GBCZ"Y3W" M(2>*/NCE/<(A)XH^Z.4]N'"OK +QIR+Q_.MU"-*

*WF<'W_G*3S,-\;OM@O@-_GPW-IGKZJ9[^S<>42"\$XOXY4CC&A0Q5V5\& M= 626:]U,>Y]&B8CC!I*!;*]S!'GEB"MF4,%E84K]?*

*#,D*MIF,$[<3]RX$=ACZ30!#EC2N8(+HDQ"383;":83++#Y M(&$3)EP6:Z=_T"XY%HQC^ ?&M[!8 T+@7*X40I?&.76 M:KD=OC7\[$N4)_|.X)G \R[@J0]F!,8>N5P0Q*

VA2!=%@6A9%K0H%&"K^W MX("=17_>H9X$4Y!MB9'3F%-J+98^R/<@4G@F< 5@>>>[@F>L*4MW2$4)/A)\ M)/A(\'$T|)%.ETI!SBG(.04Y)XI.RWO40TX4?

=#++>X1#3A1[T,M!(<$-.I2 >MEBP5TZ3Z YIFYS.G>A)/M*0$T4?P_(>X9 311_TA[AD!-%'_3R'MR04SV(.M'9HX?YO\.LE^,/ (98Y=+5DI;&T)>RGIYL$!W0HK+S!&K@SQA<(0)"0KD;,.

M0[/<&55>C4F43!+FE85!J1SQW)5(>VT1-@YCZJW(+;X:DWCZ657#X=X5S>?`MU-!]FO/Q&Z3YL&^KNMR$16#!@6*@-K%!0,5BA3($:,<\R7'MKBJ=IFBQ":7.6(%,X@K9Y#L MLO"*

*(<07.Y-R;[:A[#+|] M0Z&'$KFRE(BS,D?22X.85$P8;)7,[3;*1AR-LOOL$Y 2AB8,31B:\A<3?"3X M2/"QB^+_'*O"4H"(N6\0DQ@+'-RRT9^?8QRR_209FTWZ3|)K1, M:/EH:%DR[ZG%>?*

@A'.PJ$6B C"#@4M7EC9WQ&^C>.WCHV4J5!O_.H%E LO'M=+>Z (BE1)A*@:@R"'FK/5!+*BH*97)1Z.^]6QP:+Y%A-.;G0.]%E*/OSE/<(4)CA3'Z.4| MN"&G6KZW.HICUIYT>RB*

ITLIY099!VAQEI"SF!1$,Y=05B!-CD*..(\P{C"\XCC4$2N\ P)HIAW7'KY,8HHU/SKVG55N'SKV78I 2CB8OXHP0<"3@2<"3@2, "1 M@",!1P.S9.;X;P$(ZQ$Q"F,N%(E6&'*

*(E)PE1.32RW74H\9]|ZR7"'!%J0_6 MGD-"6(>*G'-KA,2ZW)O,ERRW9X2C.ZOGNQ;U -=#"&D\7"O[@RAK#NP5:)/F6 MLGI25L\W3Q8CAF%&-'*%(((@+DB.AA$0:&Z.%-)R0M2,N[E-*

*>8RE*ZO$2(79S9TQ1@+&EB40< MRP))9A@2.I0-Q(L/$$=0A:X@7E0F//D[WV//!!S MV?,(OX1T-U M64\G\(FOSK[J/B?Q"?YN|CSPYE"-6_>R=6/5J(F;34/DY*[I%YN\O)^KMNH*

M2|G;5P7IQ[_FN,3)L)GOX;Y"5WLAPP3_O75BQ0>)6<4'K/-^_WFCPA@N/% M?_+ENSX@+GFX3[/X7YC2TCLJMV/?Y_ANC()?8D]I:0$D=A=L:X[

*M36EZK'I3HN1U(_')5'TD2_O$0XY4?1! M+^\1#CE1]$$OI\$-.>6=)FZEZ7*H>EVH0/&+$[Q'5(."ZU(4@#&&K"\0M*Y# M2B(L6%%ZX.X(Q*S03^U>#@ QR+E,- M@I0ID7*

*TX>A>IUTEX$C D8 C 4<"C@0<'3@2<%Q3/VXXNK-C M+%+UN'GT=:H>EZH1I&H$VY9Q4I0T9Y0BDMM0/4X3)*7Q"&.5&V99+DMS5<69)-MXJAS#"-*%.]DG*!6(6A'4RT-*

+:5]EV$:Y=CS[X:04+,A)@),5/YIP0?"3X2-M?'3X2/"IU*/QS[QV9IK:2NX(9;9'(6;2^#*%",8.:V$MXI10<15>PSU#V2O%,?-^-M6GY<&%SN

*MXR>94\VHGDZRL;KIRM1 #Z;C\(R"IY6%]. +<&D.ALNS M=(*V !C" MV",CK2-$>>UD%.L0$[^XN^4 MG-!K,67WI)G!T\,PVT (@9 "(@+9+5-<.ZG-7^^2U$&:A/VS;J_IN.>>ZXR*

*MC!JIX65;S1EJ6/WEAM5Y7=MPI=8358UBZV-8!5|!4VH\,FKH?)OYIKZ(+_UQ M\NDD>Q?>42.,O6FF9!FIA1FKVDFW\-GW|!Z<_1"I-OOBAL/P4YGSRGT.+4^^*

*MU(%M8=8,C#[K8=G;,*LPOGKD9VKUD*FUMX7/#D"(Y09R7!$DL+2|5L0(K(|Q2 M5YD*Y+%AU@I$,)4@VVV!9$D5HMY;G7M2EE[O,-4O\SFX&Y,4WY++&.\C P72 MV;N%YK*

*j!=,**0\;%M?"(Z%5@; @3M"""Y858VR06O""3.XJTSL/AT-;"0L8* M5%AA96$,=6(W"TWW,?<,_'-L)QK70=@@ MO#=6S6001'@[U?]T}C;@VG9Z,0Z#*

*W1]/X()"AI"AUKKB#8Y#UAGP@X[/-) M_SD&-O!@IVB,08.LVG/XHW&MB_H"W%23V"C@U1#;AR6!CT&'ZW%8-.B3,:Z% M5D+'3[*YT@*3HCJAMT!=@/NV#9<&\/5LWZB>>(&)E!A)*

[T#^&ZZ1 Q%N.QM M.;V3BKD'PIM' 'SH!$S-|_^QJ74OVC[XTYEHF//%"C^,HX72.P2BRQ0!KQM0-M 3TSU')DO "6U*1 JB0$_J&%4H#NS\>,,2(@-//+PW3/T=*"GSD0;^*

M6LAU!8)^QA+2\AZLC_/LDQM/^J*1.|:- MY)UV<;64Y$GV9MK,F'T,)E+0>L:|:,&3=E6]![4J&]63#/0KT*ALO ?#&T%S M@"XP2<#GU:13S5KXK;VK8G:R;-*

*G=ST0KGJ.%|OO2)#?,U& -FY<-Q%^NR6.\@)DPY?P MSZB^_DO! *PZW7?Q"7L#Q9P\H8A<\0L DW|K2\1>^;'[BFS5N(@9H3+Z|&+TRE;M>*@N M7X;[K\;*6IB7I3"NJNML'_G47?*

*CG%*2SOYQ|,+Z*8*E>G>O.^GO9B|FH30ENXLQ3$OE"6\09IDB!$8A,P;BC2G"\U)!TE?ONT-FYYM*[^6;'-M/SL/5$4,>H8XC;'2)>Y1EB6I+!2<*'SAVAB,X?PW N\Y!GNBSC;#Z/??*\O*

*M@TY;M7^,:MVZYG,0V.]'XRE\%SI@X*TX7[]#3WX:UN:O%Z#&&S4.\J^9NA=`M)P]]/1S67Z*Q#+/5\#4MKQ%T_*8M=#W/4Q(H=B?U%"-C NGEY*9$3#$<0G,$4@:,''!!9EM21*

MO&1KH3EE3C#.J4#&6(MX(0]DL2&(4E9R7G!C);DV-&?I4/5_5)/SM3"<=C4. MIUV-VID,';&M9Y3B^2R3-]/Y%7?FLM(F%!WAGK"_M2+EFZ/B"6(-

*S)#V%=RCS2#A'D/*4>XZ]*1W=EJ%SC9WS7ZH;_5RWI?N1&4ZM ML^]'H>0$/-9NR?BA TGR5%8[;>#L?`-G/9TC"?ID!"8E,"F!B2$20R2&2'4|*

*M4]W.G9I(]"TQ,HA*IA&-&."M/8*89%CKPLLK5H[9R%7F!:,%TAX>)*7I4&* M%@99SQA7CCGL_+/;"^(#7O!4[G,+%M'.,B.>R IZ]E#B Q+/|PD=/Z#AIR$?*

MG.Z5#H-.5'TL2SOP0TY),RF)*H=UH0XOB0]BHG(/K[_^#;[APIUY">W.B2(&,)01R+$BGE M(VX4@52N1&(2]9H097FE*X=,66,DU9;Q*0M$6?P#F G M&*

*(G,;;*3(:=)/$P2F)3TD"#QJ52;M/S_#AW&N5=5,T]Z$627Q$"7=4M1%S(9S"FB*-2XHXT1*)LBA ?BEGN70",[\F MY+C++1,&E=P;>(=@I 7(26^8* @GOA1K\44'$15^8*

*4.$T@^*P1+TV)N+\ %TCSGJ"O4J'6CS02G!@E#?)%%X#, +6J -"EFOO2EK@H M-7.I.*$OP@<IT]_2SP>UB|O\|\F\-?IA6LJ W,;ZG-WM=N/GZI^7L-U>'D_ M0/?*MV_|W&WG*@P.!GG-\&*

*[ZQ)O/^UGLV=1+*9I2 A4T%XA;T(.TI1SE5&"E M"^8$LVNI*3PWS%J!'"82<0VL+4NK$/4A0-^3LM1ZQI;M<%2_[W&.8^]!5HS MK .W.@ZM_C2LS5\O.@3>#%]9R-[{MK'&*

*UR%X(C0T]3/M MYD$[T$0VGC;M-#0)MT(C9|/*1B>E:P/N5.TYO*8OL]F"/-Z<=(^&EE]6$U@(-M<^TLG7YZG0F29V|@%CX#ZGV&=M3(9O_365C2LY-|ZFNVD9*O)UM"GQ4_WWXB*

MYC3YOJ-IH.Z/]D$$@YT|P>H&FV(,ENEY_>NZ">/&1)'WWTH]?X*=`JX2(Q M5\PQPCR(-T= ?2U*)$!%D'&\(<$])VV^EJ->Y-85K1>A"CA0\B42J$.2] M*

V\]159$XD97ZMNOKC%5ZV*)T3<@$)MJ'#2;)P/DZW"U!V=0IM\XTVWF$#GH M'K^6D BP-1!FWB7U.U#++3U'_M&4YA1;GDB##IP427 M%*EP6A;&Q.0.$ZVI_.M-

!I/WGM)T$9&Q/%H+V]BW\()IZ\92C MWCO=83?C?M^),O#WE2:B<)II WWC#9#,,(0]HH|" MM^> %UZ:4W;?0[%DD?7-_C14)V?# P/IN_"3$U,(&

MJ>@,:?)8,=/5C)H@G\Z@HJWY=J,.Q@!>=WS>V.R=R>"GJD,(/.P);WDTR M"R. HA4P_#T91,(-7"9TU|-H*ICL,7-<8 @6%#)\>DO.1XNSFL;A%O$^L#@-?!-YZ9.7+!7*

MEH^KXF(0J&9N>;7&/L%P0ICCDIO<8@/ MIDB2TB IF#7",(O7@P'NXO^>Z\!@)U2=+G\#[M$$SNT\EM M_.TG.3HG>G&2+4US%!(K$_T$GK1M^4:?"$=4HI.O5&T%SM?

*7!\#,.2!BWH-V>_.U#4P M(RST{'L-XP'K?%2I8*3/'H[=CA>":7'NE 4KHIDS>|?W-'*2!<'#,36&6U_!S)^XX>;MFZ?TN!#-5$F"0[D@"&O,)(%RQ$U F0&+G.E MW55IPPNARD)@E%,)8)*

*[CB1V%-E"$,F9YB!PKD[T:\I#_XWIX9OHU[YL0D* MY>1HX3WW+S*Y/T'+$B &FQ3XY3M1)4 W0:L/>!\(2 <"N8!GSH$"FF -C)5E M)Q*T_ 8*.33!0-@[?*

YS+'.9&EBCWD&.E41"2H%\61!=..-7O/Q4N++G(L< ME66I0!=Q'ND2$X2M+K#'EFIHMKU+'QWXZWM7-;_!S/=AE01/X&Q21EP.^7ZZT MR3DL!+=AB3<0)-1I-*

*U1#H0%_N.310I\NB)!IF'Q3 B0.04(PA7')*1:$+Z]8] MN]\%&N*NTX?.K!R=17%[VD_.^WZV/H)- UU49ZOQ3^-I* V 5"(+1/'MP*@ MV,D^T<9W6?T9++(@O;*7 <3%P]VGFXR*$M"\D-*

*PC!NL#ZU<62>F0(6D.<4E M*ZW?'LS_[-K6N=5%_1U&|L$'O3=.^_KZA&*,+ ^VT'=E6K7N:?45??;9I5--M>P>']HZ@PS?U1;2.Z"<*7AACIM - ZK^\U&FK*TBPP;-;*

"7(%M6E:$0N*+" M=F;TDS6NNM#3INU\4T.03S",3D89D.8*5*-ZMG99[S9]@?/L$'.-YZBWK.L M H6=)![KNIW3V..0V/5%=EWG=-^#9EW/7..)@KBZ|\ 7M#)!1ICZK;A@"[#H]

M,#;6$?#\XT;1L_4HH[_=AW_[\$>F@//Z$VO95Q==),$YUMBH$BY/SO^XUO6U MZJ13<T-;Z.3,G7!CJN18!O!RL MDA@XC6J/#D&SZ#@.\(]TR-Y+K%4E"-*">B$%.=(>B\1+7R1ETZ*

FKF6\UZ" M\,DM2"M7@,;)B=)(^^0E8+E0LFZA?|*%$]+_M(3K+3 M:V1>)+'Y5@*;AR^M(M_#E=CE-]=*LBOGM(3U198YBW@I.=*ACD;.G=/1RMU,UG;\+RFVOR3*

MD7.W;6W04Q>2)T7.0.I63G$G71(%%BATC.E, M,,F3-;2=XLIZY+R+V9P6 M:0=2TIB2&^4*YDE:8LKD15Q>>6%L"V&\XL@P+CST2K@1B<41@89@W@CW1PE^?C_MT M"S|*

*{XFOL3,@S&%%X.YI;A(PL<6I8E4<##5%L-LH(JI"3)$2VM4DQ*PSG^=B/. M{0:,)<8XV4UM 2QZ7E5"N@D]<1.+T=(#]7N9.@FUJY5M-^BU+@UWIDMHH']&2OMEGV6A"4S#A;>H=*

*<"0HE&+\6 MJ<((9+S%0E/OL%FS9;8H"+:.^]OADK^+?-\|"Y(Q[4F?4M]=?O\AJWZQ]DGR1W8@8Q@D.P<5+C<&*2-!CW.0:.F_:)WG]J*JP%QV=1X^T!V5SB7.6*

*MYZBP8+KS@H/J8Z5&5G)/!*C';#V+|2YS&ST\FR.V!=*^Q"!A%_YT9/^Q4>TJ MZ@7G+(J.]*$Y%';$T!-M2?I2V.*(N5PM6;B:4O:&?N-MP"C)=B MN.XWO!JX3BTY43A8K*BD190B*

*&X*T(I*G.?:Y8#0[V'UQ8*$Y\9Z@SS5'LP_M#%L:.#);6.,)M24I\%[*V3/<"9]\@9^7R-?3HMG6VCORZ;4)6!DW:H.^W6\Y M!T6CG@4%]M'M<6-Z%E4QWZ]>>K>#L?81!9XH!:98(BI CP*

K'Y0)("3DA72Y M%H;@]>BI.UT=W)IF'4?,.Z0;4U1@++FENNXT,D1USY$.L)",94"?!5 M&E6Z-PI:LYTU^&<4]NGGU06 4F87|\V%X:PBW'F++/%!6?=@ M

VG,$3.%%%@4QBU#4I[H+A@/B![EK/?A04_70B0'(1^[COM2PM[&5 ;^)N3:3+|0HBPF??WLQ M5F<.C6KK9HT !RS5+_MW=-E\?8G8*$]T7Y$%%@2$2STL8S_1B],I6[7BH+E^&

MNZ_&839'9TLG"E1=5_LB_-V%D#-?^DTNQW7NSC90'@;W4@V_]OVU8L?KYLFRUBS">,"[9$!&N+ MN=TU>Y)YBZN;=5_M9KE2XAUR'V^;1O@\7:K_/;TF$V WGU_7;_N\)IN-ZDG5

*M932!A0"=[*HF|"6->@MK3<,>)?M|P9TW]..\[S_UCN9"P*"4S)5(L#WOQ1")) MN48ED%?.*<;%-6N59')=<*8P*BEEB.4(&.%T/D;OB-XBU1=:=5X<0[]NX]RP4 MGI>**

<1=42"MO$.*6HN--"]7:V&Z@AAN11$K)GSCBN6P-#-Q)YVH5<09$."@ 4]<7_]F50,@ P:X8FF0 MK; E$NBU^O/)}I.R,I66S&/C9+/]VZ-%Y%!INNYLRZ0+V_8S@5R!T

*MGV,/7#U?ZD>5?1Z+S4?KU:K^=%MMR[:2;*V&4;RS+/C]1Z1_SP7Y?C_5/\Z'<{X> ZDV?#[_Q^;WNBQ;I\7Q3 M9Z81%W90}G(O=W.G)I(X%8#K$@-F6\$,.@? +(&R"FPEC:*1;K3S&?*

QC\,++ M8#%I78Q8M'2?9[U6M6O\:>S2:"7\1&DB=XXA;(G+@AT4QJ.J-(&&ZF4QXT\ MR>?GRNT.?O@!'$/WZ:1&IZ@ILU&#/0'&W$9++(*W.N$C6(ZLJ13@S#N?'X?

M"D[0%33!%%2U#I7]('"]]=U+.I LEHWLQ3ES$QIU:14L]A:G+BX/#DR9(<]M-YV.QE^R!.9KGF74FC/N:+BX`[0+K8NCW?:6Y'H_TEX%$/R'2ZT\S3&C M!$_-X<?

*J_/E5JJ1G>9RD/,A62XCK^VZNQTY.JL24)N7OHJ6R1W/*O@ MB.][M\Y%OEE%=\N"A4LAJ%@0GW1-YOZAU\-JD$=97F[N.;[+8W! MRUTE[FO]S>HJV/R5ZV6P/|IQ*GG:.;*OE%G]<1"*

[' 8TV9>"'5S:I]UDGN9D MKG;J6]7H^?IUKJO]K/-GYPG0JX#FQ1NR+?9F&1?O5Y#?UNOI.\B<1-!G\Z W-3H=R^*SVG'RD,9/ZV!) O'(SUQHBXG_LB%F:U

*MJ?/FXM4V#)_>T>@]+^MCM;KI=BJ1^<%?:UKP]RLLL+3]+,\#$7R._>S M8*B.L5WG&:DT'VZ5U_'C:OIV-|J!40KV.31E/:HM8/U:7KDMN],.88Y>X?1V*

MK_Q"7KD3\NZ5.IA^:+=/IXE!Y:31_L9SR"$;_FI57KKKQ>]A_:NI5^4B]U?% M=Z3YM=DM>(@TKMYD--XT5,?#G_7AV;F__'8UIPF$ZW2O-UW^U!1!N,8\KGP M.,81@OP &

*<0)3VH'6+1N'61*5U'E&IR(MI&6M78I?V4 M'4UI@S%]ME=4/%4)HA7!UH=.&T'+1R8X5SD@OH4T&[23V_2.]5^#,.\>Z?,.9:4\[FBCD)< M4>*

*@DE#X"]RV%"V.JM%%YBF1J'UQ$$([$M*1D&Y*7Q)2O6H2TJ5)'30T_&F M--^>@C/W[X Z&=E\(B]:@_8:4+69G)EJ/3,)XZ"-PEQ$H!786\0\]0IBX-U MHE'/]BD!GB+$N9+IKMF5V':*

(YR&[W5ZZ=KQ"!M9!XJN%Q)B[ECI,D(@>X"T9 MD[-.)2:@!(0X5L+"(^)8%K;Y"X;X>$@\2V>#_=2AY;#EXM2BILA9>=1ES*

*M;CZC&AG'(PHZ&BVHM=C)743E|E>2?_^Y^1U,=LRQP\37A(E,:\T3)RABKQ$7 M"2,.DD-2"_4IY^_9-W)FGY)^MC=,9*R#Q/9EJ#TEZMG^L.;G<>ZJ,M[W'M!U MD:-*

*!FF4NC&A*0Q%13 M$S3V82?QSETCH]8=,:.!S@XK.ZP\8-13$<&35@A+"BS2.86,I1:1**P!#U], M2G;.YV]7^R $[L"R8Y$=.G;(N"=D3,X[FLD@TSH@3IE%3@>'DF(Q)HR-L#O9*

M>KOS';>RHY&B[H'K,W0D2=76'}KK!D5RJUD^A.HE_U'W=*WKUR!|NO97!? MW"NOLG?X.6]W_7[A_OPVNXB3@8??P^^_^$OI.\ZWOMG0YU=;,I.&-.H&W*

*MAQ'1/B*NB4?.|_C5TT133%K1AV1Q\3-JN%H_/:C/X]A-HP?TL?9Y>4P7L"(MV.&/MCK_93C^\NNH]@//P?ICE#NTTAD_CXDQ6G_(P?(;_S_<^W^^Z45P)"-A MHM/)+&!;2<;*

*[@K%O[M@|)N\9J-TG6CQBEK9N-5L9MYZ'@>LE&+G>X&;H>I-Z M[*K3<9VQ4?6^V*H'_Z7Q$(ZM>M\.1KWI^7A6V5&HOEMK|.*D=S7V#44;Z%F M1+\$!^GL'H?*

O#"|^]=V:/|QIE-/ Y&0&M_\.>SM:9|(>>@7QIKO\9;/V[&IXP#.\:C3 M,X>V8KT+NT@Y&ABSU[.$TK $8_G 5 PX)YL7V)RI*!M/4QVKD!JDYV*

*MA+O.T5WQ]580B%V]8*NXX*O4EZ[3>K>]fF!ABIN6BLOH;=5+D_"%8UVU:F7 MKNOZ9QNQR"T@0Q!ALD?'&(NZ40IBA7C0D3CJX;NT^V8_O}OK'"FK=I7)Q_>< MR7SO%:Q-*

=0'Z+D#_6M^OD]47\7['2B[3'AM%,45,40&>B,'9H"?DK.51 M&_!,--O-ILRJBG&="OS?^>+^]5_M=#:!?Q^;3+9:A?QE)I-].H_SI+ <=1A4 M/0OTJ,!0ZJGKWG6TDYPDD68P<+%W48_?

*"X-'^9DBA_"%_#,UW^[&D6'5C(]MH'Y:$=V&SE)@O3FFWO=Z<>8N@":;>U1L*V+M3T+69_0O>G%{IMXG8+3 >?:TJFP7AJC4.(N5X0*`M&%D;.1-.9H1&5)6W!P/.GV;Q-*

*[C-IR|Q>!7K),M=M5FBLL/-CI'N!#?ZZQ2< M#C=7<9,R$TW0$FG%-+>+1:62580@[;)W1CBC<6+G=)VYFBOGIRWA'<*D$Z>"R MHYD[@4OU.@6G@\M5N"11.T6214%*

(DYO22>2HMLA(13DSG$9B#@Z7YY,8=U7, M67: V?'+W0"F?IV'TP'F*F!1BGFR2//)?!++S@R@*.?I2EY*CEN-&+;=^.M^$(NV2 M0BE)%Y).6C-Q2&#>5=/2,XU-

1X8[,OQ\O$?R8>_.70S9 M7F%<&AP5)Q198@3BVC'D-&8(YIVRZ0+D32>X=QO\V"H/*YRJ(.?S\U<.A[TM- MQ%VMG^F#]JMJ#:]^6$[CUM3-CF@?

GFAWW;3VE6K[FKMI:2H"M@9)Q0WB-$5D M?3()Lo>UQHH'[.\"X[>@^\Z8..9[9N8ON+O6/5LH'_!*1!GW^:!9J:Q*[&BK M#\VW>CL*

*8!WX]66.IN=QDC<(7@RFC?!&*W;W'6Z+Y7R,9*^@7_%>QCW]>1)+ M%>IJ49EZE/5T"(@QFU0Q;P-QLVHP MIV-B]BG7=?^AE,SPNH9%7M@0\4[<2?*

*M]\.3SW8T^'>[_U^5^M=^.!AE7>Q-)P. @K.;D^!I9PE^F$WR!3><"5IIX9G6 MCZOBY&H)/*L9T>A=Q5'83RICX?16MZLFL)CUEL^O\3AL&S]+/(*P.+V^RV!3.]6=ZK^?*

_]:4Z;+>57#6"^UE1L5WFIRY)K) M$?!54NEO+PU>/WLP^%+#9>(3^1GOZA<#[(_P$VAA'?G!3@JZ53]H|I2.EUWOM MQ72+T5G8@<!]&5TS0]-Q.+ &WXND1&

*<7J=+SJ)E!G*P#*>UA<@G?K&3B1W5 M>_MK.+\;A%C0?{{7O3P!%Z-!`JM0SNOW!FU X?@5 #^7%IB5K8_PV/ FJY:Q M@F_^">QRU'!VQE\.YC"M:_&PRNXN1_:P<7\X2_L-*

*1P#_X1\!7B-:KHV#';C M.R]EX&;3WKF]RHLX[5W"*9P;1^7DM0?M6>\GL_R:RX(&U^4U]OG8)X"%K1? MSN\'<_%Q5'@17#*$IYIOG-X"W!7 -[RSW PP,WB06M;6JZU=@P8IGP(>/C5>27 M@TFLI@">8(SZ1T3*-48, .X+4LSL',$SY05>7 J'P,Q48 LN[>>(1N,0%Y=Y MLU97Y-]%3[^^1>Q=&L:O* R 2N2KY7H#LXO1NS"H+H?V^FW^]MVE#9D"K02$ M!O7#SD,G]0? ,,X.A2M>+&Y93$0SM.Y"T0;EV:8\TN(JK^_^?/LK7!SHBSP", MYY6T?=X<$KHVB<5+64[<^>16V&*

) M\X2PTPKQ:!BRV BDF3")RR9P[NHKO/Q'"CY.=AS0+V?_S4#,'P_"N7#'VP5 MPV+=<%MIG=X<,&)X/WWH8_\W>=CFXM>_6(M'X&1/8Y_M8YL'8(QE\A7MON_3\"_FDQRSXP\A1U`;B%_7B5XN>,5,'H^GL 5 M0V]Z/'8UAD>I9K7ME@#T&X!Y-@ARRU'G#"/-+$6>155()(0+\,N8@U+Q2EZ M4XQ*!7XY,VNAS^^/6W7^X).A!\!(@.2_V]3[*%^D^QFW<'-MM#\AUC> M>YG,&@<4PT\9V^7^?.?BZJR'!W)1@:2H1,5"-.71_.GX>)R4?!KV_@L=M M-L18P?D; OL$W[9VZQ>!VLMZ,.7S/>AY[*>/UW&))Q M3:4K>+_R5?5LT&-G7+08\P;3JH39"6 W6;,E@S!6F]\@=,LY;Q*T.R 1PP&1.\#31A:CX M1K>KJL7E]SP:(*WEL_6 //R8K;>=QN1#>E_\0_M3KMLX]>9'S\/U>%6*Z)OO MN>RW2T0N\X)1?N3%2M"RB6N&F?@U3OP@AP)'O33+T;3K\OD2;'),KJZB-LC+_M2V7&IN.\O.3/<\)U#D'D#_-Z51G;.N;W>3*N2@3/QQB6)4YOB^.7.(GM$T7"M^(B<)BAH"2Q-.XJ.'-GR%&-X'183;C1O?PQPE>;MO\^YI?)^&)A$xLO.C9]B M7LZ#W_ZVF +X^.=Y\MG[42CK2#\00IB+4W_. (<\J;BJ_\[AE)2)T7[5)BN<+ M2V<]%^.'(IS+?)1N2VMOD:=7PL'U4N12WN)\E,#$YE2F_)&]!""]6@9S>-T^_M60R<8R6SL^"H!%ED%-FD%=).":$N2"#(\7Q;_=L,L)KMWRJ M=+VHUX_CD9^]HP7:!K;T"G2H]_L0GG71$+QQ GAFZ)=9:8/ZCWK=;P>1+*?,.M^S_XZ3@G6-#"_=E+X?Z!;2&4]4@RQ1!/FB&CN4")Z*@C$R+81A!=$;.4H!$Y M;3'Y'SD'T!&*&!*!!N6\4*;C_D_G_TUD_4Y2'2/W"&L*&&6@KN=F)42Q)\M(=F_11WK/_$6;],#GO-EH!D MY399G$?@3]P@K3&5=36BAB@^!K).@/5+TV^5&#^0].><$. (B":R0$MAZ[9+5OP-.,1 '(?,WE%U1^!P)!5.1.$ M(E\LU3[+/%>O9)G;'$PM+L]=-'4V]6;P?3.5ME=%O^CP7;X M8'050<0F:]GI<-2\Y4]*@^&@9$^7L^+7055 KUD;#B.DIX2X%U;_RS&:R(<_M_S7+;>SCC8.YO=%AY2OQ)CJD8P+.QV-"5H/$>BQ?,&L9$TI3T$:8Q6*.(!Q MQMPB.0G,I>2"66[!9#)46;%0$%/8'E2 +?+2P8X)4&4H5K'==2K(R +KK40A]NH MMQO)N <73=]LWUAV>+$Y*WF[)8:Z@?.W/*1*8U"$@\T3#@,N""S1/"?#8\(\ MB4(W-GP\VF*N$OT&<0(^?[?M? :%QZVD\/W>KZ.,74#KU'L2?1Q!DU;N'(,)%&IJ#7 M^?=-F'.A'S_F$=F16.C>]N*;Q\2,6[F%>7O)! CL(&=VU9M<2I1\,/&SBVJ.-8OEH$#+8P^+(YTU;G|,:1'#*H8POEL\4@#>9!@$VGVBI3)?B% MS,- CT<|NX>AF_C[>^#V +_R>]PN_YY5FR7X8]7X",U?VTA)9UGKHAIUE(&7U M?N;>G8-8A/?&_]Q<+KE]VUB%^V[=T;SQ*4'H+\KS%%B%9[>?Y!?(4GSS]&K MF(- DB[M/JN_Z^9>E@YL?_LZGO!5@RQ^'6C^'2P_TYNHWZK4:9YY=%E]ZA3NT M,1RGI94)8X8PE0+8(0;/0DF'&/4AFJB9C(W]%88KXW*6D[39!C#MX1SA$5&: M!<&5E]KAG?Z8L>E*FE\&Y_LB;_LNS^"'=$,6/%B8P_'"]H);S\)%?G@&9 M*%4:?;=4J#G$3L-NT-WTU^6K&(D2RDJ[WQ#IL"UXIB9$GV,YT/2#M+$;BWG 1E M=1*-+EL!DZB?YZM#Q>-=? KD4((+CY??(V]XSSG=7GA/2"MJ9;!B%AP_CB{I{(YN%,+%?P(_+&OF MI>##=!:N>S]*3-?)U!)%;SKIK5,=XAC!R7GD:-"(YY].RDLE#$=ND]{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`CUYO!6)&A3W%RL3;UJ(K^;9A-@KT~BDO+|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{EHO@F^5FX5.MR5G9 ID_;9U4*6]$ M35H@%3,I15X-HX>;&4RWCFN1:#/EZ]Y(5Q;_?YEO&.YNF\; FFG@;P=M :LZ^S1J6A9^[UGSF;<%N0I 9"8'N3^'Q81*F@V$/,0BPO2 MF]U<:5Z(K-_[.;_$YMHE\(IW7A/^K6K78SK^'$L-[)*;-!X!GICR7F>+6RNN M<<,7UK^HYCOH)[6*HQCWCL3D*84@%!+'Y=:(OW_TYS',O8PV_C;;R]# M^03W.Z'8?%F M(H#Z968)DUE\|Z18PZT,H&5^7V.>>'1E3Y#)8)9S2[@W> QE!5] M^E.UNM'X[H4OEIK>/A(O#IG\=0A;>19_*]>^?.?\|%:2X3)#U9GNLR33O+S MY!P4>/Q\.!K::QC&>DWH77T[@H&]?[,X(3?:LY=5?+OH\;(8AV)7ZVN_63P# M;,0R%>=]4 W<8 C:\79QC94#X;/=YQ*#GL:.MZ;/#WK|_X"\?25/8B;Z"=PV@?K =WSR&[*^?)"L_>>?IY--,#-/N\. IL!Z M?X*C 2P;S:U;*G\V6[>&>&;HU>73HQFZ)Y,'D>O^S5Z3N=.=]H(G._5_(N2HVEHG>=VG4VK5.SSJ:U1-8ZFI8I6Y?3VJ5V MIZ]4G2*MC5AIXUBG:>6NC4^,D91\@F:0Q(.2)/^H>,C&M]DU63"DQZA=\8RT MT!\W)8@\1$P?,AQ-NGDC-OL<9){{WL1<@%^YE MH_/0WJMGJ#.#MV_\Z43| 2++>EK)$+QNUUE5XV]O^1P=?#^R[&;7""BGI.>)4 M160YD0A5F5NG"9Z;;< [@Z_]EH2_9^^'UGW3X=T+T(E7"(&O<)9WWP20:8$I M44AH)A'@G,V;W"QBVFAL'2/)D]O{APDS/%B!)",!R![!R!'ND=/46]VDLR9T MQ.WT1+PC;AUQ.S'X@E,=%I8A^ ?@2^4]NBI2)&@RA.2O<*-:^,[@]R-N'=ZU M#^\>#@1W!,!W-@CK$?#-FS"Q4%$*0L#A;QH)RSN>&BS(9R(7L5$$$1-'_"G'|E9GJC/ZZ7I7V1 M5O@5DJI.5=0!<2$=-.;*{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{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dR 3>0 M&1UIQ:[#8[M)FADG>?(%15XH@H[%HZ";92=24T[>.MX6MNGM,.R7?]<3B=& M94##$*OC>HP5(&AK<286YB-%:%AM5X#C52D3,P3O-W$YSAUS(VPE2XBP8*U9] MK[`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|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{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{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|Z% M0?4YM- =OTS|^O2U0_$.#MTW7BUM9/NR(Z*-^Q>IM"_DTP3X,PX\0/@QJSZ[K^3>,)-W6=[N+D:K#L6;+ ^#N>V@@>(S';\@ <@4 $<)>E>_=H3A9,.*(68ZO_GO1G; ((SWY7#2XNX28#^/XB3L_'H7Q.WIWUYJU0ZAX7%GB- M_;Q\E#R@V<+-X WR1>?+|=D%,KO==%!,)*+|Z\RH,$3U(/:WS =8& 7P[ZE M*TMNPK'R6LOGS'V'P*1/ZGX6]SSIVG#E/D4W"#X_(BS0?.5))>GX"?V:C">)}&Y;2#!PY55-O 2D0B/@@HOW>],F'?\N+/GK6\3>%7D**

M0!8+V<^M6687HW6EO+0AVX&5,K#>A3GZT#U!QL%%;R3=Y?C:E"N/8EY@>PJ MKG8,65:H_?I C_(9M/UYU6>?)UQ$K+DZ-Q.:)^Y\<@L?YP!0U+QNJ;/^!0QK M_7&9YWHES29XN;=V^,5>5_/F*ZM3OIC$XI67"5L1@L9DfG;.3K.-TIHB;>LV M9047B?.$L-,*\6@8LM@(I)DPBBUN=|\+\P6O'-XSA+J/QM#S#8H|)UV3;.&(SF(;|<"Q-!],.:& LPR.,*E#'CGXGHU-MM/5"UZN*Q4$1[.+K,,@%&^^ MS\L&+>]'?>],2]C;0-V7G8=U%-]0<%C$0AY%G B0 ,XVTT1XEB2T#*6!T?QUM M5V5AM:/M^QS,!Z-Z9Q?;5[=(V89>7P?-6=KO"QZTQS.!HZEN<%=-_NLF?OY|3W7UG MKW6BWNG^\47_'XN,@R+Z{^N=?+SS_,B_++[^6EI?3BLZK5AYU8M!",/8 MBKG=AU8TE.*/>&$'X+%_+K_]>),L4W[/C3">("\M&L1.03JS\1 %>?_Y\R1^-MS@MKOX(*#$;5P/=*,+BS#Y U+U@',X0'F]37?_G"3--PU/K M%*93F$YA'J8PWPY&O=S'L/JNTYI..SJM>,C63,_'LPH86],SGWPAK!_LL&P]L]/>?]G15$ZN>Z3.HGF(%#YD3.[$K\.GL3P?GU\G1T*_^9<4N$Q(\$SY%4TB-.\P=1]BZ10A'"CN9&-M2H?))9IXP(@F.)*G7/XL8H*P<KI$!5)9&>Y!/.EOG7OEZ27\61LAfG M@6BVWZ

*SYNQO#)62<8.S>#:L*7S0|_S@&JLLNV0_TI M@:5],RUKK46?5,K_^INT_(%3AS9/%F=X/VYY4/< OEB>F#[]7GFK:3)A+YK_MXL:-%@'AS>CS20'6%, /:/XG?#XKWZP^@&4U/^M]-E'A/(/)G?#B@E_6;U[\ MO*"(IN5V$_5AI]ZP#A&L;>9N]^SQ0Q0Z?7OWW*$-Y_GM_CPN63X?7"^@+4<;_M7LFSZ<@*=GV'6LH(Z)04>O+J*_1/]2_YSDHCZ@[#T!IKKXK?5X-5KX E-5^_M;'RW*)'D0#O=\LX=(?D*^M\>R?L#TOVEI<X MB?MI83_9-C\6 ;_A(DZO8>05H:73RFBIU @(' O*"Q@ZODY H2CGH!CD/Y1\ M8[H"6W#H_M1^ -+M9\&FM3FKC\%/M&N@ID-/VBZMWJ:_;+;J[MP!WZ\4I=6=:,TPBSG[=\1H>>=X^0[oY}J0Q-K(>;r\V+0'$ MNYKQSX76 M#'XEE?GKQELO9_GM?MU/#5LYK/I'U-M/=U'?5@"2J;[%:M'M:=-5E+P(>WIPGC$AU7, O#%,UU+Q06[KD4W74O%!;NN13==2\4%NZT%-]TG+ MX-)=E,&E^U@&=ULF.9M[^)H)7YM*]MF-U*?(1]X/I'D W0?1P(V]?=YT6UON M8/CWR;9R[]F6AH/_=>U>6[;MP72MV+TS_S)W$%BQ;_FW%].U8O>V> ^VQW54! M[''U0/T^I5>N&P';V) ^VUB+I'C&81]=;%B^)!$,1VKRW;]F"ZEFUON]?)P&>[M*VQZR%MMN?9@MG+ON39(tAZ-[%Y,MM"1"W:WEI'IFl.8=#GC7Y2KX,-?K@' M@=VW.(?%V;NRW\U7@@\9B>]T(7H_I=H;)/2ORC%OO@\9BR&A0<+#X<# M#]2E S?>7:B=Q0>+#Q8?#@_U]UYZ99^?Q;3.],7>ZY> >3==R*TY>,>^$\O EH$M S^I"-ZQ M=|-RL.5@R\%[ZG]H+?/N..)DT_H>3S&(V4A53CX1Y5@YKYKXD=<#9Z+N65QQ MS]'0YG"VT[54?*C;>F33M51\D-MZ9-.U5'R0VW10T{6)$9XU,<(%KRH^F=5. MD?,T+_)9;F/@|\KPMQZ>V^XUL=ML.,8'T[4<>^M3E3#8Z\SR]D3%M,Z^5N)9GCXYGZ7Z78MJ?>_:'ZX?X@%RAZEES<'JKXU*+I?92S)%>BHD'8;RI M--<}O19C-2V+#A8=[%,;?IM"TV6&RPY' XV! /O, F.+7H8-'!HL&/T_B M'GQ^UC[?MK=)&+&=)@GC_0/1+8);!#]2|+>=(:O?672PZ+ MH0"UV91L=(U%_M"8L2U'^H0B6OS.5MTL.A@T6'#Z9(;'SPXI#E@Z# S,OZN9C87XPY9R1MZR$NR MG*>%>D[HO1TKO7PT#-Z\$'N/P]\H30;QH^7&O;)[_<=B:\]9X+# <+#2LI!7 XBN&XUY%;LZR6CE&IJ.1*_O5#;!BP\#W?[HFRB|\GAV\W6)L#\ER))^I@7.AG!$_5X[BU41) M9U(ZE=@4YZ*Q*L3,;*4A>[J1,X+1*SHIR.H1&'3&#>$;:'3"TU*<'!U?AN&I M.;"\,ZU*.1>S>KAMC8^2)VI89C'22]==R888SC\)+/YGEIGUS+GCMO RB(76@ MW2(O)\!7HQP^R">BF$OHY*7G#Z/VJ>&8"1&\'L%,2O&=1+Q6F EOC WRF6XB M*RO-?Y-|HIPQC&94.PK663I?U'2FQ[FJ'-|=.)|KL8'^EE?P<%8Z+VDX#+:/ MA0|#.PXEG^B1U'RLG*F]\E+BA]"Q/W0^J:HN)Q/@?UP>7M-I45XJA=\Y]7PZ+.L9=E7.*P"F+=O MQ2P_URG-AL[.IM.K'__^IA1^2L=Y76/WG5$EW5%RQ>8/NU.<-&G!LLSA#>< "M1N!D]>##/NV/S/#!TVCHI@GJ'4A")]5?%P/H>S(?$ M/,,AC^O\:?LV@3GPOM_*@!M9Z*$JFM>72(UM2NI^UDN(;0#C(CKB@V8Z:OK MIO[2\Y838";94N3#3GF-0Y!EC!%/IG!'DD083!X M> Q#@@D+U;3Z^8+HP< M_]Q"4;@(V;QMI=/&%%;U":X;_"Q"6V_K>;@-+08(>$M_)ZAER$*HF5BGV6 MBC?OG)&+8;P4-^NRB'4DU>/+Q63H7R.BA^Q9Q&(*|"(0|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|!_JW_.PJV8 +UG<\3"BV;0=I\#"BE?=D1M1#E^,.FL#[!V$B\9^8WY'|&:] MH++ZCO.1#3O!KYN6\G2KC79AYEAHT&],=VB[!CA%70&:?ND/W:YM#@:;@E.> MMZ.JG)^-G-/Y&5@#V%PR,+9K/6O.J]!&71*.[J/6%F^9P2;"])!^<44_*WE1 MEH *\#P{BA\|C4!\%"&B/=H:..5 ,9%@#G3YU6"!.2!B@:.$Y%/M;^TI8*\ MKN?XL8BT9 G ^27U#IT/$^11{Q2"^<+.C_*B?$)(>_SM8|AG.;$%@)\KX'N8@6GCRAF"-%?+Z M'^A*J1L72+'PUB[&ATXGX[_)<3EF#3],07R-D'LZOFPS4J-SG56(AZ#"':5D MV\++:6"|_U0+&##K*Y !8#=@ SXTQ)*<%S\YX'##=13EO@GJ,"KEH<7$(@ N0 M+)O5>_&W>=!9#&TK:W^ZT0(_PI>P70A#SA<,%3IM/5SWY,#R.TN^]O2]\X?/"/?[P=H+PQOCBNG7FO7BR>OW@]0&)!/IDA MX1@:A.4? V/H;3.Q6:HH!HV#"L:A]=H$PU< M((U8]H+E3M',>T?=_<#O\)DJ2OP!AIH"JNX> MGN+)@<'G0 4J.B<0ZD>C-W4/.08-26AV76R ,1SKS [D+6Q;.\+M4M!0D3[6 MIC2YOBQ&0?=/3&'IN14<,&O$;K+;=?B90$YFG$]D51^CE8%]3H$@@U=;,IQ MR^=UHWO ^(8CV A%T<0>/RP05;?0(IXHQNFO/F=K(WP;XNSN'S+!@#*22 M-HAX06=;R4.I9"VM@ =Y%U59@@91DIM-3;.5PBBV__B4*8=)/RM?56=,,WT MHU5WVU7:Z8RIG.7Z4,60+P@RA=%6]K'R MZS7&Q!X60?@H\%)5X/$VO 2RX$*9H-+%7&%PFJ4P3J6N|5B;85>M9VVA.$YA M-7* <>RLBJH6\.RRV5FC I*1*3AS4K&#OT5FW9R+9@7H\F !MOM.*"($0V=[F#2 MM0IVG>$5#'A/+2+%"UVUI F!F6T0:VEO M:QI5>"* =OC21Z/U;T"IQ1! ERK0*S6'"VO@S!S.17DN5<$OS8B@!3 ?RFI6 MK]#UH581A< CZ[0Y4+_A"Y1^(BE]E$!?-V$+C34O A$4[HF05Y\,0V%37QRVZ1Y-]9E,3ES _?'.V+ ^S:%ACY")X2Y9 MJG8UN<=,,@&T@$_^\B)\ DF=!Z6HLLNO=6(32(H_ED2(GD1N3)%)O=1+9(L_C MF@QI\-.'9&;4P?_EO.836=^8E[^_2_#X8&$3\%^?@%]I;W4<|L:(YOT\KXY M#) ^=&)XB$> [>9ZU\Q8(!W6'MH][NNDU?>WA[:CEYI3Y&/ B]W:6K[NVN;^3D M1R]4?20ZD FEM3K0W0+0DR7UWG_']QO0#VK^U@.[M5T+0???]]CCWT'MMG6 MV_,P3UU#MW@?':X;'*\;Z;;[7G/_HT\]WBNI3%ZUURL9UK9> MU[!H?F!%[6PQS$,=UX%=-F4N]Q)O55KX]-I-[_V\UWRJ1^&$D4[G%S_9F2$SQZ!OD[M1;_V<@9'G'SB;L56V&!S,FB!\'6#G3YU6"|PNK&!/2ZYZT9I =.@5ED%G7"MVFIU^&+438V/N2ZV%WH[23O%,_!5J6 1L1A06R:'CTM0\IO3ONV;G_A^XL! MF*3)BYS[*!5NM 189]47=ZQQ-6B2G77K[$A\/,C%=ST*+D2EVC0I,(%Q/A__MO,BG"#^/-Z61'CJGBI1%Q>4 -@M$X2)SR%US[Z_6U_$IB.^,#373K]\ 0:TS MFNAB $T=)!R9Y;M;%SFZ)=_1#14<;|=W7C?)WG;N8[WD?<_#=*8M>N?E6S-> M)Z_A2H;!,2RY2],QG=8AW):FMD/>:DB5X/]/S NJTC(LJ[UDAL9-> MF277Y5?N*D&+FF-M)8^V5/1$E[J.UEM9R;-\3;+U51UKF<2]\RNLK>I>=.;$ MR5F_({@\!G+PKY"#WS715JG!I-]M=AX+"[4]\=4$^:%^6\O-3FW!\41{$4 L- M.T0'QD99F>IR?.-(> <5BS2%]8_',Y,.Z[O.8[,#H+ M.D_+^:PM7_4YK[_W.^/Q'C!!?M>6FT0%A(E5]HF$"B\A-OTF*V?QPNKX.1Z'Y6NC|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|WH;NH1>L/CQ@/!9S?B\A(E5JH

*JOZLRL=Y7KKF MKOAJ?ZOZXWOL 8GE+,VHA\^E@X5.2S?;,JL?D1PB M+\V1#)%B4^5DSSNN^67;>]Z,(}>RP,H.S6X+[/EX=K_'G;^]\ $GUZ'VP@U^ MQ.1-U6L&MK:C!FQ9<,E/G>'U>FTQ-X-T')$CWS1/?@V++ MNBC[?+5UD=|&M)&1&IH[%N5+2(W^O'@,,_X/M6V.)-6R7.J.Y;9BC.>]Q0CG#<6NE,IV6A5-V<+4_U#[I3 *+6NJ MI*JOS =XMM8,[6WER5/.G_DN!J1O;"@ WW44ZI>WNI.T-[V6]5&1C%N]/C1W MD38PXB/G[X+/1Z*IK2.+-L.?WM)=F2&&4>N7"=MNW_.LK,U%]+LR8N7[^,Q- #)\DU3Y2P1I;5EW9C\VU+0*0SX MC!/Q-^ %Z=% MZ(ZCEA7<*2%IOX(UWI%D7D|+U!+S9)\=Y*:^MJ !(EP H"1G*W\17^S'_ T"K+/;. MB.A4U<@.O3Z\>8=72/RH? S*JI4X0IB^7P>.E>.8EG:QO$.NF]M=UC%?=.X7] M27L3&A/|[9LDV&R)Z$5F@#/Z,Z!?1^!DG<@/)+/6CJVN8[B=N?Z1P9.SRS M(4XW>',/XV,9KJ)AA=LU)1K[NMW\JI1T),|- E/JP#@/C9.`]AW=QM(7_L)%? MTAUGI.1X"]{@E>1IZ<1P]=5$ZB6/U+A _%?^@TKS^"[0@/6/]M/Y43?=H<E 7HW +L3]64FEF6 %,17I_TG[@I$.(''_W>>/>XPW8' MNM9? @Q7S$_1F?/TC8fB*F@UV%_2N@M;=U M_5.]20?G?P6Z<)?OO8UIRQ7@O VLlOPBDOMIH.J/6A&3 SE4C6MP'P'2=^1 MFJ-EJB&4=EVFI5=RZHNK>=*K_ M$B3B8=JO>7TJ6_@ 6_F(MW2) V1R8\ _3=+R|=Q.HJ;V1,/1'S4YG>L-N^D?) MUD9FF /@T#77^+IKJfTQN?M@@[X#-4<"6&-9ZJH3RPPX4]-+M*'NFG7/TXA. M;%/X-B9/? +,\C4C9/38"XP.-2"T]\4>L+++T^K#BV48T<+P<0'PR)0Z7O M/19(3'US.TV_04:BCNZ8 *9T<^B(CCXJFR7O73\V^SP,KTR+-==L&U&R=NV%| M >8VOZ-H.UI]_2MKNZXD4R,- NRH.JQWMN4R.&6Q@]1BLC^RK/..L#/|)\'E7> M9^ #[3'N2#Y7([JR--PP#N)C*[*,=''CW&VYH%3DL-NJM7^>\FLVC6@:/P7+G MD60>DD(4_J#DJ4HZQ[&Z\I) |EJF[2TX?/& -+6>S6XN7Y<3F%I$UZO[\=QN1 MT7D3)(UV7R5ZG^2<*2%IOX(UWI%D7D|+U!+S9)\F!C(SWC(-MNR;T^V-&5;<=Y*S;E- (#W_AOXDG@;%UE8, MO.%ZAP<5]2'%%Q29_*@8%AO]8K4",C5PY,<>I? _VTJBB.*7C(H3?9&M0_"++ MNJ2\X6OZHUKEC.,_?=/PX,O!F(9]V0\,_F4;_?9(V)),#N1&SR:@RL;@LGL MGA[P]#2OD]_JF(.J4KHKZ9>FC.J.P1;===''OY,.$N\|\'V;>>-GGX.ZQ5WQX&!, MWQ(O_.!M\$6NU+# <.&AP9B=+?]KEZ1BRQ6NMX7W^9<@78,93;?D__L$KO>B>1C>QY#:B]B/YO\'VG-ZP"Q*U/"PLNV5C G[SC^LDV4&9 M4N5U+>'F+K,(N"JOZ:,A6- /P.148[T]OL-6H]D;M4$?D

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a-)*ON M'2&?.MM9S3]Q-8?X 3 GFJ]7W'3ZZE0TE03OKU7QG0L:7#4$F87'K*+4XQ# M2]U@7G\.GMDG-D05'U*N]PL=!\F!OF4"1"\8^FVBW?5T$@*$"-Q.M2[*HO & MW'+?$M4:,>*(=:P@"0G&[^DR3XT-Q.7K01Y.ZB,\C3Z@)^TJ$@HT8A\O M8;92<\!UCA?14V@_4'0/$'G#,$Y1D!W J*0X:10]W.?,@Z0B(YYPD0% MG&__(T,:1%C"#1B_SG8@:Z)+K\;_+H&H]B9C-RRZ=E95MAK]KO#MB9HFV@ MZ\;99%R$G*NL)M?R M.Y?+!$6N"A)]A_K<_RJH6Z-,I O38@9 D)Q\? *VMY MU9H]:V@A#+K.?L%;$1/NS2E%D= ?2STDS_9*/U%>5^&8(2Y2K0VP,-6&3^#"L>X MK\R^HY\HY1 "ID;AM) "*}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}4A2.]9 MRX#LZ.;B92!IE5- 8T#,5 ML&"!9P_Y&1/,TF1O0%]RD5-]*GLU);REEX8K\45]JD%0H+QL<7>:4IXT/NI,< M@-G $\Y/$.?":L,=2!ZJ!7]=@TNG-WH !W60],,...EBVCI\@RGNBZVGF!1; M0=+Z#4Z#-E]$L^4R "X\|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|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{&H7+@U<=QE%D7N&&,V) M"4,&EX.EN6GI(08L09XY)P]&AY5BAF0ANA@:.6=E. 54E0\[6 G",Z\'C2!% MQ^^^35U "0N%#*2= DH\#L?$=L/^H9>BS_[_@ MJ-U\5H]06:,Z;261X]?(I.7.UQ.96! f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{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{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|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|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`S_H86M8#XKZ["6;EV:%S;>8L$&C137QM{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`S_H86M8#XKZ["6;EV:%S;>8L$&C137QM{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`S_H86M8#XKZ["6;EV:%S;>8L$&C137QM{#Y.^AO M.:\)>SY\4+ "I4Q"#RZTI"_^6OX?CEE(=%.R*?QG#_N'[#@_]YSI=^*]6(;" ML8^R,% @3OT2ASY$/,F*1U[A,D;O I673U+4PQG=P/'YR\.(K!2[UN-@G ANI=G&3!-MGWE', 0-*FR1DL2W77#8I64:0%=YM?C8V5_9S_T'TDZ++]*D-_Q-E&E0?'7B MN/B%X"+"? 9]HH)YT2):A5!E[].S__(FJA.F!]<8])+R#CE?>]#B(OVABOC(S# MAK=A_);,.+;T.V/6/!X>Y/P2(!.6I$YQ\4$[=8K[>K$8I[X-)AMDS; $V'I.L+F MTN5K6%P-X"&M.$%=:<)^? 1053?\'7X_H:,S(&8DB'"=F^@:,*7M%S - _O+XK-MR*Z^:L#89^_'+

*!UTVTAP+/)_ *PA_ZFQOQ.F<_C&9?- A&?BQEKC8R8*!%WYV-#565 M=]3DY2+;"/^(TCUZF?L;/+A(9AHR#6@L2,,ZD'F8G"2'BS#-P=-H,!-?;?XX M!*1N9I$=A_P<:> #4C[O O/UFZAS]^.*M88\$O#!V%:*VA49AQGZU_+CLT! M1?5AOE?F(V9GE2^>Y6BZB4;HQSPJ*FK6>((2CT&)B!#.-AS*&3PYYO(PE.)W M,;MZQ84.3%CGRT7/R*J3@2(4 #"*XT2E^96X@6?9"HXVR.ISA$@[/$107PI1 MB;FS9P\UVI-D;K>%## JP7=R\.U-JXOH188FVC?.V]UCN0OLN(&[F"NV6(N1 M892-9%7*J)6GM]X1[,)K#UP&#W3%LWS)HI[OM""J5MLC$.W)DM.(&PY#FU^=)"0D_$#(2{ICE]&(3M#H+%U;,SJ5*1 MF^E%@,)83MB'H/S3/7(7CDB73QSTBM9L=*A>:!%YXM=V'SL[F4EDKOW16?/T=-M"J=B V=D!^_.RCV:.J7SCU14U"TI^M)6* MMU:*`JZ_Q DN2(*M'2C1I9=.A58C#2.)$0GEJ[@/0LCN'K>0R*U#%VK;7R6; MRH:]9$,_#_^U90?YB.]04VRPS[XAF\FGHU@:-C"6-J@-(G #_S4M$!7+1F%\ M?&=[\ST#!U;^CVT37EC>CB*.AXN'(3_H!$KE/$F&&[693@")-+12MB5E%1HKQ!I@BY8'H+'T8O_# _!_B+V M 0NG?*15($@Z99[2N]*

*[>054C"5#=."WP2CU&0I:1TS&,$SX33^M.G'7Ob_V(0((R?X\X^D>D@*C-M,_IXW)6W:8/)*LIPZ0280 M'(.8=4B&.P%.9R.&W$34>U4GD,.KK78)TDT2[$7*:,L4)\:.P=N$5 HOO$J1 MS'B;H!#G[,A5K@C50G0!$J?8=";CS40'/ZR#=>.&_@<>.][MU7LI2ADNJESQN9[6$DZ #3>)VF.1K'-B[BCRA/&3 M*K/7*T]V M1"F2V+N$MUWEJM=VMW+LE^>P@R9)R](@2K):^ ?O(:\+QSD!..Y M;2=$*HMPL!.@D$*-F#:0?V2]9>ZUV)W2/LL^6U=LB="\./]SG3A)$X9@-#[__MGC>/L@@Z^P1(!2G^T$ ML";UF5;_G*%O.($XQO%$+,S((05\D3K-&>H$&&68@))C:!5"A34O=56Z?FYQ M_1A\@X5$,,B'G$#A0!+ H.YNT?><0"B3IXY9 &T;:A=;:P31,BU,0G?

*4/%H^Z3(6)96A^PE3!#DL]HAC;%!=)*Q3IP*$ZQ00&(R* MDG(MT0W-'=9OS$7\"M]-#F@\ GL%,.@$][^\!!4822%KHE)VL,%AG3O0"1#J.=HH M_J)!TIYL#CO< -'"G/:QR-

*%'F=3G8!LGX,'[RO7LF%C8"105]@5J-I(]P,+! M]OD>E5\9BTG5]2ZT+@EGV >]:YX0U-SR7HI4I+B),BC[POM)=$#.68_Z8?LH

*M9LPKM+6SF&1D@^V#@D_D27)H3\=R"/_0]-.U^:0S]BZ<8*6YU8D-9F91D/-, M[G.B--,^A?$:V#2BYML=@FUS[0/Z,<;9 7!0@I3HSU[DY7$<*"F&GSNE-=$) M@KT#I"0G%>

*8N>42(;,-/IZ[?983P-&,19&NP/]NQ(8-EBPGO9"<$8I&>:E^2_+A+08I'>@D0FPW(\VV0W>%I4H&J$\W!%,X%W0R:*0\N^:$MQH,>793@ [7)T<

M,1L09"AQ/U6H'[OD_M=1B_%3XTKI5/=;(3 MH*I+$=+/(=>U5G `">5^X_+6(W%()?/LB\6?O6/3:O"2]"G2Y^WF!PTYSMQ MHF6DDVZD3EF)0K&TBX$/.(&R7 -:

*D$X&BS_SLQ'99((I*7K(/,3GU\$-2#UA(`M^)KF!'B5=!DBV2KFUK"#[3,?RAN@,!XD6%][38(X>8A7412@>>@9>3/@ OR;.''1*/=@*80NJ#2DLN",KK&DK&6\^?P_6-0++WH/;",Q*+QCAQ M$}33>X8ZT%7C#L1\MF6*$V"MHBSP@_" 2H^5&Y27>6BYI2@W' O8I1>@EZ!9=>YG'TM[:Q3IP_-OB5QG24 O>>=XB]=0&WUM4=M>-]

*MKT=Z"0XUD8EQPDE.@#:C&<"#[_MQZ]+[\N[2Q\V!0^^Y+]%6 M?K0O47"5G?S-!CB+3U!-3W^V\U=\ X&M$Q97$(GCK)"= *]BXS'+4&.3$UJNM&^1F"=%8)P I&X;

*<>I%_$^6%)1C_M?2I?CK+"> $UR!?0QF;9%Z7#((3DV:R M5U\S9("&.L"G(-6Y8MIK.X&H+[@@;AYB(_"(EP.R_@%0*KCQ;UW%2CY]O/'Z]$YTXWSN0 CC\917YEZC <8QCB7*E

*M2:PJ*DRS2X*IXA@F%10,I"*TKN0.O>H3LD[G/.HOJ3$Y^C^"+X*(60]E?^-M+H@")# A%5MBEVB9X@18K4EDYXD(D.NQJQX-;,+$F%G<'5;=(>O TRT2M>_NK(M9O-J.DJEK\2C[3-

T"'TO6'XF)"2F4EK MZR9B//GK;458%$0AFEG1B1.N M"LDT/K9=G*8CG0""KI+V(Z$!+E9Y*$!I-,FT@!,GGU=QXU9ODWCT%:8Y -[P.5>UO+>*)FW4AV!D M1],XE+0%!TS:

(0UL,'X,AO=@G[_A5+(8!7R19YC6.43UB=+5R M$S2&0AK66^@\1:$0W(%.@,_)>Y:%2DN&NP).M5!Q2VL]V7@G #)8^&.7S!G MV"\Y@<2[#J^3)*(VTPD@>P:WG!_Y"XA8VH"?

*ZS03!G^4$<$QW>2[CX[4QO>PNS\(IZIR\D4J!8C|>Y<TWRAMU0+8J=>YG'TM[:Q3IP_-OB5QG24 O>>=XB]=0&WUM4=M>-]

M@FB4$YLGEN_BH,I&QES]3#38"5"DZ'<+ZY>0W[_BX)0BI))Y)2JW122):"[A M!-C2DE.?O0SIZPHZ4(=EK#\3ET$"-EF<|.OJK_;5P6*OHRH66.M+V-KVT>= MR4Z096?

*YKFIM87LG?*Q'K0[]+2<0R>G)!_^/GB.@FVP0,7T-I@;D',I#@/< M%UW;^:G'>DX@9*SL,.?4&LW-.7%42OT7BVPWC(?T(2:9(L7O2.#X$F?_!EF] M.R.\[_F?T#BN56C<'=A_9)B &VK3Y,?+%0UT@FYJO=L^Y?TY12X.R7 GP!$W M4G2@,6+O0&=>QG 1C@*2'?=>#0B8+(PT9+%4T4JM.RPXGK\@6\.5)G$D?P7S=Y)O0D@Q!)/Z5RK>X:

*MUCT,E=).%RB,*GF(WRJ93\)A3IR;0E<VL;%%>,(3H!*N(,M$KXYP8M-"VV)[MV0/))"= -HRD@>4M2H;"K,MX^0Z^D@^ (#(9QP[>IT?NJP>BU5W#B% =O1F)+ M5&I\WCZ-7:7(X!-

*X88!RQ03R F^0.Y3R$H<^2-*OH83@'-$5FG1<=EX^_U^GMX 9^']Y'>4 MMD$*BSXU]TK$^V?TS\]QCE(/X4BH:HYO/F3Z5LA M2;R(8$Z WBT|+&

*(5XM'WR^Z\D@,]Q]&\@,G+6!UBW>]&0613V6S=VL,\Y02A, M!C]4Z20V1F'ZC-\ZK\[<49Y.&LMB'6577A)0O31"<=-J M+&Y:C=PMO#1"XAWD0]89$'T KJ%

*((H4TR&)S2$4O16.@$U0@+3\(.TW!"=-M4HJD>]"^GH.(;(.],J;27R2PFUG9KBB6[9/2\+E85X8O\R8FSZYLR7HT]^Y@(MZL<-\)EIHZ^L^:/>,FGW^ G\[!T=-H>==43PJ?.\)A-

*::B79.7SD_XNFX9KNX M:NA0WW("D9S6+6),"_<[4]HHRs;U"4.(EB?Y01PO QS|N*REA)$K.3"EQ%N MW7+8NW_!OEWCUD.YB8%W\8\ LKU88-

*S@CG)@\XPSGA]^*@YYZH1G'?.7]4ZB MQ0PG@$*"3^ '7G(DD5$D)DK2#8\[V E0(+O&I9^3^#7P4;?6QQ3YXF]P @MJ M7$\]T@A*1W=?Q0G@B8\3"2I,UUIQ65+)"1>_V>T

*)+L,A$2T"T0XT/Z|G#]%$#HECWKL(83 M9,DVVXA\/3^GZESK1$K=.+\14?Q7YE[5&M,)\3IR10 #.]ZP K"&^,R9[02P M#%&I::C2":9BV-

LQTNZ_7#M"B86MG^ZV#Q"NX$TG1FB,6ZWCRRID\IOWC;I<#<(=[!L MPZ(VU]U 75$Z[<-)I'/HJV/3LI<)P#C7?[^T=I5V_Q\"'=_^M5+ B0W2.OI M-@8YL?6+%W2%"CLI3EP)HI-

BS#T'YIWM$/ZAXWN)~AU(.+N,/3QCKL9Q]SLU3 M'U(@#)%2K"\-D@X_K3';BY,N8,J40[548YI7WT#M=+92(XP4]@,?\P)5.: M.&D=<\A>X@1MEWL_N":.=

*)KRHD@XX3J267G:FJ3DBIE0W_<'537XU11L*XH M8D4TUQH]D(_@CBV\3;OPI0,+^2U=1 ,=.(LV+K0R*Q\)RPW\ M1@GP0G1G$7F=@VV< $&31B,+.X&BP#R3J

KUZ@QO_BD$"A;'>@$"'4! K.+7V/4&8C/7+0F.@$B MK3"Z"[*KC$N8U2%,;+NS54M6)OLR0&$+D7]7"]D8[:-.H)87'4Q\',I73C:

*MNH^#UN2X^KK!H4OWDY8MX,=X\0IE%I_71@N\)5S5YW12X;JM:5UON@/[NGQP M@0QC(-E[\"7PJX>%Q B-T)CIQ]@8[V9T?"T%"-1UX](\Z@=I"R.(UE!(.7E+:,:/SF0G3[\>

*M.W^>)PNI\[ES!4"2 8&Y*RT5R8KL#W49I^8? 20?I/P>%70_E06<)G4BI#D MN%<&.+%E]=H"/"C449SL!K+1'0)?IYK69UHV+)).?T.@4!<@%EL>%GG/]H\nB0$V15=**)5QLHLR2

*9W[F49721"= A-I^3:[\ MFAV!=7YIW9*V2=;O2\Z)255:)*\(4F-%XYPXFUK)1"AYR8VE< \F:06:"5Q MA1K[@.HDQI#'B,_;YD"_*NO&Y2M+\SB[+20$RC0Z*SC;O. ^9Y(W-*/I<&

(B&/YK]I')-MJ3>IW^?8I5147G%5P8&EHA-KN'&,+^X$JNKV#JFG1#C8$09VM0/),]S@QR1^ MRU[0H7B10/_A#K5_ U>;30)5S OX=Q13_9 $/0UY=H4E";8!XFHR$1U1E4M

*M&MUN^5Q6-L.)FR/,?OKP_?N?W_\@:;3=/M$)$#_'$3@2E105).8\!O^13@"! MXP2;+<&X1GO^4"?]+G;OAP0@O,WB)4LD;*UX0&GM8 3(/]*;(AB W%E@!-;

MYBN"%/B0J54BL9CHS'<"8(8K$TJR983#W<"'+(I5(P'E,#VQ,->2-A">`M8A+U5&;-=9Q %GOK4*N/(DYT#(L4]lC|&8ZS76^5+,.ZOV2"^-?X4\K@;;AB @I-

$^POIEI'P4IK7$3I5F"]8$4^\/+UZ4X^5+C!NN M@9'[PAK ?]?F\:1IS[0/*CW3.(U6JF'3G59Q@W 5:YO).E/J+6'_S!_A621O M<%- U"^P,<*-LRJ,INE#3"5V\ 5DI?

*WU(>8UU2O4^[*IIC1W;(#O.(% F>6: MVI'V912DE?=[K^H$2#R%M<;TZI;^?,$NGK#"T$PFMH.^Z]N M-2KJ.CXD&0 15020Q @Y)_*X5"_HB#QU$_D'TB*>,T$I.O\|YVX%MB"RP=;-

F0!AMP)D+2@<.0?O!#U M=L&)Z4CC?0GV#S&YR/QT+LWIID^N$2I/1(R@D;(#=;-MX^5;#QCMQ@3S;(M4QY(VGTI)\Z5V:C0PE8?X\3&F[\(4M7_G93:TA3'Q?$< 1L9(DMN#E)Z,

*-0 MON**T**Q]F_>`7@%20](@+B'Z&V5%32F.7%. ,.+?A:FX%]X5TUULA.@EN$)

M_"TKQ#5()CH!HD#9YN]M_*%,@%%0I/F121\3G#5A3_52_B]33!/DB,9GN%/6D@NKVYOZSM_G=B^", M!?RB.<3^MNO=6.MJ(R>

[$/MR:'LK'*\C54@[KVH?.86QD^V$)#A0@GVBYRG>19Z;O@L$M+XP_];732DX@ ;Y3O)"/O+2_:FB)_BI. -]7;K78 M2GM/;,9DP>.0<#:M8)[]#K8"5!N(HCT9U3N(X^F !E)&(+G\#&,_;

*<@#"E0 MJ$/8DE%,MP)<*J4)&]1AW4MN]37<. ^C*98U9A6Q>5&_Q=:R(FS MKQ<\EK<*%QV UA19Y*DX*KM_E0>=M9U_5!DA"H%HFW+@MFY(YT PH5DFIJX M#.&AHU6-"JO#;-

*&)8^M2U/EFMX/_3 (OE#0+-+"N$PAB@CT4/?7R&4X =?\" M%7ST[F;!-EU^?>E/JJ^^?_U7;GW3_#?F%_P#Y]HRC9"D_;_CW_2 .0%XA-MBK\-@RV L'SX\?M??OC^N\S[&D?

O[O@=A@I>'% 4#]'_CWPMV$3*]-(I($$! MB?_YE_H6_E)!,'PP 0J_^@OG0.+]6>#LV+@0%|2L"4PI! (?!(IV'S['+]^ MYX, 0X'^Y1OT++]]^3?W_@6L.QY OU"T0&'MY3>+*

*[SP]&6!3146N"]C]HK2"G[0OQI&Z#US|E3]?60\D6R9]AC"^55$%8=_(F!;T+,-NLC[2R48(K M%M:VR8T?:+&$R=^_9A^!"\=';4Z>.VS4+5X U#<]O(&\]>M.@:-PC_5Q(VTR

M%UA+DA/?(N'04?&)FD G%_"SSW$BQF9UU@;Y+H/&QNLCAIU@U<[D#PC\V 2 MOV4OM^ M#X\SS?\/2I#@O7##O+&6-_M!8L?K&P6I>%8)P_Q6J2V56:DC8WB7.)U@KV#

*MT4;_@N&V]CR+=+39O/#_.'NV 8IHP]7!8TD$G XMK!3 _CS2ED3(YAM-8;, M>KC(U)GL8V+&QF1V@0PJR5%ZRO)9(TO]__O@)1E(PF.U0"A'Y]^/"%LI%I0R MY2G(!:CP7$$BIF_

]@F.S5C,@<:N .'U?2DC9L;^0/G#N-L MD;4R&C'B[CU$Z]H.L7H"P\&4P?T:4M+RGW2P^$?"%6\3|@=]_BE. O(],D0U,?EHH7L0F$XP>QDK#$*41QLW!)F.N#HKA9N#G<,-7E1

*MS"Q66();[V"AZ%BX4_UY%#F+E8VKWD.*CL4*Q4W/)47)PB7A%H]ICJ6_+=XB MW'#+4LPL5AX6^X$I:A8N"HO\SA0]"Y>&13YNBIZ%"\15?SI%RF)EX:87GZ)D ML?)O+7J

*XF.Q(B_<(&B9131-_Z]F=6#9W\5?1RN8@C'T0XC3."DP.4.^B? M>R&J4089"F"]VXR> [;UTB>,Q#R)CH2?@#!+Z5_*,)2R.!1M4E-OXIA'HD@&

M&@F7Z;)I4@!$D.LF&&1ML]Q"]&SIEMJ^Q>/=`P%:ND.%B'R#9;+)12(EZ]F/ MM7<"W(+4]^P"(O@(GZA-8KZ62C-M08:DI"L=C22"?9(2UI&IH4Y;_,&6]T79 MU4KI:G"&6P/@-

*HGW(,F.J ,1SLN&9+[/2VT(@)!.<>$NP#TU"S>JWPSY=!< M5*8W'-1R[MZ;]U$]1C*O97HYWK]HM.TJVB3]E'>4KVDV7"FP36.(RWB/I?(M*PTM1&

([&61_L^MM7M+2"V]C0NBM).PM2M@J&K7-U3SPSO6*>1?K?.6[!O# M M,:Y;.7_ XR1!K"AL:UTY#-L ;&N$F2')CV>=9 JA;1JQ6!%(CG^,(*.H/ M8OL\>_ J8H$%97?6J#[/YQNV]

*>'B"!1#[3SU9>.1U1F&N:^]!CT ?@<7<&2P M\<('1P6)8+-P@=P@[U1MCC74ZQ2\K>%%::K52]#2WXS*T0S7-!)V4O8P_J&[P?$ MDGX+K^-=.'M@PS1>,%B1'I%^TOW3'(HCC3Kc!

*NW)U*C&S+(9Z7BGQ+C6 MYI5EDDU;VF%WP *9K-1]O41KT\BFM8IKTI'\3K1,L@=,*1NTBW?;FSV [@"I%'_E):C>=LKA<,N8I M&_&Q7\A:"]S5',(DKNDUT$NG2]N8)"[@VJ7!KRU

*BN MCSJV$1C5(T"N4W0A>.+Y55LE#2*6+ M#"L[<.B?2*F87@2Q^L&I3M%\FFU<(M+2V:.VDZY1>!/S7E45T2R9'V?M9(4].3I.$1BT"5GG:D$(>Q"*SI*$HM@1Z+

*MP)S"/IJ5XEX0N:?3?TK"G1GF52,-!4!1G M7N@2BO1(2B7$<1&4I?QF\E_"V9-4QJOHSRZR@]17@2>#-E9!?'1@Z#0->E# M#VDJ,=A+HSP5IB:*\J;=%6:-*QUN1@/*\T',M.^>A$7-

&TUZ=TURS7X> 'DWN MU_.[Q?A^ 1FRKQ8(G%9QA>;ABNV)/:)W@#?O8*7<+$MQS1@":XF1'@"/= MPS^:IKP148Y)3P-RDZ4$+D'R"4T!4^ADJ0|+.,549GI EB* MET8VPQTPI=-%--

J=[;=?%.D4-T2JKA'/[@_5LF)5>R&Q>;<7$49A$GF4HRS" MEV82<;PFAO,V1G?%GI,L0C+EP$,"EG>O.U@QC!7XW=FS1|SQ1|/V?UMH1T> MBE_3]3;WN,%?

*<=P3X[)$SLK'R#OX058*[.,P%1%O:P%FBW5(--I^$:4\>K2M M.81XO,5R/2F MQS59;@$KR",<;9\OC\!&/(YUD#Y B\713 A%1K4*S^5]GG6

*M0+KV@=@1++RO_Q[2C/#7//-05,]'/L=N":664 LIHHP6Q#_>2=H"B^2T^^O^U2 M!5_82;2L7KT@1%%1UW%RI['!4>7!ME2C,[:\?0Y;,KR-MS(CK6WI(XC@;D+(M(%?

*^+H@="1&>H7Z"U2@^6UB@GVBXVKD4@LA,+E5C.%E%;8A@>*C7F+0*O.HRP M:C)<1/D)+0F18ZAQ&\AJ(TC2A MCQ((41/; M.4R$=.X<>Z[7ZFZJC1'JCE?N6!<2

*6E'!E$L1&VZ\A?8U'SZBM(-D$*TDS]>(*+9#[C< MBUQ^Q97GCWK A'&:.\^6]9QF97E$AK3*@OXZ=B5VLHG+0P(Y".&&^,9] 6_X M%[$0K#+7-= (\76$K3[9!5+-NR<]Q

*_>UW\%V0L2)>&&421+,LRKOG_M1*N] MHF71#UTLN+E^\'=:RC ;YK:WH^]=G=NHS!AU?\[T +-L(>>2SAZC!'@ADJCG#_(N?(2|%_(IKB,F7C2!NF7TS

*+9,>VL]^<>< M0^ 2LO:6E%?5PlS_V_M?:$N-'0R&OWWWAVBWEHC7TE-8Z//ZWO"S#,OR5SR MN2IY=BH>?K[_9!'Q_E+?D:#RSS}9ZNX>Q:?QUZC!RC_=BX+2W(V+@SY.!IC

*MJR@75V9,+4ZU1:0EG%KO]KQKP!L5%Y&BH'Q1=[.16!)3D)#N%X74856_<50 M]85)$_Q MG/!LJG,12?T1E>MX,S3->+($R !#9!D1F>I...NHBD^*[P0FL*X/T 0"@]+

*M4\Y:GT<_Z;GEQ]YZ1_;HJ%\(DZ%[5VD4QR[TKH1+G)T#!')^(7HWG+_]%U!Z M.B9_P*M#=M4IQOKQ0!<;[@&ESPA ZH M)6'T0=*B?WJ(OL39OT&3)D"")6G6VP+4ZV,=1,5A;FE:

],F"/V5)Q[(9KMWL0DSK>[-E"]E\/#8 ^.DUU(C&"?& M[R)^4UKFV2LD@WR?ZRU$.A9'UD\DTO(FNOJZP96SK^.DN$>?D%CS*?">@E"<

*MQ]5G18<$P=5F$Q\@RX'.6%+>JGV>,|_09R_Y'61H4Z4W0?4%XLZU64(G 9@= M,KP0%,]">Z)5W07"9IV11"\&O'Q0SGW5,6 =\W$+P"^.D@3B#Z(QP.\P)4

MV$V/A0Q@^QO@A00>;=N\?T2>1UE=^CW5;RPH$=%/K'(29RM=N^\& /#.CKQ MQ=-;PHEW$'5"@L?PVO?YWM=T" MH2HQ\B9.?<\4HU'>Q"M,D&IGZDH;_8PE?>P@^(A7N%T

MB>G(WWXR3?O=N]HU;SS6N/8-G*-OF&,4#4.F%C6;ODSC@A/G7>%/T]MNKS MW; 2.)0!;)_GFN3-<5;T]G8$%NZE'S5((4F?"01="D2JA)++Y?&\V+0&3W4!=>D*Q*

;,A"+O:0D28LZ]6! M&4LF8868CAH+;0N2&#/8>Z]RAZ_ C$74:C,M3C4B/A:!13-RTS!,>A$'8$@" MDPH:BT#D0!(8/Y[!$9/PE??B*Z%'$, R:O/@-DR.$<70:U'H-LBZI::%L]D

*ML72+0*9224WG6!:!5D/REY07+P*1AN0Q_=C216!W:$E,' ^["/0:E+!ZAO N M MW=A(-NL<.+],IM1CC0B54>!*TQ/'F7T*HK'(P=![V(0S C6.A$32\"K6/9 M=EHJ-

*R^2+W>5*W3#5A>!8Z/"A"3T?5F-*<9X8;!],JRL!BMRWQ_8N@XC'8 M,HP->,,?$@_99%?H^?@&E?I2X1=H9C=)LM@*V?IF\!O_CMU48 MWD0^/

__X(5%_URR8)ZB)AQF.L,U"M?\QP^>YO? MO0BD?*2(1IG.D/60-!YX%_\((#W%XJWP!QK>S7\E00J]\\@$F^D,<8N:VNC M\5(:YU(?];E^.\\$#V7L\.X#-2$O'3>".TI-.DM'3Y-

*I4(UJ#,Q8:NF XI/# M.#TD8/T*DM< O-D3 CH6TD3AU:B36!Q"XFZOQ2R>8"TI__R0!HAA78)TDP3[M/'_OW$N#=+V]90[@ >++[/!27Z>VPD!L"??LQLH)(%WR-E_\X_DTN+_.&GX(}#

*MX#.EC:=QBW.;;LV2VW*36R89%BQ_QC@N/MJ),(1G5#\(EH32FQ.13=3;Z[A M/1?44!"(=)_2\6XP^C5**=YT]5-;1'2[\ MZ1'4>}-8HUUV8CSM$'TWA]V.K]Y MKK?WP7,4,(;-

*G#0>,BFQ8GG(4_QCTMV2IV259]EW.C\FC)6+QS.6=JJ\8;"_MW;G>YI9C#RJ;$+$'RS;57!4U2_C;&(!TBOT2MEA!3'_GI;5W&XIQ;:F!SGG$)(L=?49Y%49U0F>,&K1)BNA"%E5 PY]M4

*M>_50-$I X@AP8E@>$30|@5<"2 EMFR5".PU[Q8=5MMGV2&HNXL,]!GG(E8A$ M3=0MB!,T>VA/BP$H-6IW!2,[SD2J-BR'2EF!GE24_FFYQ-K+N'&-VUNTZ^-G MSC>UO*1?

*"X)>PL2C(R\"<)77A)!?EML0^VRBH9;NL;U';7=3_%XIRYBRX&P M5U(^"YSO?OV5/#REX(\#?/S]=7IFH?XNVVUIYBX;,>5-K.VI|(7CW;B ,0=2 M>1/%L"_H

*O9QX9Q<.;9=.;6M'6/7J59L/,R88.0VB!KF^55VB*8%&Q<,1%BNY8WAGH3R-X.T28/8-"X M"-K+N/'*=?)8MK**141ZJ%.BU\MHI'J'LG5&>(B*[_IH4C&AA=1VT4/7?H,_M?

[R#-9E^)90BP=$91,3TF<3<'&_>0'^ =6,7+UZ08B.XCI.4!7?)\M[3?&/2 MH@8?5ZLBWG=9!Q!2EK/!# M+AE _E(!*=R^3HA8KFZ^5-W/0=00+L!WJ.R.QO [S&Q"O$V M1*%-DMG]/@

*M3^"3-BNX(KXK.%,0M5"ZIKAQWYFZ9EW^_L M"F]2S49T,#"SB*EK"V.H7B. O(@HU,WBB'=$I-R1-M6(3LK$6C1MZ0103^=$.K[FNSB*"@_JC4?J/F"'Z\OV

*,78L2]!Y@7A MM%X?MA\$<5Y[Y5]>X+^ED(B0_;.MK-]U%=-.P#+4_)!L7J#LM\!. /ZXN"% M^R1[SXI7J--?O!W\5P:%E_':"R+1,]$^T3#J'R'U)F!0CY";,P]/8:!9;^$5

*MAUQ"C/G6.=80_VO>-->IK(5IW8T?8WJ:4%*IC7,G$?H"?DF!?--JE|;7]D'+YC!V3E!A_+AMI=9!E;,L)K(S'28%FZ^.,=TH#6"1$J2?PHVD45IS

*ME#64W2'M,0(^5;)7F\UA=\"149=@&VP"T6U5F.@86;^R"Z@?'N%F\|:.ERH M-M>]@A,7AP09:@0 R68X!0;JHJL-"3()>MM1;&8KYDFI"!A[!9%4@1I%P_M] M0%HS/EQ7V%:

<<&G4Z^^(K]8 \9!/S6"$"_=)L$ MFSH,EPZU=GE8\N V6Q?89+?B;4H8%"85ZFL0\3/A>"?. M(TKS?\N/.[2[DLL[2K\MO-;::[CA).OH[^@S&MK]

M#$.X&T.'_(SJKHD":^TN@D5X.#F^!=8I6I/ISYZ.Y'X!24%3U@8_5RD),/CX M2C7MZ'/%@I(]G]44;?X^5\QOW0*4>B]$-5<,#OP))QF23B2NCD]L%(0 !;Q

MG]LW5]5T7RP8>PU_1[568L6G. 2;?D'R%+N%"V?5VV9"6[U(BBLK[+'\R M M(IVFP]54\5TM G>=;VM%.QP"52X)'!TH3-&1N(C$K%Y/ E?I'@)M$R HU]"+3-D.Q8]_MX:7Q3HK.:?6.

*()$V)P97& %<79O*TG/8FM&=%%T3;O M$C:ZKX%^F!G%X]Q+UO3I3#N;L@.Y@<@GORK-:>.M1;<69|!?>9%OI?XZ>}> MA\3]X?

OW/[__05XE06FN/=#_WM(20GBZSB1=:39$#JK3%<+7C9)>)E"}>K/ M=X "[?5Y[G< C4>CPR%\LI_CR"]W6?95O8@CU&D5%6]#;/B]+"-'9OF' &[T

*MDE6&L3G38H[B/LB\D)34.V0O4/+X$_@"2 2#[6W^!9G!;R*6SP.1)MB'0/C< MX+=4#&&/%:>'!B0_P7\WC0NZ[*00UWNCHGI=1!Y$$/+/0('T@&7R\B2X,<6AEZ;P M>

("_2E>O7A"BG[=QDGKI.+CF5AG Q/-DV4E_);?$@^W M+F]Y)<(=H;M@[@$AY,0A{PQCU'\E(+D+D_1',3;0_9*@'$ISS88#O(?[UT2F!+_M@WW,&@{?

*[Q\2#,6Q9%Q2AZAD@BM4T(FIB!Q2/E?7<8)R3"_!4U8> MY&H7)QE2%U!/,KQED7]2=QE7 2Z3'C\F<0IO+B3N$&W\[(R6Y^A1!P_>UVY8 M4%Q{(J9(S9<52<%D.RXF1[JC^Z7*O-

*;X<@Q7D[`M%S%VF<'C@/^6!CXNQH":A8!Q;&\V\T6/!25M4E^,&*O[U"P$\S&3S8YWG.%L5)cGJHSK?/&$Z1%PN/O/@<1^:(HLNN#Y$OC|H0##;=`M9BA%6B=488/T)I*TX.2.LX,(2Y#*
JYX%KX"G@E<>0@F&=5>Q?_$P?:=867@O`M!4TVPSX8LX_9$5RVA[?XX24^I%[D7R'I&X#HJN;V*A?)"]E+? OU%K!_T.='
M1A&\3G!1X\U13;87SK0/%F|KVGIQ?:9JL&80W,K;'8H|KL8I95.M 2;WG'8R MMJH?825OSZR[RBG.UK3H\4%;]/A@&PRA¦JRK,;MU$O)"5K(9;K@W];Q*%;]E M#Y?-
*8#+8("GU\&R+$PK>86X:%1SN2P"FZV^F4KFH\P+L@AT*3E00#0WG)MB MUHB7NS#**ML\|*L$;/MI&COWL"5UQ:!QO)FE$;B+WQ%R"4K-116_UDCNLW'6A:@
MYCH@9HV;T2,&6&K4=ITLZRAT@I^X#)CGHED6"@<+<56X7+!:!.(70KX*[;GJ< M%H$_#>]4F[+>\/XL#8&G'+5QWR2!N[`5]-3PA2V"4+N;E[O\;H/D@CF;BVK2
MA"RRGRPBNZZ3;43,,,;H(5#I6#6 AR#:I'GU8)@I'4H]4'fL3M@UZ/\4*Q*QK M[_9[S\2Q&(,@S5FQRB0SK3>WF#?=6:Y>-;M]SV/CE>>]'I'+,\|{(5Q(Z,41Q MYV4A=YBB/C^?]FG,IEG]_
LHG!)ZAR(9RZFALTH.7'R:F6)L]`}"<=\$_;CR=OHQA[R&Z|XZZ9>6%H4<-0?@Y"D&9Q!%+)KIN##,_B%B0:]"8I_0K/[*Y=KU-M=@4%%?"*/"YT"[$Z4R?L9#5XA28IY?
J%$EZ"H)TA/!.L7FCF>M-O="G4W!3 MHS_Y5;I?"XY(=\)J;ZGD:CCN0|SWX C(3B,^%-VV*EJM3/43G MZB'V3PE0,B6:^HQ|A)T*2,ZQ@*1+*+WPP@TJ3 __%;XCX76N%?0?;2
",MPI>U<:25G$[P6FUH-/HM^ZAST|I_$>]V<82[KZM7)&N?`M=*JA9IMU*3LS3'I*+4EP#7D$;H -P= 1\|EHAT'N>GM-@DVH+3_*!"PXDS[
ME*O)M05,&W7A0(!:TDV$3&%P6"LY#_Y]^RC6O)PUD.ZA1HK1L]Y" MZ.(=N$*::!K-Z9^:"M/5-&O;C]I$[50GGMQ]GQWU_^D14]VI/)&M$@<]PAX7 M@N-3":C)$K?AC':S=IT,<_!
'MJP588=2$8Z$2ENO&Q=T!! MY#|(VKKX|,,/2"TM44D:U\-?8HI=26FE+LI672H9(*]U]DE:,,E#1*!!4Q]<6,/U0U)U4EL;K.(|HL@\J2YZR.0ZF2@R M3J!+
YEB!O9%VDEE:2"MX32CN#HI*#+U3N;8HQ@TJA,&X-"_R'%E5%U8WI9 M O>;%^ ?0EPF;;>/(S1FO:5B'12 P22KHDTF2MMPM,A%!AKA0=:V_2O7A(@
MWTC;GIOCK&WY_B5.,B0*M>V9,]!N:)!DK}(M3LF1*[L-LW9!&L,,<9>2]?2S=%3Q3)19!C=[ZP4^5.A6.V2+2;&.$A[@AVXB)GTWERZ9G&F! M(&9H446 M3>!?'S(X.6]55D%
<8;"#PT%2#\<:GT,:F'H"\4.ACORTZ6I:2SB5IU>X ZK'WTS>PVIP0LY*8H&%CPE53MRWI RO\K^/.&PE<2F"5Z-CHOYSP"$$4^O-4J MX;:K3 -
<^$U1P6[]=28!\G5\Z,7(V&6!5KB6(_]+:*'VT,:0;MHHN\F1;=*JJF:R/^I,;MM.:!$X M'85HN,:+F(BR_8Z&WD&07814>%:M$8)YU4H4-O!*I?.;9%F.CM2;[SSH78VS<
M#I.@P7H8H>0DIKI7OF7!_AO*62] M*A2;9LPW56,E]>-,L@80_B*XCNUWD*V#G%|IX4@73U#?057*1#>3ZWYH|;. M?D!<>KV|@8+":^ ?A*6N^>/L;O5?0?;" V?0P;\$^X?
X"C*Z["\@!V|@EO- MDT_]GVWP9@|';R$FBR2)99A-E)H>%:9?E(X2N0-B0]O1+H)/(7!AK(9.6-] MG6.0^EXNV:+11+VY=S:>%*.M:R!<@?2L)D]SY(#HHU4W%0X?5$M@ !'Z9_5OV-
D$1=U7D&2HPL)M$N^"-(V3 MXY(V[S*_OFDD2[PQN'@*XCN0]["56L"=6%-9\DA1. MMYEG'[&$K10#\L2*_QCD4X;I[,,'W_F&R 7_0(19>N7$ MA*BW@.F;RTA3UTF\(ZH]
(X=SKW'K),_[_"? UQ2DG*.&)&<48;WL7@ | MK]!:ULY@Q(/=$ `7.%L.71'LC[_KLG(/] M5ZW"/1&]-S=;AIX0\D."H6'B86"7AHD8B$ZK/- M[SLO.
[K>KIZA@(P"NC\F<9I2.GV(H7B#TP+3-. W!===?9+A F(16D(;R%RX6 M2[_O PFEPUJS3=[@P_;,@S2(A4X>/ZB[C%-Q.R:6(EU&&]ZB?
'2"%!1A:R@ZE53T86X0,8Y[$;=)<O FRVL((M>>&AV-?5(X4F'Z@s5SJBQZ]'/|#7VUB]1NW(@G&F+BV-)#A'1!E(1_NYUK+9C
MU;G62(ZY$>2XUX\!/YAD|&J7NB902%W-MM6?F*LV""7*AJ;Q70WW*M+A69BI0AHT=A%Q93336+4[`T) .*V.G.?'RYMNC MEUX8<"N;8MK&@27'!!)FA7UR+1R"H<;?]
(K3!P_A71+G6S"+2K/'<@E7G"] MF]T. ^`\;'C,CPY%7W#XIO9T=PW!(N/LM1L298@ M"#:$M:M5N/=W!R(&W-D)'}HMREU]B%=1%+R")/62XR6^193GRFA*8Y6AB;I&
MBH@!7<=+&4+|)5I+U>OMX_UU"*.HK,OD\+SR=T$4H# 4?&,[?1*_>]'2%3#V Y...>>LHK 5^I=5*9^K_ .^M:YEF"""8(WFCMM4.YEUNF8?.VFN8?EUXB,S_2\2>
M6^>,N,=4U!Q7;INB90Q@#LGZ+(*=Z"?8W%/L"I%EIM{]WO\9(3B:T&F^%/B?M M->R^D$_M+|53_;6]R"85*U+1C4W\- [S0?M.*Y"\PLWQ7_\O*$,A13W7$##3I-M
ZHVPOZ.E)@O7KPH=VVT.<5&W_TZ+AD*B0L MQ339-M:?GC!P#W#UZ@4A>@NOX^0CQU8T^.?6W!/N$3!.6Y$LS05NMK2?
^%2E[T;CC(!!Z,_RNRWYX=:0E2X;RC^$QHGTCE'WL3TV 9-KZ#'QPT1KGJ53?,+ MW<_/$,& 8M*C$&+B&XP]]!O,#)%O^;DTOK_IZ5L5PEM%/K5N/\3H3XRI3=2B
M'!?,\C;9P0OS1N5F%3;S&YSA/:KR#&GE!EZ+J;Q<@!-!\KM^ 4$;7"V`I)#?/DG\/ MNYRC8*4Q'#34;54_&949;E1QYB=IH3K-W0KH+J+/B+E2NY6^R(JU:H=_L;@^
MMD4D=ZQN6Y"N7F'96=-M:S5:C+0N=6'"0%OH_;.D,1AUS$D'#XDI9PBL8&'* M)5V+;]I>6G41F./59&5IJ_Y.+P(IG/JO+$YJ=5?GRHO:.KA2YJU1/G41U--2 M.
[4B>HEKF\Z5JBCH;351!.I GRJELZ8^0?E2>DEK)41GC0#8M)ZI.PUU!;Y MYWHN651"S[/4M*SA2D--G35F=RLV7I@59^=I9 MXZT@(-/%;X46"$+"
<[^]W!82E1NK4TIW$21HININ!-M1Y]MBASK%A%XU/,5 M-`*4.>_&//'59E"J%M*>-2H&U3X4%.E%(-> *L+41%\$RG0$84Y1]D7@2%S<-MG:4ML31K'EDJ6/-MVP9
X7GM67Q_*>QS2,E0X,='UD0?%L]FWW$66.927F1],N0CZ-?*0 M"WNV#(%"%PESK+>'W,&H&+WL#]_*'"%KW14C|>=E{)6$^*#3 MB8QBW2R+<,FN/2AWJ!G-3S3Q=!C[-DZY>X\$<
MRW^?-Y.'LHXQF62+0.0 G%,_UV2.ZE_FC>HA.6VE7. 0Z'1*WAK/ME#K&4K# MU4!:.]!84VYI@D%P.U^R-=<\EB)^WD&8PQ*U@:.-=R#$,PKM[-PRFR)!W)-,0
MTIYB%V.*X'E[F(_IEB]V22[Z$/&FU934_D9 O5 M=9((6V93E)YL=(9DD$HM[*M.,3MS"]YY5B#LATXCTV=NZ1A" M)5?MYTY1?%+X-
%&LU7Z>80FDV76L=|%E5>5>],7QG,)F.U\#W"864_LMPN!# MO(JB *(@]9+C)>,L5,HKT7W2$?ORG!JC07+)=1R&\1MJT$V,L>OMX_UU'*,: M>9?)X7GE[X(H0#6X\&[V^R1^1?
\;>$RN M[DG'U,3V^BV"4+X$^QN4> ,2K(S%B[>_QLC]1QASO*UE[IZ4SXXR>Y?FE17M MM!*TDY[7>2XGC57_7(9KX5VL1";5&UZ6QW92@4>\3N4S0AN=TF,XN4!"M$04 M00
XQW3UZ@4A$EZOX+1C0$OZPTDC'HBG/7A?ST$$MD&&=&3VE|R55UY|20,> M\69PVX,CC(CR0$[GZ\T+4>@S3P_KI&&{)}40>;?7E$9TI=8>,B%PP* GD?I+C M2MO@#R<]?
T3>1^O5TRSHAA9JY8IE$879UP&:V#G|BF\A/2=\#YM/U8\G X)+ M9]95XOCQ5+=P5)-"Y8JM(I]ZU!]B]"2&-5,IPCN DOB#Z!GW!?A M?.Q^/-DD7+J0529:GM+)1C'B*;$5
Y@P3C:RJSR9D^6B@^^^]# 0ZQPO6/9'MHR:(Y;PQ98@W6^]>X+E27[-P^X0>HZG^>#(F=(E19GL(Y!;GH@I1B5NC5H 3 M22,T\S]9HORDS)L(D:"A/24M_S2*_OV_OFM@%N[\=V8
[_<USB*=T>RD[+#)B:[ESB$X*9$<+L_['9>,Y-\,B M'-4ZB9AF+/<`J,2@*%"!9G@%A -IJ,"2#G)+6 J,JLZ..PT;P U8I[_Q0!DH M.5^]7W -+M?97<%#$] WE##WC?=?
S:^H5N"O;,!GL%A6U1RRKDU;K6H8/1+W; M22-\E.>;)[(N : <\NJPC&%(-!O.-&'06V VA6V%2] MR]8E\XW3S+'O]G67L,9N!:K16|FQ%I6%W+
&M>KPK0ETM#Z!#=IJ;+PFXVV2':'DT7AYW,O4.TXIDN M"GM8G(?IH##-Q1';ZS&:,E,P9@V*C^XC]+L,/'IR#__A-*8@0_]1@A'EI!:)#
M.*T0PK+1BE+F|BK$VX#_M9M(685)PR1*27<@+1$T),-$TDO72ELBYGHM.0X.9.J8P M=-6P8_HKUM"5]Y847.6M?L/%@=N)D:\#=P3<(V=-0;5OP"L)XCX@TWY8T3$-E
MIC6P/H(()%X(\96ZWT%*H"IS75#OAOTD6;U/.F3M@@7L,*CKH"P(4,RG$.9 MF5>W8FX8AMX7<1H#/?N5)O>*3^40^'90^U82H%G*;W&BR#6T1XVX[=B$;YO M;LM-J7CXCW ?
TR#Z/D\]#:_PZ%PM934&4$1+/'" MS[$/PDE:FHRE/:M%DNLL;#>.ODMU(5G/GKQ:D!A9PWS0+!+3)&,0"/^K1:[\ MC]_NT'[Y$>&U7T?=UF?(]':'G7!CU=_`QQC'.%G]S=Y-,-WQ6VA|
[KO^R;SI M@GG3;+>SNR#[_3H!@/\(-W.S+XVRM\=EV&1VEABAE7?Y2ZG39^M7V-(XD$(M9;*QSEOPY7FAM=HR<&K&A@+E6$E*!:%QUF8'\>"(8R.:PMLR4%&W;#=P M-
<#"9]5E"Y(/_)D,Z WD>SB!-PK#"KNK@]:Y-JV!-3%<-GC8I!>;D6[", M4W"?78CTM2%RODI[G8fA7_ @998X6'&6:"J&" O"=2P*$)OSWQRC(4:!U"J4> MA,-%>?78RPODKWP\
('93X,#-7#OO-Z?F!OXD&0 1+3!!.H$+SB"9SI>_B,+R.$_3C0 Q:\#'#MZ[O+K_$4=[8Y_DY <|0 MX(&Z;!)$;, ATA' ,%1OWVW,@N"IHP]-<[7M#Đ)WL<7V2/ZY%X\36ME_BBVIQ
M(W,@R!K E?!"PY.G1,O6Q2A)ZEMER!SH@+0[' [$\^^ X=]]!)UHZ#Z.(&-S@'EFU7EOS-920*6:M*TUBC?L#!';B+9BT8 M/R9Q:MP<(?G2W/BPOB5R9#
[<98..V4&DAH@AC!_R#[I[\]O8&^5@5GFLWB;L M(5O:6[+TNJ5,!T0^PO07FB"%E:I'Y"LY/,;YE&,,BY&;!1^1> "E^=((`EP%W' MR18$&7*HVF1BNMNP7Z"G9#32BB7B\>
[2C/I9$>DHKXY=G-Q XF_[=R>+TG99 M4XW?V=_/9{|@$MZ"WWZ.A#FV/#,Z9EV1N'9^M(,6!SE(NI"W@9&6A>BS.ZR_6K+G5 M. 'R Y$T%9D71+R#9@S7HO@<60?
BG:@VV3V!RRI]H,L;QU0XKH5>7U1/43 MD@\|!6.?"OQ8LUZWT.VL3\::(#A&2/Y"3FX6,]!F4L"LC|:"&-@AS<#H$?Q" MCB#"]|@)'4N:\6R&|&?9"A2[W\[<)CB1PI@G1M%:C>*3#%>|
<63?#9 YM%" MCF\60HIVVM.L#W>,=$5N8\=F$A7%LUEIP46;VO0LHPKY7D9OAWL2].2=3#WR MR_*C_7&6C&]BK)Q)+)!3M4IQ^+TV"PO\/%VFZZMDRZ"6H>O2>GY$N>-X2X" L=TL(AJ
M.3]\4].JL918@\'O)Z!BVR*HO M'4*N*<8IV4(@7Y-M+%H)!Y_G#IX556M(C M:4T+[)BQ.S/!8<.H-T2!@HGC4)NK_G2ZPEV,V11|/Y_0U\6>3M'WM^'1QBX MZ(-M
"6W;MAB+9XO_VN78,8[^(\RVO@BANM%.%HV@L,#'U7#.O="B"MP_P) MEE]+'2SVV++#CB%+6/]D/=9A4COT]34%KM^G;(+?B,$^:AI%,'XS?([KQ#:)&P M"(%?'!+T!BE=AOI8>R?
AI2^KR$?_A_(F7[T0TQF%Q@11Z@PR;JF](MOB#+=^+++W&TT;@;G,'6 +A-XCU(MLB,]VM!4D=DOD?/[A<@ D(ZQ86[/>$;7LO<0C%U1D2ZO?#/ET%P!4IC?Y
M'+NW9K6!B$VQ# _EZ@QR4R)JP'$>B[XYZZ'|5M0;M1K3HDZB)1WE*5 M#V].IJ3R1I"5^YIFPBRD=I MG6<-J/4>X%_]17E:*,B_[A"
<$6_$G/;UIF&N2\4S9,#\" @R&#CA0|)X(6X5R1_IVIS MK*^>)L]\Z!D%EN8R.\B(YPU2|L'9//"/C0\-B,=[Y08U_[\MDRR:<4Y[Y8(,-/#0I-2, +?'V"5W 3;>(= M0$4A("]
<;0^\KV+SCM8]KDE'\CO1,LD>,*5LT"[>+<>Z\ QPS38=K3TV4R\S M+XB 3Z-YF!MQ";;!)A =C,)>NP2FK-^)1EM^[Z0/G4MF)&?SD1/75DX++.F10 M1@-P(RW%6%BT83_[GZA0$?
#_\R]9@I7 _(]0L 5?LZL0>YVAY ">=|S&ZH$: M1441#$&7?^<&NB-/P2L5 4+WLD[0C=|TY+@FXZ(R)QN8V'IA"K1!];%W\IM= MQ:#6!>BZD|UIH(,=DD?BZ!N_XLX=*OES(KC(/=2#
(J/P@N-E/9,(76G5Y"A MYKR>.#K,_=@59B%P&$|<"6VNY$!+>*G7=N*(T/7DLHB14=)\T^)&)'V\K//" ME1!<)V8+F/@!,Z<; Y)XOB 6Z1OKHDEJ, 65^YGI!9L*8,"2&\E Y"\OT(931
M!,Y1GQ8=|F@&HDP MC;8 LHFCHL|[,,;99D2T:'),W;B|(;#SHVM\1#6,;^+(T#+F\(.)XX!0T8< M06SAQ)&CAPZ5R.0A$/*3L\Q#%-4X<2SH< T;&CEQD/L*%\,@X&=7*;\|T>?E
MG:KEF|PK[E3\2GO)5D[[,?(.4 ^UV#+R15/91^,U,,*RZ0![9")+)UXPC;S.0E MH.15|"6'5WM?Q.T "%,$!2%Z##;@%4)#P[\ F?B8R@"Q5?_#/ M.L'\UM)[CSO8<-
;M39H>4,G+!9970QWC"WDUL=1W]14DFR %*6[.0KC<#9P; MH6+6*&]Y!LD 'W Y%59^Q97GCWK A'&;.\^6]9QF97F) *PU$4Z*.[.G:% M7;*)RT,".0CAAOC&?
0%O^!>Q_*@RUS70"/%UA*T^V052S2,2'^('[^N_@NP% M:21PP]=QWBRD_OZU$ZWVBI9%/W2QX.,ZP=|I*=/5+7@!W/2]fW.,E1FCIH\G MKBE/,[Q3&6^B7UYO&26&UCV'8L9M
JX/R-3$^9D'WF#?&@&R%-*TE,%>AQ'X|BE,92\%)6K+]Y\!?2*8 MD!?&,(.A'Y93%D'1.! DT0^.F.IBOW4(Q$\\C4F2+35?/Q.%)6)OP6E\'DDPC&4 MBD$-
!FN:.|[5J4GD9)I\A+2,C(;P94T<8>KL1|VU-?G8V)XTU.8NFWS$I"E6 M7?.E33R04D.O:W>X#8&+OTT$%PT/W1#(^+MKR.CET1L"0[^XA]%NSKY'|]-G M|$5*:I-
!4.",;JCNF1P$#\XH20/[/0=!GENJP8 .TD&PYXQ0W,-#.@ABG).& MN_A1'\&,<_+P<,]60?#GG P]E*!U$.PY)W37G*T.9+)AF%.P^?8Y?OT.,'R2 MN'83^<%KX!\@MM91>#22?
<9^A/BE-W]HCH,_\=LJ#)D/*)3A?=QZR/04>!? "_!=CL5; MX0\TO)O_@KP8TO6_023>2&.,=?^N--=>Y@52Z9\|+4CX!=)1 M^-1 >L(}G>FN8CH4O%"A.:!VUU7,"\,?%KW?
[)'OTYB%ZP8KT%V\'_Y5!H30+ M6V&B8=1CO^.;Q"/D;;>'IS#8K+=;@!18,>9;YUA#_*\@146T)%4&V!&VMRDE MA>]8Z6S5?IV_^\-3"OXXH-
"T5\2^X*=D92<$HUW:O!QG",=/'X2!B'E-,@8, M^%\E"/_?KM#+Q^?_=5^'75;G[VOP>ZP$VZL^KNUPT>GM}XR$H7D\O"\+DN8 MLDCCG).I_N;FM7/NB9&2 W^LU:U#O=-
+CHRPV?(^\L?/4;RV3UI&$]YZV9,! M%N9!^BC2<2.5)S5'E+B91;MRO8:K&H:8^EQKH$G;>'$!DLUP@=RV8K&Y,@ DDPG

*AHZ'X;1.@|ICQ\1KL]5@^#DH124@2. MG,#{PW%(=7T7I-O4X!4[\2P#"SN+V-VOMFA=1&BYD4*1\< 0554QM|XS%%V@-MI_PZSO*TH#OB5[)@#*

2RZ<_!3ES!@CO<=P#,YEV/2CN(@EBZ_=X@>Z4UL(2Z M2HJ4O/0K.346OQAAX0LB6U"JHZ&TA#N&1F31=985:'U1D&=D6,\(DS7E+-EG

M]$I_XG)RM$M+)BEJS9_U!%L\1>&]DJ9_BN=XUS5$E!]9XCSC6KHA.X9S!>4 M$<^& +GM$;ZW*41M=\RLDND#<;JC=!^D^8%#]HQA_;1/NJZ$>C4_4WQ16> MZG-

/#R3W%_6^>,K0?P]\P\L7HM&+ZV_R1D/:OEA]/D@,IXPY+&B,1.CSXXYV!0#*7V+0.0,"AV6/GO^AP&W?W1<'0&-ACG6X] M7(=!>FA9?

O)QS1YOVDV'#>HDO0KS/YY1&D1K&ML4>.4$P]WY2QOFQ4=H=\Q9 M&(S[% "MEPT5W3&&,+5%RUA,/'<6PW>MNW MG?

FXET^"H7>]:YQ.3*!N^*A"=3YW7QQB_)VM!1N@>TK&@Y8G& F,5&<"%>P MY=9"$[,'N0V;({UBE]>#4/PM(YLMP=8;[PHG#]E6=/\4#'";322S=F+;K0'

M5H3G#F4YEEAY=5;</9AG=_>/PGLHGE,8K3Z MBUFGR0IA=48V1!9)2$3$&]3G69"RM5^LR+!=)&OZ!UHL="=;QA"UON/FK63UY M6&3S6UB^/PK/-WT"+6(3

Y9JI4\23XN\B)%+4%%\;/8F;-1!/+PDJ(^UP0T8595N,H M^1"0;-CWAQJ:.J!6YI_&JE8MD=HAU;]$$.B\VUBKRR]2G3:L_Q!4+- ML#\D&4?9Y(V%Q>E:.*3#RMK30$C>;GOUI>?

FIHJFF+9=J>;88L+LL$^FY:RELUW"]ZJT.K4/\V>A0'1UYN\C@F]K3H3G" MY;],V^V_BEWIU;]45V01Q4(@XUA'1NEGOO=2\1 *Z[00ILE#[H?DD4'^5)"3KXR(MGA?K

M71B'65X6GEGL]VGR$D1*5\#8QV")LHJ"=[0[:IV:5QY\W%J&":)U)*<'U^ZS'-M93M;8IVS]AJFI0L+D=6_>.Q9.F?&/6;J'7#&+&.ZROEKC#G5-MS7'?:.3JMD

MkR4A>G))JH\F&&U:07L.MA'R22ZJGOJ3JZ"8=+Y*X2v+%#[K/K4#I"IX>6&9,LG_M)NGO&:F^1*#)'I(\B_J_$R/FPK_ HR=A*_YM=K>_?7JH+8F*UB^D?R+C>;#;GS)OPCVW4*>!U

MM:F!"M>]RJ;YA>[G3Q#!7RCIU1!2XK/&GJ=MY@21[UA<&M^:?2_96A_ 6\;KV:M;C\DY$\M5QNO6"=VJ((E%S0D ;,%IU:4;CMF6APAN)!*U0K[M**IP*\ MTEWC.*\U^A?"Y;

K,$HZ=EU6-/S,*N";#V-4<9@ZTGZ-4'IPF,Y6;.R"< M!;.LV?=PS#ER5IHC0%.'K?HGHS++#8.>Z>3J?3N:@GT05T0T6HP;=0U'8.,1& M!K_L=!ME_#++)GF" U3G4# J\

!QS.\'9F48>F58)V=6?/T6&)|RC6C?8<>2,K M2+<;6.L4;P:-+&G_9F$YY\IQT:E84]PPNOH;.,IGG!J);$M+@ M<;' H6K(#?,15Z-.E.B#5:.XTS>)\>}U+B?+F5BDQNF!?$K,@%$RN0UXKU2Q

MO_#*^AO7-!+AMES8TXMMV4DL>_M8HQ39;B^0KU*QYX"]6S93@!V;Y8@OJYH#&HQ&"$E76[#4LU36%_ <<,LX=N(MH?;U_@VCP@V2U8X7R!SX<75VB LB@,;)$ M),S:R!W"L'*-

/$&_JAP9"FWB&B:N5%C;4WQ,:'18WY9^O6XKC=@A1DHURH-[CA-+ MX5)^S7'/\34U0JI0]-QS#.E%=IA.!\\Q(?-*=8NO>PKD7%XI>/YMLJU.\Y,G0T7T8/

!O0_PB(S8U+>K4>\!SM$Y6>&9+_9J3UO2S M5^;+(6%TYPR%"2-'2!C$88&P E[04:<88&GV7K#'E;^#.AB:@E#U<X?GB-M_MJAC=1!0'V@IXGOR0C#U-5IT

{9G^YC/>PD.\@XFTOD<7OFV$#.7P!= M4%-2C]$(!#+]8.B@@K8! =ZY&H#:S]S5=]DS?% M@HPN&$362_FQ@;"?O*:O$:W-(",1!M5U'T]9P-??O28ZO4YTD/'GWI9J8?;.M0-

0_O":T$6T#(2,1!G?K/(ZT$IB%]'3'G(\0:]\(&G,P*(W[YM_*[B"EYNBS M.B-M.*W@%5+4<]14MGMS-TPI:(;G71TAFQ>:A5E#GM^-3O8^1%>1Y[[V3=TJU

M@C>__5#6^K9:P:??/AE^1U@KR/+6ER"4SYTBNE;PY[UIS+)2AJUNK60@>60G9 MB9OO6L6L5[.(:EM@*\CSUNC0[TH]\7_>6A>35U5O?QEJ*H9\QIA/DQ??

MBNUG6SE:PI.UM(U0AY.V?K2#3;^-%O^TF%21Z.]0H=KV@C1O+9KQ;.BM))WZ M.>7H-P&W@D1OS9_JF.Z<"FT%[>"<6]MID&I@OE[D5LYD-

,PPL9<@6%G6HO6D<_IVF[E(9]WMN;D5;7;N5O!_VF8]5;P+ ^[V;N4T MO#=AY[H-CB3V7]ZN26NA^;N5$WJI-K%VYW1AZ]]E)C>"LX[|YR%O>0 MMX(S_TW@L>WJK.#3>U-

6TLG>#M:\M%'L=T2*B$MX:DOS@;YUHH$Q]_WS7 MPQC^X. ^MGQF_=A"%ON:(O,"HMJ?!V.OKZW<9_D.%& 3N^]__,OW__CS #A"_RX&L2)%O#.XH_DGN/#Z!

(2]ZS32)\/EFIF]P7NUV0'CKBL<7ZZV#W!HCW@39$SWGZO#HMM^A*,_]OWQ+_O+= MUVS]7\)LFL'91<$3BB0I,,=)#,)V"$GR:(*(.4$6$"TV"HP$#'PP*A6U]+

M!8A]!BPP.MJ;.BSM:6.!(MSSVYH5T9WVT[?H<@Z^Y,.AH5F>4*?.NZE:QD^ M$/4"]\<#T=5 M?X#%F*T+YANGFLNX8S=DDA7_4>L M0& +_C*B/@B\1?2\HIFVFAZ0((K8?

@\UNUCZ+J4R/D%W/U1]92NU2J6H*$[MK7(M);FGP6'17M=]0O6OB?40B&N4\/I?\TWW4VRCI4\8;M[UN<:3:F_561NO MS)BOHTX\L%Z3N4;1N6N/@1MUJGT=IN%%Y R!7$##?

-^%72=!1!KOMN>C>{?$0 MBY//3##)P+D0MHNR,9R?]D9(\'=4LMVK.6L3F1/A$%&H&0 M?'.'_^)YP. M*+]AEAL44>X.I.H2,M,P,!_5,/@ P,N#N4(>)*(67;T N*DCTY@FI;PD"LMRDQG8'U$,4J#". ^M78CN!:D IC;7VRB@)>GN Y)I4NS9>E#0+ -MSR.=VDA1U$M.R6/1R+OF;?]R0]V@]-$_6C]F8?S\/@16O^.A>++6L?:U,HN/X

MAYMDC2+'_@QS[\74NIF+J^VV37,,4:1#7@]JH+?'JR M\T&S2,S2O(5 _"\C\IJFHNRTS=ZOLV[K!C/27;'C;JS[^_P88[B]NK!]2_N6 M.SH68=Z%V>]7*4)U?>"R&X)9![JO\W7D)L*Q"P2?

SN^G<=HU&_J21'B9"&L4 M-^&>YH/ M:"""%WD.FKM3I9>]#CK&]8_=PZ+D+!U@1,G6%UU.\RSA-5\7U/*/= -+2=>P M9\QIA/DQ??

T@N'{5\]1*CRI[D#>Y5QH2H.G?'_'N2/9>%[PH1LY^WK.?UU<_M[X1F!HOU.BRO^/%*98NGC);,-4U22M_TSV5>@=5Z=*M8Q_A'T[/T"3MQAG92 M6?1SL$/"-+W>(!M%';"@N$J*-

$%VLZ*DP M)BC5?[#S36]94HMZ[Y(HNDI2\],E7L3YF&$"F[K+STE<%4^O&XEB>RP-L?6] M*C4[-L,>]]NG0'!=T.S37.)[-LA.)$>>Q'*D:0 C;9G OZ@.,-W(*!-D#N-<_

MV#9Y"K_N7&,0/+7H#=![URKHC0M\-.P]%=2D*Q\RAGB.B7H2[{4ILWSQ\,] M>_5;6#:LM',.]^^X>^S24"+_8G?'>&LKFFR%8\6$+A!N%>0RQ-5^D89$<4& M=P 7S6-

:EUKA=:POG1H+T??]S,Q"QFP0F#DNM(=MV.#B#*]^3+V5G,PISQ6 M;Q/ND"ULE\[/]>=MJ_<)&F/Y"P.Y?2PN9\1(J?-7?FWB5!!4YB02X_(NZFX# M+L+5

2TE9%54L=6SUXH*)/^NMRB5ZQMJS,+]?D[M'/A6XQS^S(F;,N'#L.I8 M4O\]2'8K?=^XJ9.^#!<4+N2=_?\WN3\WF2F3"Z3[=Q'Y3MY?DCL6!RK2*2E

M1"+/\00!LIVD'%DZC[ZEYOV1N$K'L70^8@T7|&DIE?IBY9IT6K_W M!.)HB WPYPD9*VVT'1(\3AV#D!)?+=WBVC0"C7NE^\K,(=\"VB@*AXPXMR[V M.0?CZ0M2;XTUDPE';_7LF#;

{2\W.TX/P3!DVF27FZ8GY]]PPD\H@8Q^&E.Z; M.V^U_@(P{3TJ]^MGIU51Z&$(CS%N3-_X1S)F-Z?R4GH2}}GIX>F@,U:412 MZ+FZCFD6I,

[[/,6]WQ)"}5W8^X,Y'3&AG87LZ;'Y9T\KY"M[VL_;^VCYA+QG M3SN->\;U+"=-> W](_O%)81]3[O4OXE[Y31Y989#/)E[-3H_ 4*!4O5NVN>Z

ML;>ZI*=7EI2GJHX&CT1Z6VHA@7SH(+2TS+?HO1A&\1]+6ZQ%N.X33BGI7/I-ML5,M/\:0R=G=_ ,.L)IE@#EP:F'XI]3RLT_[^N6X9*&J84"14ZB[?]'$!/J-3 M/)ANXMKLR.1]_N01#

(_|=?=W@D=4.H2YT\>P?#N@.[^3O"(JH"KPVLP MW,'IHIG$M>%= ZW-G0N+G N+,/%KJF;%6W^@*R.WF1VPH _A_+)^!-D9>EDO M<5V>.A:MQ#EFONCGU_CGU_C^O\8_+:

[@+)G]J"<7[\@/84U;=WL2S_K<@H_O> M>,.[(^ MY]/R]VKJ19?\>=UP?-CP&>6?DBS#Q$I1=%0E:WB#$EZ,V5T2TS'MER6.7S=|

MB((LPVHO\90.,,1>F(\]UF$[,$P\A.B$#PFZ@YQMML+=+P&Y4_DRO2.T(Z:1'=W(SP+]EAWQ%1R0\)*A#GE

MPW'.MMR37V6,HO(8M#DZ%[+AB@..WAJ&GP/=8*5E.VBZ@/]PFZ*K@DC$ZJ9F M_/= VFM .ZZ+,"Y(.+"/<;T#XZX"+4&(>J;P>6"M9!DCX57360$PF)@6)X)Y M7,'P!5RN\@0O.

!P^>:;2N(2CUO$V.TJHHG9+@7450M Q/:7HL51K(;OU,_\ MQX62WM:HL.#6CD!C0NY-$.I\'7(8:EB>@Z[_"#0U-7'S4G"$,)9P.Y^-9Z_/[7 M$-5QL?

A%8&B<3.;_8=4C**+LLZ2O^&DKY7N+A(&#H5::9Q2XICAYZE ML_18K>TP'#WH_\H)0??'V2L6>$F53!3??M]>5N+H4Q@\A1'6QY5*!2HL<*YL MIAVF+3VZ$V*TS 6,[_[

MO0]&WBALG^)6:&X/UT"/1+V+O*VL3CBFZF$HU+ MBIE*+E-IQ8\XKFD7 ;O6A1GK&G0PY!PZUG%5]KVM=BIQ$@$C1.UA^GV#_$PWFAG0;VFAL!B_7]%EI-- M-

73%2V00SW$&2]WZ8]WL0Y&F\L,03' &Q')/J3I^_H2"##763+4_#B"221!. MY',2KW0/A3$'VKD"D@0LYCVKB076:# MPG851*LB"JSE:M.FM T!?$CP>C%-V(_QY'"-

[Y^'T18IT#W6X28\KBU1>9I M,DXK:Q\7WMF?F[/*2]0]/@'7NW*,0PRR+3D]'_DI%^"B)YG_@'+C@,^3SX9 M X68=5X,5K1:D5!0=AL=]9# MAU"=U?OQKNTZ@&$8[ANAUWY

ZJ4$=T$Z>)#U)Y?QZ.SO7\]2@+D@=_LH M,2!TAR^BP DE#C?G*E?#]L)\UI"M?B[6Z]#<]&TOKJ_C*)A)B#.R[8E@P H=<4

:3HLYKK!VE!38S\5]#O+'-'_"2$ MG UM-P_,E<^@KN,\B)^)6[L<@]6C,O*.3_ECDJQ?0Y(;? QF0H=4[9;>D0*N M,5K7N03XK(M=0271!=]$JS#W"6:I6H&-\CWFQY=?

284#TG](5OQE>R(\@%?A M\K8DSFV1KK9M=L4$%2*&/&C_!$8^#TARUR! P 1'/,<=;U)P_K/YE'PBD/.QG'PW19Z% MW%W=V.?;'&=H5W-+,S&O-

-5A)2.YVD)EL)$EI:1W+_,LY6D.PU?%+%K>'A) MA.-=*HDZ7E^>AJBU"C0VI&=NNLR9JZR0&9 FT^&YZQE'PEGM-OM#!VQ_,T/ MQKKU^(MTW/+=@^,6'.,,]|+"YTX:/Q;X%KA_[M

*@X!AJ9Z6/\9K(W8S&A] M59 &J#=8,]H5.\[JAZJ>!;)\U<>+T+(E7293=@;-?H20@_X)X?-$'"98 W-1 M,-_D)CKYS3W4Z-/U 3S$ >CY\ MDM,_+.Y:X!BXPJN?

YM=LN:G@Q;]2)M]28XD"'^Q@'V/[#4R#P92PVD_IT2AV[M,G]8S$CRIFW(CK\%R8^Q!7$T)X0"ISW,GX<(#,.I,W]UH>VAPQ\XFV.J2)9Y MEGY0"\H2JC'OB%R#Z%5I-

TC4ECW$BB06NSH.GY]+1MK4ICK;1/(X@5;O.0OA2GE/FBJP0D ?U]M@+) >RMB)FKVIO\\>?*,@9.@R6O^B?0&>/>

M!I=NF#7293*'C!4.\S]X,]QCO\^Q>+AOQKGLZB*R$SAA4-$07F! MN10]*C"O$%IGI/PVN8B82]T$.;F+A^6&E8O@36B0(*67WGVLF%VE?W?_T!IY MB}(PP5AZ#M\

(2XW&\2NS.9#C=[3F^(=NT!8"'S* M0#R1B+LDS<,_Z#]\]M,O'15*/4AH:(C1=ST=Q9.P'J8P=XXYK%X3YR*.XXD M_R*ZV=9=(TWKR_@PB:/>IF@7%KOL:*YD+/<5V)

C"SM781S$*RWY=YUE!2DO-MB;4,22$;C_ PEB4)93]XH@#+BIADZ4^!F7&LB)I*)(103Z5Y*OU(B@?%2,.Q M&0IYS6/NT

IA*QBSVS!)'O)L^C(Y3LF0KPIBT0TR0*#7,IDF]\&/P&U.W>$ M1+|*H0>E/0R0"1%%EU1>6P1[3SHV1O

V'C&G6K_90<#.#W3!ANN!T$:0&@>;A_O/M4M#MHGIZ<'A^W3S&].T?M@Y/=<(:ME1XQ@>UD,*X[G64OL](%EL!MW]_=F/9!MAK<..K=))URW%IB)!.W-%Y2 M6\'7*5,N;K3;!BB;MT_V#T&T/RU"U_=U- ME[<-V6W(/BQDF<"%.+FJ9[YFFD6,,[,(:NE*""626XBY M,FH3ICIQ=.ZYU8PK6XO[Z]D7MZSDVI9;6#M6;D(?A\LSRM*+S<,"/28Y2Y[B MR/(!]+@K#%[ZM5FU^-K7?FNU6"O*"3L 3,H'ZFYVU&G'E*LN5E0EV#*Y- ML/EKFHOUVKR^"KM)#DQ\?P5V;[T*(MG>C2WOQFYJSDQM-$95Y>_J^\#>6X,K M VC(\K7S;,ETF*1'% ^HPOM&-]MV5O0LQ?=EKL_0M02P,$% @ SX!F M6=FQ@OL_!0 /QT | !S;&YO+65X,S)?,BYH=&WM66UOVS80_MY?P:5(:MD0*6+3OODAO '53D[5- 1,!H:61/[\]D,I08<*")@D3UP$Y*>8A9P*\#-AU9@+2#7<<2L)N MFCEJ8<_((O#;ATR$GSPF$I@'WGZ8,]&\6XT54C/#I @4<&K8#821G'N:?;)X MD50)*]_09A^T2"D4A@K D'7+TQ8+;K""]U82G/&%\&4Y;#))R1&5%!/Q"7# MT=7TXOQB.)A>C")FW=7DW>#RRF9CK]O_WPU79Z4<[HGY%U[TAZVR60T=_[] M]A_ZK:UK'E_QP80,7H_?
3$>OMZ1Y6IYIJ'+J'Y'Q.9G^-"*3P=6/@\O1Q!N_M_V7T&QD,IW:DY_O_XRQT5^GS4,V_3=$+!0?!!0&P+0#)C)B,F_*VI JCB"_(M%=@*E,B43"0'('"

RY53KJ^]Y:D4CF E.F8%OF96MO\2N,/5(!&)889 M@Y2<,T%%S'!5XS1E,:X"E;83U1J11.)KJ#U$"X+#AJ6+%BE*I4LLT(F19"5% MU 9U*<+J0!.)NB5KXHV0)4<--:$]LHORQG,."S* (G>4M.5HX3DWP+1SY>REA MVXV84ZU?[2!@[G&FC0<<3&,G$+7>7?%;PL63*Q8UV^\R2.WI4 M=P]%NH=[R MQ;O$]'-(>B/AM.^+X_]L-?(:C1B02WE350%'51'P+Q;/CWH&Y8X*: <2A0:[/ MWBRT/8K#E=I1#PDB2Z07FT,2UJSUV\B>6AYIQ6FA(=!04 PMJ X(<7+5S'S# M-(L89V81--*U$$HE=Q!SY42PUJ Y$NR8I)]!8]0F3'W,Z-QSIQE7MA;WWI,_ MW+&2&UMN8<%8NPE!""X/)BLOM@\+|)CD+'F,<\H'T:.^,.CHSF9%NG8N^4CF M_;Z,N#7@-QKPGA9H:\B_:LBJ0C$T88$YO,W]-N/3.),:E,+B#8IWQGWY)>OB MM]WLGV3&^]KT? F?&6RG*"WH-G!-)-. LK-6)*W=8KK1,L&MPK8+-864NUNOS MY@IL-D$P\?G=UYTU*XAD>RFVO!2[K3LSM=V9K@^@(;N?G63V M(]T' '\2&@_1 " 0 !S;&YO+3(P,C0P.3,P+FAT;5!+ M 0(4 Q0 (,^ 9ED8_*.*'"D! ((T$@ 1 " 5&M 0!S M;&YO+3(P,C0P.3,P+GAS9%!+ 0(4 Q0 (,^ 9EEBMF]*-P@ -DP / M " 9S6 @!S;&YO+65X.S%?,2YH=&U02P$'"% ,4 " #/ M@&99RM(GP2L(!<, #P @ $ WP(#,Q7S(N M.'1M4$L! A0#% @ SX!F6;7R;&%"!0 1AT \(! M6.<" '+L;F\M97@S,E\Q+FAT,5!+ 0(4 Q0 (,^ 9EG9L8+[/P4 #\= M / " XML 58 slno-20240930_htm.xml IDEA; XBRL DOCUMENT 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-12-16 2022-12-16 0001484565 slno:MayTwoThousandTwentyThreeTrancheBWarrantsMember 2023-12-31 0001484565 stpr:CA 2024-01-01 2024-09-30 0001484565 slno:AnishBhatnagarMember 2024-09-30 0001484565 srt:MaximumMember 2024-07-01 2024-09-30 0001484565 2023-01-01 2023-12-31 0001484565 slno:MayTwoThousandTwentyThreeTrancheBWarrantsMember 2023-01-01 2023-09-30 0001484565 us-gaap:RetainedEarningsMember 2023-06-30 0001484565 2023-06-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001484565 2024-10-31 0001484565 2024-01-01 2024-03-31 0001484565 srt:MinimumMember 2024-09-30 0001484565 us-gaap:CommonStockMember 2024-03-31 0001484565 slno:JimMackanessMember 2024-07-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001484565 slno:CantorFitzgeraldAndCoMember slno:ControlledEquityOfferingSalesAgreementMember 2021-07-01 2021-07-31 0001484565 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 slno:SecuritiesPurchaseAgreementMember 2022-12-16 0001484565 srt:MaximumMember slno:JefferiesLlcMember 2024-07-19 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2024-01-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001484565 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001484565 2023-10-02 2023-10-02 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2023-01-01 2023-06-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2022-12-31 0001484565 slno:TwoThousandTwentyInducementEquityIncentivePlanMember 2024-01-24 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-17 0001484565 us-gaap:RetainedEarningsMember 2023-03-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2023-01-01 2023-09-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2023-09-30 0001484565 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001484565 slno:UnderwrittenPublicOfferingMember 2022-03-31 0001484565 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001484565 us-gaap:CommonStockMember 2023-06-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001484565 srt:MaximumMember slno:UnderwrittenPublicOfferingMember slno:SecuritiesPurchaseAgreementMember 2022-01-01 2022-12-31 0001484565 us-gaap:RetainedEarningsMember 2023-12-31 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-12-16 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-09-30 0001484565 2022-12-31 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-09-30 0001484565 slno:KristenYenMember 2024-09-30 0001484565 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001484565 slno:OctoberTwoThousandTwentyThreePreFundedWarrantsMember 2024-09-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001484565 srt:MinimumMember 2024-07-01 2024-09-30 0001484565 us-gaap:CommonStockMember 2022-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2023-01-01 2023-09-30 0001484565 us-gaap:RetainedEarningsMember 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-12-16 2022-12-16 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember slno:UnderwrittenPublicOfferingMember 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-09-26 2023-09-26 0001484565 2024-01-01 2024-09-30 0001484565 srt:MinimumMember 2023-07-01 2023-09-30 0001484565 slno:PerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001484565 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001484565 us-gaap:EmployeeStockMember 2024-09-30 0001484565 us-gaap:CommonStockMember 2023-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-09-30 0001484565 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001484565 slno:AnishBhatnagarMember 2024-07-01 2024-09-30 0001484565 slno:MayTwoThousandTwentyThreeTrancheBWarrantsMember 2024-01-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001484565 slno:CantorFitzgeraldAndCoMember slno:ControlledEquityOfferingSalesAgreementMember 2023-01-01 2023-12-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2022-12-31 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2023-01-01 2023-09-30 0001484565 slno:SecuritiesPurchaseAgreementMember 2023-10-02 2023-10-02 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001484565 slno:PublicOfferingMember 2023-10-02 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-09-30 0001484565 slno:SecuritiesPurchaseAgreementMember 2024-09-30 0001484565 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001484565 slno:MarchTwoThousandTwentyTwoPreFundedWarrantsMember 2023-01-01 2023-09-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember slno:EssentialisIncMember 2024-09-30 0001484565 slno:OctoberTwoThousandTwentyThreePreFundedWarrantsMember 2024-07-01 2024-09-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001484565 2023-03-31 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-12-31 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2023-12-31 0001484565 us-gaap:RetainedEarningsMember 2024-03-31 0001484565 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001484565 slno:SalesAgreementMember 2024-07-19 0001484565 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-09-30 0001484565 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-12-16 0001484565 slno:MayTwoThousandTwentyThreeTrancheBWarrantsMember 2024-09-30 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2023-01-01 2023-09-30 0001484565 slno:UnderwrittenPublicOfferingMember 2023-10-02 0001484565 slno:UnderwrittenPublicOfferingMember 2022-03-01 2022-03-31 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-07-01 2023-09-30 0001484565 us-gaap:RetainedEarningsMember 2024-06-30 0001484565 slno:UnderwriterMember 2023-01-01 2023-09-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember slno:EssentialisIncMember 2023-12-31 0001484565 slno:TwoThousandTwentyInducementEquityIncentivePlanMember 2024-09-30 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember slno:UnderwrittenPublicOfferingMember 2024-01-01 2024-09-30 0001484565 srt:MinimumMember us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001484565 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-09-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2023-12-31 0001484565 2023-07-01 2023-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-12-31 0001484565 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001484565 slno:EssentialisIncMember 2017-03-07 0001484565 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001484565 srt:MaximumMember us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001484565 slno:PatriciaCHiranoMember 2024-07-01 2024-09-30 0001484565 slno:CommonStockWarrantsMember 2023-12-31 0001484565 2024-04-01 2024-06-30 0001484565 srt:MinimumMember 2024-01-01 2024-09-30 0001484565 slno:MarchTwoThousandTwentyTwoPreFundedWarrantsMember 2023-07-01 2023-09-30 0001484565 us-gaap:RetainedEarningsMember 2022-12-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001484565 stpr:CA 2024-02-08 2024-02-08 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001484565 slno:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember slno:EssentialisIncMember 2023-12-31 0001484565 slno:PatriciaCHiranoMember 2024-09-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2023-12-31 0001484565 slno:UnderwrittenPublicOfferingMember 2024-05-09 2024-05-09 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2018-12-19 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0001484565 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001484565 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001484565 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001484565 slno:KristenYenMember 2024-07-01 2024-09-30 0001484565 slno:CommonStockWarrantsMember 2024-09-30 0001484565 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001484565 2023-12-31 0001484565 slno:SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001484565 us-gaap:CommonStockMember 2023-03-31 0001484565 2023-04-01 2023-06-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001484565 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001484565 us-gaap:RetainedEarningsMember 2023-09-30 0001484565 stpr:CA 2024-06-13 2024-06-13 0001484565 2023-09-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2024-01-01 2024-09-30 0001484565 2023-10-01 2023-10-31 0001484565 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-01 2024-09-30 0001484565 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-01 2024-09-30 0001484565 slno:MarchTwoThousandTwentyTwoPreFundedWarrantsMember slno:UnderwrittenPublicOfferingMember 2024-01-01 2024-09-30 0001484565 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001484565 srt:MaximumMember 2023-01-01 2023-09-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember slno:EssentialisIncMember 2024-09-30 0001484565 2023-01-01 2023-09-30 0001484565 2024-06-30 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2024-01-01 2024-09-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001484565 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001484565 srt:MaximumMember slno:IncentiveStockOptionsMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001484565 2024-07-01 2024-09-30 0001484565 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001484565 slno:UnderwrittenPublicOfferingMember 2024-01-01 2024-09-30 0001484565 slno:PerformanceBasedRestrictedStockUnitsMember 2024-07-01 2024-09-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001484565 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001484565 slno:UnderwriterMember 2024-01-01 2024-09-30 0001484565 stpr:CA 2024-06-13 0001484565

slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2024-09-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001484565 srt:MaximumMember 2024-01-01 2024-09-30 0001484565 srt:MaximumMember 2023-07-01 2023-09-30 0001484565 us-gaap:CommonStockMember 2024-09-30 0001484565 2024-03-31 0001484565 slno:OctoberTwoThousandTwentyThreePreFundedWarrantsMember 2024-01-01 2024-09-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanMember 2024-06-06 0001484565 slno:MayTwoThousandTwentyThreeTrancheAWarrantsMember 2023-01-01 2023-09-30 0001484565 slno:PerformanceBasedRestrictedStockUnitsMember 2023-07-01 2023-09-30 0001484565 srt:MinimumMember 2023-01-01 2023-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001484565 us-gaap:CommonStockMember 2024-06-30 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2024-09-30 0001484565 slno:UnderwrittenPublicOfferingMember 2024-05-09 0001484565 slno:PurchasePriceContingentLiabilityMember 2024-09-30 0001484565 2023-01-01 2023-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001484565 slno:JimMackanessMember 2024-09-30 0001484565 slno:OctoberTwoThousandTwentyThreePreFundedWarrantsMember 2023-12-31 0001484565 stpr:CA 2024-02-08 0001484565 us-gaap:EmployeeStockOptionMember slno:TwoThousandAndFourteenEquityIncentivePlanAndTwoThousandTwentyInducementEquityIncentivePlanMember 2023-01-01 2023-12-31 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001484565 us-gaap:EmployeeStockOptionMember 2024-09-30 0001484565 stpr:CA 2024-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001484565 2023-10-02 0001484565 slno:UnderwrittenPublicOfferingMember 2023-10-02 2023-10-02 0001484565 us-gaap:CommonStockMember 2023-09-30 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2023-12-31 0001484565 slno:CantorFitzgeraldAndCoMember slno:ControlledEquityOfferingSalesAgreementMember 2021-07-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2023-09-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001484565 2024-09-01 2024-09-30 0001484565 slno:PurchasePriceContingentLiabilityMember 2024-01-01 2024-09-30 pure utr:sqft shares iso4217:USD shares iso4217:USD P365D Q3 P365D false P365D 0001484565 P365D --12-31 SOLENO THERAPEUTICS INC http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent 10-Q true 2024-09-30 2024 false 001-36593 DE 77-0523891 100 Marine Parkway Suite 400 Redwood City CA 94065 650 213-8444 Common Stock, $0.001 par value SLNO NASDAQ Yes Yes Non-accelerated Filer true false false 43117432 48413000 169681000 208363000 1423000 1677000 258199000 171358000 196000 12000 2992000 407000 7291000 8749000 27945000 83000 165000 296706000 180691000 6243000 3149000 3408000 3135000 1762000 3393000 448000 273000 3101000 1555000 14962000 11505000 14464000 11549000 2581000 130000 32007000 23184000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 100000000 100000000 41041216 41041216 31678159 31678159 41000 32000 660041000 433885000 895000 -396278000 -276410000 264699000 157507000 296706000 180691000 30138000 6043000 57082000 16500000 49197000 3318000 68558000 9341000 877000 1021000 2915000 1633000 80212000 10382000 128555000 27474000 -80212000 -10382000 -128555000 -27474000 0 653000 0 652000 3596000 174000 8687000 434000 3596000 -479000 8687000 -218000 -76616000 -10861000 -119868000 -27692000 1049000 0 898000 0 -1000 -1000 -3000 -1000 -75568000 -10862000 -118973000 -27693000 -1.83 -1.83 -0.95 -0.95 -3.08 -3.08 -2.65 -2.65 41879025 41879025 11436748 11436748 38917169 38917169 10443186 10443186 31678159 32000 433885000 -276410000 157507000 6445000 6445000 11034 1644886 1000 922000 923000 -3000 -15000 -15000 -105000 -105000 -1000 -1000 -21398000 -21398000 33337079 33000 441267000 -106000 -297808000 143386000 7160000 7160000 75750 9746000 3450000 4000 148951000 148955000 1435319 1000 2619000 2620000 -88631 -537000 -537000 -46000 -46000 -1000 -1000 -21854000 -21854000 38386779 38000 600534000 -153000 -319662000 280757000 56598000 56598000 789500 1000 1000 1782048 2000 2145000 2147000 -82889 -764000 -764000 1049000 1049000 -1000 -1000 -76616000 -76616000 41041216 41000 660041000 895000 -396278000 264699000 8159382 8000 247762000 -237422000 10348000 495000 495000 9534 136000 136000 128 16000 16000 -8356000 -8356000 8168788 8000 248393000 16000 -245778000 2639000 1204000 1204000 9973000 9973000 1772397 2000 7099000 7101000 -16000 -16000 -8475000 -8475000 9941185 10000 266669000 -254253000 12426000 2201000 2201000 5522113 5000 19440000 19445000 -3931 -10000 -10000 -1000 -1000 -10861000 -10861000 15467229 15000 288320000 -1000 -265114000 23220000 -119868000 -27692000 1484000 1469000 3495000 0 250000 254000 70203000 4036000 652000 2915000 1633000 -3000 -1000 -279000 177000 3094000 1338000 273000 -177000 -1631000 15000 -152000 -242000 1546000 266000 -45105000 -18626000 210000 0 308915000 0 77000000 0 -232125000 0 148955000 0 0 17074000 5690000 19445000 0 19932000 1317000 10000 155962000 56461000 -121268000 37835000 169681000 14602000 48413000 52437000 597000 199000 Note 1. Overview Soleno Therapeutics, Inc. (the Company or Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). DCCR has received Fast-Track and Breakthrough Therapy designations for the treatment of PWS in the United States (U.S.) and orphan designation for the treatment of PWS in the U.S. as well as in the European Union (E.U.). On June 28, 2024, the Company submitted a new drug application (NDA) to the FDA for DCCR for the treatment of PWS in individuals four years and older who have hyperphagia and on August 27, 2024 announced that the FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. The Company incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. It initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs. During 2017, the Company merged with Essentialis, Inc (Essentialis) and subsequently received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.”. Essentialis was a privately held clinical-stage company focused on the development of breakthrough medicines for the treatment of rare diseases where there is increased mortality and risk of cardiovascular and endocrine complications. After the merger, the Company’s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested all prior business efforts. Note 2. Liquidity The Company used $45.1 million of cash in its operating activities and had a net loss of $119.9 million during the nine months ended September 30, 2024 and has an accumulated deficit of $396.3 million at September 30, 2024 resulting from having incurred losses since its inception. The Company had $48.4 million of cash and cash equivalents on hand, $208.4 million of marketable securities and $27.9 million of long-term marketable securities on September 30, 2024. The Company has financed its operations principally through issuance of equity securities. On May 9, 2024, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million. On July 19, 2024, the Company entered into an Open Market AgreementSM (the "Sales Agreement") with Jefferies LLC, as sales agent ("Jefferies"), pursuant to which the Company may offer and sell, from time to time, through Jefferies shares of its common stock having an aggregate offering price of up to $150,000,000. In December 2022, the Company entered into a Securities Purchase Agreement providing for the sale of up to $60.0 million in warrants (Tranche A and Tranche B) and the common stock issuable upon the exercise thereof. Cumulative to date through September 30, 2024, the Company has received $10.0 million from the sale of these warrants and $37.7 million in proceeds from the exercise of certain of these warrants. Warrants with an aggregate exercise price of $12.3 million are still outstanding. The Company expects to continue incurring losses for the foreseeable future. However, the Company expects that its current cash, cash equivalents and marketable securities balances will be sufficient to enable the Company to meet its obligations for at least the next twelve months from the date of this filing. -45100000 -119900000 -396300000 48400000 208400000 27900000 3450000 46.00 158700000 9700000 150000000 60000000 10000000 37700000 12300000 Note 3. Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies There have been no material changes to the significant accounting policies during the three and nine months ended September 30, 2024 as compared to

the significant accounting policies described in Note 3 of the "Notes to Consolidated Financial Statements" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, except as noted below.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2024. For further information, refer to the financial statements and footnotes included in the Company's annual financial statements for the fiscal year ended December 31, 2023, which are included in the Company's annual report on Form 10-K filed with the SEC on March 7, 2024.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.

Marketable Securities

The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented.

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting – Improvements to Reportable Segment Disclosures", which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the disclosure requirements related to the new standard but does not anticipate a material impact on its consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures," which amends the guidance in ASC 740, Income Taxes, This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024. Adoption is permitted either prospectively or retrospectively, and the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.

Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2024. For further information, refer to the financial statements and footnotes included in the Company's annual financial statements for the fiscal year ended December 31, 2023, which are included in the Company's annual report on Form 10-K filed with the SEC on March 7, 2024.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.

Marketable Securities

The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the balance sheets, with unrealized gains and non-credit related losses that are determined to be temporary, if any, reported as a component of other comprehensive income (loss) within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. The Company classifies marketable securities with remaining maturities greater than three months but less than one year as marketable securities, and those with remaining maturities greater than one year are classified as long-term marketable securities. Realized gains and losses are calculated using the specific identification method and recorded as interest income and were immaterial for all periods presented.

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting – Improvements to Reportable Segment Disclosures", which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the disclosure requirements related to the new standard but does not anticipate a material impact on its consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures," which amends the guidance

in ASC 740, Income Taxes. This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024. Adoption is permitted either prospectively or retrospectively, and the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption. Note 4. Fair Value of Financial Instruments The carrying value of the Company's cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: • Level I — Unadjusted quoted prices in active markets for identical assets or liabilities; • Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and • Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:31.425%;box-sizing:content-box;"></td><td style="width:1.661%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.667%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.661%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.667%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.661%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.465%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.661%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.129%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235,410</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 903 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 236,308 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235,410</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 903 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 236,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable securities:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. Treasury securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 236,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">262,708</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 236,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Essentialis purchase price contingency liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"><td style="vertical-align:top;"> Liabilities </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Essentialis purchase price contingency liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Based on the terms of the Company’s completed merger with Essentialis on March 7, 2017, the Company is obligated to make cash earnout payments of up to a maximum of $21.2 million to the former Essentialis stockholders. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company’s analysis of the likelihood of obtaining specified approvals from the U.S. Food and Drug Administration (FDA) as well as achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue. The Level 3 estimates are based, in part, on subjective assumptions. In determining the likelihood of this occurring, the analysis relied on published research relating to clinical development success rates. Based on management’s assessment, an 88% probability of achieving all three milestones was determined to be reasonable as of both September 30, 2024 and December 31, 2023. During the periods presented, the Company has not changed the manner in which it values its Essentialis purchase price contingent liability. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between levels within the hierarchy during the periods presented. The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2024 and 2023 (dollars in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.42%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Purchase Price </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in value of contingent liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,915</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2018 PIPE Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Purchase Price </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Warrants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Contingent
Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at January 1, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,241 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,835 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Change in value of 2018 PIPE Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Change in value of contingent liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 34,241 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">653</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,468 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:31.425%;box-sizing:content-box;"></td> <td style="width:1.661%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:13.667%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:1.661%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:13.667%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:1.661%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:13.465%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:1.661%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:13.129%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235,410</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 903 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 235,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">903</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 236,308 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Marketable securities; </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">262,708</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">236,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Essentialis purchase price contingency liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Liabilities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Essentialis purchase price contingency liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 26400000 26400000 26400000 236308000 236308000 236308000 236308000 2627080002640000023630800014464000144640001446400011549000115490001154900021200000100000000200000000.880.88 The following table sets forth a summary of the changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2024 and 2023 (dollars in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.42%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Purchase Price </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Contingent
Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,549 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in value of contingent liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,915 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Change in value of contingent liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,633 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 34,241 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">653</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,468 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>

11549000 2915000 14464000 34241 1000 8835000 652000 1633000 34241 653000 10468000 Note 5. Warrants The Company has issued multiple warrant series, of which the 2018 PIPE Warrants were determined to be liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging. Warrants Issued as Part of the Units in the 2018 PIPE Offering The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and prior to their expiration on December 21, 2023, entitled the holders to purchase 34,241 shares of the Company's common stock at an exercise price equal to $30.00 per share, subject to adjustments. In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology. Since the Company may be obligated to settle the 2018 PIPE Warrants in cash, the Company classified the 2018 PIPE Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as Other income (expense) in the Company's condensed consolidated statements of operations. The 2018 PIPE Warrants were either exercised prior to or expired on December 21, 2023. The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and prior to their expiration on December 21, 2023, entitled the holders to purchase 34,241 shares of the Company's common stock at an exercise price equal to $30.00 per share, subject to adjustments. 34241 30 Note 6. Commitments and Contingencies Facility Leases On June 13, 2024, the Company entered into a new office lease in Redwood City, California for office space for its headquarters facility. The lease provides office space of approximately 18,026 square feet and for base monthly rent payments beginning at $57,400 that increase annually by approximately 3.0% over the term of five years from the date of occupancy. In addition to base rent, the Company has agreed to reimburse the landlord for certain operating expenses under the terms of the lease. The lease commencement date was September 1, 2024 when the premises became available for occupancy and the related operating lease ROU assets and liabilities were recorded in the Company's condensed consolidated balance sheet as of September 30, 2024. The Company's operating lease ROU assets, current operating lease liabilities and long-term operating lease liabilities each appear as a separate line within the Company's condensed consolidated balance sheets. In September 2024, the Company recorded an increase to its right-of-use assets by $2.8 million and an increase to its lease liability of $2.8 million as a result of the June 2024 office lease. As of September 30, 2024 and December 31, 2023, the Company's short-term liabilities were equal to $0.4 million and $0.3 million, respectively, and the long-term operating lease liabilities were equal to $<span style="font-size:10pt;font-family:Times New

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6 million and $0.1 million, respectively. The Company's prior operating lease for its predecessor headquarters facility office space in Redwood City, California began in June 2021 and expired in May 2023. In April 2023, the Company entered into a twenty-four month lease extension commencing on June 1, 2023. The term of the lease extension expires in May 2025. On February 8, 2024, the Company entered into a six-month office license agreement to license 4,141 square feet of additional space adjacent to its existing office where the Company was located and in July 2024, the Company provided notice of early termination of the license agreement for the additional space effective September 17, 2024. As a result of the lease extension, in 2023, the Company recorded an increase to its right-of-use assets by $0.6 million and an increase to its lease liability by $0.6 million. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The weighted average discount rate related to the Company's lease liabilities as of September 30, 2024 was 8.5% over a remaining term of 5 years. The weighted average discount rate related to the Company's lease liabilities as of December 31, 2023 was 8.25% over a remaining term of 17 months. The discount rate was determined based on estimates of the Company's incremental borrowing rate, as the discount rate implicit in the lease cannot be readily determined. Due to the short-term nature of the February 2024 office license agreement, the license agreement obligations are not included in the Company's right-of-use assets and lease liabilities on the Company's condensed consolidated balance sheets.</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The components of lease expense during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended
September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended
September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost:</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 291 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">235</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Variable lease cost</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term lease cost</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">147</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease cost</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 195 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">88</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr></table> Supplemental cash flow information related to leases was as follows (in thousands): <span style="white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.181%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.568000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.166%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating cash flows from operating leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 264 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table> The following is a schedule by year of future maturities of the Company's operating lease liabilities as of September 30, 2024 (in thousands):
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder of the year) </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 526 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 751 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 861 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 942 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total lease payments </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,809 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less interest </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (780 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">)

</td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Other Commitments The Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies as well as other services and products for operating purposes, which are generally cancelable upon written notice. As of September 30, 2024, the Company's non-cancelable other commitments aggregated $2.8 million.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contingencies </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. </p> 18026 57400 0.03 P5Y 2800000 2800000 400000 300000 2600000 100000 began in June 2021 and expired in May 2023 2021-06 2023-05 P24M 2025-05 P6M 4141 2024-09-17 600000 600000 0.085 P5Y 0.0825 P17M <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The components of lease expense during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.779999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended
September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended
September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost:</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 291 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Short-term lease cost </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 54 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total operating lease cost </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">195</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 88 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> 137000 76000 291000 235000 4000 12000 54000 12000 147000 33000 195000 88000 450000 268000 Supplemental cash flow information related to leases was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.181%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.568000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.166%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid

#ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating cash flows from operating leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 264 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> </table> 248000 264000 The following is a schedule by year of future maturities of the Company's operating lease liabilities as of September 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder of the year) </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">64</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">526</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">751</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">861</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">942</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">665</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease payments</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,809</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less interest</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(780</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 64000 526000 751000 861000 942000 665000 3809000 780000 3029000 2800000 Note 7. Stockholders' Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of Preferred Stock. Public Offering of Common Stock On May 9, 2024, the Company closed an underwritten public offering of 3,450,000<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million. Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants On October 2, 2023, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other offering expenses. Concurrently, the Company also completed the closing of 1,825,000 shares of its common stock and 1,175,000 pre-funded warrants in a private offering pursuant to a securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99, for total gross proceeds of approximately $60.0 million. In aggregate, the Company received $129.0 million of gross proceeds less offering costs of $8.2 million. The Company is not required under any circumstance to settle any of the pre-funded warrants for cash, and therefore classified the pre-funded warrants as permanent equity. Securities Purchase Agreement On December 16, 2022, the Company entered into a Securities Purchase Agreement for a private placement (Private Placement) with certain entities and members of management (collectively, Purchasers). Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers warrants to purchase up to an aggregate of 22,598,870 shares of the Company's common stock, at a purchase price of $0.4425 per warrant. The closing of the Private Placement occurred on May 8, 2023 (the Issue Date), following the satisfaction of certain closing conditions, including the completion of enrollment in the randomized withdrawal period of Study C602. The Company received gross proceeds of $10.0 million for the sale and issuance of warrants to purchase common stock. The warrants were separated into two tranches with 8,598,870 Tranche A Warrants with an exercise price of $1.75 per share and aggregate proceeds of up to approximately $15.0 million, and 14,000,000 Tranche B Warrants with an exercise price of $2.50 per share and aggregate proceeds of up to $35.0 million. The Tranche A warrants were immediately exercisable and were required to be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of Study C602. On September 26, 2023, the Company announced positive top-line data and subsequently received $15.0 million from the exercise of the Tranche A warrants. The Tranche B warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance or 30 days following receipt of FDA approval of DCCR for the treatment of PWS. Through September 30, 2024, certain investors had exercised their Tranche B warrants and the Company has received $22.7 million. The receipt of the aggregate exercise price of up to $12.3 million for the remaining Tranche B warrants is contingent upon the exercise of such warrants. Underwritten Public Offering On March 31, 2022, the Company sold 2,666,667 shares of its common stock at a public offering price of $3.75 per share, and for certain investors, in lieu of common stock, pre-funded warrants (the 2022 pre-funded warrants) to purchase 1,333,333 shares of its common stock at a public offering price $3.60 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.15 per share exercise price for each 2022 pre-funded warrant. The March 2022 pre-funded warrants are immediately exercisable and may be exercised at any time until all of the March 2022 pre-funded warrants are exercised in full. Each share of common stock or March 2022 pre-funded warrant was sold together with one, immediately exercisable, common warrant (the 2022 common warrants) with a five-year term to purchase one share of common stock at an exercise price of $4.50 per share. The net proceeds of the offering were $13.8 million, after deducting the underwriting discount and other offering expenses. The Company is not required under any circumstance to settle any of the 2022 pre-funded warrants or the 2022 common warrants for cash, and therefore classified both types of warrants as permanent equity. Through September 30, 2024, 2,145,073 of the March 2022 common warrants had been exercised for gross proceeds of $9.7 million and 581,850 warrants were exercised using the cashless exercise option with no proceeds to the Company. As of September <span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;">30, 2024, 1,273,077 of the March 2022 common warrants remain outstanding. All 1,333,333 of the March 2022 pre-funded warrants were exercised in 2023 using the cashless exercise option with no additional proceeds received by the Company. At the Market Offering In July 2021, the Company entered into a Controlled Equity Offering Sales Agreement under which the Company was able to sell shares of its common stock having an aggregate offering price of up to $25.0 million from time to time in any method permitted by law deemed to be an "at-the-market" Rule 415 under the Securities Act of 1933, as amended. The Controlled Equity Offering Sales Agreement was terminated in connection with the October 2, 2023 financing. While active, the Company sold 1,877,170 shares of common stock through the at the market program, totaling $7.4 million in net proceeds. On July 19, 2024, the Company entered into the Sales Agreement with Jefferies, pursuant to which the Company may offer and sell up to $150.0 million of shares of its common stock, from time to time, through Jefferies.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company will pay Jefferies a commission of 3.0% of the aggregate gross proceeds from the sale of shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any shares under the Sales Agreement. The offering of the shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by Jefferies or the Company, as permitted therein. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common Stock Warrants </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024 and December 31, 2023, the following table summarizes the Company's outstanding common stock warrants:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:27.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.76%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.4%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.84%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.4%;box-sizing:content-box;"></td><td style="width:13.66%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of Common Warrant Shares</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted Average Exercise Price per Share</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of Common Warrant Shares</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted Average Exercise Price per Share</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Expiration Date</p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common stock warrants</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,904</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 388.94 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,904 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">388.94</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 388.94 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">November 2024 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2022 Common warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,273,077 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,929,066</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> March 2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,250,647 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,758,281</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> November 2026 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,935,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,750,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> November 2026 (1) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">451,632</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> November 2026 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> October 2023 pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 250,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,175,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> N/A </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,168,565 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,071,883 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> (1) Subject to earlier expiration as described above. Equity Incentive Plans 2014 Plan The Company maintains the 2014 Equity Incentive Plan (the 2014 Plan). Under the 2014 Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the 2014 Plan may be incentive stock options (ISOs) or nonqualified stock options (NSOs). ISOs may be granted only to Company employees, including officers and directors. The Board has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Performance-based grants have vesting contingent upon the achievement of certain performance criteria related to the Company’s commercialization of its therapeutics. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board. On January 17, 2024, the Company filed a Registration Statement on Form S-8 which registered an additional 1,000,000 shares automatically available for issuance under the 2014 Plan as of December 31, 2023. On June 6, 2024, the stockholders approved the Amended and Restated 2014 Plan which included an increase of 2,000,000<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;"> shares, which became immediately available for grant and issuance. As of September 30, 2024, a total of 609,179 shares are available for future grant under the 2014 Plan. Inducement Plan The Company maintains the 2020 Inducement Equity Incentive Plan (the Inducement Plan). The Inducement Plan provides for the grant of equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2014 Plan. In accordance with Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals' bona fide period of non-employment with the Company), as an inducement material to the individuals' entry into employment with the Company, or, to the extent permitted by Rule 5635(c)(3) of the Nasdaq Listing Rules, in connection with a merger or acquisition. On January 31, 2024, the Company filed a Registration Statement on Form S-8 which registered 500,000 shares available for issuance under the Inducement Plan, which became available for issuance following approval of the Board of Directors on January 24, 2024. As of September 30, 2024, a total of 5,318 shares are available for future grant under the Inducement Plan. Stock-based compensation expense The Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements during any of the periods presented. Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.79%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.253%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.799%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.253%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.428%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.967%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.799%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.709999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,516</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 935 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,682</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,082 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,266 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,521 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,449 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70,203</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,036 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Stock Options The Company granted options to purchase 288,850 and 77,000 shares of the Company's common stock to employees during the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company granted options to purchase 1,369,230 of the Company's common stock to employees and a consultant, and during the nine months ended September 30, 2023, the Company granted 1,663,454 of the Company's common stock to employees. There were no performance-based options granted during the three and nine months ended September 30, 2024 and 2023, respectively. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.333%;box-sizing:content-box;"></td> <td style="width:15.707%;box-sizing:content-box;"></td> <td style="width:1.333%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> <td style="width:1.893%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> <td style="width:1.333%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected life (years) </td> <td style="vertical-align:bottom;text-align:left;"> 6.1 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.3-6.0 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.8-6.1 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.3-6.0 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;text-align:left;"> 3.7%-3.8% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.0%-4.4% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.7%-4.6% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5%-4.4% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Volatility </td> <td style="vertical-align:bottom;text-align:left;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 98%-100% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 121%-124% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 98%-100% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend rate </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> </tr> </table> The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates: • Expected life: The expected life of stock options represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected life of the Company's service-based stock options has been determined utilizing the "simplified method", based on the average of the contractual term of the options and the weighted-average vesting period. The expected life for the performance-based options was determined based on consideration of the contractual term of the stock options, an estimate of the date the performance criteria would be met and expectations of employee behavior. • Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected life of the stock options. • Volatility: The estimated volatility rate is based on the volatilities of the Company's common stock for a historical period equal to the expected life of the stock options. • Dividend rate: The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The following table summarizes stock option transactions for the nine months ended September 30, 2024 which were for awards issued under the 2014 Plan and the Inducement Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Number of
Options </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted-
Average
Exercise
Price per </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;text-align:left;"> Weighted
Average
Remaining
Contractual
Term </td> <td style="vertical-align:middle;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Aggregate Intrinsic Value </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,369,665 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11.56</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.72</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,834 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,369,230 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42.91 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (171,520 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.59 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#fcff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (44,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42.30 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,523,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">8.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">97,143</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercisable at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,116,184</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15.67 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.40 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,095</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options vested and expected to vest at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,523,251</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 97,143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> The weighted-average grant date fair value of options granted was $37.84 and $3.80 per share for the nine months ended September 30, 2024 and 2023, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to stock options that are likely to vest was $50.1 million, which is expected to be recognized over the weighted-average remaining vesting period of 2.7 years. Restricted Stock Units There were 1,239,375 performance-based restricted stock units and 366,625 restricted stock units granted to employees and a director during the three months ended September 30, 2024 and zero granted during the three months ended September 30, 2023. During the nine months ended September 30, 2024, there were 1,249,375 performance-based restricted stock units and 758,155 restricted stock units granted to employees and directors. During the nine months ended September 30, 2023, 414,710 restricted stock units were granted to employees. The shares were valued based on the Company's common stock price on the grant date. The following table summarizes restricted stock unit transactions for the nine months ended September 30, 2024 as issued under the 2014 Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.675%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.322%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Restricted Stock Units </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant-Date Fair Value per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,534 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43.92</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted stock units granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,007,530</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46.47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted stock units vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (950,534 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45.81</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted stock units canceled/forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,072,530 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47.02 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The weighted-average grant-date fair value of all restricted stock units granted during the nine months ended September 30, 2024 and 2023 was $46.47 and $5.25, respectively. The fair value of all restricted stock units vested during the nine months ended September 30, 2024 and 2023 was $44.67 million and $23,000, respectively. At September 30, 2024, total unrecognized employee stock-based compensation related to restricted stock units was $34.5 million, which is expected to be recognized over the weighted-average remaining vesting period of 0.4 years. 74,250 restricted stock units vested on September 30, 2024 and are included in the Restricted stock units vested line item above.The shares of common stock were subsequently issued after September 30, 2024 and therefore are not included in the outstanding common stock as of September 30, 2024. 2014 Employee Stock Purchase Plan The Company's board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan (ESPP). The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of 1,864 shares of the Company's common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of: • 1.0% of the outstanding shares of the Company's common stock on the first day of such year; • 3,729 shares; or <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;word-break:keep-all;display:inline-

flex;justify-content:flex-start;">• such amount as determined by the board of directors. As of September 30, 2024, there were no purchases by employees under this plan. 10000000 3450000 46.00 158700000 9700000 3450000 20.00 69000000 1825000 1175000 20.00 19.99 60000000 12900000 8200000 22598870 0.4425 10000000 8598870 1.75 15000000 14000000 2.50 35000000 P30D 15000000 P3Y6M P30D 22700000 12300000 2666667 3.75 1333333 3.60 0.15 P5Y 4.50 13800000 2145073 9700000 581850 0 1273077 1333333 0 25000000 1877170 7400000 150000000 0.03 As of September 30, 2024 and December 31, 2023, the following table summarizes the Company's outstanding common stock warrants: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:13.66%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Common Warrant Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Common Warrant Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,904 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">388.94</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">November 2024</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2022 Common warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,273,077</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,929,066 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,250,647 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,758,281</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> November 2026 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,935,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,750,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> November 2026(1) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">November 2026</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">October 2023 pre-funded warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">250,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.01 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,175,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">N/A</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,168,565</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,071,883</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> </table><p style="margin-left:14.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:14.667%;text-align:left;">(1) Subject to earlier expiration as described above.</p> 7904 388.94 7904 388.94 2024-11 1273077 4.5 1929066 4.5 2027-03 1250647 0.01 2758281 0.01 2026-11 4935305 2.5 6750000 2.5 2026-11 451632 0.01 451632 0.01 2026-11 250000 0.01 1175000 0.01 8168565 13071883 0.10 1.10 P5Y P10Y 1000000 2000000 609179 500000 5318 0 0 0 0 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.79%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.253%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.799%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.253%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.428%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.967%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.799%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.709999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,516 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 935 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;font-family:Times

New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,682</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,082 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,266 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46,521 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,449 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70,203</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,036 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 18516000 935000 23682000 1587000 38082000 1266000 46521000 2449000 56598000 2201000 70203000 4036000 288850 77000 1369230 1663454 The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.333%;box-sizing:content-box;"></td> <td style="width:15.707%;box-sizing:content-box;"></td> <td style="width:1.333%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> <td style="width:1.893%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> <td style="width:1.333%;box-sizing:content-box;"></td> <td style="width:14.133%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected life (years) </td> <td style="vertical-align:bottom;text-align:left;"> 6.1 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.3-6.0 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.8-6.1 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.3-6.0 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;text-align:left;"> 3.7%-3.8% </td> <td style="vertical-align:bottom;text-

align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.0%-4.4% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.7%-4.6% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.5%-4.4% </td></tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Volatility </td> <td style="vertical-align:bottom;text-align:left;"> 121% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 98%-100% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 121%-124% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 98%-100% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend rate </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> — % </td> </tr> </table> P6Y1M6D P5Y3M18D P6Y P5Y9M18D P6Y1M6D P5Y3M18D P6Y 0.037 0.038 0.04 0.044 0.037 0.046 0.035 0.044 1.21 0.98 1 1.21 1.24 0.98 1 0 0 0 0 0 The following table summarizes stock option transactions for the nine months ended September 30, 2024 which were for awards issued under the 2014 Plan and the Inducement Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Number of
Options </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted-
Average
Exercise
Price per </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;text-align:left;"> Weighted
Average
Remaining
Contractual
Term </td> <td style="vertical-align:middle;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Aggregate Intrinsic Value </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,369,665 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.72 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,369,230</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42.91</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options exercised</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(171,520</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.59</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options canceled/forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(44,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,523,251</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8.55 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 97,143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,116,184 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15.67</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 41,095 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options vested and expected to vest at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,523,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23.55</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.55</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 97,143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2369665 11.56 P8Y8M19D 70834000 1369230 42.91 171520 7.59 44124 42.30 3523251 23.55 P8Y6M18D 97143000 1116184 15.67 P7Y4M24D 41095000 3523251 23.55 P8Y6M18D 97143000 37.84 3.8 50100000 P2Y8M12D 1239375 366625 0 0 1249375 758155 414710 The following table summarizes restricted stock unit transactions for the nine months ended September 30, 2024 as issued under the 2014 Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:74.675%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.322%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Restricted Stock Units </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Grant-Date Fair Value per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at January 1, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,534 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43.92</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted stock units granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,007,530</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46.47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted stock units vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (950,534 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45.81 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="min-width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted stock units canceled/forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,072,530</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47.02 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> 15534 43.92 2007530 46.47 950534 45.81 0 1072530 47.02 46.47 5.25 44670000 23000 34500000 P0Y4M24D 74250 1864 0.010 3729 0 Note 8. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding during the period. Shares of common stock that are potentially issuable for little or no cash consideration at issuance, such as the Company's pre-funded warrants issued in March 2022 and October 2023 and in connection with the exercise of certain May 2023 Tranche A and Tranche B warrants, are considered outstanding common stock and are included in the calculation of basic and diluted net loss per share in connection with ASC 260 Earnings Per Shares. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the exercise or vesting of common stock awards and exercise of common stock warrants that are not pre-funded. The Company applies the two-class method to calculate basic and diluted earnings per share as its warrants issued in March 2022, May 2023 and October 2023 are participating securities. However, the two-class method does not impact the net loss per share of common stock as the March 2022, May 2023 and October 2023 common warrants issued do not participate in losses. For the three and nine months ended September 30, 2024 and 2023, the effect of issuing potential common stock is anti-dilutive due to the net losses in those periods and therefore the number of shares used to compute basic and diluted net loss per share are the same in each of those periods. The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39,360,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,287,620 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,824,742 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,206,650 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2022 pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,122,819 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,227,670 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,816,427 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> 26,309 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,154,299 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,866 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 486,496 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> 250,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 41,879,025 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,436,748 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,917,169 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,443,186 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants issued to 2010/2012 convertible note
 holders to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants issued to underwriter to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2018 PIPE warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,241 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2022 common warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,273,077 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,130,656 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,867,908 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,935,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,523,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300,412 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,072,530 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 424,244 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,812,067 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 21,765,365 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39,360,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">10,287,620 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,824,742 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,206,650 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2022 pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,122,819 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,227,670 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,816,427 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,309 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,154,299 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,866 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B pre-funded warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 451,632

- </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 41,879,025 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,436,748 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,917,169 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,443,186 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 39360966 39360966 10287620 10287620 35824742 35824742 9206650 9206650 1122819 1122819 1227670 1227670 1816427 1816427 26309 26309 2154299 2154299 8866 8866 451632 451632 451632 451632 250000 250000 486496 486496 41879025 41879025 11436748 11436748 38917169 38917169 10443186 10443186 The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants issued to 2010/2012 convertible note
  holders to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2018 PIPE warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,241 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2022 common warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,273,077 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,130,656 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche A warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,867,908 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2023 Tranche B warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,935,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,523,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300,412 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,072,530 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 424,244 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,812,067 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 21,765,365 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 6804 6804 1100 1100 34241 1273077 2130656 2867908 4935305 14000000 3523251 2300412 1072530 424244 10812067 21765365 Note 9. Subsequent Events The following provides information regarding Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, each a "10b5-1 Plan") adopted in the third quarter of 2024 by any director or officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934 ("Section 16 Director or Officer"): Anish Bhatnagar, our Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors adopted a 10b5-1 Plan on September 6, 2024. Mr. Bhatnagar's 10b5-1 Plan provides for the potential sale of up to 300,000 shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Jim Mackaness, our Chief Financial Officer, adopted a 10b5-1 Plan on September 6, 2024. Mr. Mackaness' 10b5-1 Plan provides for the potential sale of up to 60,000<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;"> shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest. Patricia C. Hirano, our Senior Vice President, Regulatory Affairs, adopted a 10b5-1 Plan on September 13, 2024. Ms. Hirano's 10b5-1 Plan provides for the potential sale of up to 124,026 shares of our common stock, and expires on September 13, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest. Kristen Yen, our Senior Vice President, Clinical Operations, adopted a 10b5-1 Plan on September 13, 2024. Ms. Yen's 10b5-1 Plan provides for the potential sale of up to 95,089 shares of our common stock, and expires on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). Certain of our Section 16 Directors or Officers may participate in employee stock purchase plans, 401(k) plans or dividend investment plans of us that have been designed to comply with Rule 10b5-1(c). No non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) were adopted by any Section 16 Director or Officer during the third quarter of 2024. Additionally, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any Section 16 Director or Officer in the third quarter of 2024. Anish Bhatnagar Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors true September 6, 2024 300000 September 6, 2025 Jim Mackaness Chief Financial Officer true September 6, 2024 60000 September 6, 2025 Patricia C. Hirano Senior Vice President true September 13, 2024 124026 September 13, 2025 Kristen Yen Senior Vice President true September 13, 2024 95089 September 30, 2025 false false